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ABSTRACT 
 
Early Treatment Initiation and Outcomes in Perinatally HIV-infected Infants and Young 




The 2013 case report of the “Mississippi baby,” who was started on antiretroviral therapy (ART) 
within 30 hours of life and maintained off-treatment remission for 27 months before HIV was 
once again detectable, generated renewed interest in the benefits of early ART, as well as 
optimism that HIV remission is a possibility if ART is started very early.  The overarching goal 
of this dissertation was to advance our understanding of the relationship between early ART and 
three outcomes – the possibility of HIV remission, improved viral outcomes, and epigenetic 
changes – in HIV-infected infants and young children.  First, a systematic review was conducted 
to assess current published data in support of the possibility of very early ART leading to HIV 
remission in infants.  Evidence from this review suggested that although early ART does appear 
to be associated with better sustained virological control and smaller reservoir size, there are 
limited data at this time to support a strong link between early ART and HIV remission.  Second, 
the association between age at ART initiation and virologic outcomes after ART initiation was 
empirically assessed using data from five cohorts of HIV-infected infants and young children 
initiating ART before 2 years of age in Johannesburg, South Africa.  In three cohorts, there was 
no consistent evidence of an association between early ART initiation and rates of initial viral 
suppression.  However, there was a consistent benefit of early treatment initiation on long-term 
viral control in two cohorts.  Finally, an epigenome-wide association study was conducted to 
identify differential DNA methylation patterns between ART-treated HIV-infected and HIV-
uninfected South African children.  A total of 1,309 differentially methylated CpG sites 
associated with HIV status were selected (FDR q-value <0.05; |Δβ| >0.05), after adjustment for 
age, sex, and cell type proportions.  In addition, 315 differentially methylated regions associated 
with HIV status were selected (Stouffer p-value <0.05, maximum |Δβ| change in the region 
>0.05, and containing at least two or more CpG sites).  Many of the genes identified in both the 
site and region approaches were located in the major histocompatibility complex (MHC) region 
on chromosome 6, a region that plays an important role in the adaptive immune system.  This 
novel study provided evidence of an association between perinatally-acquired HIV infection and 
a large number of changes in DNA methylation in school-aged children on ART, and highlighted 
potential new lines of investigation into the biologic pathways influenced by HIV and its 
treatment.  Overall, this dissertation increased our understanding of the timing of early ART 
initiation in HIV-infected infants and addressed gaps in our knowledge relevant to outcomes 
associated with early ART initiation.  As public health practice continues to move towards infant 
diagnosis of HIV at birth and early life initiation of ART, these findings help to inform future 
research that will guide HIV care in infants. 
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The global scale up of prevention of mother-to-child HIV transmission (PMTCT) efforts has 
progressed well over the last decade, with coverage increasing from 15% in 2005 to 77% in 2015 
(Figure 1.1) (1).  However, new HIV infections continue to occur in infants, particularly in 
limited-resource settings.  This is largely a result of several factors, including the high prevalence 
and incidence of HIV in women of child-bearing age, incomplete implementation of PMTCT 
interventions, and the inability of antiretroviral interventions to block 100% of infections.  
Although the estimated number of annual new pediatric infections has declined over the last 
decade, in 2015 more than 150,000 children became infected with HIV (2).  Thus, the pediatric 
HIV epidemic remains far from over.  
 
Without treatment, perinatally HIV-infected infants and young children experience rapid disease 
progression in the first two years of life (3).  In resource-limited settings, over half of untreated 
perinatally HIV-infected children die by 2 years of age (4).  The introduction of antiretroviral 
therapy (ART) early in life has led to dramatic reductions in morbidity and mortality in HIV-
infected infants.  Guidelines now advise initiating ART irrespective of clinical and 
immunological status in all HIV-infected infants and children as soon as HIV is diagnosed (5-7).  
Traditionally, other goals of early ART, in addition to reducing morbidity and mortality, are to 
maximize normal growth, neurodevelopment, and immune function, as well as to improve 
quality of life (8-14). 
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Although children with HIV who initiate treatment early in life can now live healthy lives, ART 
does not clear HIV infection from the body and its long-term use, together with ongoing HIV 
replication, may result in a spectrum of co-morbidities and complications over the life course.  In 
adults, HIV-Associated Non-AIDS (HANA) conditions, including cardiovascular disease, 
cancer, bone fractures and osteoporosis, liver and kidney disease, and cognitive decline, occur at 
earlier ages and at higher rates in HIV-infected individuals compared to uninfected individuals 
(15-18).  Early manifestations of co-morbidities are also observed in HIV-infected children on 
ART, such as dyslipidemia and decreased bone mass (19-21).  It is possible that early ART may 
reduce these co-morbidities by reducing chronic inflammation and immunosenescence; some 
evidence for this association has also been observed in a recent randomized controlled trial in 
adults (22).  It is critical, therefore, to develop a more robust understanding of the pathways 
through which HIV and ART may drive co-morbidities.  This knowledge potentially can be used 
to develop effective strategies to ensure optimal health of treated HIV-infected children as they 
age into adolescence and adulthood.  
 
In 2013, the case report of the “Mississippi baby” generated new questions for the field of 
pediatric HIV relevant to early treatment and treatment outcomes (23, 24).  In brief (Figure 1.2), 
the Mississippi baby was born at 35 weeks of gestation to an HIV-infected mother with no 
prenatal care.  The child was initiated on a three-drug antiretroviral regimen of nevirapine, 
zidovudine and lamivudine at approximately 30 hours of life.  The child remained on ART until 
18 months of age, at which point ART was stopped against medical advice and the child missed 
several clinic appointments.  When the mother returned with the child to the clinic at 23 months, 
HIV was undetectable in the child’s blood.  Multiple blood tests over the next 12 months were 
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unable to detect signs of HIV and the child was deemed to be in long-term remission.  
Researchers stated that introduction of ART at 30 hours of life may have resulted in “HIV 
remission”, which we will define as maintenance of plasma viremia below the threshold of 
detection in the absence of ART.  However, disappointingly, HIV was detected in the child’s 
blood at 46 months of life and treatment was restarted in the child.  
 
Despite the news that the child had not been cured, the Mississippi baby represented a critical 
shift in thinking, and generated optimism that HIV remission is a possibility if ART is started 
very early, which we define as the first 28 days of life (neonatal period).  Very early ART may 
restrict the size of the latent viral reservoir, thereby reducing the likelihood of viral rebound, and 
increasing the possibility for prolonged ART-free remission of HIV.  However, it remains 
unclear if early ART can lead to HIV remission.  Limited evidence is available on the association 
between early age at ART initiation and virologic outcomes.  
 
The Mississippi baby has also reinvigorated interest in other benefits of early ART, including 
potential long-term implications across the life course, as children now survive into adolescence 
and adulthood.  There is a need to better understand the mechanisms that may explain better 
outcomes in children who initiate ART early, and tools such as epigenetics may provide clues to 
identify mechanistic pathways.  Overall, as the window for starting treatment moves closer to 
birth, better understanding of the response to treatment in children initiated on ART at different 




1.2. Dissertation Overview 
 
The overarching goal of this dissertation is to advance our understanding of the relationship 
between early antiretroviral therapy and outcomes in HIV-infected infants and children.  More 
specifically, I evaluate whether early ART can lead to HIV remission in infants (Aim 1); whether 
early ART is associated with improved virologic outcomes after ART initiation in infants (Aim 
2); and whether HIV infection is associated with epigenetic changes in young children (Aim 3).  
 
A conceptual diagram with a life course epidemiology perspective was developed to 
contextualize this dissertation (Figure 1.3) (25).  In this dissertation, I focus on three “short-
term” outcomes (possibility of HIV remission, improved virologic outcomes, and epigenetic 
changes) in early childhood associated with very early and early life initiation of ART that may 
have implications for long-term outcomes in later childhood, adolescence, and adulthood.  The 
empirical data with which these hypotheses were tested were drawn from cohorts in sub-Saharan 
Africa, a region bearing the burden of pediatric HIV infection both now and in the foreseeable 
future.   
 
This dissertation is comprised of five chapters.  Following this introductory chapter, Chapter 2 
presents a systematic review of existing literature relevant to Aim 1.  For this review, six 
relevant questions were developed to help inform whether early ART may be able to lead to HIV 
remission in some infants.  These questions include 1) How rapid is viral suppression in neonates 
who initiate very early ART? 2) Is the initial viral suppression rate different in infants who 
initiate ART early vs. late? 3) Is later virologic control on ART different in infants who initiate 
ART early vs. late? 4) Is the size of the viral reservoir different in infants who initiate ART early 
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vs. late? 5) What are the outcomes of randomized trials of structured treatment interruption in 
children? 6) What is the likelihood of viral rebound after stopping ART in neonates who initiate 
ART very early?   
 
Chapter 3, which addresses Aim 2, is motivated by the limited available data on the effect of the 
timing of ART initiation on virologic outcomes, including initial virologic response and later 
virologic control among those starting ART early in life.  Here, the association between age at 
ART initiation (≤6 months vs. >6 months) and virologic outcomes after ART initiation is 
assessed using data from five cohorts of HIV-infected infants and young children initiating ART 
before 2 years of age in Johannesburg, South Africa.  
 
In Chapter 4, the association between HIV infection and epigenetic changes is investigated as 
proposed in Aim 3.  Epigenetic changes alter gene expression without directly altering the DNA 
base pair sequences in genomic code (26).  These changes may suggest mechanisms through 
which HIV and ART exposure during critical developmental periods alter biological pathways 
and disease risk.  One of the most commonly studied epigenetic changes is DNA methylation, 
the addition of a methyl group to a cytosine followed by a guanine (cytosine-phosphate-guanine; 
CpG), which can affect gene transcription and regulate biological processes (27).  Epigenome-
wide association studies (EWAS) can test for DNA methylation changes at a large number of 
CpG sites and identify affected biological pathways.  Thus, characterizing DNA methylation in 
the host genome may provide insight into the pathogenesis of HIV infection.  Using data from a 
cohort of 4-9 year old ART-treated perinatally HIV-infected and frequency age-matched HIV-
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uninfected children in Johannesburg, South Africa, an EWAS is performed to identify 
differential DNA methylation patterns associated with HIV infection.   
 
Chapter 5 presents a summary of the findings of this dissertation along with a discussion of 
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1.4. Figures and Tables 
 
Figure 1.1: Prevention of mother-to-child transmission (PMTCT) of HIV coverage over 































Figure 1.2: The case report of the Mississippi baby.  Data from Persaud, 2013 (23) and 





Figure 1.3: Conceptual diagram of the impact of very early and early antiretroviral 









CHAPTER 2: EARLY ANTIRETROVIRAL THERAPY IN HIV-INFECTED 




Despite tremendous success in prevention of mother-to-child HIV transmission, new HIV 
infections continue to occur in infants.  Strong evidence indicates that combination antiretroviral 
therapy (ART) for treatment should be initiated in HIV-infected infants to prevent early 
morbidity and mortality.  In 2013, the report of the “Mississippi baby” who was started on ART 
within 30 hours of life and maintained off-treatment remission for 27 months before HIV virus 
was once again detectable generated renewed interest in very early ART initiation.  In addition, 
the Mississippi baby experience resulted in a critical shift in thinking, stimulating interest in the 
possibility of “HIV remission”, which we define as maintenance of plasma viremia below the 
threshold of detection in the absence of ART, following early ART.  In this review, we evaluate 






Despite tremendous success in prevention of mother-to-child HIV transmission (PMTCT), new 
HIV infections continue to occur in infants due to several factors, including the high prevalence 
and incidence of HIV in women of child-bearing age, incomplete implementation of PMTCT 
interventions, and the inability of antiretrovirals to block 100% of infections.  In 2015, more than 
150,000 children became infected with HIV (1). 
 
Strong evidence indicates that combination antiretroviral therapy (ART) should be initiated in 
HIV-infected infants early in the first year of life to reduce morbidity and mortality.  In 2008, 
there was a paradigm shift in treatment guidelines from initiating ART in children based on 
clinical and/or immunologic status (as in adults at the time) to starting ART in all children <1 
year of age as soon as diagnosed (2).  Support for this shift was largely due to results from the 
South African Children with HIV Early Antiretroviral Therapy (CHER) randomized trial, which 
showed a reduction in mortality by 76% among infants randomized to immediate ART compared 
to deferred ART (3, 4).  Data from observational studies provide further support for this 
recommendation (5-7).  This guideline was later extended to advise initiating ART irrespective 
of clinical and immunological status in all children <5 years in 2013, and to all children in 2016 
(8-10).  However, despite the recommendation to “treat all early,” the optimal timing of when to 
initiate treatment in infants has not been elucidated. 
 
In 2013, the report of the “Mississippi baby” generated renewed interest in the timing of ART 
initiation for infants.  This child was started on ART within 30 hours of life and maintained off-
treatment remission for 27 months (from 18-45 months of age) before HIV was once again 
detectable (11, 12). A pragmatic consideration necessary for early ART initiation is early 
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diagnosis.  Diagnosis in infants is reliant on virological testing, specifically HIV-1 DNA 
polymerase chain reaction (PCR) tests (10, 13, 14).  Enrollment into the CHER trial was largely 
reliant on routine diagnostic testing which was scheduled at that time around 4-6 weeks of age. 
Infants enrolled into the CHER trial were a median of 7.4 weeks (IQR 6.6–8.9) of age at 
enrollment.  Thus the findings from this trial cannot directly address the question of very early 
ART initiation.  For the purpose of this review, we define “very early” as within the neonatal 
period i.e. first 28 days of life.  In addition, the Mississippi baby experience resulted in a critical 
shift in thinking, stimulating interest in the possibility of “HIV remission.”  We utilize this term 
to refer to the possibility of maintaining plasma viremia below the threshold of detection in the 
absence of ART (15-17).  The aim of this review is to assess the current published data in 






For this review, six relevant questions were developed to help inform whether early ART may be 
able to lead to HIV remission in some infants.  We overlay these questions with the clinical 
trajectory of the Mississippi baby (Figure 2.1) (11, 12).  These questions include 1) How rapid is 
viral suppression in neonates who initiate very early ART? 2) Is the initial viral suppression rate 
different in infants who initiate ART early vs. late? 3) Is later virologic control on ART different 
in infants who initiate ART early vs. late? 4) Is the size of the viral reservoir different in infants 
who initiate ART early vs. late? 5) What are the outcomes of randomized trials of structured 
treatment interruption in children? 6) What is the likelihood of viral rebound after stopping ART 
in neonates who initiate ART very early?   
 
Search strategy and selection criteria 
A search of PubMed for relevant peer-reviewed publications from January 1, 1993 to November 
1, 2016 using the search terms (“HIV”) AND (“antiretroviral therapy” OR “ART”) AND 
(“infant” OR “neonate”) was conducted.  Recent HIV conference proceedings from 2013-2016 
(CROI, AIDS, IAS) were reviewed for additional relevant abstracts.  From this search, we 





Question 1: How rapid is viral suppression in neonates who initiate ART very early? 
 
Without treatment, evidence from studies in the era before use of effective antiretroviral 
regimens for PMTCT indicate that plasma HIV RNA levels can be high in the postnatal period 
and peak at a median of 100,000-1,000,000 copies/ml in the first 2-3 months of age (18-20).  
After this peak, without treatment, levels of viremia decrease relatively quickly to reach a viral 
set point, while others continue to decrease gradually for months of years (21, 22).  
Theoretically, initiation of ART prior to this viral peak may favorably influence the viral 
reservoir.  In addition, earlier initiation limits the period of pre-ART viremia for the infant.  Here 
we review the published evidence describing viral suppression by 6 months after starting ART in 
neonates.  
 
We identified eight publications and two conference abstracts reporting details on 13 neonates 
who were initiated on ART for treatment <28 days of life (Table 2.1) (11, 12, 23-30).  Bitnun et 
al. presented details on four neonates, but also mentioned eight additional HIV-infected neonates 
who started ART within 72 hours, one of whom was presented in the abstract by Samson et al. 
(23, 30); no specific details on the other seven neonates were provided.  In addition to Bitnun et 
al., based on information of ranges of age at ART initiation, it was inferred that 11 other studies 
reported on neonates initiating ART but no specific individual data on these infants was provided 
(Table 2.2) (3, 5, 6, 28, 31-37).   
 
Of the 13 neonates with details reported, 10 started ART within 48 hours of life (11, 23-25, 29, 
30).  The remaining three neonates started at 4, 23, and 29 days (26, 27).  All but one (N=12) 
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were initiated on nevirapine plus a nucleoside reverse transcriptase inhibitor (NRTI) backbone of 
zidovudine and lamivudine.  The other was initiated on lopinavir/ritonavir (26).  Early viral load 
measurements for the 13 neonates are plotted in Figure 2.3.  The overall pattern in viral load 
decline is biphasic: an initial rapid phase-one decline followed by a slower second-phase decline 
(35, 38).  Viral suppression to below detection was achieved in 12 of 13 neonates by 6.2 months 
of age (mean 2.7 months).  One neonate had low level viremia in the first year of life despite 
reports of excellent adherence, and eventually suppressed <20 copies/ml and target not detected 
(TND) at 18 and 20 months, respectively (25).  
 
Overall, these data appear to support the notion that initiation of ART in the neonatal period has 
outstanding success in terms of achieving viral suppression by 6 months of age.  However, the 
generalizability of this virologic suppression pattern is questionable.  The true denominator of 
HIV-infected neonates treated is unclear.  We suspect that the published viral load data represent 
a highly selective group of neonates.  For example, in the study by Bitnun et al., only data on the 
four infants who achieved virologic suppression were published (23).  Studies reporting on the 
viral load experience in larger and more representative cohorts of HIV-infected neonates, with 
clear descriptions of denominators, are urgently needed.  
 
Question 2: Is the initial viral suppression rate different in infants who initiate ART early 
vs. late? 
There are considerably more data on “early” initiation of ART if the focus is expanded beyond 
the neonatal period to throughout infancy.  Two trials conducted in South Africa randomized the 
timing of ART, allowing for a comparison of early vs. deferred initiation of ART (3, 4, 37).  The 
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first clinical trial (CHER) did not routinely monitor viral loads or report on rates of initial viral 
suppression in their randomization groups.  Reported rates of later viral suppression of the 
CHER cohort are further complicated by planned treatment interruptions in the early ART group 
(39).  In the second clinical trial by Prendergast et al., which randomized 63 infants to immediate 
or deferred initiation of a four drug regimen, 28/36 (78%) who started immediate ART (median 1 
month) and 11/13 (85%) with deferred ART (median 4.7 months) were suppressed <400 
copies/ml on their first-line regimen by 12 months after starting ART.  No suppression rates were 
reported for 6 months after starting ART. The study noted that time to viral load <50 copies/ml 
was not significantly different between the groups.  
 
Inclusive of the study by Prendergast et al. (37), we identified 22 studies presenting results on 
initial virologic response when ART was initiated in infancy (Table 2.3) (5, 6, 28, 31, 33, 34, 36, 
40-53).  For each study, data on the median age at ART initiation in months as well as the 
percentage of infants with initial viral suppression were extracted.  If not presented, the median 
age at ART initiation was estimated by taking the midpoint of the age interval during which ART 
was initiated; this was done for three studies (34, 47, 50).  The majority of the studies reported 
initial viral suppression at 6 months after starting ART, while two studies only reported the viral 
suppression rate at 4 months (28, 36), one study at 9.75 months (50), and two studies at 12 
months (37, 42).  Stratified data were extracted if the study specifically presented stratified 
results among those starting ART <12 months of age (e.g. by age group or treatment group).  
Overall, the reported percentage of children who achieved initial viral suppression varied greatly 
across studies, ranging from 19% to 81% (34, 52).  
 
 19 
Shown in Figure 2.4 is an ecological plot of median age at ART initiation in months by the 
percentage with initial viral suppression at 4, 6, or 12 months after starting ART by study.  On a 
group level, there is no clear association between median age at ART initiation and viral 
suppression rates.  If data were limited to those starting ART before 6 months, there is a slight 
trend in the expected direction but variability is great.  
 
A limited number of studies provided a direct comparison of initial viral suppression between 
infants started early and late, with no consistent findings (6, 34, 36, 40).  A European 
observational study reported a better response in children started early (<3 months) compared to 
children started 3-12 months of age (34).  Similarly, a multi-center Italian case-control study 
found better suppression among infants starting ART early (<6 months); however, their 
comparison group had a wider age range, including those who started ART between 6-52 months 
(6).  A randomized trial of infants initiating ART conducted in the United States (PACTG 356) 
that stratified their participants according to age–early (<3 months) and delayed (3-24 months)–
did not find different short-term viral suppression at week 16 or 48 between groups, but did find 
differences in suppression <400 copies/ml later at week 200 (36).  One study with an older 
comparison group found that infants (median 3.9 months) were less likely than children (median 
4.8 years) to suppress <250 copies following 6 months of ART (40). 
 
Taken together, data from the first two questions indicate that infants who initiate ART very 
early (in the neonatal period <28 days of life) can achieve viral suppression, but there is not 
strong evidence to show that initial viral suppression is higher in infants who start ART early (<6 
months) than among those who start later. 
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Question 3: Is later virologic control on ART different in infants who initiate ART early vs. 
late? 
Understanding long-term virologic control is important to determine how long an infant should 
be suppressed on ART before treatment could be interrupted to achieve HIV remission.  We 
identified four studies that compared later virologic control between infants initiating ART early 
versus later, finding reasonably consistent results of better long-term viral suppression on ART 
in infants who start treatment early (54-57).  A study of 20 South African infants who 
participated in the CHER study compared later virologic control between 12 infants who 
initiated ART early (<2 months) and eight infants who initiated ART late (2-9 months of age) 
(57).  At 7-8 years of age, 75% of early group had an undetectable plasma HIV RNA compared 
to 38% of the children who started late (p=0.17).  An updated report from Chiappini et al. (6) 
reported that 40 infants who started ART at a median age of 3.48 months had significantly lower 
median viral load until 6 years of age than 91 children who started ART at a median of 2.21 
years of age (54).  
 
Question 4: Is the size of the viral reservoir different in infants who initiate ART early vs. 
late? 
HIV establishes diverse and dynamic viral reservoirs where replication-competent forms of the 
virus persist and can replenish the pool of actively replicating virus in the human body.  HIV 
remission is a greater possibility if early treatment can reduce the viral reservoir. The ability to 
characterize the viral reservoir is important as both an alternative approach to studying virologic 
outcomes as well as a method to evaluate if HIV remission has been achieved.  However, it is 
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difficult to measure since latently infected cells are located throughout the body and at different 
concentrations; thus, the most appropriate measure of the viral reservoir is not clearly established 
(59).  Currently most studies in children measure the reservoir by 1) the quantitative viral 
outgrowth assay to measure the frequency of latently-infected CD4+ T-cells that release 
replication-competent virus after cellular stimulation (i.e. induced replication-competent 
provirus) or 2) real time PCR to measure total and integrated cell-associated HIV DNA in 
peripheral blood mononuclear cells (PBMCs) or CD4+ T-cells (60, 61).  
 
We identified 17 studies of the viral reservoir in children (11, 12, 23, 32, 46, 53, 56, 57, 62-70), 
including 5 studies that provided a comparison of the reservoir after treatment initiation in 
children who initiated treatment earlier compared to later (46, 56, 57, 65, 68). Three of these 
studies measured HIV DNA by PCR, one study measured the frequency of latently-infected 
CD4+ T-cells by viral outgrowth assay, and one used both methods. Data from the four studies 
ranging from 8 to 30 subjects that measured HIV DNA are presented in Figure 2.5. Three 
studies measured total HIV DNA in PBMCs, while one measured it in CD4+ T-cells. The 
reservoir was measured at different median lengths of time on ART, ranging from 12 to 200 
months. In all four studies, reservoir size was smaller among children who started treatment early 
compared to children who started treatment late. The median age at ART initiation in the 
children who started early was between 1.8-2.4 months of age, whereas the age range in the older 
groups was between 6-155 months.   
 
Evidence of a relatively smaller reservoir size in children starting ART early is also observed 
when using the viral outgrowth assay in two studies.  One study compared four children started 
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at 0.5-2.6 months of age to 4 children started 6-14.7 years (57) and the other study compared six 
infants started on ART <6 weeks of age to eight started between 6 weeks-6 months (46).  
Additional longitudinal findings from the latter study reported lower but not significantly 
different levels of HIV DNA by PCR at 6, 12, and 24 months in the early ART group (62).   
 
Additional data from children who started ART very early with no comparison of early vs. late, 
indicate the viral reservoir is low and sometimes not detectable.  In four neonates who initiated 
ART within 72 hours of life and achieved sustained virologic suppression, HIV-1 DNA was not 
detected in CD4+ T-cells of the four children at 2.5-7.5 years of age (23). HIV-1 DNA was 
detectable at low concentrations at a median of 6.3 years in a group of 15 children who started 
ART at a median of 17 weeks in Thailand (32). 
 
Overall, these data provide support for the concept that treatment at earlier ages may result in a 
smaller viral reservoir compared to treatment at later ages.  However, measurement issues make 
it difficult to interpret the actual size of the latent reservoir. PCR methods measure the total 
number of infected cells, but many of these “infected” cells are not clinically relevant (e.g. 
defective and non-replicating), leading to an overestimate in the number of latently infected 
cells.  Alternatively, the viral outgrowth assay may underestimate the number of cells with 
replication-competent virus, as it only measures induced proviruses rather than the entire intact 
reservoir.  Thus, it is unclear what reservoir characteristics are required, such as how much the 
reservoir needs to be reduced by or how small the reservoir needs to be, for HIV remission to be 
achieved. In addition, studies that compare the viral reservoir in those who start ART early vs. 
late have a wide range of older ages, making it difficult to make more precise comparisons (e.g. 
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2 vs. 3 months).  More data from across the spectrum of ages of early ART initiation are needed, 
as well as consideration of other factors that may determine the size and composition of the viral 
reservoir, such as maternal characteristics and host genetic factors.  Furthermore, these studies 
only study reservoirs in peripheral blood, but there are likely relevant reservoirs in other tissues, 
e.g. brain and lymph nodes, that should be considered. 
 
Question 5: What are the outcomes of randomized trials of structured treatment 
interruption in children? 
As HIV remission requires the ability to maintain viral control in the absence of ART, it is 
important to review studies of the likelihood of viral control off ART.  In children, treatment 
interruption studies were originally conducted as a potential strategy to reduce drug toxicities 
and the burden of taking daily medication, and were not designed with remission in mind.  
Despite this caveat, these studies still inform the question of whether children can maintain viral 
control off treatment.  
 
We identified three randomized studies of structured treatment interruption (STI) in children.  
The PENTA 11 trial studied STI versus continuous ART in 109 HIV-infected children and found 
no greater risk of adverse clinical outcomes, but 98% in the STI group had HIV RNA >400 
copies at 12 weeks compared with 2% in the continuous group (71).  The majority (86%) of 
children randomized to the STI group were returned to ART by trial end (72).  
 
Another trial in Kenya (OPH03) randomizing STI vs. continued ART also did not detect short-
term differences in morbidity or growth between groups, but had to be stopped early because in 
the STI arm 66% had to restart ART by 3 months after STI and 86% by 18 months (73).  Restart 
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criteria included CD4 percentage <20-25%, a decrease greater than 1/3 of the peak CD4 cell 
count or CD4 percentage, more advanced WHO stage, or weight loss.  Children in the STI arm 
had a trend for higher incidence of lymphadenopathy compared to the continued ART arm but 
there were no differences in serious adverse clinical events.  In both trials, initiation of ART was 
at a median of two and three years of age, respectively, well outside the time that would be 
considered early in the current context.  
 
More informative for the possibility of STI after very early initiation of ART is the CHER trial 
which compared early limited ART for 40 weeks or 96 weeks to deferred ART.  In CHER, 
infants were initiated on ART at 6-12 weeks of life, closer to the time of infection.  The study 
found that early limited ART was associated with better clinical and mortality outcomes after 5 
years compared to deferred ART.  However, this study did not include an early continuous arm 
as a comparison group and viral outcomes are yet to be published. Of note, up to 80% of children 
in the STI arms had to restart therapy by the end of follow-up.  Although there is some evidence 
indicating STI may be safe to consider under study conditions with close monitoring as a means 
to decrease drug exposure and the demands of daily medication, it is currently not a 
recommended treatment approach.  
 
 
Question 6: What is the likelihood of viral rebound after stopping ART in neonates who 
initiate ART very early? 
The only direct way to test whether viral control will be maintained off ART is to stop treatment.   
Five of the 13 neonates who initiated ART identified in Question 1 stopped ART (11, 12, 24, 26, 
27, 30). All five experienced viral rebound.  The time to viral rebound of the five children who 
 25 
stopped ART is presented in Figure 2.6.  There is a clear difference in time to viral rebound 
between the Mississippi baby who did not rebound until 27 months after stopping ART, and the 
other 4 children who rebounded within 15 days after ART cessation.  Table 2.4 shows 
characteristics of the neonates.  With one exception (4 days), there was no noticeable difference 
in the age at which ART was initiated in the Mississippi baby (30 hours) compared to the other 
infants (30 minutes, 12 hours, and 24 hours).  The infant started at 12 hours of life was 
suppressed initially on lamivudine and zidovudine before nevirapine was added at 21 days of 
life. Time to viral suppression was faster in the Mississippi baby (0.95 months) compared to 
three of the other infants (1.3, 5.8, and 6.0 months), but not the fourth (0.4 months). Maternal 
viral load from close to the time of birth was known for four infants.  Two were relatively low 
(156 and 2736 copies) and comparable to that of the Mississippi baby’s mother (2434 copies); 
the fourth mother had a “high” viral load.  To better understand differences in time to viral 
rebound between these neonates and others, various factors related to achieving HIV remission 
e.g. timing of in-utero infection, genetic differences, co-infections, immunological parameters, 
etc. urgently need to be investigated.  Of note, post-discontinuation of ART, clinical symptoms 
including decreased energy, development of angular cheilitis, new cervical adenopathy, and 
faltering weight were reported in one infant; these may be indicators of disease progression or 
syndrome consistent with acute infection (24).  No clinical symptoms were reported in the other 
four infants.  
 
Not included in the aforementioned five cases is the French teenager who initiated ART at 3 
months of age, beyond our criteria of the neonatal period (74).  This young adult is of interest, 
however, as she has maintained undetectable and low levels of plasma RNA for more than 12 
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years off treatment.  Given that clinical guidance discourages treatment interruption, other than 
the CHER trial and these anecdotal reports, there has been little opportunity to investigate viral 





Using currently published data in this review, we assessed six questions relevant to advancing 
the study of early ART and HIV remission.  Systematic review of the published literature yielded 
the following conclusions.  First, there are limited data describing viral response in neonates who 
initiated ART, and existing case reports likely represent a highly selective group of infants. Thus, 
the generalizability of published viral load patterns is questionable.  Second, there are very few 
studies of virological outcomes comparing infants who initiated ART early compared to late.  
Most studies were not designed to answer this question of treatment timing, and thus there is 
limited consideration of the conditions that select infants to be in one group or the other, limiting 
the inferences that can be made from these data.  Third, although early ART does appear to be 
associated with smaller reservoir size, the predictive value of this small viral reservoir for other 
outcomes is unknown, and the measures that are available have their limitations.  Finally, the 
numbers of children who have been taken off treatment and followed closely are few.  Thus, it is 
difficult to assess the possibility of HIV remission.  
 
Taken together, the evidence from this review suggests that although early ART does appear to 
be associated with better sustained virological control and smaller reservoir size, there are 
limited data at this time to support a strong link between early ART and HIV remission. 
Although a reasonably long period of remission was achieved in the case of the Mississippi baby, 
it may be attributable to other factors and not solely to very early treatment. In all other reported 
cases of very early treatment and subsequent interruption, viral rebound was reported to occur <2 
weeks after interruption.  The one exception is the French teenager who initiated ART at 3 
months and has had low level viremia off ART for >12 years (74).  It is clear that we need larger 
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cohorts of neonates initiating ART with systematic measures of virologic outcomes, including 
improved markers of the viral reservoir.  In addition, determining the feasibility of HIV 
remission will require studies to build in STIs to test if virologic control off ART is possible.  
This brings in ethical considerations of safety and long-term consequences.  Trials of brief 
treatment interruption in children do not report overt adverse clinical outcomes but data are 
limited. 
 
Very early treatment is reliant on drug options that are potent, not toxic, and supported by 
dosing, formulations, and safety data.  Currently, drug options for combination treatment of 
neonates are limited.  Neonates are unique from older infants and children because they have 
physiological differences and differences in metabolism that change rapidly in the first few 
weeks of life (75-79).  Premature neonates are even more complicated as are neonates with co-
morbidities.  There are only a handful of antiretroviral drugs that have formulations, dosing and 
safety data that allow for their use in neonates (Table 2.5).  Several of these drugs are considered 
suboptimal and no longer used in adults.  Neither formulations nor dosing are ideal; some drugs 
are using investigational doses (e.g. nevirapine) and others are not approved for neonates <1 
month (e.g. lopinavir/ritonavir, abacavir).  Special issues affect the ability of these drugs to be 
used broadly in neonates.  For example, in sub-Saharan Africa, many HIV-infected infants 
harbor resistance mutations to non-nucleoside reverse transcriptase inhibitors and NRTIs (80, 
81).  Lopinavir/ritonavir is a potent antiretroviral agent and available as a liquid formulation in 
the neonatal period, but due to toxicities associated with lopinavir and/or other components of 
the oral formulation, which contains alcohol and propylene glycol, it is not recommended for use 
in infants <2 weeks of age, as well as in premature infants until they reach 42 weeks of 
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gestational age.  Meanwhile, newer potent drugs such as the integrase inhibitors raltegravir and 
dolutegravir are under study but both have special issues.  At high concentrations, raltegravir 
may displace bilirubin from albumin and can increase the risk of bilirubin neurotoxicity in the 
neonate (82).  Dolutegravir, in addition to bilirubin displacement concerns, interacts with other 
medications including nevirapine, which is given to infants as part of perinatal prophylaxis 
regimens.  There is an urgent need for better drugs and formulations for use among HIV-infected 
neonates.  Data from several ongoing clinical trials investigating a three-drug combination ART 
regimen of zidovudine, lamivudine and nevirapine in neonates, including IMPAACT P1115 
(ClinicalTrials.gov identifier NCT02140255) (83), BHP-074 in Botswana (NCT02369406), and 
the Leopard Study in South Africa, (NCT02431975) will generate additional dosing and safety 
data.   
 
Finally, implementing very early treatment raises several programmatic and logistic challenges.   
Early ART cannot occur without early diagnosis, which remains a weak-point in the PMTCT 
cascade in many low-resource settings.  Birth PCR testing, even if blood samples can be 
collected in the first hours of life, relies on central laboratories with turn-around times measured 
in days or even weeks leading to inevitable attrition as mothers need to be recalled for results 
(84, 85).  The introduction of point-of-care tests for early infant diagnosis, particularly at birth, 
holds promise for reducing this attrition but still requires coordinated linkage to care (86-88).  
Furthermore, in order to initiate infants on ART early and continue them on treatment (with 
undetectable virus) long enough to attain HIV remission, infants and their mothers need to be 
engaged and retained in ongoing care.  This is challenging giving the nature of the affected 
population and existing health services.  With broadening roll-out of PMTCT programs, new 
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pediatric infections are increasingly concentrated among women who are diagnosed late in 
pregnancy or at delivery, have had less previous engagement with the healthcare system to 
access antenatal care and PMTCT services, and/or are non-adherent to treatment or disengaged 
from care.  There are also many structural challenges including inadequate transportation 
systems, health care services with limited hours of operation, as well as persistent HIV stigma 
within family communities and among health workers, that affect long-term engagement in care.  
 
HIV-infected children currently face a lifetime of treatment with ART, which has led to 
remarkable increases in survival but sustaining adherence to ART life-long is a formidable 
challenge.  The potential for long-term remission off ART after very early neonatal ART 
initiation is provocative and elicits hope.  Review of existing data suggests that this goal may 
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2.7. Figures and Tables 
 
Figure 2.1: Six questions developed to help inform whether early antiretroviral therapy 
(ART) may be able to lead to HIV remission in some infants, overlaid with the clinical 








Figure 2.2: Flow diagram of study selection procedure  
 
 
1PubMed search terms: (“HIV”) AND (“antiretroviral therapy” or “ART”) AND (“infant” or “neonate”) AND (“1993/01/01”[EDAT]: “2016/11/01”[EDAT])  















Figure 2.4: Ecological study plot of median age at antiretroviral therapy (ART) initiation (months) and percentage with viral 
suppression at 6 months after starting treatment. Note: size of bubble reflects size of study 
 
 
Notes: *Median age at ART initiation was estimated as the midpoint of the range; **Did not have 6 month suppression rate; ***Has 






Figure 2.5: Data from studies of infants and children that compares the size of the viral reservoir in children who start 
antiretroviral therapy (ART) early and late  
 







Figure 2.6: Time to HIV RNA viral rebound in days after treatment cessation in HIV-infected infants who initiated 
antiretroviral therapy (ART) in the neonatal period and later stopped ART (N=5).  Legend indicates the age at which the 









Table 2.1: Characteristics of neonates initiating combination antiretroviral therapy (ART) (N=13) 
 













Age at  
suppress 
Bitnun, 2014 (23) Canada 
1 
-30 yrs 
-Baseline VL: 97701 
-Baseline CD4: 190  
-C section 
-34 weeks 4 
days 
-BW 2980 g 
F None <24 hours 
NVP + 3TC + 
AZT 
None reported 6.2 mo 
2 
-32 yrs 
-Baseline VL: UK  
-Baseline CD4: 10 
-Vaginal   
-27 weeks  
-BW 1070 g 
F None <24 hours 
NVP + 3TC + 
AZT 
None reported 3.0 mo 
3 
-29 yrs 
-Baseline VL: 6326  
-Baseline CD4: 61  
-Vaginal   
-36 weeks  
-BW 2270 g 
F None <24 hours 
NVP + 3TC + 
AZT 
None reported 2.2 mo 
4 
-29 yrs 
-Baseline VL: 6326  
-Baseline CD4: 61  
-Vaginal  
-36 weeks  
-BW 1640 g 
M None <24 hours 
NVP + 3TC + 
AZT 
LPV/r + 3TC + 
AZT (day 25) 
3.6 mo 
Butler, 2015 (24) Ireland 1 
-31 yrs 
-Diagnosed 34 weeks  
-LPVr + 3TC + AZT  
10 days before delivery 
-Baseline VL: 2736 
-Baseline CD4: 960 
-C-section 
-36 weeks 6 
days 
-BW 2530 g 
F 
AZT and NVP  
at labor onset 
30 minutes 
NVP + 3TC + 
AZT 
LPV/r + 3TC + 
AZT (48 mo) 
1.3 mo 
Clarke, 2016 (25) Nigeria 
1 
-28 yrs 
-RAL + LPV/r + AZT + 
3TC 6 wk before delivery 
-Baseline VL: 379481 
-Baseline CD4: 57 
-Vaginal 
-38 weeks 5 
days  
F None 2 hours 
NVP + 3TC + 
AZT 
LPV/r + NVP + 







-Baseline VL: 41896 
-Baseline CD4: 360 
-C-section 
 
M None 2 hours 
NVP + 3TC + 
AZT 
LPV/r + NVP + 





(26) Italy 1 
-Diagnosed at delivery 




AZT and NVP 
at 12 hours 
4 days 
LPV/r + 3TC 
+ AZT 





(27, 28) Belgium 
1 -UK -Vaginal  UK 
AZT and 3TC 
by 12 hours 
29 days 
NVP + 3TC + 
AZT 
None 0.4 mo* 
2 -UK -Vaginal  UK 
AZT and 3TC  
by 12 hours 
23 days 
NVP + 3TC + 
AZT 
None 0.4 mo* 
Persaud, 2013;  
Luzuriaga, 
2015 
(11, 12) USA 1 
-No prenatal care 
-Baseline VL: 2423  
-Baseline CD4: 644  
-Vaginal 
-35 weeks 
F None 30 hours 
NVP + 3TC + 
AZT 
LPV/r + 3TC + 
AZT (day 7) 
0.95 mo 
Persaud, 2014 (29) USA 1 
-No prenatal care 
-Baseline VL: 138811 
-Baseline CD4: 70  
UK UK None 4 hours 
NVP + AZT + 
3TC 







(23, 30) Canada 1 
-Started ART during 
pregnancy 
-Baseline VL: 3000 in third 
trimester; 156 copies 2 
days prior to delivery 
-C-section 
-38 weeks 
M None <24 hours 
NVP + 3TC + 
AZT 
LPV/r + 3TC + 







Table 2.2: Additional studies with neonates initiating combination antiretroviral therapy (ART) and no specific individual 
data 
 
Author, Year Reference Country (Study) Total N Age at ART initiation 
Inferred N of unique neonates initiating ART 
that are not reported in Table (ages at ART 
initiation if known) 
Special notes 




Median: 2.5 mo 
Range: 0.9-4.7 mo 
≥1  
Ananworanich, 2014 (32) Thailand 15 
Median: 17 weeks 
Range: 0–25 weeks 
≥1  
Bitnun, 2014 (23) Canada 12 <72 hours 7 
* 5 of 12 with details are 
reported in Bitnun, 2014 (23) 
and Samson, 2014 (30) 
Chadwick, 2009 (33) USA 10 Range: 3.6-5.9 wks ≥1  
Chiappini, 2006 (6) Italy 30 Range: 0.8-5.8 mo 1 (0.84 mo)  
Faye, 2002 (5) France 31 
Median: 3.7 mo 
Range: 0.2-12 mo 
4 (0.2, 0.2, 0.5, 0.7 mo)  
Goetghebuer, 2012 (34) Europe 96 Range: 0-91 days ≥1 
*Overlap with 6 from Van der 
Linden, 2007 (28) and 2 from 
Hainaut, 2000 (27) 
Luzuriaga, 1999 (35) 
USA 
(PACTG 356) 
16 Range: 0.5-24 mo 1 (0.5 mo) 
Overlap with Luzuriaga, 2004 
(36) 




Median: 2.0 mo 
Range: 0.5-3.0 mo 
≥1 
*Overlap with Luzuriaga, 1999 
(35) 
Prendergast, 2008 (37) South Africa 40 
Median: 30 days 
Range: 8-167 days 
≥1  
Van der Linden, 2007 (28) Belgium 17 
All <2.2 mo 
Range: 7-77 days 
6 (7, 8, 10, 13, 15, 30 days) 
*2 additional are reported in 
Hainaut, 2000 (27) 
Violari, 2008 (3) South Africa 377 
Median 7.4 









Table 2.3: Studies of infants initiating combination antiretroviral therapy (ART) in the first 12 months of life and percentage 
with initial viral suppression 
 














Percentage with initial 
viral suppression 
(definition) 
Aboulker, 2004  (31) France, Europe  20 20 All <4.7 mo 2.5 




40% (<400 6 mo) 
20% (<50 6 mo) 
37% (<400 12 mo) 
21% (<50 12 mo) 
Asbjornsdottir, 2016 (40) Kenya 245 121 All <12 mo 3.9  
38% PI, 62% 
NNRTI 
Median: 6.6 
IQR: 6.1, 7.0 
32% (<250 6 mo) 
Chadwick, 2008 (41) 
USA, Brazil 
(P1030) 
21 21 All <6 mo 3.4 100% LPV/r 
Median: 5.8 
Range: 3.7-6.9 
48% (<400 6 mo) 
Chadwick, 2009  (33) USA (P1030) 10 10 All <1.5 mo 1.4 100% LPV/r 
Median 6.0 
Range: 4.7-7.2  
80% (<400 6 mo) 




Median: 5.84  
Range: 3.4-7.2 
43% (UD 6 mo) 
Faye, 2002 (5) France 31 31 All <12 mo 3.7 
10/31: RTV 
21/31: NFV 
Median: 5.8 53% (<500 6 mo) 
Goetghebuer, 2012 (34) 
France, UK, 
Ireland, Italy  
139 
96 All <3 mo 1.5* UK 
Median: 5.0 
IQR: 3.9-5.8 
63% (<500 6 mo) 
54% (<500 12 mo) 
43 3-12 mo  7.5* UK 
Median:  
5.2 (3-6 mo) 
5.0 (6-12 mo) 
19% (<500 6 mo) 
42% (<500 12 mo) 
Judd, 2011 (42) 
United Kingdom, 
Italy, France, Other 
(EPICC) 





62% (<400 12 mo)** 
Kay, 2012 (43) Uganda  34 34 All <19.9 mo*** 8.6 100% NVP 
Median: 5.8  
Range: 3.5-7.0  
45% (<400 6 mo) 
58% (<400 12 mo) 
Lockman, 2007  (44) Botswana 15 15 All <12 mo 8.5 100% NVP Median: 5.9 
50% (<400 6 mo) 
42% (<400 12 mo) 
Luzuriaga, 2004 (36) 
USA and Puerto 
Rico (PACTG 356) 
52 
25 All <3 mo  2.0 
16/26: NVP 
9/25: NVP + 
NFV  
Median: 5.3  
Range: 3.3-6.4  
64% (<1000 4 mo)** 
60% (<400 12 mo) 
27 3-24 mo 7.6 
18/27: NVP 




59% (<1000 4 mo)** 
41% (<400 12 mo) 





63  All <12 mo 7.2 100% LPV/r 
Median: 5.9 
10-90%: 5.2-5.9 
77% (<400 6 mo) 
82 (NVP) 60  All <12 mo 7.2 100% NVP 
Median: 5.9 
10-90%: 5.1-5.9 
55% (<400 6 mo)  
Persaud, 2012 (46) 
USA (P1030)  
Overlap with 
Chadwick (33, 41) 
24/31 17 All <6 mo 2.0 100% LPV/r 
Median: 6.1 
IQR: 5.7-6.5 




















Percentage with initial 
viral suppression 
(definition) 
Pillay, 2015 (47) South Africa 749 492 All <12 mo 6.0* UK Median: 6.0 64.2 (<400 6 mo) 










Median: 5.99  
IQR: 5.41-6.45 
28% (<400 6 mo) 
56% (<400 12 mo) 
Prendergast, 2008 (37) South Africa 63 
49 started 
ART 
All <13 mo*** 1.4 
46/49: NVP + 
NFV (4 drug) 
3/49: NFV 
Median: 5.97 80% (<400 12 mo)** 
Purchase, 2012 (49) South Africa 129 129 All <12 mo 8.6 
38% NNRTI 
61% PI 
Median: 6.2  
Range: 1.4-7.9  
52% (<50 6 mo) 
75% (<400 6 mo) 
57% (<50 12 mo) 
78% (<400 12 mo) 
Reitz, 2010 (50) 
South Africa  
(Neverest 2) 
254 79 All <6 mo 3.0* UK UK 66% (<400 9.75 mo)** 
254 96 6-12 mo 9.0* UK UK 70% (<400 9.75 mo)** 







72% (<400 6 mo) 
Van der Linden, 2007 (28) Belgium  17 17 All <2.2 mo 1.1 
15/17 NVP 
2/17 ddI, 3TC, 
ZDV 
UK 65% (<400 4 mo)** 





36 All <12 mo 8.4 100% LPV/r 
Median: 5.9  
10-90%: 4.8-5.9 
81% (<400 6 mo) 
147 
(NVP) 
41 All <12 mo 8.4 100% NVP 
Median: 5.9  
10-90%: 5.0-5.9 
59 % (<400 6 mo) 





67% (<400 6 mo) 
 







Table 2.4: Characteristics of the HIV-infected infants who initiated antiretroviral therapy (ART) in the neonatal period and 
later stopped ART (N=5) 
 
Study Butler, 2015 Giacomet, 2014 Hainaut, 2000 
Persaud, 2013;  
Luzuriaga, 2015 
Samson, 2014  
Neonate # 1 1 2 1 1 
Reference (24) (26) (27) (11, 12) (30) 
Maternal HIV RNA 
(copies) 
2736 “high”  UK 2423  
3000 (3rd trimester) 
156 (2 days before delivery)   
Age at ART initiation 30 minutes 4 days 12 hours / 21 days 30 hours 24 hours 
Initial ART regimen NVP + 3TC + AZT LPV/r + 3TC + AZT 
3TC + AZT / NVP + 3TC + 
AZT 
NVP + 3TC + AZT NVP + 3TC + AZT 
Pre-ART HIV RNA 
(copies) (log) 
653 (2.81) 152560 (5.18) 230456 (5.36) 19812 (4.30) 808 (2.91) 
Age suppressed 1.3 mo 6.0 mo 0.40 mo 0.95 mo 5.8 mo 
Time to suppress 1.3 mo ~6.0 mo 0.40 mo 0.95 mo 5.8 mo 
Age ART stopped 49 mo 36 mo 9 mo 18 mo 39 mo 
Time to viral rebound 
8 days 
14 days 
15 days 7 days 27 mo 14 days 




36840 (4.57) 50000 (4.70) 16750 (4.22) 7797 (3.89) 
Clinical symptoms after 
ART discontinuation 
Decreased energy (36 days), 
development of angular 
cheilitis (57 days), new 
cervical adenopathy (57 days), 
faltering weight 









Table 2.5: Antiretroviral drugs, formulations, dosing, and special issues for neonates 
 
Antiretroviral drug Relevant formulation Relevant dosing Special issues 
Nevirapine (NVP) Suspension: 10 mg/mL 
 Investigational dose (not FDA approved) 
 34-37 weeks: 4 mg/kg twice daily for the first week increasing 
to 6 mg/kg twice daily after 
 ≥37 weeks: 6 mg/kg twice daily 
Drug resistance 
 




Pediatric Oral Solution: 
80 mg/20 mg LPV/r per 
mL  
 
Pediatric Oral Pellet: 
40mg/10 mg LPV/r  
 (Solution) Not approved for neonates age <14 days or <42 
weeks corrected gestational age 
 (Solution) Age 14 days-12 months: 300 mg/75 mg per m2 of 
body surface area twice daily 
 (Pellet) Not approved for neonates (studies ongoing) 
Toxicity: cardiac toxicity, 
neuromuscular toxicity, respiratory 
complications, renal failure 
Lamivudine (3TC) 
Pediatric Oral Solution: 
10 mg/mL 
 Age <4 weeks: 2 mg/kg twice daily Drug resistance  
Stavudine (D4T) 
Oral Solution: 1 mg/mL 
 
Capsules: 15 mg, 20 
mg, 30 mg, and 40 mg 
 Birth to age 13 days: 0.5 mg/kg per dose twice daily 
 Age ≥14 days and weight <30 kg: 1 mg/kg per dose twice daily 
Toxicity: toxicities with long-term use, 
no longer approved for use in children 
and adults; increasingly unavailable 
Zidovudine (AZT) Syrup: 10 mg/mL 
 ≥35 weeks: 4 mg/kg orally twice daily (birth to age 4 weeks) 
 ≥30 to <35 weeks: 2 mg/kg orally twice daily (birth to age 2 
weeks); 3 mg/kg orally twice daily (age 2 weeks to 6-8 weeks) 
 <30 weeks: 2 mg/kg orally twice daily (birth to age 4 weeks) 
Toxicity: hematologic toxicity, bone 
marrow suppression 
Abacavir (ABC) 
Pediatric Oral Solution: 
20 mg/mL 
 Not approved for neonates (or infants <3 months) 
Toxicity: life-threatening 
hypersensitivity reaction for HLA-
B*5701; screening recommended in 
the US 
Dolutegravir (DTG) 
Dispersible Tablets (in 
development): 
10 mg and 25 mg tablets 
 Not approved for neonates/infants (studies ongoing) 
Toxicity: Displacement of bilirubin; 
interactions with NNRTIs 
Raltegravir (RAL) 
Granules for Oral 
Suspension: Single-use 
packet of 100 mg 




CHAPTER 3: EARLY AGE AT START OF ANTIRETROVIRAL 
THERAPY ASSOCIATED WITH BETTER VIROLOGIC CONTROL 
AFTER INITIAL SUPPRESSION IN HIV-INFECTED INFANTS 
 
 
Chapter 3 has been published as:  
Shiau S, Strehlau R, Technau KG, Patel F, Arpadi SM, Coovadia A, Abrams EJ, Kuhn L. Early 
age at start of antiretroviral therapy associated with better virologic control after initial 






Background: The report of the “Mississippi baby” who was initiated on antiretroviral therapy 
(ART) within 30 hours of birth and maintained viral suppression off ART for 27 months has 
increased interest in the timing of ART initiation early in life.  We examined associations 
between age at ART initiation and virologic outcomes in five cohorts of HIV-infected infants 
and young children who initiated ART before 2 years of age in Johannesburg, South Africa.   
Methods: We compared those who initiated ART early (<6 months of age) and those who 
started ART late (6-24 months of age).  Two primary outcomes were examined: (1) initial 
response to ART in three cohorts and (2) later sustained virologic control after achieving 
suppression on ART in two cohorts.   
Results: We did not observe consistent differences in initial viral suppression rates by age at 
ART initiation.  Overall, initial viral suppression rates were low. Only 31, 40.1, and 26.5% of 
early-treated infants (<6 months of age) in the three cohorts, respectively, were suppressed <50 




control after achieving suppression on ART among infants starting ART early compared to late.  
Children who started ART early were less likely to experience viral rebound (>50 copies/mL or 
>1000 copies/mL) than children who started late in both cohorts.   









Evidence from the Children with HIV Early Antiretroviral Therapy (CHER) randomized clinical 
trial in South Africa and other observational studies indicates that initiation of antiretroviral 
therapy (ART) early in life reduces morbidity and mortality in HIV-infected infants (1-5).  These 
findings have informed treatment guidelines which now advise initiation of ART irrespective of 
clinical and immunological status in all HIV-infected infants and children (6-8).  The report of 
the “Mississippi baby” who was initiated on antiretroviral therapy (ART) within 30 hours of 
birth and who maintained viral suppression off therapy for 27 months (9) has further stimulated 
interest in the possible benefits of initiating ART soon after birth. 
 
Data on the effects of the timing of early ART initiation on virologic outcomes, including initial 
virologic response and sustained virologic control after suppression are limited.  Some studies 
have reported better initial virologic response in children started on ART <3-6 months of age 
compared to children started after 6 months of age (4, 10) while others have reported no 
differences in short-term suppression rates (11, 12).  Reports of infants started on ART in the 
first months of life with no comparator group of children started at older ages have shown varied 
rates of initial suppression (13-16).  Few studies have compared later virologic control, i.e. 
maintenance of suppression without rebound after achieving initial suppression, between 
children initiating ART at earlier versus later ages.  One study of children who initiated ART 
younger or older than one year of age and who achieved virologic suppression found no 
association between age at ART start and rebound of HIV-RNA >400 copies/mL at later ages 





With increasing attention to the possible benefits of ART initiation in newborns, it is important 
to investigate the effects of the timing of ART initiation on virologic response in larger cohorts 
in sub-Saharan Africa where the vast majority of new pediatric infections occur (18).  Here, 
using data from five study cohorts of HIV-infected children initiating ART before 2 years of age 
in Johannesburg, South Africa, we examine the association between age at starting ART and (1) 










Five cohorts of HIV-infected infants and young children in Johannesburg, South Africa were 
included in this analysis (Table 3.1).  Three cohorts of children initiating ART (Cohorts A, B, 
and C.1) were suitable to examine the association between age at ART initiation and initial 
response to treatment.  Two cohorts of children who had achieved virologic suppression after 
ART initiation (Cohorts C.2 and D) were suitable to assess the association between age at ART 
initiation and later virologic control. 
 
Cohort A included newly-diagnosed, treatment-naïve HIV-infected infants and young children 
identified at hospital admissions, prevention of mother-to-child transmission (PMTCT) follow-
up visits, and immunization services as part of an active surveillance study intended to improve 
engagement in care and ART initiation at three hospitals and two affiliated clinics conducted 
between January and December 2011 (19-21).  We restricted the analysis to 219 children known 
to have been initiated on ART before 2 years of age.  At enrollment into the surveillance study 
(pre-treatment), blood samples were collected from each child for plasma HIV-RNA tests 
(Roche Taqman HIV Test v2.0) and CD4 percentage.  Sociodemographic and clinical 
information was also collected.  Subsequent information on survival, HIV-RNA, and CD4 
percentage, as close as possible to 6 months post-ART initiation, was abstracted from medical 
records. 
 
Cohort B included 718 newly-diagnosed, treatment-naïve infants and young children who 




Research Unit at Rahima Moosa Mother and Child Hospital (RMMCH) between January 2004 
and July 2012 and who had at least one follow up visit after ART initiation or died after ART 
initiation.  At this time ritonavir-boosted lopinavir (LPV/r)-based was given to children in this 
age group and viral load testing was recommended every 6 months after ART initiation (22).  
Demographic information, age at ART initiation, HIV-RNA, and CD4 percentage were extracted 
from a routine database maintained by the site for clinical care purposes. 
 
Cohort C.1 consisted of 323 newly-diagnosed, treatment-naïve infants and young children 
enrolled into the pre-randomization phase of an ART strategies trial that took place at RMMCH 
from April 2005 to June 2010 (23).  All children had been exposed to nevirapine used for 
PMTCT given to the mother, to the child, or both and were initiated on LPV/r-based ART before 
2 years of age.  Blood samples for plasma HIV-RNA quantification (Roche version 1.5 Amplicor 
assay, Roche, Branchburg, NJ) and CD4 percentages were measured before treatment began and 
at 4, 12, 24, 36, and 52 weeks after treatment initiation as part of the pre-randomization phase. 
 
Cohort C.2 includes all 195 of the children from Cohort C.1 who met criteria for randomization 
(HIV-RNA <400 copies/mL for at least 3 months within the first 12 months of treatment) and 
were assigned to remain on LPV/r (N=99) or switch to nevirapine (N=96) (ClinicalTrials.gov: 
NCT00117728) (24, 25).  Children undergoing randomization after viral suppression had been 
achieved (a median of 9 months after ART initiation) had additional blood samples collected at 





Cohort D included children 3-5 years of age with a history of nevirapine exposure for PMTCT 
who were suppressed on LPV/r (HIV-RNA <50 copies/mL at the time of enrollment into the 
study) and randomized to either remain on LPV/r or switch to efavirenz as part of an ART 
strategies trial that took place at RMMCH from June 2010 to December 2013 
(ClinicalTrials.gov: NCT01146873) (26).  This analysis was limited to 293 children who 
initiated ART before 2 years of age, including 145 children randomized to remain on LPV/r and 
148 randomized to switch to efavirenz.  Plasma HIV-RNA (AmpliPrep/COBAS® TaqMan® 
HIV Test, version 2.0, Roche, Branchburg, NJ) measurements were obtained at randomization 
and scheduled post-randomization visits (4, 8, 16, 24, and 48 weeks). CD4 percentage was 
measured at study entry and 24 and 48 weeks post-randomization.  
 
Studies were approved by the Institutional Review Boards of Columbia University (New York, 
New York) and the University of the Witwatersrand (Johannesburg, South Africa). Signed 
informed consent for all procedures and data was provided by each child’s guardian for Cohorts 
A, C.1, C.2, and D and for data sharing for Cohort B. 
 
Statistical analysis 
To examine effects of the timing of ART initiation, we compared children who initiated ART <6 
months of age to those who started ART 6-24 months of age.  The <6 months age category was 
refined further in some analyses.  Two primary virologic outcomes were examined: (1) initial 





Initial response to ART was examined in Cohorts A, B, and C.1.  HIV-RNA (categorized as <50, 
50-1000, ≥1000 copies/mL) measured around 6 months post-ART initiation was compared 
between age at ART initiation groups.  We defined the window for “6 months” to be between 3 
and 12 months.  If more than one result was available, the result nearest to 6 months was chosen.  
Secondary outcomes for Cohorts A, B, and C.1 included CD4 percentage as a continuous and as 
a categorical variable (<10, 10-15, and ≥15) at 6 months post-ART initiation.  Vital status by 6 
months post-ART initiation was also determined.   
 
Later virologic control after suppression on ART was assessed in Cohorts C.2 and D.  The 
proportion of children in three HIV-RNA categories (<50, 50-1000, ≥1000 copies/mL) at 
scheduled visits post-randomization was compared between age at ART initiation groups.  A 
generalized estimating equation (GEE) model with an unstructured correlation structure was 
used to examine the overall effect of age at ART initiation on HIV-RNA outcomes at repeated 
visits.  Other correlation structures produced similar results.  We adjusted for treatment 
randomization group (LPV/r vs. nevirapine in Cohort C.2; LPV/r vs. efavirenz in Cohort D). 
 
Additionally, we compared area under the plasma viral load curve (AUVLC), a measure of 
“cumulative viral load,” between age at ART initiation groups.  The AUVLC in log10 copy-
weeks/mL at scheduled visits in the two cohorts was calculated using the trapezoidal rule, 
whereby larger areas indicate higher cumulative viremia (27).  The data were normalized so that 
a child with an AUCVL of 0 was considered fully suppressed and a child with a detectable 





Statistical comparisons were conducted using chi-squared or Fisher’s exact tests for categorical 
variables, ANOVA and t-tests for normally-distributed continuous variables, and Kruskal-Wallis 
tests for non-normally distributed continuous variables.  All p-values are 2-tailed and p-values 
<0.05 were considered statistically significant.  Analyses were performed using SAS version 9.4 









Characteristics of the children included in this study are shown in Table 3.2 stratified by cohort.  
Cohort A included infants who were actively identified to improve engagement in care and ART 
initiation and Cohort B included infants accessing routine clinical services.  Cohorts C.1, C.2, 
and D were comprised of infants enrolled in clinical trials.  Sex distribution and pretreatment 
characteristics, including HIV-RNA, CD4 count and percentage, and WAZ were similar across 
the cohorts.  Mean age at ART initiation ranged from 8.7 months in Cohort A to 10.5 months in 
Cohort B.  A higher proportion of children in Cohort A (47.5%) and Cohort D (46.4%) initiated 
ART early (i.e. <6 months of age) than Cohort B (35.1%), Cohort C.1 (31.6%), and Cohort C.2 
(27.7%).   
 
Initial response to treatment 
Pre-treatment, a higher proportion of children starting ART early (<6 months) had higher HIV-
RNA levels (≥750,000 copies/mL) than children starting ART late (6-24 months of age) in all 
three cohorts (Table 3).  Pre-treatment CD4 percentage was consistently higher in the early 
initiators and the proportion of children underweight (WAZ <-2) was lower in children starting 
ART early compared to late in Cohort A only (Table 3.3). 
 
Post-treatment, it was only in Cohort A that children who initiated ART early were more likely 
to be suppressed (<50 copies/mL) at 6 months than children who initiated ART late.  This was 
not observed in Cohorts B and C.1 (Table 3.3).  In a finer stratification of age at ART initiation 




were 35.5, 25.9, and 9.8% in in those who started ART <3 months, 3-6 months, and 6-24 
months, respectively.  This trend was not seen in Cohorts B and C.1.  Adjustment for pre-
treatment viral load or other pre-treatment characteristics including sex, CD4 percentage, and 
WAZ did not change these results (data not shown).  When the three cohorts were combined, 
there was no difference in suppression to <50 copies by 6 months for children who initiated ART 
early (<6 months) vs. late (6-24 months), even after adjustment for pretreatment HIV-RNA and 
CD4 percentage (OR=0.99, 95% CI: 0.71, 1.39).   
 
In Cohorts A, B, and C.1 the mean CD4 percentage at 6 months post-ART initiation was higher 
in children who initiated ART early (Table 3.3) but after adjustment for pretreatment CD4 
percentage in all three cohorts, the difference was no longer statistically significant (p=0.087, 
0.403, 0.201).  There was a trend towards lower mortality among children treated <6 months vs 
treated 6-24 months in Cohort A (p=0.076) (Table 3.3).  In a further stratification of age at ART 
initiation categories into <3 months, 3-6 months, and 6-24 months, the proportions of children 
who died by 6 months post-ART initiation were 4.6, 16.4, and 20.2% respectively in Cohort A 
(p=0.006).  No differences between age at ART initiation groups in the proportion of deaths was 
observed in Cohorts B and C.1. 
 
We combined the data from the three cohorts to investigate effects of the timing of ART 
initiation in monthly increments in the first 6 months of life.  No clear trends in the proportion of 
children suppressed by 6 months post-ART initiation were observed by age at ART initiation in 
months.  The percentage of children suppressed <50 copies/mL ranged from 25% to 49.3% 





Later virologic control 
Age at ART start influenced later virologic control after viral suppression in both Cohorts C.2 
and D.  Of 195 children in Cohort C.2, children <6 months at ART start were less likely to have 
a plasma HIV-RNA 50-1000 copies/mL and plasma HIV-RNA >1000 copies at all scheduled 
post-randomization visits than children 6-24 months at ART start (Figure 3.1).  In a GEE model 
accounting for repeated visits, the odds of having an HIV-RNA 50-1000 vs. <50 copies/mL was 
lower in children who initiated ART early compared to children who initiated ART late, adjusted 
for randomization group (OR=0.34, 95% CI: 0.19, 0.61).  A similar trend was seen in the GEE 
model for having an HIV-RNA >1000 vs. <1000 copies/mL (OR=0.29, 95% CI: 0.08, 1.11). 
 
Of 293 children in Cohort D, children <6 months at ART start were less likely to have a plasma 
HIV-RNA 50-1000 copies/mL at all but one scheduled post-randomization visit than children 6-
24 months at ART start.  There were no consistent differences in the proportion of children with 
HIV-RNA >1000 copies/mL by age at starting ART but HIV-RNA >1000 copies/ml was rare in 
both groups (Figure 3.1).  In a GEE model, the odds of having an HIV-RNA 50-1000 copies/mL 
vs. <50 copies/mL for children who initiated ART early was 0.46 times that of children who 
initiated ART late, adjusted for randomization group (OR=0.46, 95% CI: 0.24, 0.87).  
 
In Cohort C.2, a smaller proportion of the children who started treatment early had a detectable 
AUVLC compared to children who started treatment late (30.0 vs. 50.7%, p=0.012) across all 
scheduled trial visits.  Among those with a detectable AUVLC, children starting treatment early 




p=0.03).  Similarly, in Cohort D, a smaller proportion of the children who started treatment early 
had a detectable AUVLC compared to children who started treatment late (19.1 vs. 31.9%, 
p=0.013) across all scheduled trial visits.  Among those with a detectable AUVLC, there was no 









We did not observe a consistent benefit of early ART initiation on rates of initial viral 
suppression in the first 6 months of treatment in three non-overlapping cohorts from 
Johannesburg, South Africa.  In one of the three cohorts we observed better virological 
suppression by 6 months in children who initiated ART compared to those who initiated 6-24 
months but no differences were observed in the other two.  Pre-treatment viral loads and CD4 
percentages in all three cohorts were higher in children younger at ART initiation, consistent 
with the natural history of HIV infection in infancy (28-31).  However, even after accounting for 
these differences, in a combined analysis of the three cohorts, there were no significant 
differences in initial viral suppression between children starting treatment early and late.  The 
higher pre-treatment viral loads suggest that the rate of decline was more rapid in the early-
treated groups but truncation in the upper range of the assays in use at the time limited our 
capacity to measure this directly.   
 
While the better virologic response in children initiating ART early observed in Cohort A is 
encouraging, the lack of confirmation in the other two cohorts leads us to suspect that other 
factors may be involved.  Cohort A was a surveillance study which was intended to actively 
identify mothers and infants not already engaged in care.  These children were predominantly 
identified through hospital admissions and, in particular, more children starting ART early (<6 
months) were identified through routine PMTCT services.  Hence these children may have had 
less advanced disease and benefit most from early treatment than children in the other cohorts 
starting treatment early.  There was some evidence to suggest this speculation may be valid, as 




better in children starting treatment early in Cohort A compared to the other two cohorts.  Better 
surveillance systems in place to identify HIV-infected infants in order to initiate ART at an early 
age may improve initial outcomes.  A prior study has also reported higher rates of viral 
suppression <500 copies/mL by 6 months in those starting ART ≤3 months of age compared to 
those starting treatment 3-12 months of age (63 vs. 19%, p<0.001) (10).  Another study reported 
more early treated infants (<6 months of age) reaching undetectable viral load than later treated 
infants (6-52 months of age) over a median follow up time of 4.1 years (73.3 vs. 30.1%, 
p<0.0001) (4).  Two other studies reported no differences in initial virologic suppression at 6 
months between children starting early and late (11, 12).  
 
Of note, overall rates of initial viral suppression at 6 months were low.  Only 31, 40.1, and 
26.5% of early-treated infants in Cohorts A, B, and C.1, respectively, were suppressed <50 
copies/mL at 6 months after starting ART.  The large proportion of infants at risk for viral failure 
is concerning, particularly since options for second-line regimens are limited for children. 
  
In children who had initially achieved suppression, we observed a consistent benefit of early 
ART initiation on rates of sustained viral suppression in the two cohorts we examined. 
Compared to children who started treatment later in infancy and early childhood (6-24 months of 
age), children who started treatment early (<6 months) were less likely to experience viral 
rebound and had a lower cumulative viral load in follow up than children who started treatment 
later.  This benefit was observed in both cohorts and across the different treatment regimens 
(nevirapine, efavirenz and LPV/r) that were evaluated in these two trials.  Although age at ART 




associated with rebound of HIV-RNA >400 copies/mL in one study (17), other studies have 
reported better long-term virologic control in infants starting ART at an early age. In a group of 
20 children from the CHER trial maintained on suppressive ART for 7-8 years, 9/12 (75%) of 
children starting ART before 2 months of age had undetectable plasma HIV-RNA compared to 
3/8 (37.5%) of infants who started after 2 months of age (p=0.17) (32).  A study of HIV-infected 
children maintained on ART for up to 18 years and virally suppressed on conventional assays 
found plasma viremia by ultrasensitive assays to be below the limit of detection (<2 copies/mL) 
in all four children who initiated ART early (before 3 months of age) but detectable (median 8 
copies/mL) in all four children who did not initiate ART until later childhood (6-15 years) (33).   
 
HIV infection requires life-long ART because of its persistence in latent viral reservoirs located 
in long-lived resting memory CD4+ T cells and other anatomic sanctuaries that harbor dormant 
replication-competent proviruses (34, 35).  ART targets replicating virus and has not been shown 
to eradicate these replication-competent HIV reservoirs.  The establishment of the latent viral 
reservoir occurs early during primary infection (36), and evidence in adults supports that early 
initiation of ART close to the time of HIV acquisition may limit HIV reservoir size (37-39) and 
lead to HIV remission in certain adults, termed post-treatment controllers (40, 41). In infants, 
several reports have indicated that early ART initiation limits the size of the viral reservoir (13, 
32, 42, 43).  A study of 17 HIV-infected infants starting treatment in the first 6 months of life 
found a significantly smaller viral reservoir in infants treated before 6 weeks of age compared to 
children initiating ART between 6 weeks and 6 months of age (13).  Although eradication of 
HIV with early ART has not yet been shown to be feasible, treatment early in life with sustained 




rebound, as demonstrated in this study, and increasing the possibility for sustained suppression 
with potent ART.  
 
Our study had limitations.  Our analysis used a 6 month cut off for early ART initiation, but even 
earlier age intervals are important to investigate.  In all of our cohorts, there were only small 
numbers of children initiating ART before 6 weeks of age, too few for a subgroup analysis.  In 
addition, although we combined data from three cohorts in our evaluation of initial response to 
treatment, we were unable to account for differences in viral load assays as well as changes in 
drug regimens, dosing, and clinical practice taking place in the time period during which children 
were enrolled. 
 
In conclusion, our study demonstrates improved virologic control after initial viral suppression in 
children starting ART before 6 months of age compared to those starting at 6-24 months in two 
large cohorts.  We did not find consistent benefits of early treatment on initial viral suppression.  
Our results suggest that there are virological benefits of early treatment in addition to those 
shown for reduction of mortality and morbidity (1, 2), growth (44), and neurological outcomes 
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3.7. Figures and Tables 
 
Figure 3.1: Percentage of children with plasma HIV-RNA 50-1000 copies/mL (cpm) and 
VL ≥1000 cpm at scheduled trial visits in Cohort C.2 and Cohort D by age at antiretroviral 













Figure 3.2: Percentage not suppressed (a,c) and median area under the viral load curve (AUVLC) (b,d) at intervals between 
scheduled trial visits in Cohort C.2 and Cohort D, respectively, by age at antiretroviral therapy (ART) initiation (<6 months 
vs. 6-24 months) 
 
Cohort C.2:  
a)                                                                                    b) 
   
 
Cohort D: 
c)                                                                                                        d) 







Table 3.1: Description of five cohorts of HIV-infected infants and young children initiating antiretroviral therapy (ART) 





N Years Brief description Purpose – to examine: 
Cohort A (19-21) 219 2011 
Newly-diagnosed, treatment-naïve infants and young children identified 
as part of a surveillance study 
Initial viral response 
Cohort B NA 718 2004-2012 
Newly-diagnosed, treatment-naïve infants and young children initiating 
ART at a routine HIV clinic 
Initial viral response 
Cohort C.1 (23) 323 2005-2010 
Newly-diagnosed, treatment-naïve infants enrolled into pre-
randomization phase of ART strategies trial and initiated on LPV/r-based 
ART (ClinicalTrials.gov: NCT00117728) 
Initial viral response 
Cohort C.2 (24, 25) 195 2005-2010 
Children from Cohort C.1 who met criteria for randomization (plasma 
HIV-RNA <400 copies/mL for at least 3 months within the first 12 
months of treatment) and were assigned to remain on LPV/r or switch to 
nevirapine as part of an ART strategies trial (ClinicalTrials.gov: 
NCT00117728) 
Later virologic control 
Cohort D (26) 293 2010-2013 
Children 3-5 years of age who were suppressed on LPV/r (plasma HIV-
RNA <50 copies/mL at the time of enrollment into the study) and 
randomized to remain on LPV/r or switch to efavirenz as part of an ART 
strategies trial (ClinicalTrials.gov: NCT01146873) 








Table 3.2: Characteristics of five cohorts of HIV-infected infants and young children initiating antiretroviral therapy (ART) 
before 24 months of age 
 
Characteristic Cohort A Cohort B Cohort C.1 Cohort C.2 Cohort D 
N 219 718 323 195 293 
Sex, N (%) 
   Male 
















PMTCT exposure, % 69.0% Unknown 100% 100% 100% 
Age at ART initiation (months), Mean ± SD 
   <6 months 
   6-12 months 
   12-24 months 




















Pretreatment HIV-RNA quantity (copies/mL), N (%) 
   <100000 
   100000-750000 
   ≥750000 


























Pretreatment CD4 count (cells/mm3), Mean ± SD 1260 ± 1193 985 ± 802 1006 ± 754 1063 ± 704 1213 ± 793 
Pretreatment CD4 percentage, N (%) 
   <10 
   10-15 
   ≥15 
   Missing 






























21.7 ± 10.6  
Pretreatment weight-for-age z-score (WAZ), Mean ± SD 
   WAZ <-2, N (%)  
   N Missing 
-2.20 ± 1.9 
118 (55.4) 
6 
-2.53 ± 2.4 
345 (62.8) 
169 
-2.49 ± 1.7 
169 (58.3) 
33 
-2.18 ± 1.7 
91 (51.7) 
19 
-2.16 ± 1.6 
106 (52.7) 
92 
Treatment Initiated On, N (%) 
   LPV/r + lamivudine + stavudine  
   LPV/r + lamivudine + abacavir 
   LPV/r + lamivudine + other 
   Ritonavir + lamivudine + stavudine 
   ATZ/r + lamivudine + abacavir 













































Table 3.3: Characteristics, plasma HIV-1 RNA quantity, CD4 percentage, and weight-for-age Z-score pre-antiretroviral 
therapy (ART) initiation, and plasma HIV-1 RNA quantity, CD4 percentage, and vital status 6 months post-ART initiation in 
Cohorts A, B, and C stratified by age at ART initiation (<6 months vs. 6-24 months) 
 
 Cohort A Cohort B Cohort C.1 
 Age at ART initiation (months) Age at ART initiation (months) Age at ART initiation (months) 
 <6 6-24 P <6  6-24  P <6 6-24  P 
N 104 115  252 466  102 221  
Characteristics          
Sex, N (%) 
   Male 

























Age at ART initiation (mo), Mean ± 
SD 
3.3 ± 1.3 13.6 ± 5.4 <0.001 3.8 ± 1.3 14.1 ± 5.6 <0.001 4.1 ± 1.1 12.8 ± 5.0 <0.001 
Pre-treatment          
HIV-RNA quantity (copies/mL), N 
(%) 
   <100000 
   100000-750000 
   ≥750000 














































HIV-RNA quantity (log 
















CD4 percentage, Mean ± SD 26.6 ± 13.4 18.8 ± 10.4 <0.001 22.9 ± 11.8 17.4 ± 8.7 <0.001 23.0 ± 9.6 16.4 ± 8.1 <0.001 
CD4 percentage, N (%) 
   <10 
   10-15 
   ≥15 











































Weight-for-age z-score (WAZ), 
Mean ± SD 
   WAZ <-2, N (%)  
   Missing 
-1.99 ± 2.0 
48 (47.1) 
2 






-2.55 ± 1.8 
107 (60.1) 
75 






-2.54 ± 1.8 
52 (58.4) 
13 






6 months post-ART initiation          
Time since treatment start of 6 
month HIV-RNA quantity (mo), 
Mean ± SD 







HIV-RNA quantity (copies/mL), N 
(%) 
   <50 
   50-1000 
  1000-100000 
  100000-750000 
   ≥750000 

































































CD4 percentage, Mean ± SD 31.1 ± 10.0 24.6 ± 9.1 <0.001 28.3 ± 9.4 25.3 ± 8.7 <0.001 28.3 ± 10.2 26.1 ± 9.3 0.086 
CD4 percentage, N (%) 
   <10 
   10-15 
   ≥15 






































Vital status, N (%)  
   Alive 
   Dead 































1Note: Assay to assess HIV-RNA quantity in Cohort C.1 used an upper limit of detection of 750,000 copies/mL, which led to truncation of more than half of the 
measurements. 











Table 3.4: Characteristics, plasma HIV-1 RNA quantity, CD4 percentage, and weight-for-age Z-score pre-antiretroviral 
therapy (ART) initiation, and plasma HIV-1 RNA quantity, CD4 percentage, and vital status 6 months post-ART initiation in 
Cohorts A, B, and C.1 by age at ART initiation 
 
 Age at ART initiation (months)  
 <1 1-2 2-3 3-4 4-5 5-6 6-12 12-24 P 
N 7 29 89 129 107 97 373 429  
Characteristics          
Cohort, N (%) 
   A 
   B 




































Sex, N (%) 
   Male 



























Age at ART initiation (mo), 
Mean ± SD 
0.6 ± 0.2 1.6 ± 0.3 2.5 ± 0.3 3.5 ± 0.3 4.5 ± 0.3 5.5 ±0.3 8.8 ± 1.7 17.9 ± 3.7 <0.001 
Pre-treatment          
HIV-RNA quantity (copies/mL), 
N (%) 
   <100000 
   100000-750000 
   ≥750000 




















































HIV-RNA quantity (log 
















(5.2, 6.0) <0.001 
CD4 percentage, Mean ± SD 33.9 ± 26.6 30.0 ± 17.9 27.0 ± 11.0 25.0 ±11.6 19.9 ± 9.7 22.1 ± 10.3 18.0 ± 8.9 16.7 ± 8.7 <0.001 
CD4 percentage, N (%) 
   <10 
   10-15 
   ≥15 












































Weight-for-age z-score (WAZ), 
Mean ± SD 
   WAZ <-2, N (%)  
   Missing 
 








































6 months post-ART initiation          
HIV-RNA quantity (copies/mL), 
N (%) 
   <50 
   50-1000 
   ≥1000 




















































CD4 percentage, Mean ± SD 22.8 ± 11.9 30.0 ± 10.2 31.7 ± 9.6 29.6 ± 9.6 25.8 ± 8.9 28.2 ± 9.9 26.7 ± 8.8 24.6 ± 9.0 <0.0001 
CD4 percentage, N (%) 
   <10 
   10-15 
   ≥15 












































Vital status, N (%)  
   Alive 
   Dead 







































CHAPTER 4: DIFFERENTIAL DNA METHYLATION PATTERNS 
BETWEEN HIV-INFECTED AND HIV-UNINFECTED CHILDREN: AN 
EPIGENOME-WIDE ASSOCIATION STUDY 
 
4.1. Abstract 
Background: Recent evidence suggests that HIV infection and antiretroviral therapy (ART) may 
modulate changes in the host cell epigenome.  However, little is known about DNA methylation 
in the context of pediatric HIV infection.  We performed an epigenome-wide association study to 
identify differential DNA methylation patterns between ART-treated HIV-infected and HIV-
uninfected South African children.   
Methods: Genome-wide DNA methylation was profiled using the Illumina Infinium 
HumanMethylation450 BeadChip array in blood samples from 120 ART-treated HIV-infected 
children and 60 frequency age-matched HIV-uninfected children aged 4-9 years (mean age 6.4 
years) in Johannesburg, South Africa.  HIV-infected children were initiated on ART ≤24 months 
of age and currently suppressed (HIV RNA <400 copies/mL) on a LPV/r-based regimen.  Pre-
processing and normalization was performed with the R/Bioconductor RnBeads package.  We 
first selected differentially methylated individual CpG sites using the limma approach if they had 
a False Discovery Rate (FDR) q-value<0.05 and |Δβ| >0.05, where Δβ is the mean difference 
between the average methylation of the groups.  Next, we selected differentially methylated 
regions (DMRs) using the DMRcate approach if they had a Stouffer p-value <0.05, maximum 
|Δβ| change in the region was >0.05, and contained at least two or more CpG sites.  Analyses 
were adjusted for age, sex, and cell type proportions. 
Results: After pre-processing and normalization a total of 370,683 CpG sites and 179 samples 
remained suitable for analysis.  In the CpG site analysis, 1,309 were selected (FDR q-value 




group and 38 CpG sites that were hypo-methylated in the HIV-infected group.  The top 
hypomethylated site was located in the promoter region of the NLRC5 gene (NOD-like receptor 
family CARD domain containing 5) on chromosome 16, which plays a role in the regulation of 
major histocompatibility complex (MHC) class I molecule expression.  Six CpG sites were 
located on EBF4 (early B-cell factor 4) which belongs to a family of transcription factors 
involved in B-cell maturation.  The DMR analysis selected 315 regions, including 28 regions 
consisting of 686 CpG sites on chromosome 6.  A large number of the genes identified in both 
the CpG site and the DMR approach were located in the MHC region on chromosome 6 which 
plays an important role in the adaptive immune system. 
Conclusions: Our novel study provides evidence that perinatally acquired HIV infection is 
associated with widespread changes in DNA methylation in South African children on ART.  
The CpG sites and regions with differential methylation identify genes involved in the adaptive 
immune response.  Our results provide new insights into the biologic pathways influenced by 






Combination antiretroviral therapy (ART) has dramatically reduced mortality and increased 
survival for HIV-infected individuals (1-3).  In the era of ART, HIV-Associated Non-AIDS 
(HANA) conditions, including cardiovascular disease, cancer, bone fractures and osteoporosis, 
liver and kidney disease, and cognitive decline, occur at earlier ages and at higher rates in HIV-
infected individuals (4-7).  Antecedents of many of these conditions are also seen in children 
perinatally infected with HIV, including metabolic complications such as dyslipidemia and low 
bone mass (8-10).  As many of the behavioral risk factors that contribute to these chronic 
illnesses (e.g. smoking, physical inactivity, drug use, and poor diet) are less predominant in early 
childhood, perinatally HIV-infected children represent a unique model population to study 
mechanisms that drive complications of HIV and ART.  Furthermore, children are affected by 
HIV and start lifelong ART during critical periods of developmental plasticity that can elicit 
long-term effects on the child’s health. 
 
An increasing number of studies are now focusing on the epigenetic contributions to disease 
manifestation that result from perinatal or early life insults (11, 12).  Epigenetic changes alter 
gene expression without directly altering the DNA base pair sequences in genomic code (13).  
These changes may reveal potential molecular pathways through which HIV and ART exposure 
during critical developmental periods alter biological pathways and disease risk.  One of the 
most commonly studied epigenetic changes is DNA methylation, the addition of a methyl group 
to a cytosine followed by a guanine (cytosine-phosphate-guanine; CpG), which can affect gene 
transcription and regulate biological processes (14).  Epigenome-wide association studies 




affected biological pathways.  Characterizing DNA methylation in the host genome may provide 
insight into the pathogenesis of HIV infection and its treatment. 
 
Emerging evidence from studies of HIV-infected adolescents and adults have begun to elucidate 
the effect of HIV on epigenetic processes in the host genome.  A study of a monozygotic twin 
pair at age 15 years (one HIV-infected, one HIV-uninfected) reported 4,679 differentially 
methylated regions associated with HIV, including hypermethylation at two genes IGFBP6 and 
SATB2 (15, 16).  A recent study of 137 HIV-infected adults and 44 HIV-uninfected adults 
identified decreased methylation in the region encoding the human leukocyte antigen locus in 
HIV-infected adults (17).  A recent EWAS of 216 HIV-infected and 117 HIV-uninfected adults 
in the Veterans Aging Cohort Study (VACS) identified 20 significantly differentially methylated 
CpG sites (18).    
 
However, little is known about HIV and DNA methylation in pediatric HIV infection.  The goal 
of this study was to conduct an EWAS to identify differential DNA methylation patterns 
associated with HIV infection among ART-treated HIV-infected children and HIV-uninfected 








Study population  
 
The study population consisted of HIV-infected and uninfected children aged 4-9 years 
participating in an ongoing prospective observational cohort study being conducted at two sites 
in Johannesburg, South Africa: Empilweni Services and Research Unit (ESRU) at Rahima 
Moosa Mother and Child Hospital and the Perinatal HIV Research Unit (PHRU) at Chris Hani 
Baragwanath Hospital.  The HIV-infected children were former participants in clinical trials at 
these sites (19-23) and the HIV-uninfected children included those attending the study site for 
preventive health services. 
 
From 553 HIV-infected children and 300 HIV-uninfected children enrolled in the cohort, 180 
were selected for this analysis, including (1) 60 HIV-infected children who started ART <6 
months of age, (2) 60 HIV-infected children who started ART 6-24 months of age, and (3) 60 
HIV-uninfected children.  After limiting the HIV-infected group to Black African children who 
were initiated on ART ≤24 months of age, consistently on treatment, and currently suppressed 
(HIV RNA <400 copies/mL) on a LPV/r-based regimen at their enrollment visit, we randomly 
selected 60 children who started ART <6 months of age and 60 children who started ART 6-24 
months of age.  After excluding any siblings of the selected 120 HIV-infected children, we then 
selected a random sample of 60 HIV-uninfected children frequency matched by age at 
enrollment.  
 
Children provided assent if they were old enough to understand, and their guardians provided 




University in New York, USA and the University of the Witwatersrand in Johannesburg, South 
Africa. 
 
DNA methylation quantification 
At their enrollment visit in the cohort study, each participant had blood samples obtained under 
standardized conditions and kept frozen at -80 °C.  Samples were shipped on dry ice from 
Johannesburg, South Africa to Columbia University Medical Center in New York, NY, USA.  
Genomic DNA (50ng/µL) was isolated and quantified with PicoGreen (Life Technologies, 
Carlsbad, CA) by the Biomarkers Shared Resource at Columbia University Medical Center.  All 
but one (N=179) samples yielded sufficient DNA.  
 
DNA methylation levels were measured at the Genomics Shared Resource at Roswell Park 
Cancer Institute (Buffalo, NY).  Genomic DNA samples were bisulfite converted using the EZ 
DNA Methylation kit (Zymo, Inc.), according to the manufacturer’s instructions in order to 
convert unmethylated cytosine bases to uracil bases.  The samples were then amplified, 
enzymatically fragmented, and hybridized to Infinium HumanMethylation450 BeadChips 
(Illumina, San Diego, CA).  Samples were randomly distributed across the BeadChips taking into 
account group, sex, and age to minimize potential batch effects (24).  Following hybridization, 
the chips were stained, washed, and scanned using the Illumina iScan System and raw intensity 
data (IDAT) files were obtained. 
 
Filtering, normalization, estimation of cell type proportions, and batch effects 
 
Pre-processing pipeline procedures, including filtering and normalization was performed with 




found in Table 4.1.  We removed control probes (N=65), non-CpG probes (N=1,266), failed 
probes with detection p-value ≥0.05 (N=1,602), single nucleotide polymorphism (SNP)-enriched 
probes (N=79,432), probes (N=23,038) previously demonstrated to potentially cross-hybridize 
non-specifically in the genome (26), and sex chromosome probes (N=9,556).  This resulted in a 
total of 370,683 CpG sites remaining for analysis.  
 
In addition, background subtraction was performed using the normal out of band background 
(noob) method provided in the methylumi package (27).  Probe type adjustment to correct for 
Infinum I/II probe types was done using the Beta Mixture Quantile Method (BMIQ) method 
(28).  
 
The methylation status at each CpG site (β-value) ranging from 0 (fully unmethylated) to 1 (fully 
methylated), was calculated using the intensities of the methylated (M) and unmethylated (U) 
probe intensities: β-value = M/(M+U+), and  is an arbitrary offset (100) to stabilize β-values.  
As recommended, β-values were logit transformed to the M-value scale for statistical testing 
(29). 
 
Since whole blood is a heterogeneous tissue consisting of different cell types, it is important to 
account for potential confounding by cell type.  The Houseman algorithm was used to estimate 
the proportions of cell types (CD8+ T-cells, CD4+ T-cells, natural killer cells, B-cells, 
monocytes, and granulocytes) in our samples based on the Reinius et al. adult reference dataset 
using the minfi package (30, 31).  Due to composition differences between cord blood and blood 




To evaluate the plausibility of the estimates, we first compared the estimated mean cell 
percentages of white blood cells to two pediatric references (33, 34) as well as mean differentials 
from one of our previous studies (19-21) (Table 4.2).  We then compared estimated mean cell 
percentages of lymphocytes subsets to a pediatric reference (35) (Table 4.3).  Next, we 
compared the methylation-estimated CD4+ T-cell percentage of lymphocytes to CD4+ T-cell 
percentage measured by laboratory assay (Figure 4.1) and found the two to be highly correlated 
(r = 0.71, p<0.001).  These comparisons indicated that the estimated cell type proportions were 
acceptable. 
 
Estimated mean blood cell percentages of white blood cells and lymphocytes for HIV-infected 
and HIV-uninfected children, as well as for HIV-infected children who started ART <6 months 
and 6-24 months are presented in Table 4.4.  As expected, compared to HIV-uninfected children, 
HIV-infected children had higher estimated blood cell proportions of CD8 T-lymphocytes and 
NK lymphocytes, as well as a lower estimated blood cell proportion of granulocytes.  These 
results suggested that it was important to correct for cell type proportion in our analysis. 
 
Although we did not expect there to be batch effects since samples were randomly distributed 
across the BeadChips by design, we applied a surrogate variable approach to assess for batch 
effects (36).  The surrogate variable approach did not detect any uncorrected batch effects.  






The primary analysis was to identify differentially methylated CpG sites associated with HIV 
status using a genome-wide site approach.  To do this, we fit a model using the empirical Bayes 
moderated linear regression approach implemented by limma (37) with DNA methylation as the 
dependent variable and HIV status as the primary independent variable.  We conducted both an 
unadjusted analysis as well as an analysis adjusted for age, sex, and cell type proportions.  
Statistical significance after multiple testing comparison was established using the Benjamini-
Hochberg (BH) false discovery rate (FDR) with q-value of 0.05 (38).  CpG sites were selected if 
they had an FDR q-value<0.05 and |Δβ| >0.05, where Δβ is the mean difference between the 
average methylation of the groups.  A more stringent significance level using the Bonferroni 
threshold (p<1.35 x 10-7) was also considered.  Selected CpG sites were then ordered by 
chromosome and position to identify 3 or more sites on the same gene. 
 
Next, we applied the DMRcate region approach described by Peters et al. to identify 
differentially methylated regions (DMRs) (39).  This method uses the t-statistic calculated on 
each CpG site by limma and then applies a Gaussian kernel smoother with a bandwidth of 1000 
base pairs and scaling factor of 2.  The model was parameterized identically to the site approach 
above, with HIV status as the binary predictor of interest, adjusting for age, sex, and cell type 
proportions.  As part of the package, a Stouffer transformation was applied to combine the limma 
p-values as a metric for ranking.  We selected regions with Stouffer p-value <0.05, maximum 
|Δβ| change in the region >0.05, and containing at least two or more CpG sites.  We compared 




compared the number of CpG sites selected by the CpG site approach to the number of CpG sites 
selected by the DMR approach. 
 
CpG sites were annotated using the Illumina 450k annotation file with their relation to CpG 
islands (Island, Shore, Shelf, Open Sea) as well as to the nearest gene (TSS1500, TSS200, 
5’UTR, 1st exon, Body, 3’UTR, Intergenic).  DMRs were annotated with their associated gene 
symbol and genomic areas.  
 
To investigate the potential biological meaning of the genes identified in the loci and region 
analysis, we conducted gene-set enrichment analysis.  To assess significant over-representation 
of biological processes among the genes associated with these selected sites and regions we used 
the Database for Annotation, Visualization, and Integrated Discovery (DAVID) (40, 41).  Only 
annotated genes were included in gene-set enrichment analyses. 
 
Due to sex differences in response to ART that have been reported in children with HIV (42, 43), 
we performed secondary sex-stratified analyses, repeating the analysis to identify differentially 
methylated CpG sites associated with HIV in boys and girls; adjustment was made for age and 
cell type proportion.  In addition, in an attempt to separate out the effects of HIV from ART, we 
also evaluated if age at ART initiation led to differences in DNA methylation patterns associated 
with HIV.  We conducted an age “stratified” analysis to identify differentially methylated CpG 
sites associated with HIV among those initiated on ART <6 months of age and those initiated on 
ART 6-24 months of age.  Both groups were compared to the HIV-uninfected group; adjustment 





Characteristics of HIV-infected and HIV-uninfected children were compared using chi-squared 
or Fisher’s exact tests for categorical variables and t-tests or Wilcoxon tests for continuous 
variables.  All analyses were conducted using the R statistical package version 3.3.2 and SAS 
software version 9.4 (Cary, North Carolina). 
 
Validation of analytic pipeline 
To validate our analytic pipeline, we performed an EWAS of the 370,683 CpG sites for sex, 
since sex-associated DNA methylation has been previously studied.  We identified 5,087 
significant CpG sites associated with sex (FDR q-value<0.05).  We compared our findings to 4 
other studies that identified autosomal sex-associated CpG sites (44-47).  In their publications, 
the 4 studies reported either their top 20 (Inoshita et al., Spiers et al., and Xu et al.) or top 30 
(Yousefi et al.) CpG sites associated with sex.  There were 60 sites reported by at least one of the 
4 studies.  Table 4.5 lists the top 20 significant CpG sites associated with sex in our sample, as 
well as their ranking among the top sites of the other 4 studies.  The top two sites in our sample 
were cg11643285 located on the RFTN1 gene (top site in 2 out of 4 other studies) and 
cg03691818 located on the KRT77 gene (top site in all 4 other studies).  10/20 of the top sites in 
Inoshita et al., 11/20 of the top sites in Spiers et al., 9/20 of the top sites in Xu et al., and 9/30 of 
the top sites in Yousefi et al. overlapped with the top 20 sites in our study.  Only one CpG site 
(cg09513416) in our top 20 was not ranked as a top site in the other 4 studies.  46 (78%) of the 
60 sites reported by at least one of the other 4 studies were among the top 1000 significant sites 








Demographic characteristics of the 119 HIV-infected and 60 uninfected South African children 
ages 4-9 years included in this study are presented in Table 4.6.  All characteristics were similar 
between HIV-infected and HIV-uninfected children, including sex, age, household 
characteristics, and caregiver characteristics.  Approximately two thirds of the children in both 
groups live in a house and more than a third of the children in both groups lived in a household 
where someone smokes cigarettes.  The HIV-infected children had a median CD4 percentage of 
33.1%, median CD4 count of 1094 cells/mm3, and all children had an enrollment HIV RNA 
quantity <400 copies/mL.  ART was started at a mean (SD) age of 7.7 (6.1) months; by design 
60 started ART <6 months of age and 59 started ART 6-24 months of age.   
 
Genome-wide CpG sites with differential methylation associated with HIV 
Using the 370,683 probes considered suitable for analysis, we first conducted an unadjusted 
analysis to test for methylation differences at individual CpG sites.  A total of 155,571 sites were 
significantly different with an FDR q-value <0.05.  After limiting the loci to those with |Δβ| 
>0.05, we were left with 1,639 selected CpG sites with statistically significant differential 
methylation.  In an analysis adjusted for sex, age, and cell type proportion, a total of 157,420 loci 
were significantly different with an FDR q-value <0.05.  After limiting the loci to those with |Δβ| 
>0.05, we were left with 1,309 selected CpG sites with statistically significant differential 
methylation (Appendix Table 4.1).  When we compared the 1,639 selected CpG sites in the 
unadjusted analysis to the 1,309 selected CpG sites in the adjusted analysis, 1,282 of the CpG 





Figure 4.2 shows a volcano plot of the adjusted results.  As shown in red, 1,271 of the 1,309 
selected sites were hyper-methylated (higher average methylation level) in the HIV-infected 
group compared to the HIV-uninfected group while 38 sites shown in blue were hypo-
methylated (lower average methylation level).  The selected sites were located primarily at the 
open sea (57.1%) compared to genome-wide sites (35.1%), and only 6.3% of our selected sites 
were located at islands compared to genome-wide sites (31.8%) (Figure 4.3).   
 
Out of 1,309 selected sites, 69 CpG sites located in 47 known genes met a more stringent 
Bonferroni threshold (p<1.35 x 10-7) (Table 4.7).  The top 2 sites (cg09239591, cg23101680) by 
significance level were located on the promoter region (TSS1500) of the gene XDH (xanthine 
dehydrogenase) and gene body of the gene SPERT (spermatid-associated), respectively.  67 of 
69 sites were hyper-methylated (higher average methylation level) in the HIV-infected group 
compared to the HIV-uninfected group while 2 sites were hypo-methylated (lower average 
methylation level).  These 2 sites can be seen in the top left quadrant of the volcano plot 
presented in Figure 4.2.  The two hypo-methylated sites (cg07839457, cg13316433) were 
among the top 8 overall sites by significance level.  The first site was located in the promoter 
region (TSS1500) of the NLRC5 gene (NOD-like receptor family CARD domain containing 5) 
on chromosome 16, which plays a role in regulation of major histocompatibility complex (MHC) 
class I molecule expression (48).  The gene information for the second CpG site was unknown.  
Four of the top 69 significant CpG sites (cg17069396, cg16426670, cg05825244, and 
cg24263062) on chromosome 20 were located in the gene body of EBF4 (early B-cell factor 4) 




hyper-methylated in HIV-infected children.  One of the 4 CpG sites (cpg05825244) had the 
largest |Δβ| (0.157) of the 69 sites meeting the Bonferroni threshold. 
 
Next, the 1,309 selected CpG sites were ordered by chromosome and position to identify 3 or 
more adjacent sites on the same gene.  We identified 18 genes consisting of 60 individual CpG 
sites (Table 4.8).  The majority of the genes (N=14) had 3 adjacent significant CpG sites, 3 
genes (FOXP1, FNDC3B, RPS6KA2) had 4 adjacent sites, and 1 gene (EBF4) had 6 adjacent 
sites (EBF4).  FOXP1 (forkhead box P1) is a gene in the forkhead box transcription factor family 
that plays an important role in the regulation of gene transcription during development (49, 50) 
and has been implicated in the biology of B cell malignancies (51, 52).  FNDC3B (fibronectin 
type III domain containing 3B) is a regulator of adipogenesis (53).  RPS6KA2 (ribosomal protein 
S6 kinase A2) encodes a kinase that may play a role in the control of cell growth and 
differentiation (54).  
 
Genomic regions with differential methylation associated with HIV 
Using a separate de novo procedure, we next searched for genomic regions (in a window of 1000 
bases) where DNA methylation in a coordinated manner was associated with HIV.  We selected 
315 regions with methylation levels associated with HIV after adjustment for age, sex, and cell 
type proportion with Stouffer p-value <0.05, maximum |Δβ| change in the region >0.05, and 
containing at least two or more CpG sites (Appendix Table 4.2).  The top 10 regions were 
associated with the following genes, with one region not mapping to any gene and 4 regions 
mapping to 2 or more genes: COL11A2, NOTCH4, DLL1, FAM120B, SLC25A2, GTF2H4, 




Four of these genes (DLL1, SLC25A2, HCG22, and PSMB9) were identified in the selection of 
differentially methylated sites in the previous section.  DLL1 (delta-like canonical notch ligand 
1) plays a role in regulating cell differentiation during hematopoiesis (55), SLC25A2 (solute 
carrier family 25 member 2) encodes a mitochondrial transport protein, and HCG22 (HLA 
complex group 2) is located near the human leukocyte antigen (HLA)-complex involved in the 
immune system (56), and PSMB9 (Proteasome subunit beta type-9) which encodes a subunit in 
the immunoproteasome (57)  
 
Overall, 81 of the 315 regions were associated with genes that were previously identified by the 
1,309 selected CpG sites.  10 of these regions were associated with genes previously identified 
by the 69 selected CpG sites meeting the stringent Bonferroni threshold: (HTR2B, 
chr2:231989146-231989824; XDH, chr2:31637622-31638511; PDZRN4, chr12:41581414-
41582362; PDZRN4, chr12:41830066-41830372; SPERT, chr13:46275352-46277286; NLRC5, 
chr16:57022486-57023715; UNC45B, chr17:33473881-33475031; EBF4, chr20:2673003-
2675996; EBF4, chr20:2728576-2731560; ZBED4, chr22:50246573-50249174).   
 
Figure 4.4 shows the total number of individual CpG sites selected by the CpG site approach 
(N=1,309) and by the DMR approach (N=2,572) by location on the chromosome.  In the CpG 
site approach, a large number of significant sites were observed at chromosomes 1, 2, 3, and 6.  
In the DMR approach, the largest number of significant sites were observed at chromosome 6.  





On chromosome 6, a large number of the genes identified in the CpG site approach as well as the 
DMR approach were located in the major histocompatibility complex (MHC) region, an 
important region that plays an important role in adaptive immune response.  The location of the 
genes on the MHC region was mapped in a figure adapted from Horton et al. (58) (Figure 4.5), 
with red indicating genes identified in the CpG site approach only, blue indicating genes 
identified in the DMR approach only, and purple indicating genes identified in both.  Overall, 13 
genes in the classical class I sub-region, 6 genes in the classical class II sub-region, 8 genes in 
the classical class III sub-region, 2 genes in the extended class I sub-region, and 4 genes in the 
extended class II sub-region were found to be associated with differential methylation in HIV. 
 
Gene-set enrichment analyses 
Among the 1,309 selected HIV-associated CpG sites, 973 mapped to genes, including 862 
unique genes.  Gene-set enrichment analysis of these genes identified 95 significant biological 
processes (Appendix Table 4.3).  Top processes included regulation of multicellular organismal 
process, negative regulation of biological process, negative regulation of cellular process, and 
cell adhesion.  203 regions of the 315 selected DMRs mapped to at least one known gene.  
However, gene-set enrichment analysis of these genes did not identify any significant biological 
processes. 
 
Genome-wide CpG sites with differential methylation associated with HIV, stratified by sex  
We then repeated the analysis of CpG sites associated with HIV, stratified by sex.  1,078 CpG 
sites were selected by the same criteria (FDR q-value<0.05 and |β|>0.05) for boys and 555 CpG 




60 were among the 1,309 CpGs selected in the overall analysis (Appendix Table 4.4), including 
CpG sites on EBF4, NLRC5, DLL1, and PRDM16.  
 
The relationship between the selected CpG sites identified in the analysis of all children 
compared to the selected CpG sites in the analyses in boys and analyses in girls is shown in 
Figure 4.6.  750 CpG sites were unique to boys only and 272 CpG sites were unique to girls 
only.  For boys the top CpG site (smallest P-value) was located on the gene body of CLNK 
(cytokine dependent hematopoietic cell linker) which plays a role in the regulation of 
immunreceptor signaling.  For girls the top CpG site was located on the gene body of GMDS 
(GDP-mannose 4,6-dehydratase).  We also ordered CpG sites by chromosome and position to 
identify 3 or more adjacent sites on the same gene.  Several genes met this criteria for boys, 
including COLEC11 (collectin subfamily member 11) which binds carbohydrate antigens on 
microorganisms in the innate immune system, ALLC (allantoicase) which participates in the uric 
acid degradation pathway, several genes on the protocadherin gamma gene cluster (e.g. 
PCDHGA2 and PCDHGB4), ADARB2 (adenosine deaminase RNA specific B2) which 
regulates RNA editing, WT1 (Wilms tumor 1) which plays a role in the normal development of 
the urogenital system, LOC254559 (uncharacterized), as well as the tumor suppressor gene 
BRCA1 (breast cancer Type 1 susceptibility protein), and its neighbor NBR2 (neighbor of 
BRCA1 gene 2).  Six genes met this criteria for girls, including B3GNT7 (beta 1,3-N-
cetylglucosaminyltansferase-7) which may be involved in keratan sulfate biosynthesis (59), 
C7orf50 (chromosome 7 open reading frame 50), GPR146 (G-protein coupled receptor 146), 




relevant to cell adhesion, CCDC144NL (coiled-coil domain containing 144 family, N-terminal 
like), and CDH20 (cadherin 20), a calcium-dependent cell adhesion protein.   
 
Two CpG sites for boys (MAN1B1, 20.5%; ADAMTS17, 23.3%) and one CpG site for girls 
(TRIM2, 23.7%) had more than a 20% methylation difference between HIV-infected and 
uninfected children (all were hyper-methylated for HIV-infected children).  Mutations in 
MAN1B1 (mannosidase alpha class 1B member 1) can lead to intellectual disability (60) and 
mutations in ADAMTS17 (ADAM metallopeptidase with thrombospondin type 1 motif 17) are 
associated with Weill-Marchesani-like syndrome, a disorder of connective tissue characterized 
by eye abnormalities and short stature (61).  TRIM2 (tripartite motif containing 2) plays a 
neuroprotective role and mutations in this gene can lead to early-onset axonal neuropathy (62).  
 
Genome-wide CpG sites with differential methylation associated with HIV, stratified by 
age at starting treatment 
 
Next, we repeated the analysis of CpG sites associated with HIV status, stratified by age at ART 
start.  The mean (SD) age at ART initiation was 3.2 (1.3) for those starting ART <6 months and 
12.3 (5.5) for those starting ART 6-24 months of age.  After adjustment for sex, age, and cell 
type proportion, 1,692 CpG sites were selected comparing HIV-infected children with ART <6 
months of age and HIV-uninfected children, and 738 CpG sites were selected comparing HIV-
infected children with ART 6-24 months of age and HIV-uninfected children.  A total of 390 
CpG sites overlapped between children starting treatment early and late, and all 390 were among 
the 1,309 CpGs selected in the overall analysis (Appendix Table 4.5), including CpG sites on 





The relationship between the selected CpG sites identified in the analysis of all children 
compared to the selected CpG sites in the analysis of HIV-infected children starting treatment <6 
months and the analysis of HIV-infected children starting treatment 6-24 months is shown in 
Figure 4.7.  800 sites were unique to children starting <6 months and 155 CpG sites were unique 
to children starting 6-24 months.  Among the 800 unique sites to the analysis of children who 
started ART <6 months, the top 3 CpG sites were on B3GNT7, MYPN (myopalladin) which 
encodes a protein responsible for tethering proteins at the Z-band region in muscle (63), and 
SUV420H1 (histone-lysine N-methyltransferase) which may play a role in myogenesis (64).  We 
also ordered the 800 CpG sites by chromosome and position to identify 3 or more adjacent sites 
on the same gene.  The following genes were identified: SLC25A2, C1orf35 (multiple myeloma 
tumor-associated protein 2) as well as genes on the protocadherin gamma gene cluster.  The top 
CpG site among the 155 CpG sites unique to the analysis of children who started ART 6-24 
months was LARGE (glycosyltransferase-like protein LARGE1) which relates to the synthesis 
of glycoprotein and glycosphingolipid sugar chains.  Ordering the 155 CpG sites by chromosome 








Our study provides the first evidence that perinatally-acquired HIV infection may dysregulate the 
epigenome in school-aged South African children on ART.  Using a genome-wide approach, we 
identified 1,309 CpG sites that were significantly differentially methylated more than 5% 
between HIV-infected and uninfected children.  In addition to confirming methylation 
differences associated with HIV previously reported in adults at the HLA region of the MHC 
region and at the NLRC5 gene, a key regulator of MHC class I gene expression (17, 18), we 
identified differential methylation at other novel host genes that provide new lines of 
investigation into the biologic pathways influenced by HIV and its treatment. 
 
This study contributes to emerging evidence of methylome-wide changes due to HIV and ART.  
A recently published study of 137 chronically HIV-infected, ART-treated white non-Hispanic 
males (mean age 48 years) and 44 uninfected males (mean age 46 years) identified 81,361 CpG 
sites associated with HIV infection at an FDR q-value<0.01 (35,141 hyper-methylated and 
46,220 hypo-methylated) (17).  Another study of 261 HIV-infected (mean age 49 years, 96.9% 
male, 67% African-American, 79% on ART) and 117 HIV-uninfected (mean age 50 years, 
88.8% male, 62.4% African American) adults from the VACS identified 20 CpG sites associated 
with HIV infection at an FDR q-value<0.05 (8 hyper-methylated and 14 hypo-methylated) (18).  
In contrast to these two studies, the substantial majority of the differentially methylated CpG 
sites in this sample of children were hyper-methylated (97%) in HIV-infected children compared 
to HIV-uninfected children, even just among boys (99%).  The reason for this difference is 
unclear, but may be due to the younger age in our sample, as age-related methylation differences 





We found significant methylation differences between HIV-infected and uninfected children on 
chromosome 6 in the MHC region which plays an important role in the adaptive immune 
response (58).  MHC molecules bind to peptide fragments derived from pathogens and display 
them on the cell surface for recognition by the appropriate T-cells.  Class I MHC molecules 
present peptides from inside the cell and are recognized by CD8 T-cells.  Although no significant 
methylation differences were observed on the classical HLA class I genes (e.g. HLA-A, HLA-B, 
HLA-C), we did detect differences on a non-classical HLA class I gene (HLA-F).  A laboratory 
study found in vitro that the activating natural killer cell receptor KIR3DS1 bound to the ligand 
HLA-F, leading to production of antiviral cytokines and inhibition of HIV replication (66).  This 
study also found that infection of CD4+ T cells with HIV increased transcription of the gene 
encoding HLA-F; our finding suggests this may be due to an epigenetic mechanism.  Many other 
genes in the class I region were affected, including several (PSORS1C1, POU5F1, and 
PSORS1C3) which have been studied in the context of HIV and ART (56, 67, 68).   
 
Class II MHC molecules present peptides from outside the cell and are recognized by CD4 T-
cells.  We detected differential methylation on one of the classical HLA Class II genes, HLA-
DQB2.  In addition, other genes in the class II region involved with immune function were 
differentially methylated.  TAP1 and TAP2 code for the transporters associated with antigen 
processing and the movement of HLA molecules.  PSMB8 and PSMB9 are components of the 
immune-proteasome that degrade proteins into peptides for association with MHC class I 
molecules.  There was also differential methylation of class III MHC molecules, including 




extensively studied in T-cell development (69).  NOTCH4 may be affected by exposure to 
ritonavir-boosted lopinavir in our HIV-infected children, as alterations in the NOTCH4 signaling 
pathway have previously been reported among adults with exposure to protease inhibitors (70).  
This finding suggests that specific methylation differences may be due in part to ART exposure, 
specifically to ritonavir-boosted lopinavir. 
 
Evidence of methylation differences in the MHC region in children with HIV, combined with 
findings of methylation remodeling in the HLA cluster in adults with HIV (17), provide strong 
support of epigenetic modifications by HIV in this region.  Findings from host genetic studies 
also suggest that classic and non-classic MHC genes deserve further investigation, especially in 
Africans (56, 71, 72).  In addition, the relationship between hyper- or hypo-methylation and gene 
expression of HLA genes will require further study, as HIV infection has been shown to be 
associated with both increased and decreased expression of HLA genes (73, 74). 
 
A top CpG site among the selected 1,309 sites differentially methylated between HIV-infected 
and uninfected groups was located within the promoter region of NLRC5, a NOD-like receptor 
(NLR) family member which controls transcription of MHC class I genes (75-78).  NLRC5 has 
been implicated in a recent EWAS conducted in adults (18).  Although we only detected 
significant differences in 1 of 2 CpG sites reported in Zhang et al., the direction of methylation 
was similar at the CpG site (cg07839457), with decreased methylation in HIV-infected children 
compared to HIV-uninfected children.  NLRC5 can associate with and activate promoters of both 
classical and non-classical MHC class I genes, including HLA-F.  In addition to MHC class I, 




Aside from the MHC region, the NLRC5 region regulates NF-kB and type I interferon signaling, 
and can be a potential target for manipulation of immune responses against infectious diseases 
(79).    
 
We found 4 out of the 6 selected CpG sites located in the gene body of EBF4 on chromosome 20 
also met the stringent Bonferroni threshold (cg17069396, cg16426670, cg05825244, and 
cg24263062).  All were hyper-methylated in HIV-infected children.  EBF4 is a transcription 
factor in the Olf-1/EBF family that is involved in neural development and B-cell maturation; it 
has been identified as an affected gene in an EWAS of individuals with down syndrome and 
unaffected relatives as controls (80, 81).  B-cell deficiencies have been reported in the earliest 
studies of individuals with HIV, and there is evidence that HIV infection directly interacts with B 
cells and also leads to B-cell hyperactivity via cytokines and growth factors (82, 83).  
Dysregulated methylation in the EBF4 region suggests an epigenetic mechanism for these 
deficiencies is also possible.  In addition to EBF4, HIV may result in differential methylation of 
other genes related to B-cell development.  DLL1 helps to mediate cell fate decisions during 
hematopoiesis, blocking the differentiation of progenitor cells into the B-cell lineage while 
promoting the emergence of a population of cells with the characteristics of a T-cell/NK-cell 
precursor (84).  We observed increased methylation associated with HIV at several CpG sites on 
FOXP1 on chromosome 3, which has been implicated in the biology of B cell malignancies (51, 
52).  Of note, FOXP1 is in the same Foxp subfamily as FOXP3; this family of transcription 
factors is recognized for its involvement in autoimmune disease, speech and language disorders, 
and lung development (49, 50, 85).  In vitro, HIV infection of human regulatory T-cells increases 





Differential methylation of sites on other genes related to the adaptive immune system was 
observed outside of the MHC region, NLRC5, and EBF4.  We saw hypo-methylation of 
cg00994804 in the 1st Exon of RUNX1 (runt-related transcription factor 1) in children with HIV.  
RUNX1 is a member of the RUNX family and is a critical transcriptional regulator of CD4+ T-
cells (87).  Zhang et al. reported that cg11429292, located 10 kb upstream of the CD4 gene, 
which encodes the primary receptor for HIV-1 and regulates T hyper cell function, was hyper-
methylated in HIV-infected adults compared to HIV-uninfected adults.  This CpG site met our 
cut off for epigenome wide significance (FDR q-value<0.05, |Δβ| >0.05) and was also hyper-
methylated in HIV-infected children than uninfected children, but did not meet the more 
stringent Bonferroni threshold.  IGF1R (insulin-like growth factor 1 receptor) is part of the 
insulin growth factor (IGF) system that is involved in the immune response to HIV and may 
influence the rate of HIV disease progression (88). 
 
The top two selected CpG sites ranked by significance with differential methylation between 
HIV-infected and uninfected groups were located on XDH and SPERT.  XDH (xanthine 
dehydrogenase) can be converted into XO (xanthine oxidase), an enzyme that generates reactive 
oxygen species (ROS) that is present in many organs, including the liver, gut, lung, kidney, 
heart, and brain as well as the plasma (89).  It has been shown that during states of infection and 
inflammation, activity of XO can increase by 10-50% (90, 91).  HIV appears to progress faster 
during oxidative stress, a state in which there is an overabundance of free radicals.  In a study of 
adults, HIV-infected adults were found to have 22% higher XO activity (92).  We saw increased 




children in the overall sample as well as in boys and girls; further studies are needed to 
understand the potential implications of the methylation direction.  The role of SPERT 
(spermatid associated) in HIV infection is unknown.  
 
We also observed differential methylation of CpG sites and regions on genes that may relate to 
HIV-associated complications.  For example, PRDM16 (PR domain containing 16) is a 
transcription coregulatory factor that controls the development of brown adipocytes in brown 
adipose tissue (93-95).  FNDC3B is involved in the regulation of adipogenesis, the invasion and 
metastasis of melanoma cells, and development of calvarial bone (53, 96).  As mentioned earlier, 
FOXP1 plays an important role in the specification and differentiation of the lungs, brain, 
thymus, and heart (49, 50).  COL25A1 (collagen type XXV alpha 1 chain) has been implicated 
in neurological disorders (97).  The HTR2B gene encodes the 5-HT2 receptors, which mediate 
many of the functions of serotonin, known to be involved in neuroinflammation and 
immunoregulation.  It has been proposed that HIV-induced degeneration of serotonin may lead 
to neuropsychiatric disorders and neurocognitive impairment (98).  
 
60 of the CpG sites selected in the male-only and female-only analyses were among the CpG 
sites selected in the sex-combined analysis, including many of the sites on implicated genes 
discussed above (e.g. EBF4, DLL1, NLRC5) and confirming their association with HIV in 
children of both sexes.  Highlighted genes unique to one biological sex, such as COLEC11, 
which plays a role in the innate immune system, and the tumor suppressor gene BRCA1, as well 
as genes relevant to intellectual disability (MAN1B1), growth (ADAMTS17), and neuropathy 





Although our “stratified” analysis of age at starting treatment (<6 months vs. 6-24 months) 
confirmed many of the CpG sites in the combined analysis (N=390) in their overlap, it also 
identified a large number of non-overlapping differentially methylated CpG sites.  These CpG 
sites represent differential methylation associated with HIV at 4-9 years of age unique to children 
who start treatment <6 months (N=800) and unique to children who start treatment 6-24 months 
(N=155).  Although the groups in this study are defined by the age at which they started ART, 
the differences could also be due to a longer duration on ART in the children who started ART 
<6 months.  This could suggest a more direct role for ART effects on epigenetic changes. A 
better understanding of these differences will require further study and may be elucidated by 
longitudinal samples early in life before treatment is initiated.  
 
This study has several limitations.  First, we used whole blood to assess DNA methylation 
differences, as cell sorting by flow cytometry was not possible in this setting.  To adjust for 
methylation signals due to different cell types, we used a method to adjust for cellular 
heterogeneity that has been widely used in other EWAS (31), although it may not be the best 
algorithm in studies of young children (99).  Second, we selected a homogeneous group of HIV-
infected children who were initiated on treatment early before 2 years of age and all suppressed 
on ritonavir-boosted lopinavir.  Therefore, due to lack of variability in the sample, we were 
unable to assess associations between methylation differences at specific CpG sites and clinical 
outcomes such as HIV RNA quantity or CD4 percentage.  Furthermore, we are unable to 
distinguish which methylation differences, if any, are associated with HIV susceptibility.  In 




allow for separate consideration of ART- vs. HIV-related effects on DNA methylation.  Due to 
the recent emphasis on early identification and prompt initiation of treatment in children under 5 
years, inclusion of untreated HIV-infected children of this age is not feasible nor ethical.  We 
also could not disentangle the effects of in utero antiretroviral exposure from postnatal ART 
exposure on DNA methylation in our HIV-infected children.  Our study was conducted at a 
single time point, reducing the ability to understand how the relationship between HIV and ART 
on DNA methylation may change throughout childhood.  Future studies may be able to address a 
number of these limitations by comparing children with and without specific clinical outcomes, 
comparing HIV-infected infants to HIV-exposed uninfected infants, evaluating methylation 
differences using longitudinal samples, comparing children before and after starting ART, and 
leveraging stored samples from early cohorts where infants did not receive ART early.  Finally, 
we used the Illumina Infinium HumanMethylation450 BeadChip array, which has been the most 
popular and practical choice for EWAS to date.  However, it only covers ~1.5 % of overall 
genomic CpG sites, which are biased towards promoter and protein-coding regions.  Future 
studies should use the newer EPIC array (850K) which covers an additional 413,745 new CpG 
sites, many in other genomic regions. 
 
In conclusion, using high-throughput technology and a genome-wide approach, our novel study 
provides evidence that perinatally acquired HIV infection is associated with widespread changes 
in DNA methylation in school-aged children on ART in Johannesburg, South Africa.  Using a 
robust analysis pipeline with cell proportion correction, we confirmed methylation differences at 
the MHC region and the NLRC5 gene reported in studies of adults with HIV on ART, and 




Our results provide new insights into the biologic pathways influenced by HIV and ART.  As we 
increase our understanding of how HIV and ART impacts the host genome across the lifecourse, 
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4.7. Figures and Tables 
 
Figure 4.1: Relationship of CD4+ T-cell percentage of lymphocytes estimated by DNA 









Figure 4.2: Volcano plot displays mean DNA methylation difference between HIV-infected 
and HIV-uninfected groups at genome-wide CpG sites vs. –log10(unadjusted P-value) after 
adjustment for age, sex, and cell type proportion.  Selected differentially methylated CpG 
sites (N=1,309) with FDR q-value <0.05 and |Δβ| >0.05 are presented in blue (hypo-
methylated in HIV-infected group) and red (hyper-methylated in HIV-infected group) 
 
 
Note: FDR line is drawn at –log10(0.02123351); Bonferroni line is drawn at –log10(1.35e-07) 
 




Figure 4.3: Proportion of CpG site locations in relation to CpG islands for genome-wide 









Figure 4.4: Number of individual CpG sites selected by the CpG approach (N=1,309) and by the 

























Sites selected from CpG site approach







Figure 4.5: Gene map of the extended major histocompatibility complex (xMHC) on chromosome 6 highlighted with genes 






Figure 4.6: Overlap of selected genome-wide CpG sites with differential methylation 










Figure 4.7: Overlap of selected genome-wide CpG sites with differential methylation 
associated with HIV in all HIV-infected children compared to all HIV-uninfected children 
(N=1,309), in HIV-infected children starting treatment <6 months of age compared to HIV-
uninfected children (N=1,692), and in HIV-infected children starting treatment 6-24 











Table 4.1: Probes filtered in pre-processing 
 
Filtering step Description 
Probes 
removed 
Control probes Removed 65 control probes 65 
Non-CpG probes 
Removed non-CPG probes including CAG 
(n=1050), CAH (n=144), and CTG (n=7)  
1,266 
Failed probes 
Removed poor quality probes with Greedycut, an 
iterative algorithm that filters out probes with the 






Remove probes that overlap with SNPs 79,432 
Cross-reactive probes 












Table 4.2: Comparison of estimated mean (SD) cell percentages of white blood cells in our 
study to two pediatric references and mean (SD) differentials from a prior study by our 
group 
 











































Neutrophils 42-54 48 
39.8  
(12.6) 
Eosinophils 2-3 3 
3.0  
(3.3) 




1Lymphocytes includes CD8+ T-cells, CD4+ T-cells, Natural killer cells, and B-cells; 
granulocytes includes neutrophils and eosinophils 
 
2Pediatric reference for children ages 4-9 years from the Harriet Lane Handbook 
 
3Pediatric reference from BARC Global Central Laboratories for children ages 6-10 years for 
lymphocytes and neutrophils, children ages 4-12 years for monocytes, children 1 month to 12 
years for eosinophils and 0 days to 12 years for basophils 
 
4Data from the 48 week visit of the Neverest 3 clinical trial; HIV-infected children were a mean 







Table 4.3: Comparison of estimated mean (SD) cell percentages of lymphocytes in our 















































1Pediatric reference for children 6-12 years in Shearer et al. (35); reported is median and 10th to 












Table 4.4: Estimated mean (SD) cell percentages of white blood cells and lymphocytes, by HIV status and age at ART start for 
HIV-infected children 
 







started ART  
<6 months  
(N=60) 
HIV-infected,  




White Blood Cells       
     CD8+ T-cell percentage 16.3 (6.3) 14.5 (5.4) 0.055 16.3 (6.3) 16.4 (6.3) 0.92 
     CD4+ T-cell percentage 18.6 (7.2) 18.2 (7.1) 0.71 17.9 (7.1) 19.3 (7.4) 0.31 
     Natural killer cell percentage 8.7 (6.8) 6.1 (5.3) 0.012 9.7 (7.5) 7.6 (6.0) 0.09 
     B-cell percentage 11.3 (4.8) 11.2 (4.1) 0.86 11.3 (5.4) 11.3 (4.1) 0.97 
     Monocyte percentage 6.9 (3.2) 7.6 (3.3) 0.18 6.9 (3.0) 6.8 (3.3) 0.76 
     Granulocyte percentage 38.3 (13.6) 42.5 (11.2) 0.039 37.9 (14.0) 38.7 (13.3) 0.73 
Lymphocytes       
     CD8+ T-cell percentage 29.5 (6.8) 28.8 (7.7) 0.55 29.2 (7.1) 29.8 (6.5) 0.63 
     CD4+ T-cell percentage 33.9 (9.2) 36.2 (9.6) 0.12 32.8 (9.7) 35.0 (8.7) 0.18 
     Natural killer cell percentage 15.8 (11.4) 12.3 (10.2) 0.047 17.5 (12.5) 14.1 (10.1) 0.11 
     B-cell percentage 20.8 (7.1) 22.6 (6.0) 0.08 20.5 (8.4) 21.0 (5.5) 0.71 
 
1P-value represents result of t-test comparing HIV-infected to HIV-uninfected group 







Table 4.5: Top 20 sites associated with sex in our study, sorted by smallest to largest p-value, and ranking relative to top sites 
(20 or 30) from 4 other studies of sex and DNA methylation 
 
Top 20 sites associated with sex in our study and ranking  Ranking of top sites from other studies 





Δβ Adj P Inoshita Spiers Xu Yousefi 
1 cg11643285 3 RFTN1 0.705 0.975 -0.271 2.23E-151  3 3  
2 cg03691818 12 KRT77 0.024 0.125 -0.101 5.55E-96 5 2 4 1 
3 cg12691488 1  0.278 0.090 0.188 2.20E-95 1 1   
4 cg04946709 16 LOC644649 0.842 0.664 0.178 1.63E-77 8 6 2 13 
5 cg03618918 1  0.816 0.676 0.14 1.02E-76 2  7  
6 cg02325951 14 FOXN3 0.764 0.655 0.109 1.03E-61  4  9 
7 cg06710937 13  0.033 0.130 -0.097 2.40E-58 14 11 16  
8 cg21148594 14  0.802 0.679 0.123 5.23E-56  18   
9 cg12052203 11 B3GNT1 0.067 0.020 0.047 6.06E-54 13    
10 cg08906898 20 RBM39 0.973 0.931 0.042 4.45E-50    12 
11 cg04858776 11  0.047 0.128 -0.081 7.93E-50   6  
12 cg20299935 17  0.728 0.861 -0.134 1.99E-48 12    
13 cg22345911 17 CSNK1D 0.024 0.047 -0.023 2.87E-45  8  17 
14 cg23719534 15  0.872 0.960 -0.088 6.82E-42  9   
15 cg15817705 1  0.825 0.685 0.140 3.46E-41 16 7 5  
16 cg09513416 6  0.881 0.796 0.085 7.69E-40     
17 cg17743279 7 CDK6 0.015 0.026 -0.011 1.82E-39    3 
18 cg24016844 1 C1orf103 0.045 0.027 0.018 3.19E-39  16  27 
19 cg03608000 19 ZNF69 0.011 0.021 -0.010 4.11E-38   20 8 
20 cg25304146 18 WBP11P1 0.630 0.526 0.104 7.45E-38 4  9 16 
21 cg12900929 12 PRDM4 0.056 0.106 -0.050 2.36E-37    30 
22 cg06152526 16 PLLP 0.825 0.735 0.090 3.69E-37    19 
24 cg09971754 16 ANKRD11 0.043 0.020 0.023 4.05E-37  20   
25 cg06759085 2 NAB1 0.940 0.861 0.079 1.65E-36   17  
26 cg23814743 3 NICN1 0.211 0.263 -0.052 3.22E-34 15    
27 cg05100634 18 SMAD2 0.015 0.022 -0.007 2.33E-32    7 
32 cg01906879 3 GBE1 0.019 0.032 -0.012 1.22E-29    18 
33 cg26355737 13 TFDP1 0.960 0.905 0.055 1.96E-29   11 5 
35 cg07628841 2 GPN1;CCDC121 0.361 0.423 -0.062 8.58E-28    22 
40 cg22266749 4 COL25A1 0.107 0.063 0.045 3.40E-26 9    
43 cg25438440 3 CLDND1 0.015 0.022 -0.007 1.91E-24    25 
46 cg26516287 7 SCIN 0.745 0.820 -0.074 6.35E-24   13  
48 cg16727519 1 H3F3A 0.544 0.488 0.057 7.42E-24   15  
49 cg23001456 17 KIAA0664; CLUH 0.025 0.037 -0.012 7.57E-24  12  23 







56 cg16169375 6 C6orf108 0.015 0.022 -0.007 1.23E-22   18  
57 cg12204423 4 PHF17 0.050 0.036 0.013 1.60E-22    15 
59 cg12177922 1 HAX1 0.120 0.205 -0.085 2.52E-22 10    
63 cg26213873 1 CTTNBP2NL 0.028 0.041 -0.013 6.38E-22    24 
68 cg06644124 1 ZNF281 0.265 0.319 -0.054 5.44E-20    21 
69 cg04874129 16 SLC6A2 0.077 0.112 -0.035 6.29E-20  15  11 
70 cg01225095 12 YARS2 0.038 0.054 -0.016 1.28E-19   14  
72 cg03687700 2 FKBP1B 0.171 0.233 -0.062 5.54E-19  5   
76 cg12614789 15  0.071 0.101 -0.030 1.18E-18  19   
101 cg11841231 2 PARD3B 0.957 0.927 0.030 2.73E-16  10  28 
124 cg22227586 10 FAM35A 0.020 0.025 -0.005 1.06E-13   12  
192 cg03218192 17 AP2B1 0.250 0.332 -0.082 1.97E-11 17 13   
 Not in top 1000 cg26921482 16 AMDHD2            2 
Not in top 1000 cg07852945 9 TLE1         18   4 
Not in top 1000 cg25568337 6 ARID1B         7  10 6 
Not in top 1000 cg17612569 21 GABPA; ATP5J            10 
Not in top 1000 cg04190002 22 SHANK3            20 
Not in top 1000 cg07816873 12 ERC1            26 
Not in top 1000 cg13323902 5 VTRNA1-1            29 
Not in top 1000 cg25294185 11 RNASEH2C         20  1  
Not in top 1000 cg17232883 11          6  8  
Not in top 1000 cg20808136 15            19  
Not in top 1000 cg06642617 2 CCT7          14   
Not in top 1000 cg22921760 14 SALL2          17   
Not in top 1000 cg23256579 12 PRR4     19    
Not in top 1000 cg17238319 3 RFTN1     3    
 
 Spiers et al. 2015; Methylomic trajectories across human fetal brain development; Table 3 – The 20 top ranked autosomal sex differences in DNA 
methylation in the fetal brain 
 Inoshita et al. 2015; Sex differences of leukocytes DNA methylation, adjusted for estimated cellular proportions; Table 1 – Top 20 autosomal CpG sites 
with significant sex differences 
 Xu et al. 2014; Sex-biased methylome and transcriptome in human prefrontal cortex; Table 2 – Top 20 autosomal CpGs with sex-biased methylation 
 Yousefi et al. 2015; Sex differences in DNA methylation assessed by 450 K in newborns; Table 3 – Results for the top 30 gene-annotated autosomal 








Table 4.6: Characteristics of 119 HIV-infected and 60 HIV-uninfected school-aged children in Johannesburg, South Africa; 









started ART  
<6 months  
(N=60) 
HIV-infected,  




Male, N (%) 55 (46.2) 30 (50.0) 0.63 29 (48.3) 26 (44.1) 0.64 
Age (years), Mean (SD)  6.42 (1.4)  6.43 (1.4)  0.97 6.05 (1.2)  6.80 (1.6)  0.004 
Age (years), N (%) 
    4-5 
    5-6 
    6-7 
    7-8 
    8-9 

































Type of home, N (%) 
    House 
    Flat 
    Shack 
    Outbuilding 





























Household member smokes, N (%) 41 (34.5) 22 (36.7) 0.77 19 (31.7) 22 (37.3) 0.52 
Primary cooking method, N (%) 
    Paraffin burner 
    Electric cooker 
    Gas stove 
 



















Mother born in South Africa, N (%) 109 (91.6) 56 (93.3) 0.78 57 (95.0) 52 (88.1) 0.20 
Mother primary caregiver, N (%) 108 (90.8) 57 (95.0) 0.62 53 (88.3) 55 (93.2) 0.32 
Highest caregiver grade, N (%) 
    No School 
    1-11 (Primary/Secondary) 





















Caregiver has paid job, N (%)  52 (43.7) 22 (36.7) 0.37 25 (41.7) 27 (45.8) 0.65 
Caregiver marital status, N (%) 
    Single 
    Married 
    Divorced/Widowed 































Pre-treatment CD4 percentage, Mean (SD) 









Pre-treatment CD4 count (cells/mm3), Mean (SD) 









Pre-treatment HIV RNA quantity (copies/mL), N (%) 
    <100,000 
    100,000-340,000 
    340,000-750,000 
    ≥750,000 






















Age at ART start (months), Mean (SD) 7.7 (6.1) - - 3.2 (1.3) 12.3 (5.5) <0.001 
Enrollment CD4 percentage, Mean (SD) 
    Missing 








Enrollment CD4 count (cells/mm3), Mean (SD) 









Enrollment HIV RNA quantity (copies/mL), N (%) 
    LDL 
    <40 
    40-400 



























Table 4.7: Top selected differentially methylated CpG sites (N=69) associated with HIV after adjustment for age, sex, and cell 
type proportion meeting Bonferroni threshold (p<1.35 x 10-7) and with |Δβ| >0.05, sorted by P-value from smallest to largest 
 
CpG CHR Position Gene Relation to Gene 






Δβ P Adj  P 
cg09239591 2 31638511 XDH TSS1500 OpenSea 0.675 0.623 0.053 2.44E-15 1.97E-11 
cg23101680 13 46277286 SPERT Body OpenSea 0.717 0.663 0.053 4.89E-14 1.83E-10 
cg07839457 16 57023022 NLRC5 TSS1500 N_Shore 0.261 0.353 -0.092 4.69E-11 2.87E-08 
cg12027254 17 76055290 TNRC6C Body;Body OpenSea 0.824 0.766 0.058 1.00E-10 4.99E-08 
cg07970325 6 106497542   OpenSea 0.569 0.512 0.057 1.39E-10 6.38E-08 
cg26280998 6 53589544   OpenSea 0.715 0.659 0.056 1.72E-10 7.29E-08 
cg12880685 10 120489658 C10orf46 Body OpenSea 0.428 0.378 0.050 1.85E-10 7.66E-08 
cg13316433 5 83140500   OpenSea 0.150 0.207 -0.057 2.28E-10 8.94E-08 
cg00390724 3 18484742   N_Shore 0.519 0.456 0.063 2.66E-10 1.01E-07 
cg22690339 6 38249061 BTBD9 Body OpenSea 0.792 0.735 0.058 3.47E-10 1.22E-07 
cg05929755 1 110663559   OpenSea 0.398 0.339 0.059 7.36E-10 2.15E-07 
cg12021671 15 42423807   OpenSea 0.744 0.690 0.054 1.02E-09 2.75E-07 
cg08237220 3 156332967   OpenSea 0.531 0.459 0.072 1.07E-09 2.85E-07 
cg05006384 14 95942319 C14orf49 TSS200 OpenSea 0.648 0.595 0.053 1.74E-09 4.09E-07 
cg13707760 9 95986383 WNK2 Body OpenSea 0.509 0.449 0.060 2.03E-09 4.58E-07 
cg18394552 5 159428643   OpenSea 0.732 0.650 0.081 2.42E-09 5.17E-07 
cg10336193 1 206848389   OpenSea 0.644 0.584 0.060 2.88E-09 5.88E-07 
cg22348290 8 72459499   N_Shore 0.767 0.709 0.058 3.22E-09 6.37E-07 
cg26898099 5 95192949 C5orf27 Body OpenSea 0.706 0.650 0.055 6.44E-09 1.07E-06 
cg14418857 7 121120431   OpenSea 0.616 0.535 0.080 6.86E-09 1.13E-06 
cg22647738 17 34304462 CCL16 3'UTR OpenSea 0.639 0.561 0.078 8.18E-09 1.29E-06 
cg05512157 12 50901878 DIP2B Body S_Shelf 0.587 0.533 0.054 8.71E-09 1.35E-06 
cg21912162 5 71447818 MAP1B Body OpenSea 0.329 0.276 0.053 9.65E-09 1.46E-06 
cg23720384 21 23747055   OpenSea 0.665 0.583 0.082 1.10E-08 1.61E-06 
cg04961225 12 91332479   OpenSea 0.578 0.515 0.063 1.12E-08 1.63E-06 
cg10689689 11 63677197 MARK2 3'UTR S_Shore 0.685 0.634 0.051 1.42E-08 1.93E-06 
cg15826519 1 19808575 CAPZB Body N_Shelf 0.796 0.742 0.054 1.49E-08 2.00E-06 
cg09083958 12 131516365 GPR133 Body N_Shore 0.696 0.642 0.054 1.53E-08 2.04E-06 
cg02341197 21 34185927 C21orf62 1stExon;5'UTR OpenSea 0.466 0.408 0.058 1.54E-08 2.05E-06 
cg08937102 1 1690389 NADK Body N_Shore 0.481 0.428 0.053 1.75E-08 2.24E-06 
cg20954180 3 54606265 CACNA2D3 Body OpenSea 0.847 0.794 0.053 1.75E-08 2.25E-06 
cg17069396 20 2731102 EBF4 Body Island 0.128 0.069 0.058 1.81E-08 2.30E-06 
cg16426670 20 2675996 EBF4 Body S_Shore 0.812 0.750 0.062 2.29E-08 2.74E-06 
cg15773890 6 17259549   OpenSea 0.866 0.812 0.054 2.73E-08 3.12E-06 
cg03705319 12 12848516 GPR19 5'UTR N_Shore 0.745 0.693 0.052 2.75E-08 3.14E-06 
cg00602295 16 81328089   OpenSea 0.441 0.375 0.065 2.81E-08 3.18E-06 







cg24399529 15 69373153 MIR548H4;TMEM84 Body;TSS200 OpenSea 0.256 0.205 0.051 2.92E-08 3.28E-06 
cg23429698 8 98878169   N_Shelf 0.324 0.268 0.056 3.13E-08 3.44E-06 
cg23992886 7 116420651 MET;MET Body;Body OpenSea 0.635 0.578 0.058 3.43E-08 3.68E-06 
cg00399027 16 85676861 KIAA0182 5'UTR;Body S_Shore 0.607 0.547 0.060 3.72E-08 3.89E-06 
cg04042861 2 231989824 PSMD1;HTR2B TSS200;Body OpenSea 0.406 0.346 0.060 4.25E-08 4.29E-06 
cg18835596 6 135540107 MYB 3'UTR OpenSea 0.725 0.659 0.066 4.46E-08 4.45E-06 
cg03182584 7 36364854 KIAA0895 3'UTR OpenSea 0.689 0.631 0.058 4.53E-08 4.49E-06 
cg00105306 15 85194978 WDR73 Body N_Shelf 0.626 0.569 0.057 4.88E-08 4.75E-06 
cg24499605 1 3142925 PRDM16 Body;Body OpenSea 0.550 0.489 0.061 5.85E-08 5.41E-06 
cg07589393 7 26984305   OpenSea 0.724 0.674 0.050 6.01E-08 5.52E-06 
cg09722609 5 149887422 NDST1 TSS1500 OpenSea 0.607 0.551 0.055 6.05E-08 5.54E-06 
cg04339360 13 73635568 KLF5 Body S_Shore 0.710 0.644 0.066 6.23E-08 5.67E-06 
cg20426710 22 50248907 ZBED4 5'UTR N_Shore 0.519 0.461 0.057 6.33E-08 5.74E-06 
cg07264238 17 33474376 UNC45B TSS1500 OpenSea 0.778 0.707 0.071 7.23E-08 6.32E-06 
cg25718604 20 57601474 TUBB1 3'UTR S_Shelf 0.831 0.774 0.057 7.34E-08 6.40E-06 
cg19683780 8 42907576   N_Shelf 0.784 0.733 0.051 7.67E-08 6.60E-06 
cg12449049 6 25088999 CMAH Body OpenSea 0.686 0.636 0.050 8.32E-08 6.97E-06 
cg00864012 17 62294665 TEX2 5'UTR OpenSea 0.724 0.670 0.053 8.38E-08 7.01E-06 
cg00991744 12 41581484 PDZRN4 TSS1500 N_Shore 0.852 0.791 0.061 8.42E-08 7.04E-06 
cg09620718 16 20702872 ACSM1 TSS1500 OpenSea 0.784 0.733 0.051 8.51E-08 7.08E-06 
cg08066875 2 163197084   N_Shelf 0.637 0.581 0.056 8.63E-08 7.15E-06 
cg08324152 19 57172404   N_Shelf 0.283 0.216 0.067 9.18E-08 7.49E-06 
cg05825244 20 2730488 EBF4 Body Island 0.428 0.271 0.157 9.32E-08 7.58E-06 
cg00876141 4 47837775 CORIN Body N_Shore 0.451 0.396 0.055 9.35E-08 7.59E-06 
cg06096336 2 231989800 PSMD1;HTR2B Body;1stExon;5'UTR OpenSea 0.571 0.519 0.052 9.83E-08 7.88E-06 
cg11329129 11 705692 EPS8L2 TSS1500 N_Shore 0.417 0.367 0.051 9.86E-08 7.89E-06 
cg12876838 4 5897223   S_Shelf 0.754 0.702 0.052 1.10E-07 8.58E-06 
cg26475911 17 73056187 KCTD2 Body OpenSea 0.458 0.390 0.067 1.14E-07 8.78E-06 
cg13561554 15 78795944   N_Shelf 0.620 0.567 0.053 1.19E-07 9.04E-06 
cg26413942 5 124081751 ZNF608 TSS1500 OpenSea 0.421 0.361 0.060 1.24E-07 9.27E-06 
cg24263062 20 2730191 EBF4 Body Island 0.636 0.550 0.086 1.30E-07 9.59E-06 















Table 4.8: Adjacent sites (3 or more) on the same gene among the selected CpG sites (N=1,309) with methylation levels 
associated with HIV after adjustment for age, sex, and cell type proportion, sorted by chromosome and position  
 
CpG CHR Position Gene Relation to Gene 






Δβ P Adj P 
cg24499605 1 3142925 PRDM16 Body OpenSea 0.55 0.489 0.061 5.85E-08 5.41E-06 
cg22497969 1 3143018 PRDM16 Body OpenSea 0.784 0.728 0.057 7.34E-07 3.35E-05 
cg26300135 1 3324243 PRDM16 Body S_Shore 0.904 0.835 0.069 1.23E-02 3.34E-02 
cg07330114 3 11624023 VGLL4 Body;TSS200 OpenSea 0.238 0.177 0.06 7.50E-05 9.33E-04 
cg00691123 3 11632974 VGLL4 Body OpenSea 0.573 0.521 0.052 1.93E-02 4.66E-02 
cg25357825 3 11697138 VGLL4 Body OpenSea 0.344 0.294 0.051 1.20E-04 1.30E-03 
cg18067134 3 71084634 FOXP1 Body OpenSea 0.728 0.667 0.061 3.56E-05 5.50E-04 
cg08173709 3 71103443 FOXP1 Body OpenSea 0.726 0.669 0.057 5.42E-07 2.71E-05 
cg20382675 3 71591429 FOXP1;MIR1284 5'UTR;TSS200;5'UTR OpenSea 0.542 0.487 0.055 6.38E-03 2.06E-02 
cg18558767 3 71592056 FOXP1;MIR1284 5'UTR;TSS1500;5'UTR OpenSea 0.442 0.391 0.051 1.19E-02 3.25E-02 
cg06508738 3 1.39E+08 PRR23C TSS200 Island 0.623 0.567 0.057 3.98E-05 5.95E-04 
cg24530147 3 1.39E+08 PRR23C TSS200 Island 0.773 0.707 0.066 5.35E-05 7.34E-04 
cg14325153 3 1.39E+08 PRR23C TSS200 Island 0.537 0.47 0.067 2.01E-04 1.86E-03 
cg17797940 3 1.72E+08 FNDC3B 5'UTR S_Shore 0.539 0.479 0.061 9.52E-04 5.46E-03 
cg14016236 3 1.72E+08 FNDC3B 5'UTR OpenSea 0.494 0.424 0.07 2.50E-03 1.07E-02 
cg06740950 3 1.72E+08 FNDC3B Body;Body OpenSea 0.473 0.416 0.057 1.19E-04 1.29E-03 
cg09357350 3 1.72E+08 FNDC3B Body;Body OpenSea 0.641 0.583 0.058 9.07E-04 5.27E-03 
cg17009978 3 1.84E+08 VWA5B2;MIR1224 Body;TSS200 N_Shore 0.719 0.667 0.052 2.84E-08 3.21E-06 
cg12821315 3 1.84E+08 VWA5B2;MIR1224 Body;TSS200 N_Shore 0.822 0.772 0.05 5.97E-07 2.90E-05 
cg21545762 3 1.84E+08 VWA5B2;MIR1224 Body;TSS200 Island 0.562 0.51 0.052 1.79E-06 6.39E-05 
cg01734045 4 1.1E+08 COL25A1 Body OpenSea 0.292 0.24 0.052 9.82E-07 4.14E-05 
cg08760493 4 1.1E+08 COL25A1 Body OpenSea 0.533 0.48 0.053 5.18E-04 3.59E-03 
cg11165912 4 1.1E+08 COL25A1 Body N_Shelf 0.258 0.207 0.051 1.25E-05 2.61E-04 
cg00421164 6 7111068 RREB1 5'UTR S_Shore 0.827 0.774 0.053 1.90E-04 1.79E-03 
cg09754197 6 7113738 RREB1 5'UTR S_Shelf 0.741 0.69 0.051 2.60E-05 4.40E-04 
cg09326832 6 7243643 RREB1 Body N_Shelf 0.25 0.198 0.051 3.04E-03 1.22E-02 
cg10718056 6 28884599 TRIM27 Body OpenSea 0.515 0.462 0.053 1.38E-03 7.05E-03 
cg10401017 6 28887586 TRIM27 Body N_Shelf 0.83 0.767 0.063 3.89E-04 2.94E-03 
cg05216056 6 28887836 TRIM27 Body N_Shelf 0.646 0.595 0.051 7.20E-03 2.25E-02 
cg11387340 6 1.67E+08 RPS6KA2 Body OpenSea 0.366 0.314 0.052 3.52E-03 1.35E-02 
cg23464284 6 1.67E+08 RPS6KA2 Body OpenSea 0.532 0.457 0.076 1.67E-02 4.18E-02 
cg13072943 6 1.67E+08 RPS6KA2 Body OpenSea 0.619 0.568 0.051 7.96E-03 2.42E-02 
cg05791862 6 1.67E+08 RPS6KA2 Body OpenSea 0.734 0.683 0.051 4.65E-05 6.64E-04 
cg00084338 6 1.71E+08 DLL1 Body N_Shore 0.598 0.495 0.103 2.67E-05 4.49E-04 
cg27246129 6 1.71E+08 DLL1 Body N_Shore 0.55 0.48 0.07 2.71E-05 4.52E-04 
cg15931921 6 1.71E+08 DLL1 Body N_Shore 0.748 0.669 0.08 1.95E-05 3.59E-04 







cg23445003 7 1.02E+08 CUX1 Body OpenSea 0.575 0.515 0.061 1.80E-02 4.43E-02 
cg17974145 7 1.02E+08 CUX1 Body OpenSea 0.617 0.561 0.055 2.14E-03 9.56E-03 
cg24786658 7 1.13E+08 GPR85 TSS1500;5'UTR OpenSea 0.705 0.647 0.058 1.90E-05 3.52E-04 
cg25263801 7 1.13E+08 GPR85 TSS1500;1stExon;5'UTR OpenSea 0.719 0.664 0.055 8.11E-05 9.85E-04 
cg09506675 7 1.13E+08 GPR85 TSS1500;TSS200 OpenSea 0.546 0.491 0.055 8.81E-04 5.17E-03 
cg10071929 9 1.31E+08 CIZ1 TSS1500;5'UTR N_Shore 0.189 0.138 0.051 6.18E-03 2.02E-02 
cg13642260 9 1.31E+08 CIZ1 5'UTR Island 0.215 0.164 0.05 1.04E-02 2.94E-02 
cg09976142 9 1.31E+08 CIZ1 5'UTR Island 0.296 0.236 0.06 8.49E-03 2.54E-02 
cg01832662 14 86086389 FLRT2 5'UTR OpenSea 0.231 0.173 0.058 1.24E-02 3.34E-02 
cg26235748 14 86087511 FLRT2 5'UTR OpenSea 0.531 0.454 0.077 1.01E-05 2.23E-04 
cg22859727 14 86090320 FLRT2 3'UTR OpenSea 0.432 0.38 0.052 1.75E-06 6.28E-05 
cg23047825 15 99317340 IGF1R Body OpenSea 0.791 0.728 0.063 4.84E-03 1.70E-02 
cg08920032 15 99332004 IGF1R Body OpenSea 0.623 0.568 0.055 2.51E-03 1.07E-02 
cg10342963 15 99443213 IGF1R Body OpenSea 0.759 0.709 0.05 6.58E-03 2.11E-02 
cg16616918 17 1686627 SMYD4 Body OpenSea 0.692 0.635 0.056 8.23E-05 9.95E-04 
cg09940188 17 1686671 SMYD4 Body OpenSea 0.599 0.538 0.061 4.37E-04 3.19E-03 
cg23679982 17 1686737 SMYD4 Body OpenSea 0.636 0.57 0.066 9.76E-05 1.12E-03 
cg13518079 20 2675072 EBF4 Body S_Shore 0.35 0.262 0.088 3.33E-07 1.90E-05 
cg05857996 20 2675418 EBF4 Body S_Shore 0.786 0.686 0.101 6.88E-06 1.69E-04 
cg16426670 20 2675996 EBF4 Body S_Shore 0.812 0.75 0.062 2.29E-08 2.74E-06 
cg24263062 20 2730191 EBF4 Body Island 0.636 0.55 0.086 1.30E-07 9.59E-06 
cg05825244 20 2730488 EBF4 Body Island 0.428 0.271 0.157 9.32E-08 7.58E-06 








The goal of this dissertation was to advance our understanding of the relationship between early 
antiretroviral therapy (ART) and outcomes in HIV-infected infants and children by focusing on 
questions relevant to early ART initiation in infants, an area of particular interest after the case 
report of the Mississippi baby who initiated ART very early, achieved long-term HIV remission 
of 27 months, and generated hope for the possibility of HIV remission.  A systematic review was 
conducted to evaluate if early antiretroviral therapy can lead to HIV remission.  From this, a 
number of gaps were identified, including limited data on (1) the association between early ART 
initiation and initial viral suppression, as well as (2) the association between early ART initiation 
and long-term virologic control, which were empirically studied using data from five cohorts in 
Johannesburg, South Africa in the subsequent chapter.  Finally, an epigenome-wide association 
study was conducted to identify differential DNA methylation patterns between ART-treated 
HIV-infected and HIV-uninfected South African children.  Below, the primary results are 
summarized and implications are discussed.  
 
5.2. Summary of Results 
 
In the systematic review described in Chapter 2 of this dissertation, six questions relevant to 
advancing the study of early ART and HIV remission were assessed.  First, in case reports of 
neonates starting ART very early, HIV can be suppressed to an undetectable level in plasma, 
albeit not rapidly; however the generalizability of these cases is unclear. Second, rates of initial 
viral suppression do not appear to be higher in groups of infants who start ART in the first few 
months of life compared to infants who start ART later in the first year of life. Third, a small 
 
 134 
number of studies suggest that infants who start ART early may have better viral control 
compared to infants who start ART later. Fourth, we examined studies of markers of the size of 
the viral reservoir in HIV-infected infants starting ART early. These studies indicated that infants 
who start treatment early may have smaller viral reservoirs than infants who start treatment later; 
however larger numbers of well-characterized children are needed. Fifth, studies of STIs did not 
identify any cases of long-term remission.  Finally, 4 out of 5 neonates who started ART (out of 
the 13 identified above) and later interrupted treatment experienced viral rebound by 15 days 
after ART cessation; the fifth infant was the Mississippi baby, who did not rebound until 27 
months post-treatment interruption.  The one exception is the French teenager who initiated ART 
at 3 months and has had low level viremia off ART for >12 years.  From this critical review of 
the literature, we determined that although early ART does appear to be associated with better 
long-term virologic outcomes and smaller reservoir size, limited data exist at this time to support 
a strong link between early ART and HIV remission.   
 
Next, in Chapter 3, data from five study cohorts of HIV-infected children initiating ART before 
2 years of age in Johannesburg, South Africa were used to examine the association between age 
at starting ART and (1) initial viral response in three cohorts and (2) later virologic control after 
achieving suppression in two cohorts.  Improved virologic control after initial viral suppression 
was found in children starting ART before 6 months of age compared to those starting at 6-24 
months in two large cohorts.  However, no consistent benefits of early treatment on initial viral 
suppression were found, even when cohorts were combined.  The results of this analysis 
demonstrate that early initiation of ART in HIV-infected infants may have implications for long-
term viral suppression.  The results coherently fit in with findings from our systematic review in 
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Chapter 2, relevant to the first two questions, with no clear association between early age at 
ART initiation and initial viral suppression, but better maintenance of viral suppression in infants 
initiated on ART early.  The study highlighted issues with studying the timing of treatment using 
observation data. In particular, there could be selection bias issues with how infants are grouped 
into an early or late treatment group.  For example, decisions to treat earlier or later may depend 
on disease severity and other indicators of prognosis. 
 
Finally, in Chapter 4, an epigenome-wide association study (EWAS) was conducted to identify 
differential DNA methylation patterns associated with HIV status in children.  The sample 
included 119 HIV-infected children who were initiated on ART before 2 years of age and 60 
HIV-uninfected children frequency matched by age.  First, using a genome-wide CpG site 
approach, a total of 1,309 differentially methylated CpG sites associated with HIV were selected 
(FDR q-value <0.05; |Δβ| >0.05), after adjustment for age, sex, and cell type proportions.  
Several sites were of particular importance.  The top hypo-methylated site was located in the 
promoter region of the NLRC5 gene, which plays a role in the regulation of major 
histocompatibility complex (MHC) class I molecule expression, and 6 CpG sites were located on 
EBF4, a gene that codes for a transcription factor involved in B-cell maturation.  Next, using a 
region approach, 315 regions associated with HIV status were selected (Stouffer p-value <0.05, 
maximum |Δβ| change in the region >0.05, and containing at least two or more CpG sites), 
including 28 regions consisting of 686 CpG sites located on chromosome 6.  Many of the genes 
identified in both the CpG site and region approach were located in the MHC region on 
chromosome 6, a region that plays an important role in the adaptive immune system.  Overall, 
this study indicated that perinatally acquired HIV infection is associated with a large number of 
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changes in DNA methylation in school-aged children on ART, and providing new insights into 
the biologic pathways influenced by HIV and its treatment.  
 
5.3. Limitations and Strengths 
 
The analyses presented in this dissertation have several limitations.  First, although our review in 
Chapter 2 demonstrated the need for data on the association between very early ART initiation 
and virologic outcomes, we were only able to use a 6 month cut off to assess the effects of early 
ART initiation on virologic outcomes in Chapter 3, as there were only small numbers of 
children initiating ART prior to 6 weeks of age.  Second, in our evaluation of initial response to 
treatment in Chapter 3, we were unable to account for differences in the three cohorts we 
combined (e.g. different viral load assays, temporal changes in drug regimens, dosing, and 
clinical practice).  Third, our study of the relationship between early ART and virologic 
outcomes would have been strengthened if measures of the viral reservoir were available.  
Fourth, in Chapter 4, DNA methylation was assessed in whole blood, and we were limited to 
using an algorithm to adjust for potential confounding by cell type heterogeneity, as cell sorting 
by flow cytometry was not possible in this setting.  Finally, for our genome-wide study in 
Chapter 4, we selected a homogeneous group of HIV-infected children who were initiated on 
the same treatment regimen before 2 years of age.  Thus, we could not evaluate associations 
between methylation differences at specific CpG sites and clinical outcomes due to lack of 
variability.  Further, the homogeneity of our HIV-infected group and the cross-sectional nature 
of our study meant we could not separate out ART- vs. HIV-related effects on DNA methylation, 





Notwithstanding these limitations, this dissertation has many important strengths.  The 
comprehensive review provided a critical analysis of existing data to inform understanding of 
early ART and HIV remission, identifying precise areas that require greater research.  The first 
empirical aim contributed new data on virologic outcomes associated with age at treatment 
initiation, one of the major knowledge gaps identified in the systematic review.  To our 
knowledge, this was the first genome-wide study of DNA methylation in perinatally HIV-
infected children, generating novel insights into the biologic pathways influenced by HIV and 
ART.  Finally, the empirical aims were conducted using data from sub-Saharan Africa, a region 
that bears the greatest burden of pediatric HIV now and in the foreseeable future.  
 
5.4. Implications and Future Directions 
 
The findings from this dissertation have several important implications for clinical practice and 
for future studies on early treatment and outcomes in the field of pediatric HIV.   
 
Clinically, the public health field continues to move towards HIV diagnosis at birth and very 
early life initiation of ART.  Given this, the “goal” of very early ART should be kept in mind: Is 
it to reduce morbidity/mortality?  Is it to improve long-term virological outcomes?  Or is it to 
achieve HIV remission?  This dissertation demonstrated that different goals have different levels 
of evidence, and it is clear that we have extremely limited evidence for some of these outcomes.  
There is a critical need to understand if the potential benefits of very early ART outweigh the 
potential risks.  The treatment of newborns is difficult, as very early treatment is reliant on drug 
options that are potent, not toxic, and supported by dosing, formulations, and safety data. 
 
 138 
Currently, there are limited drug options for this age group.  In addition, adherence to treatment 
can be challenging to achieve in newborns. 
 
This dissertation also has several implications for future research studies.  First, in order to 
understand if early ART can result in HIV remission, then studies need to be designed with HIV 
remission in mind.  These studies will require prospective data in larger cohorts with clearly-
defined and representative populations of HIV-infected neonates and infants initiating ART 
early, as well as a careful consideration of what information should be collected to measure HIV 
remission.  At the very least, future studies will need to include systematic measures of virologic 
outcomes, including detailed markers of the viral reservoir.  In addition, future studies of 
outcomes in HIV-infected infants and young children using observational data need to consider 
issues of bias that arise with assessing the timing of ART initiation.  Finally, the epigenetic 
changes identified in a group of ART-treated and well-controlled HIV infected children have 
many research implications, as they may provide clues regarding pathways through which HIV 
and its treatment may affect long-term outcomes.  Moving forward, additional stored samples 
will be used for further testing.  To validate the findings, fine-mapping of important candidate 
genes identified in the EWAS study, including NLRC5, EBF4, XDH, and others, will be 
performed.  In addition, potential associations of the DNA methylation findings with clinical 
outcomes will have to be evaluated.  It will also be important to evaluate longitudinal changes in 
DINA methylation in children before and after starting antiretroviral therapy.  These planned 
studies will use the newer EPIC array (850K) which covers an additional 413,745 new CpG sites 




In conclusion, this dissertation increased our understanding of the timing of early ART initiation 
in HIV-infected infants and addressed gaps in our knowledge relevant to outcomes associated 
with early age at ART initiation.  We did not find evidence that early treatment initiation leads to 
higher rates of initial viral suppression, but we did find evidence that early treatment initiation 
improves long-term viral control.  This was supported by empirical evidence from our study as 
well as data from other studies in our review.  In addition, the study of epigenetic changes in 
children with HIV infection identified novel genes that may be affected by HIV and its 
treatment.  As public health practice continues to move towards infant diagnosis of HIV at birth 













Appendix Table 4.1: Selected differentially methylated CpG sites (N=1,309) associated with HIV after adjustment for age, sex, 
and cell type proportion with FDR q-value <0.05 and |Δβ| >0.05, sorted by P-value from smallest to largest 
 





Δβ P Adj P 
cg09239591 2 31638511 XDH TSS1500 OpenSea 0.675 0.623 0.053 2.44E-15 1.97E-11 
cg23101680 13 46277286 SPERT Body OpenSea 0.717 0.663 0.053 4.89E-14 1.83E-10 
cg07839457 16 57023022 NLRC5 TSS1500 N_Shore 0.261 0.353 -0.092 4.69E-11 2.87E-08 
cg12027254 17 76055290 TNRC6C Body OpenSea 0.824 0.766 0.058 1.00E-10 4.99E-08 
cg07970325 6 106497542   OpenSea 0.569 0.512 0.057 1.39E-10 6.38E-08 
cg26280998 6 53589544   OpenSea 0.715 0.659 0.056 1.72E-10 7.29E-08 
cg12880685 10 120489658 C10orf46 Body OpenSea 0.428 0.378 0.050 1.85E-10 7.66E-08 
cg13316433 5 83140500   OpenSea 0.150 0.207 -0.057 2.28E-10 8.94E-08 
cg00390724 3 18484742   N_Shore 0.519 0.456 0.063 2.66E-10 1.01E-07 
cg22690339 6 38249061 BTBD9 Body OpenSea 0.792 0.735 0.058 3.47E-10 1.22E-07 
cg05929755 1 110663559   OpenSea 0.398 0.339 0.059 7.36E-10 2.15E-07 
cg12021671 15 42423807   OpenSea 0.744 0.690 0.054 1.02E-09 2.75E-07 
cg08237220 3 156332967   OpenSea 0.531 0.459 0.072 1.07E-09 2.85E-07 
cg05006384 14 95942319 C14orf49 TSS200 OpenSea 0.648 0.595 0.053 1.74E-09 4.09E-07 
cg13707760 9 95986383 WNK2 Body OpenSea 0.509 0.449 0.060 2.03E-09 4.58E-07 
cg18394552 5 159428643   OpenSea 0.732 0.650 0.081 2.42E-09 5.17E-07 
cg10336193 1 206848389   OpenSea 0.644 0.584 0.060 2.88E-09 5.88E-07 
cg22348290 8 72459499   N_Shore 0.767 0.709 0.058 3.22E-09 6.37E-07 
cg26898099 5 95192949 C5orf27 Body OpenSea 0.706 0.650 0.055 6.44E-09 1.07E-06 
cg14418857 7 121120431   OpenSea 0.616 0.535 0.080 6.86E-09 1.13E-06 
cg22647738 17 34304462 CCL16 3'UTR OpenSea 0.639 0.561 0.078 8.18E-09 1.29E-06 
cg05512157 12 50901878 DIP2B Body S_Shelf 0.587 0.533 0.054 8.71E-09 1.35E-06 
cg21912162 5 71447818 MAP1B Body OpenSea 0.329 0.276 0.053 9.65E-09 1.46E-06 
cg23720384 21 23747055   OpenSea 0.665 0.583 0.082 1.10E-08 1.61E-06 
cg04961225 12 91332479   OpenSea 0.578 0.515 0.063 1.12E-08 1.63E-06 
cg10689689 11 63677197 MARK2 3'UTR S_Shore 0.685 0.634 0.051 1.42E-08 1.93E-06 
cg15826519 1 19808575 CAPZB Body N_Shelf 0.796 0.742 0.054 1.49E-08 2.00E-06 
cg09083958 12 131516365 GPR133 Body N_Shore 0.696 0.642 0.054 1.53E-08 2.04E-06 
cg02341197 21 34185927 C21orf62 5'UTR;1stExon OpenSea 0.466 0.408 0.058 1.54E-08 2.05E-06 
cg08937102 1 1690389 NADK Body N_Shore 0.481 0.428 0.053 1.75E-08 2.24E-06 
cg20954180 3 54606265 CACNA2D3 Body OpenSea 0.847 0.794 0.053 1.75E-08 2.25E-06 
cg17069396 20 2731102 EBF4 Body Island 0.128 0.069 0.058 1.81E-08 2.30E-06 
cg16426670 20 2675996 EBF4 Body S_Shore 0.812 0.750 0.062 2.29E-08 2.74E-06 
cg15773890 6 17259549   OpenSea 0.866 0.812 0.054 2.73E-08 3.12E-06 
cg03705319 12 12848516 GPR19 5'UTR N_Shore 0.745 0.693 0.052 2.75E-08 3.14E-06 
cg00602295 16 81328089   OpenSea 0.441 0.375 0.065 2.81E-08 3.18E-06 







cg24399529 15 69373153 MIR548H4;TMEM84 Body;TSS200 OpenSea 0.256 0.205 0.051 2.92E-08 3.28E-06 
cg23429698 8 98878169   N_Shelf 0.324 0.268 0.056 3.13E-08 3.44E-06 
cg23992886 7 116420651 MET Body OpenSea 0.635 0.578 0.058 3.43E-08 3.68E-06 
cg00399027 16 85676861 KIAA0182 5'UTR;Body S_Shore 0.607 0.547 0.060 3.72E-08 3.89E-06 
cg04042861 2 231989824 PSMD1;HTR2B TSS200;Body OpenSea 0.406 0.346 0.060 4.25E-08 4.29E-06 
cg18835596 6 135540107 MYB 3'UTR OpenSea 0.725 0.659 0.066 4.46E-08 4.45E-06 
cg03182584 7 36364854 KIAA0895 3'UTR OpenSea 0.689 0.631 0.058 4.53E-08 4.49E-06 
cg00105306 15 85194978 WDR73 Body N_Shelf 0.626 0.569 0.057 4.88E-08 4.75E-06 
cg24499605 1 3142925 PRDM16 Body OpenSea 0.550 0.489 0.061 5.85E-08 5.41E-06 
cg07589393 7 26984305   OpenSea 0.724 0.674 0.050 6.01E-08 5.52E-06 
cg09722609 5 149887422 NDST1 TSS1500 OpenSea 0.607 0.551 0.055 6.05E-08 5.54E-06 
cg04339360 13 73635568 KLF5 Body S_Shore 0.710 0.644 0.066 6.23E-08 5.67E-06 
cg20426710 22 50248907 ZBED4 5'UTR N_Shore 0.519 0.461 0.057 6.33E-08 5.74E-06 
cg07264238 17 33474376 UNC45B TSS1500 OpenSea 0.778 0.707 0.071 7.23E-08 6.32E-06 
cg25718604 20 57601474 TUBB1 3'UTR S_Shelf 0.831 0.774 0.057 7.34E-08 6.40E-06 
cg19683780 8 42907576   N_Shelf 0.784 0.733 0.051 7.67E-08 6.60E-06 
cg12449049 6 25088999 CMAH Body OpenSea 0.686 0.636 0.050 8.32E-08 6.97E-06 
cg00864012 17 62294665 TEX2 5'UTR OpenSea 0.724 0.670 0.053 8.38E-08 7.01E-06 
cg00991744 12 41581484 PDZRN4 TSS1500 N_Shore 0.852 0.791 0.061 8.42E-08 7.04E-06 
cg09620718 16 20702872 ACSM1 TSS1500 OpenSea 0.784 0.733 0.051 8.51E-08 7.08E-06 
cg08066875 2 163197084   N_Shelf 0.637 0.581 0.056 8.63E-08 7.15E-06 
cg08324152 19 57172404   N_Shelf 0.283 0.216 0.067 9.18E-08 7.49E-06 
cg05825244 20 2730488 EBF4 Body Island 0.428 0.271 0.157 9.32E-08 7.58E-06 
cg00876141 4 47837775 CORIN Body N_Shore 0.451 0.396 0.055 9.35E-08 7.59E-06 
cg06096336 2 231989800 PSMD1;HTR2B Body;1stExon;5'UTR OpenSea 0.571 0.519 0.052 9.83E-08 7.88E-06 
cg11329129 11 705692 EPS8L2 TSS1500 N_Shore 0.417 0.367 0.051 9.86E-08 7.89E-06 
cg12876838 4 5897223   S_Shelf 0.754 0.702 0.052 1.10E-07 8.58E-06 
cg26475911 17 73056187 KCTD2 Body OpenSea 0.458 0.390 0.067 1.14E-07 8.78E-06 
cg13561554 15 78795944   N_Shelf 0.620 0.567 0.053 1.19E-07 9.04E-06 
cg26413942 5 124081751 ZNF608 TSS1500 OpenSea 0.421 0.361 0.060 1.24E-07 9.27E-06 
cg24263062 20 2730191 EBF4 Body Island 0.636 0.550 0.086 1.30E-07 9.59E-06 
cg13958199 9 127018815 NEK6 TSS1500 N_Shore 0.682 0.631 0.051 1.33E-07 9.77E-06 
cg02909097 17 2843206 RAP1GAP2 Body OpenSea 0.703 0.652 0.050 1.41E-07 1.02E-05 
cg16396907 11 114229775   OpenSea 0.229 0.179 0.050 1.50E-07 1.07E-05 
cg03477332 5 16178784 MARCH11 Body N_Shore 0.413 0.360 0.053 1.51E-07 1.07E-05 
cg02577773 2 208027870 KLF7 Body N_Shelf 0.652 0.588 0.064 1.56E-07 1.09E-05 
cg12588917 6 29692082 HLA-F Body Island 0.395 0.445 -0.051 1.79E-07 1.21E-05 
cg00787180 14 91751731 CCDC88C Body N_Shelf 0.393 0.340 0.052 1.79E-07 1.21E-05 
cg14659930 3 114128301 ZBTB20 5'UTR OpenSea 0.694 0.626 0.068 1.80E-07 1.21E-05 
cg26780125 8 125388806   S_Shelf 0.350 0.300 0.050 1.82E-07 1.22E-05 
cg19624420 14 48541885   OpenSea 0.869 0.798 0.071 2.00E-07 1.31E-05 
cg04982834 1 93258288 EVI5 TSS1500 OpenSea 0.666 0.609 0.057 2.14E-07 1.38E-05 
cg04223006 5 82845599 VCAN Body OpenSea 0.433 0.362 0.072 2.23E-07 1.42E-05 
cg07995200 6 108865761   OpenSea 0.809 0.759 0.050 2.32E-07 1.46E-05 
cg27579313 17 7381622 ZBTB4 5'UTR N_Shore 0.559 0.481 0.078 2.49E-07 1.54E-05 
cg16565528 8 91010920   N_Shelf 0.835 0.784 0.051 2.73E-07 1.64E-05 
cg25879365 1 40510058 CAP1 5'UTR S_Shelf 0.598 0.517 0.081 2.73E-07 1.64E-05 







cg09029192 17 76015204 TNRC6C 5'UTR OpenSea 0.709 0.654 0.054 3.16E-07 1.84E-05 
cg14905634 12 73057369 TRHDE 3'UTR OpenSea 0.707 0.654 0.053 3.33E-07 1.90E-05 
cg13518079 20 2675072 EBF4 Body S_Shore 0.350 0.262 0.088 3.33E-07 1.90E-05 
cg00059652 17 67605498   OpenSea 0.639 0.579 0.061 3.37E-07 1.92E-05 
cg25671837 6 127513912 RSPO3 Body OpenSea 0.437 0.369 0.067 3.53E-07 1.99E-05 
cg04873188 2 70143463 MXD1 Body S_Shore 0.567 0.494 0.073 3.91E-07 2.14E-05 
cg25670076 6 90807675 BACH2 5'UTR OpenSea 0.773 0.708 0.065 4.04E-07 2.19E-05 
cg18640098 5 9888660 LOC285692 Body OpenSea 0.869 0.807 0.063 4.05E-07 2.19E-05 
cg02127888 16 1665900 CRAMP1L Body S_Shore 0.428 0.346 0.082 4.06E-07 2.20E-05 
cg08036553 1 64649805   OpenSea 0.844 0.790 0.055 4.16E-07 2.24E-05 
cg11681597 1 249116587 SH3BP5L Body N_Shelf 0.507 0.456 0.051 4.45E-07 2.35E-05 
cg12039595 1 244480459   OpenSea 0.512 0.455 0.057 4.49E-07 2.36E-05 
cg13174253 8 146278678 C8orf33 Body S_Shore 0.623 0.573 0.050 4.50E-07 2.37E-05 
cg22986770 8 61648691 CHD7 5'UTR OpenSea 0.477 0.404 0.073 4.51E-07 2.37E-05 
cg00076653 4 15341878 C1QTNF7 Body OpenSea 0.527 0.472 0.055 4.66E-07 2.43E-05 
cg01232748 4 54928819 CHIC2 Body N_Shore 0.511 0.451 0.060 4.86E-07 2.50E-05 
cg00638210 3 126732518 PLXNA1 Body N_Shore 0.685 0.630 0.055 5.33E-07 2.67E-05 
cg22143698 5 10608058 ANKRD33B Body OpenSea 0.199 0.147 0.052 5.35E-07 2.68E-05 
cg23824801 12 54653403 CBX5 TSS200;5'UTR OpenSea 0.280 0.218 0.062 5.41E-07 2.70E-05 
cg08173709 3 71103443 FOXP1 Body OpenSea 0.726 0.669 0.057 5.42E-07 2.71E-05 
cg02320356 8 127237106   OpenSea 0.789 0.734 0.055 5.51E-07 2.74E-05 
cg08899667 6 31761055 VARS Body N_Shelf 0.620 0.568 0.052 5.56E-07 2.76E-05 
cg25217710 1 156609523   N_Shelf 0.649 0.591 0.058 5.57E-07 2.76E-05 
cg12409074 11 129870648 PRDM10 5'UTR N_Shore 0.489 0.430 0.060 5.65E-07 2.78E-05 
cg12821315 3 183959034 VWA5B2;MIR1224 Body;TSS200 N_Shore 0.822 0.772 0.050 5.97E-07 2.90E-05 
cg16356622 1 36351841 EIF2C1 Body S_Shelf 0.522 0.466 0.056 6.43E-07 3.05E-05 
cg10264529 14 24562064 PCK2 TSS1500 N_Shore 0.634 0.573 0.061 6.67E-07 3.13E-05 
cg20755748 12 31799116 C12orf72 TSS1500 OpenSea 0.572 0.515 0.057 6.73E-07 3.15E-05 
cg02302089 7 23401203 IGF2BP3 Body OpenSea 0.415 0.354 0.061 6.76E-07 3.15E-05 
cg11274172 11 75736215 UVRAG Body OpenSea 0.479 0.427 0.052 6.81E-07 3.17E-05 
cg22497969 1 3143018 PRDM16 Body OpenSea 0.784 0.728 0.057 7.34E-07 3.35E-05 
cg05236731 13 41035061 LOC646982 Body OpenSea 0.852 0.797 0.055 8.46E-07 3.72E-05 
cg15847685 4 62129666   OpenSea 0.786 0.726 0.060 8.59E-07 3.76E-05 
cg07349663 1 160261619 COPA Body OpenSea 0.658 0.598 0.061 8.74E-07 3.80E-05 
cg14799457 18 19927125   N_Shore 0.317 0.262 0.055 9.46E-07 4.03E-05 
cg16312514 11 70650521 SHANK2 Body OpenSea 0.590 0.533 0.057 9.51E-07 4.04E-05 
cg01734045 4 109967535 COL25A1 Body OpenSea 0.292 0.240 0.052 9.82E-07 4.14E-05 
cg20433822 10 124690751 C10orf88 3'UTR OpenSea 0.278 0.214 0.063 1.09E-06 4.46E-05 
cg25199005 1 246446300 SMYD3 Body OpenSea 0.777 0.713 0.064 1.12E-06 4.56E-05 
cg07143462 2 157289513   N_Shelf 0.688 0.622 0.066 1.20E-06 4.78E-05 
cg08597292 6 89996028 GABRR2 Body OpenSea 0.898 0.845 0.053 1.21E-06 4.81E-05 
cg20117260 19 41937434 ATP5SL 3'UTR;Body OpenSea 0.584 0.534 0.050 1.24E-06 4.92E-05 
cg00391741 3 127307227 TPRA1 5'UTR N_Shore 0.735 0.679 0.056 1.25E-06 4.94E-05 
cg13448092 3 181135878   OpenSea 0.521 0.471 0.050 1.30E-06 5.05E-05 
cg07176842 14 43972223   OpenSea 0.574 0.483 0.092 1.41E-06 5.37E-05 
cg00217953 2 97527635 SEMA4C Body Island 0.643 0.592 0.050 1.43E-06 5.42E-05 
cg26955132 12 13181499   OpenSea 0.744 0.673 0.070 1.46E-06 5.53E-05 







cg20638127 6 31023286 HCG22 Body OpenSea 0.807 0.756 0.050 1.57E-06 5.81E-05 
cg00500176 19 10396158 ICAM4 TSS1500;3'UTR N_Shore 0.591 0.537 0.054 1.70E-06 6.15E-05 
cg16321846 7 4050114 SDK1 Body OpenSea 0.751 0.684 0.067 1.71E-06 6.16E-05 
cg22859727 14 86090320 FLRT2 3'UTR OpenSea 0.432 0.380 0.052 1.75E-06 6.28E-05 
cg17044311 10 101542983 ABCC2 Body OpenSea 0.813 0.760 0.053 1.75E-06 6.28E-05 
cg21545762 3 183959118 VWA5B2;MIR1224 Body;TSS200 Island 0.562 0.510 0.052 1.79E-06 6.39E-05 
cg19956914 7 56147257 SUMF2 Body OpenSea 0.663 0.610 0.053 1.80E-06 6.42E-05 
cg24134261 2 33661362 RASGRP3 TSS200 OpenSea 0.403 0.346 0.057 1.88E-06 6.60E-05 
cg13485718 14 93315488   OpenSea 0.560 0.498 0.062 1.89E-06 6.62E-05 
cg24897320 1 110042528 CYB561D1 3'UTR OpenSea 0.545 0.494 0.051 1.89E-06 6.63E-05 
cg06121226 4 72134060 SLC4A4 Body OpenSea 0.829 0.774 0.055 1.92E-06 6.69E-05 
cg11945474 2 55717980   OpenSea 0.773 0.711 0.062 2.00E-06 6.89E-05 
cg13089335 1 167203243 POU2F1 5'UTR OpenSea 0.543 0.492 0.052 2.04E-06 7.00E-05 
cg14989243 6 76203530 FILIP1 TSS200 OpenSea 0.527 0.452 0.075 2.08E-06 7.10E-05 
cg24243879 10 76614628 MYST4 Body OpenSea 0.260 0.207 0.053 2.13E-06 7.23E-05 
cg12081645 4 157920476   OpenSea 0.444 0.375 0.069 2.31E-06 7.68E-05 
cg16305292 8 142219965   N_Shore 0.627 0.572 0.055 2.36E-06 7.81E-05 
cg02329430 15 73921385 NPTN Body N_Shelf 0.391 0.328 0.063 2.50E-06 8.13E-05 
cg13717434 9 97854044   OpenSea 0.602 0.545 0.057 2.65E-06 8.50E-05 
cg19288514 22 25594918 CRYBB3 TSS1500 OpenSea 0.526 0.473 0.053 2.75E-06 8.71E-05 
cg25015371 6 108874950   N_Shelf 0.580 0.527 0.053 2.99E-06 9.26E-05 
cg23970645 14 89695299 FOXN3 Body OpenSea 0.777 0.714 0.063 3.10E-06 9.52E-05 
cg26837192 2 48813184 STON1;STON1-GTF2A1L Body OpenSea 0.778 0.714 0.063 3.18E-06 9.69E-05 
cg07425204 17 66511183 PRKAR1A 5'UTR S_Shelf 0.481 0.421 0.060 3.26E-06 9.86E-05 
cg01282174 11 119630144   OpenSea 0.484 0.415 0.069 3.35E-06 1.01E-04 
cg11429292 12 6888035   OpenSea 0.178 0.128 0.050 3.41E-06 1.02E-04 
cg08129017 17 17728660 SREBF1 Body S_Shore 0.412 0.357 0.055 3.61E-06 1.06E-04 
cg17082225 7 56673049   OpenSea 0.667 0.613 0.054 3.65E-06 1.07E-04 
cg17301248 12 112467203 NAA25 3'UTR OpenSea 0.642 0.564 0.078 3.66E-06 1.07E-04 
cg26943120 4 5472116 STK32B Body OpenSea 0.631 0.574 0.057 3.68E-06 1.08E-04 
cg12549908 10 4230567   OpenSea 0.761 0.705 0.056 3.80E-06 1.10E-04 
cg03820688 2 55477848 MTIF2 Body OpenSea 0.744 0.683 0.061 4.03E-06 1.15E-04 
cg16479633 8 20080666   OpenSea 0.564 0.512 0.052 4.17E-06 1.17E-04 
cg24760467 10 102760784 LZTS2 5'UTR S_Shore 0.622 0.565 0.057 4.18E-06 1.18E-04 
cg00583068 1 224972796   OpenSea 0.592 0.542 0.051 4.34E-06 1.21E-04 
cg15034267 22 39106452 GTPBP1 Body S_Shelf 0.768 0.700 0.068 4.36E-06 1.21E-04 
cg26959655 8 103379529 UBR5 Body OpenSea 0.525 0.473 0.052 4.36E-06 1.22E-04 
cg07039560 5 140683681 SLC25A2 TSS200 Island 0.667 0.613 0.054 4.43E-06 1.23E-04 
cg27416489 2 149823115 KIF5C Body OpenSea 0.750 0.686 0.064 4.46E-06 1.23E-04 
cg25688583 15 57510460 TCF12 TSS1500;Body OpenSea 0.674 0.610 0.064 4.48E-06 1.24E-04 
cg07793033 16 85256423   OpenSea 0.745 0.695 0.050 4.63E-06 1.27E-04 
cg17568809 5 142153529 ARHGAP26 Body S_Shelf 0.742 0.681 0.061 4.83E-06 1.31E-04 
cg01948202 3 122400474 PARP14 Body S_Shore 0.156 0.211 -0.054 4.85E-06 1.31E-04 
cg05264870 2 206599315 NRP2 Body OpenSea 0.606 0.545 0.061 4.90E-06 1.32E-04 
cg07922843 1 92083173   OpenSea 0.705 0.653 0.051 4.95E-06 1.33E-04 
cg16153042 6 3282307 SLC22A23 Body OpenSea 0.646 0.587 0.058 5.15E-06 1.37E-04 
cg15059804 1 33766318 ZNF362 3'UTR OpenSea 0.731 0.649 0.082 5.34E-06 1.41E-04 







cg16317516 11 47294196 MADD 5'UTR S_Shelf 0.557 0.498 0.059 5.86E-06 1.51E-04 
cg11973132 11 67052656 ADRBK1 Body Island 0.584 0.534 0.051 5.96E-06 1.53E-04 
cg06899237 6 153353519 RGS17 Body OpenSea 0.427 0.371 0.056 6.22E-06 1.57E-04 
cg06832406 10 4230482   OpenSea 0.810 0.758 0.052 6.22E-06 1.57E-04 
cg04083076 1 169452126 SLC19A2 Body N_Shelf 0.697 0.633 0.065 6.23E-06 1.57E-04 
cg05475386 12 65723693 MSRB3 Body OpenSea 0.304 0.243 0.061 6.25E-06 1.58E-04 
cg22491058 1 207277466 C4BPA TSS200 OpenSea 0.502 0.448 0.054 6.38E-06 1.60E-04 
cg01123957 14 34081647 NPAS3 Body OpenSea 0.286 0.234 0.052 6.57E-06 1.64E-04 
cg00950497 10 116393423 ABLIM1 Body S_Shore 0.630 0.569 0.062 6.73E-06 1.67E-04 
cg17111025 2 111936357   OpenSea 0.944 0.887 0.056 6.87E-06 1.69E-04 
cg05857996 20 2675418 EBF4 Body S_Shore 0.786 0.686 0.101 6.88E-06 1.69E-04 
cg14289429 9 134139878 FAM78A Body S_Shelf 0.440 0.388 0.053 6.90E-06 1.70E-04 
cg13547053 2 179184864 OSBPL6 TSS200;Body OpenSea 0.717 0.659 0.058 7.13E-06 1.74E-04 
cg10897223 6 30113774 TRIM40 Body OpenSea 0.666 0.613 0.053 7.48E-06 1.79E-04 
cg03529358 17 78198361 SLC26A11 Body S_Shelf 0.935 0.875 0.060 7.78E-06 1.85E-04 
cg06071730 10 112021300 MXI1 Body OpenSea 0.714 0.658 0.055 7.87E-06 1.87E-04 
cg10366878 4 79531297 ANXA3 3'UTR OpenSea 0.657 0.594 0.063 7.98E-06 1.88E-04 
cg05684528 5 76473917   N_Shelf 0.636 0.577 0.060 8.11E-06 1.90E-04 
cg10437839 11 64701910 PPP2R5B 3'UTR OpenSea 0.657 0.604 0.052 8.11E-06 1.91E-04 
cg18808261 3 18464935 SATB1 5'UTR N_Shore 0.290 0.231 0.059 8.33E-06 1.94E-04 
cg08340023 16 23098187 USP31 Body OpenSea 0.689 0.623 0.066 8.33E-06 1.94E-04 
cg02220129 11 58598239   OpenSea 0.837 0.774 0.064 8.50E-06 1.97E-04 
cg08602008 19 48076841   Island 0.337 0.284 0.053 8.80E-06 2.02E-04 
cg19662895 14 69074455   OpenSea 0.398 0.346 0.052 9.06E-06 2.07E-04 
cg02061820 3 152046751 MBNL1 Body OpenSea 0.459 0.385 0.074 9.36E-06 2.12E-04 
cg01618151 6 35707957 C6orf81 Body OpenSea 0.512 0.461 0.050 9.55E-06 2.15E-04 
cg27192248 15 65285669   S_Shelf 0.409 0.517 -0.108 9.67E-06 2.17E-04 
cg07661704 4 139144433 SLC7A11 Body OpenSea 0.561 0.496 0.065 9.74E-06 2.18E-04 
cg15644413 1 36185939 C1orf216 TSS1500 S_Shore 0.699 0.643 0.056 9.98E-06 2.22E-04 
cg26235748 14 86087511 FLRT2 5'UTR OpenSea 0.531 0.454 0.077 1.01E-05 2.23E-04 
cg10902738 8 134895500   OpenSea 0.667 0.605 0.062 1.04E-05 2.29E-04 
cg07291349 4 40964962 APBB2 Body OpenSea 0.643 0.572 0.071 1.07E-05 2.33E-04 
cg04139359 1 45085438 RNF220 Body S_Shelf 0.808 0.747 0.062 1.07E-05 2.33E-04 
cg03819286 16 4673974 MGRN1 TSS1500 N_Shore 0.725 0.674 0.051 1.07E-05 2.33E-04 
cg03546806 12 114297307 RBM19 Body OpenSea 0.740 0.689 0.051 1.15E-05 2.45E-04 
cg02059519 9 137250935 RXRA Body N_Shore 0.797 0.741 0.056 1.17E-05 2.49E-04 
cg01621943 17 53531409   OpenSea 0.697 0.646 0.051 1.17E-05 2.49E-04 
cg10196532 13 50134640 RCBTB1 Body OpenSea 0.818 0.734 0.084 1.18E-05 2.50E-04 
cg26293423 5 71613149 MRPS27 Body N_Shelf 0.749 0.695 0.054 1.19E-05 2.52E-04 
cg00021275 2 128142155   N_Shelf 0.731 0.674 0.057 1.22E-05 2.56E-04 
cg20141108 1 165907859   N_Shelf 0.653 0.587 0.066 1.22E-05 2.57E-04 
cg27408285 12 54653364 CBX5 1stExon;TSS200;5'UTR OpenSea 0.331 0.265 0.066 1.23E-05 2.58E-04 
cg11165912 4 110220063 COL25A1 Body N_Shelf 0.258 0.207 0.051 1.25E-05 2.61E-04 
cg05708073 1 109637162 TMEM167B 3'UTR S_Shelf 0.745 0.690 0.056 1.26E-05 2.62E-04 
cg14342532 2 233916534   OpenSea 0.355 0.299 0.056 1.28E-05 2.65E-04 
cg07624918 3 136533970   N_Shelf 0.752 0.699 0.053 1.31E-05 2.69E-04 
cg24235882 4 54928822 CHIC2 Body N_Shore 0.572 0.518 0.055 1.32E-05 2.70E-04 







cg20675439 6 82466362   S_Shelf 0.695 0.636 0.059 1.34E-05 2.73E-04 
cg18470427 17 33842301 SLFN12L Body OpenSea 0.840 0.768 0.073 1.37E-05 2.78E-04 
cg19841423 20 62366755 ZGPAT;LIME1 Body;TSS1500 S_Shore 0.713 0.660 0.053 1.38E-05 2.80E-04 
cg22992279 4 26414901 RBPJ Body OpenSea 0.745 0.691 0.054 1.39E-05 2.81E-04 
cg05808246 1 221741553   OpenSea 0.799 0.740 0.059 1.43E-05 2.88E-04 
cg10440877 2 208378475   OpenSea 0.723 0.666 0.057 1.47E-05 2.93E-04 
cg08106319 6 37849427 ZFAND3 Body OpenSea 0.381 0.309 0.073 1.50E-05 2.96E-04 
cg01822050 20 304156   N_Shore 0.748 0.686 0.062 1.50E-05 2.97E-04 
cg20790648 3 151619923   OpenSea 0.447 0.394 0.053 1.51E-05 2.98E-04 
cg16778107 16 381873 AXIN1 Body OpenSea 0.511 0.451 0.059 1.52E-05 2.99E-04 
cg05739816 6 135989395 C6orf217 Body OpenSea 0.534 0.459 0.074 1.53E-05 3.01E-04 
cg11952493 10 28570835 MPP7 5'UTR OpenSea 0.744 0.693 0.051 1.58E-05 3.09E-04 
cg14819618 8 8180214 PRAGMIN Body S_Shelf 0.793 0.729 0.063 1.67E-05 3.20E-04 
cg11356156 19 55416788 NCR1 TSS1500 OpenSea 0.727 0.677 0.050 1.69E-05 3.24E-04 
cg02543850 11 33346306 HIPK3 Body OpenSea 0.595 0.539 0.057 1.70E-05 3.25E-04 
cg00204748 12 29376779 FAR2 1stExon;5'UTR OpenSea 0.707 0.656 0.052 1.71E-05 3.26E-04 
cg00569896 4 204382   N_Shore 0.761 0.705 0.056 1.76E-05 3.34E-04 
cg18784409 11 67868331 CHKA Body OpenSea 0.509 0.456 0.053 1.78E-05 3.36E-04 
cg05850338 17 79933123   N_Shelf 0.686 0.623 0.062 1.78E-05 3.36E-04 
cg19995856 14 91574593   OpenSea 0.520 0.440 0.080 1.79E-05 3.38E-04 
cg03319082 16 1295309   OpenSea 0.713 0.662 0.050 1.83E-05 3.43E-04 
cg24786658 7 112727423 GPR85 TSS1500;5'UTR OpenSea 0.705 0.647 0.058 1.90E-05 3.52E-04 
cg17781958 17 79428404 BAHCC1 Body Island 0.758 0.702 0.057 1.93E-05 3.56E-04 
cg15931921 6 170597588 DLL1 Body N_Shore 0.748 0.669 0.080 1.95E-05 3.59E-04 
cg22143285 17 68070411 KCNJ16 TSS1500 OpenSea 0.550 0.498 0.052 2.00E-05 3.65E-04 
cg03680873 3 148844300   N_Shelf 0.600 0.535 0.065 2.04E-05 3.71E-04 
cg20176142 8 81408357 ZBTB10 Body OpenSea 0.728 0.678 0.050 2.11E-05 3.79E-04 
cg12114888 8 107738435 OXR1 Body OpenSea 0.336 0.283 0.053 2.28E-05 4.02E-04 
cg14384158 9 140348828 NELF Body N_Shore 0.160 0.107 0.053 2.33E-05 4.08E-04 
cg24392970 13 86373600 SLITRK6 TSS200 OpenSea 0.539 0.481 0.058 2.33E-05 4.08E-04 
cg06857116 17 15885326 ZSWIM7 Body OpenSea 0.594 0.540 0.054 2.36E-05 4.11E-04 
cg24247537 11 457278 PTDSS2 Body N_Shore 0.230 0.179 0.050 2.37E-05 4.12E-04 
cg16674514 17 42145043 LSM12 TSS200 S_Shore 0.748 0.695 0.053 2.38E-05 4.13E-04 
cg18638434 14 74486651 C14orf45;ENTPD5 Body;TSS1500 S_Shore 0.732 0.670 0.063 2.39E-05 4.14E-04 
cg21636683 5 140683699 SLC25A2 TSS200 Island 0.834 0.781 0.053 2.41E-05 4.17E-04 
cg03291835 13 110802745 COL4A1 Body OpenSea 0.681 0.618 0.064 2.47E-05 4.25E-04 
cg11909574 11 58598338   OpenSea 0.694 0.641 0.054 2.53E-05 4.31E-04 
cg26136772 7 4754681 FOXK1 Body N_Shelf 0.708 0.647 0.061 2.54E-05 4.33E-04 
cg11367259 8 89969235   OpenSea 0.828 0.773 0.055 2.56E-05 4.35E-04 
cg04567302 6 31846956 SLC44A4 TSS200 OpenSea 0.789 0.730 0.059 2.60E-05 4.40E-04 
cg09754197 6 7113738 RREB1 5'UTR S_Shelf 0.741 0.690 0.051 2.60E-05 4.40E-04 
cg24023489 8 103129227 NCALD 5'UTR OpenSea 0.723 0.673 0.051 2.67E-05 4.48E-04 
cg00084338 6 170595920 DLL1 Body N_Shore 0.598 0.495 0.103 2.67E-05 4.49E-04 
cg18388786 10 134924050 GPR123 Body N_Shore 0.312 0.254 0.058 2.70E-05 4.51E-04 
cg27246129 6 170595947 DLL1 Body N_Shore 0.550 0.480 0.070 2.71E-05 4.52E-04 
cg08500171 6 31590674 BAT2;SNORA38 Body;TSS200 S_Shore 0.782 0.732 0.050 2.73E-05 4.56E-04 
cg02354658 5 95151391 GLRX 3'UTR OpenSea 0.318 0.267 0.050 2.75E-05 4.57E-04 







cg11254053 1 33497125 AK2;AK2 Body OpenSea 0.554 0.496 0.058 2.77E-05 4.59E-04 
cg00634542 2 219254588 SLC11A1 Body N_Shore 0.556 0.495 0.062 2.85E-05 4.70E-04 
cg19723805 5 33147539   OpenSea 0.452 0.396 0.055 2.92E-05 4.77E-04 
cg20438472 3 184293365 EPHB3 Body S_Shelf 0.588 0.538 0.050 3.00E-05 4.87E-04 
cg05142445 14 76309157 TTLL5 Body OpenSea 0.716 0.657 0.059 3.04E-05 4.92E-04 
cg12559197 5 76654783 PDE8B Body OpenSea 0.515 0.440 0.074 3.21E-05 5.10E-04 
cg11505048 1 183622726 RGL1;APOBEC4 5'UTR;TSS1500 OpenSea 0.766 0.715 0.051 3.23E-05 5.13E-04 
cg07539709 17 80545454 FOXK2 Body Island 0.598 0.538 0.060 3.24E-05 5.15E-04 
cg14324502 9 88898587 ISCA1 TSS1500 S_Shore 0.555 0.489 0.066 3.31E-05 5.23E-04 
cg12700074 6 131571435 AKAP7 TSS200;Body OpenSea 0.180 0.127 0.053 3.32E-05 5.24E-04 
cg26423322 2 33905480   OpenSea 0.539 0.487 0.053 3.46E-05 5.39E-04 
cg13573513 12 14996143 ART4 5'UTR;1stExon OpenSea 0.763 0.698 0.065 3.49E-05 5.42E-04 
cg18067134 3 71084634 FOXP1 Body OpenSea 0.728 0.667 0.061 3.56E-05 5.50E-04 
cg01634388 4 129405035   OpenSea 0.301 0.238 0.063 3.57E-05 5.51E-04 
cg08632701 21 37451849   OpenSea 0.860 0.912 -0.052 3.59E-05 5.54E-04 
cg03529189 12 64292138 SRGAP1 Body OpenSea 0.743 0.689 0.053 3.60E-05 5.55E-04 
cg23711422 21 43442085 C21orf121 TSS200 OpenSea 0.502 0.430 0.073 3.66E-05 5.62E-04 
cg08739755 2 172815385 HAT1 Body OpenSea 0.803 0.737 0.066 3.82E-05 5.78E-04 
cg19560014 12 31799118 C12orf72 TSS1500 OpenSea 0.614 0.554 0.061 3.86E-05 5.83E-04 
cg16901361 8 107526473 OXR1 Body OpenSea 0.253 0.201 0.052 3.87E-05 5.84E-04 
cg05071334 8 86195487 CA13 3'UTR OpenSea 0.643 0.589 0.054 3.88E-05 5.85E-04 
cg08461760 7 25703644   OpenSea 0.790 0.736 0.054 3.94E-05 5.91E-04 
cg10584024 1 84234998   OpenSea 0.541 0.469 0.072 3.95E-05 5.92E-04 
cg04098052 7 24517414   OpenSea 0.674 0.620 0.053 3.95E-05 5.92E-04 
cg15516558 1 161091980 DEDD Body S_Shelf 0.488 0.434 0.054 3.98E-05 5.95E-04 
cg06508738 3 138763852 PRR23C TSS200 Island 0.623 0.567 0.057 3.98E-05 5.95E-04 
cg07951201 13 103340215 C13orf39 Body OpenSea 0.444 0.378 0.065 4.01E-05 5.98E-04 
cg12647970 6 3234297   S_Shelf 0.805 0.750 0.055 4.23E-05 6.22E-04 
cg05233670 12 109058033 CORO1C Body OpenSea 0.479 0.415 0.064 4.24E-05 6.23E-04 
cg08707875 1 224575077 WDR26 3'UTR OpenSea 0.702 0.646 0.056 4.31E-05 6.31E-04 
cg21781157 20 47874111 ZNFX1 Body OpenSea 0.530 0.468 0.063 4.37E-05 6.37E-04 
cg17846127 15 89940505 LOC254559 Body N_Shelf 0.688 0.632 0.056 4.39E-05 6.38E-04 
cg06663615 17 79423959 BAHCC1 Body N_Shore 0.565 0.513 0.052 4.42E-05 6.42E-04 
cg21043558 7 140625365 BRAF TSS1500 S_Shore 0.717 0.663 0.054 4.53E-05 6.53E-04 
cg05791862 6 167189213 RPS6KA2 Body OpenSea 0.734 0.683 0.051 4.65E-05 6.64E-04 
cg03077077 4 122685352 TMEM155;LOC100192379 5'UTR;TSS1500 N_Shore 0.684 0.624 0.060 4.66E-05 6.66E-04 
cg06633438 19 6272158 MLLT1 Body Island 0.606 0.525 0.080 4.67E-05 6.66E-04 
cg22596016 17 61711557 MAP3K3 Body OpenSea 0.266 0.201 0.065 4.82E-05 6.82E-04 
cg17129188 8 134307597 NDRG1 5'UTR N_Shore 0.774 0.722 0.052 4.82E-05 6.82E-04 
cg18115721 11 73567838 MRPL48 Body OpenSea 0.807 0.751 0.056 5.02E-05 7.01E-04 
cg02112168 14 45579561 PRPF39;SNORD127 Body;TSS1500 OpenSea 0.663 0.592 0.070 5.06E-05 7.06E-04 
cg27134944 13 76111107 COMMD6 Body N_Shore 0.560 0.501 0.059 5.10E-05 7.09E-04 
cg08064068 14 60671024   OpenSea 0.663 0.603 0.060 5.15E-05 7.14E-04 
cg00808648 14 105779910 PACS2;PACS2 TSS1500 N_Shore 0.307 0.256 0.051 5.34E-05 7.33E-04 
cg24530147 3 138763894 PRR23C TSS200 Island 0.773 0.707 0.066 5.35E-05 7.34E-04 
cg19161559 7 101465759 CUX1 Body OpenSea 0.720 0.669 0.052 5.42E-05 7.40E-04 
cg26104475 5 169693176 LCP2 Body OpenSea 0.640 0.584 0.056 5.45E-05 7.43E-04 







cg09777883 11 112093696   N_Shelf 0.744 0.688 0.056 5.51E-05 7.50E-04 
cg07769015 8 142238770 SLC45A4 TSS200 S_Shore 0.624 0.568 0.057 5.55E-05 7.53E-04 
cg02065051 20 25674725 ZNF337 5'UTR N_Shore 0.480 0.426 0.054 5.56E-05 7.54E-04 
cg13607230 2 103352296 MFSD9 Body N_Shore 0.473 0.404 0.069 5.56E-05 7.55E-04 
cg08481967 6 166765599   OpenSea 0.358 0.272 0.086 5.59E-05 7.57E-04 
cg17510957 11 121466629 SORL1 Body OpenSea 0.700 0.637 0.063 5.61E-05 7.59E-04 
cg22249612 12 56121485 CD63 Body N_Shore 0.659 0.589 0.069 5.65E-05 7.63E-04 
cg14210119 2 182319707   N_Shelf 0.561 0.504 0.058 5.71E-05 7.68E-04 
cg20925233 17 47661136 NXPH3 3'UTR OpenSea 0.563 0.505 0.059 5.84E-05 7.81E-04 
cg17164954 6 157345266 ARID1B Body S_Shelf 0.457 0.396 0.061 6.06E-05 8.02E-04 
cg16805291 7 36022575   Island 0.692 0.623 0.069 6.14E-05 8.08E-04 
cg06190046 16 83986382 OSGIN1 5'UTR;TSS1500;Body OpenSea 0.500 0.427 0.074 6.26E-05 8.20E-04 
cg06487194 6 15345097 JARID2 Body OpenSea 0.589 0.525 0.064 6.27E-05 8.21E-04 
cg20043649 2 47537239   OpenSea 0.699 0.636 0.064 6.60E-05 8.50E-04 
cg10601026 10 64579140 EGR2 TSS1500 S_Shore 0.517 0.464 0.052 6.65E-05 8.55E-04 
cg14044785 2 43560368 THADA Body OpenSea 0.692 0.623 0.069 6.70E-05 8.60E-04 
cg16702362 2 135078044 MGAT5 Body OpenSea 0.719 0.654 0.064 6.94E-05 8.82E-04 
cg05407338 17 8213522 ARHGEF15 TSS200 OpenSea 0.484 0.429 0.055 6.95E-05 8.83E-04 
cg24165638 19 831456 AZU1 Body N_Shelf 0.640 0.586 0.054 7.00E-05 8.88E-04 
cg09803321 10 104913480 NT5C2 Body OpenSea 0.727 0.670 0.057 7.10E-05 8.96E-04 
cg05217983 6 45406867 RUNX2 Body OpenSea 0.350 0.291 0.060 7.39E-05 9.23E-04 
cg07330114 3 11624023 VGLL4 Body;TSS200 OpenSea 0.238 0.177 0.060 7.50E-05 9.33E-04 
cg14179944 14 35867515   OpenSea 0.471 0.421 0.050 7.52E-05 9.34E-04 
cg10805254 3 72433837 RYBP Body OpenSea 0.581 0.518 0.063 7.58E-05 9.38E-04 
cg26698460 19 58716004 ZNF274 Body;5'UTR Island 0.641 0.588 0.053 7.63E-05 9.44E-04 
cg02209770 20 35062903 DLGAP4 Body N_Shore 0.553 0.502 0.051 7.80E-05 9.58E-04 
cg05687149 11 112035945 IL18 TSS1500 OpenSea 0.278 0.227 0.052 7.82E-05 9.60E-04 
cg27416337 3 32748004 CNOT10 Body OpenSea 0.343 0.280 0.063 8.04E-05 9.79E-04 
cg11562411 6 35206618 SCUBE3 Body OpenSea 0.522 0.471 0.051 8.06E-05 9.80E-04 
cg03305017 7 151036715   N_Shelf 0.494 0.434 0.060 8.07E-05 9.81E-04 
cg25263801 7 112727506 GPR85 TSS1500;1stExon;5'UTR OpenSea 0.719 0.664 0.055 8.11E-05 9.85E-04 
cg01290904 4 5708474 EVC2 5'UTR;Body N_Shore 0.629 0.577 0.052 8.18E-05 9.91E-04 
cg16616918 17 1686627 SMYD4 Body OpenSea 0.692 0.635 0.056 8.23E-05 9.95E-04 
cg20663365 2 127729097   N_Shore 0.836 0.783 0.053 8.52E-05 1.02E-03 
cg07772516 15 52107742 TMOD2 3'UTR OpenSea 0.611 0.537 0.074 8.54E-05 1.02E-03 
cg13127231 13 111806949 ARHGEF7 Body;5'UTR S_Shore 0.459 0.409 0.050 8.59E-05 1.03E-03 
cg21579539 18 43751229   N_Shelf 0.709 0.656 0.052 8.78E-05 1.04E-03 
cg02512559 16 75414554 CFDP1 Body OpenSea 0.240 0.179 0.061 8.79E-05 1.04E-03 
cg25757140 19 38039469   N_Shore 0.611 0.553 0.058 9.06E-05 1.07E-03 
cg18169971 5 134702492 H2AFY Body OpenSea 0.815 0.764 0.051 9.08E-05 1.07E-03 




PCDHGA7;PCDHGB3 Body;TSS1500 N_Shore 0.699 0.641 0.058 9.15E-05 1.07E-03 
cg05581469 12 49413435 MLL2;PRKAG1 3'UTR;TSS1500 S_Shore 0.368 0.313 0.055 9.21E-05 1.08E-03 
cg09305680 8 117778069 UTP23 TSS1500 N_Shore 0.600 0.545 0.055 9.26E-05 1.08E-03 
cg02134705 3 149388151 WWTR1 5'UTR OpenSea 0.849 0.798 0.051 9.26E-05 1.08E-03 







cg23679982 17 1686737 SMYD4 Body OpenSea 0.636 0.570 0.066 9.76E-05 1.12E-03 
cg02363526 7 150674012 KCNH2 Body N_Shore 0.552 0.502 0.051 9.83E-05 1.13E-03 
cg07572909 1 113467640 SLC16A1 Body OpenSea 0.648 0.596 0.051 1.00E-04 1.14E-03 
cg24926791 6 31082187 PSORS1C1 TSS1500 OpenSea 0.653 0.483 0.170 1.01E-04 1.15E-03 
cg14495033 9 140707378 EHMT1 Body N_Shore 0.714 0.657 0.057 1.01E-04 1.15E-03 
cg06865642 22 50174028 BRD1;LOC90834 Body;TSS200 N_Shelf 0.637 0.586 0.051 1.03E-04 1.16E-03 
cg03885343 5 98108198 RGMB Body N_Shore 0.675 0.624 0.050 1.03E-04 1.17E-03 
cg02391509 3 27766382   S_Shore 0.304 0.253 0.052 1.03E-04 1.17E-03 
cg00791854 1 154392070 IL6R Body OpenSea 0.345 0.295 0.050 1.04E-04 1.17E-03 
cg06705237 9 97402555 FBP1 TSS200;TSS1500 S_Shore 0.636 0.584 0.052 1.05E-04 1.18E-03 
cg05916684 17 49008322   N_Shore 0.503 0.444 0.059 1.05E-04 1.18E-03 
cg21452188 1 156095914 LMNA Body OpenSea 0.472 0.422 0.050 1.06E-04 1.19E-03 
cg24590430 10 99097076   S_Shelf 0.792 0.718 0.074 1.06E-04 1.19E-03 
cg21697512 1 208081541 CD34 Body N_Shelf 0.575 0.515 0.060 1.07E-04 1.20E-03 
cg01238669 7 21797276 DNAH11 Body OpenSea 0.446 0.386 0.060 1.09E-04 1.21E-03 
cg23098068 2 172650722 SLC25A12 Body OpenSea 0.420 0.343 0.077 1.15E-04 1.26E-03 
cg00522048 10 121172431 GRK5 Body OpenSea 0.640 0.590 0.050 1.16E-04 1.26E-03 
cg06740950 3 171878318 FNDC3B Body OpenSea 0.473 0.416 0.057 1.19E-04 1.29E-03 
cg08131499 12 109090588 CORO1C Body OpenSea 0.308 0.247 0.061 1.20E-04 1.29E-03 
cg25357825 3 11697138 VGLL4 Body OpenSea 0.344 0.294 0.051 1.20E-04 1.30E-03 
cg02291010 5 96079433 CAST Body;1stExon OpenSea 0.669 0.612 0.057 1.21E-04 1.30E-03 
cg23735745 1 230248121 GALNT2 Body OpenSea 0.304 0.249 0.055 1.21E-04 1.30E-03 
cg10789050 3 31713847 OSBPL10 Body OpenSea 0.509 0.425 0.084 1.21E-04 1.30E-03 
cg25723459 11 126245829 ST3GAL4 5'UTR OpenSea 0.678 0.619 0.059 1.21E-04 1.30E-03 
cg17797863 4 2009396 WHSC2 Body N_Shore 0.542 0.489 0.052 1.21E-04 1.31E-03 
cg24506197 7 158201392 PTPRN2 Body S_Shelf 0.308 0.249 0.058 1.25E-04 1.33E-03 
cg18071202 12 1609470 LOC100292680 TSS200 OpenSea 0.552 0.499 0.053 1.26E-04 1.34E-03 
cg02457461 8 9913680 MSRA Body S_Shore 0.251 0.193 0.058 1.27E-04 1.34E-03 
cg06392753 2 102783282 IL1R1 Body OpenSea 0.549 0.488 0.061 1.29E-04 1.36E-03 
cg19947463 7 1113237 C7orf50 Body OpenSea 0.459 0.384 0.075 1.30E-04 1.37E-03 
cg00225858 16 84223841 ADAD2 TSS1500 N_Shore 0.620 0.569 0.051 1.33E-04 1.39E-03 
cg24265969 3 55654481 ERC2 3'UTR OpenSea 0.322 0.262 0.060 1.33E-04 1.39E-03 
cg02769705 1 202975059 TMEM183B;TMEM183A TSS1500 N_Shore 0.588 0.520 0.069 1.35E-04 1.41E-03 
cg27301230 7 65761563 TPST1 Body OpenSea 0.737 0.682 0.055 1.35E-04 1.41E-03 
cg18281939 5 77783895 LHFPL2 3'UTR OpenSea 0.452 0.390 0.062 1.38E-04 1.43E-03 
cg02112621 3 78387362   OpenSea 0.640 0.589 0.050 1.39E-04 1.43E-03 
cg16745596 19 39695801 SYCN TSS1500 S_Shore 0.552 0.499 0.052 1.40E-04 1.44E-03 
cg06794244 2 196434818   OpenSea 0.470 0.416 0.054 1.40E-04 1.44E-03 
cg08915824 1 204911863 NFASC TSS1500;5'UTR OpenSea 0.451 0.397 0.055 1.41E-04 1.45E-03 
cg21932231 2 36668864 CRIM1 Body OpenSea 0.543 0.488 0.055 1.43E-04 1.47E-03 
cg00819078 5 16615081 FAM134B Body N_Shore 0.686 0.627 0.059 1.48E-04 1.50E-03 
cg01014262 16 48533930   S_Shelf 0.354 0.294 0.060 1.49E-04 1.51E-03 
cg14989033 1 215179151 KCNK2 1stExon;5'UTR OpenSea 0.463 0.410 0.052 1.51E-04 1.52E-03 
cg24238409 10 93998677 CPEB3 Body N_Shore 0.759 0.704 0.055 1.51E-04 1.52E-03 
cg01966334 2 128378434 MYO7B Body N_Shelf 0.579 0.523 0.056 1.51E-04 1.52E-03 
cg05141432 3 81812214 GBE1 TSS1500 S_Shore 0.361 0.309 0.052 1.53E-04 1.54E-03 
cg04100124 10 69611755   S_Shelf 0.531 0.480 0.052 1.53E-04 1.54E-03 







cg11071448 1 202584465 SYT2 5'UTR OpenSea 0.581 0.530 0.051 1.55E-04 1.55E-03 
cg00796963 6 84936558 KIAA1009 5'UTR N_Shore 0.518 0.463 0.055 1.61E-04 1.59E-03 
cg21487561 2 11990393   OpenSea 0.916 0.850 0.066 1.62E-04 1.60E-03 
cg23362032 7 126990845   S_Shelf 0.770 0.717 0.052 1.62E-04 1.60E-03 
cg27586596 7 41426609   OpenSea 0.444 0.390 0.054 1.64E-04 1.61E-03 
cg03854238 6 22071933 FLJ22536 Body OpenSea 0.619 0.554 0.065 1.65E-04 1.62E-03 
cg25287268 13 50694004 DLEU2 Body N_Shelf 0.439 0.379 0.060 1.66E-04 1.63E-03 
cg01550445 11 72929983 P2RY2 5'UTR S_Shore 0.633 0.581 0.052 1.67E-04 1.63E-03 
cg13643040 9 132456332 PRRX2 Body N_Shelf 0.943 0.852 0.091 1.69E-04 1.65E-03 
cg25731553 15 101715276   OpenSea 0.673 0.620 0.054 1.71E-04 1.66E-03 
cg21203569 11 47279365 NR1H3 TSS200;TSS200;5'UTR OpenSea 0.496 0.431 0.065 1.72E-04 1.67E-03 
cg25791430 11 59574962 MRPL16 Body N_Shelf 0.677 0.627 0.050 1.75E-04 1.69E-03 
cg06838283 5 111090142 C5orf13 Body N_Shelf 0.471 0.412 0.059 1.76E-04 1.69E-03 
cg18011273 4 7203326 SORCS2 Body OpenSea 0.665 0.611 0.054 1.78E-04 1.71E-03 
cg08151370 3 43073152 FAM198A Body OpenSea 0.693 0.623 0.069 1.81E-04 1.73E-03 
cg25589001 10 98605052 LCOR 5'UTR OpenSea 0.557 0.501 0.055 1.81E-04 1.73E-03 
cg24159514 19 11785248 ZNF833 Body Island 0.454 0.378 0.076 1.84E-04 1.74E-03 
cg00421164 6 7111068 RREB1 5'UTR S_Shore 0.827 0.774 0.053 1.90E-04 1.79E-03 
cg10368935 10 18240316 SLC39A12 TSS1500 OpenSea 0.733 0.666 0.066 1.97E-04 1.83E-03 
cg15939920 17 35457385 ACACA Body OpenSea 0.543 0.491 0.052 2.01E-04 1.86E-03 
cg14325153 3 138763899 PRR23C TSS200 Island 0.537 0.470 0.067 2.01E-04 1.86E-03 
cg19619014 8 37250930   OpenSea 0.392 0.331 0.061 2.04E-04 1.88E-03 
cg12341018 6 56176155   OpenSea 0.284 0.231 0.053 2.04E-04 1.88E-03 
cg22798247 6 32807372 TAP2 TSS1500 S_Shore 0.862 0.736 0.126 2.05E-04 1.88E-03 
cg26861460 22 44575455 PARVG TSS1500;5'UTR;Body OpenSea 0.528 0.474 0.054 2.06E-04 1.89E-03 
cg18854872 2 198292151 SF3B1 Body OpenSea 0.631 0.576 0.056 2.06E-04 1.89E-03 
cg01966791 20 62572875 MIR1914;UCKL1 Body S_Shore 0.479 0.411 0.068 2.08E-04 1.91E-03 
cg21549285 21 42799141 MX1 5'UTR S_Shore 0.552 0.614 -0.062 2.12E-04 1.93E-03 
cg07023317 8 28961315 KIF13B Body OpenSea 0.740 0.688 0.053 2.13E-04 1.93E-03 
cg03673989 11 380069 B4GALNT4 Body Island 0.884 0.828 0.055 2.14E-04 1.94E-03 
cg12884009 2 219079038   N_Shelf 0.780 0.729 0.051 2.21E-04 1.99E-03 
cg16462183 5 54281733 ESM1;ESM1 TSS1500 OpenSea 0.606 0.552 0.053 2.22E-04 1.99E-03 
cg24142603 8 72753888 MSC 3'UTR Island 0.789 0.851 -0.062 2.28E-04 2.03E-03 
cg14312063 3 85010606 CADM2 Body S_Shore 0.505 0.443 0.062 2.30E-04 2.05E-03 
cg03062454 21 30362034 RNF160 Body N_Shelf 0.573 0.522 0.051 2.33E-04 2.07E-03 
cg22422264 15 50792856 USP50;USP8 3'UTR OpenSea 0.728 0.678 0.050 2.35E-04 2.08E-03 
cg27223827 2 106054920 FHL2 1stExon;5'UTR OpenSea 0.806 0.752 0.054 2.36E-04 2.08E-03 
cg11058932 7 130372167 TSGA13 TSS1500 OpenSea 0.706 0.649 0.057 2.39E-04 2.10E-03 
cg04777091 4 6050440 JAKMIP1 Body OpenSea 0.229 0.172 0.058 2.41E-04 2.11E-03 
cg16858211 7 36765349 AOAH TSS1500 OpenSea 0.660 0.607 0.053 2.46E-04 2.14E-03 
cg15694715 11 118402280 TMEM25 5'UTR S_Shore 0.331 0.278 0.052 2.46E-04 2.15E-03 
cg13059136 11 2986541 SNORA54;NAP1L4 TSS1500;Body OpenSea 0.664 0.607 0.056 2.47E-04 2.15E-03 
cg21078654 15 52130305 TMOD3 5'UTR OpenSea 0.287 0.233 0.054 2.48E-04 2.16E-03 
cg25711003 3 111522050 PHLDB2;PLCXD2 5'UTR;Body OpenSea 0.755 0.704 0.050 2.52E-04 2.18E-03 
cg05351887 16 3988869   N_Shore 0.425 0.362 0.063 2.55E-04 2.20E-03 
cg02566775 6 144382964 PLAGL1 5'UTR N_Shore 0.570 0.518 0.052 2.57E-04 2.21E-03 
cg12961733 22 50165244   Island 0.552 0.498 0.054 2.58E-04 2.21E-03 







cg12285640 6 140001095   OpenSea 0.738 0.681 0.057 2.61E-04 2.24E-03 
cg21390082 17 33842255 SLFN12L Body OpenSea 0.852 0.795 0.057 2.63E-04 2.25E-03 
cg09723776 8 126320143 NSMCE2 Body OpenSea 0.626 0.573 0.053 2.66E-04 2.26E-03 
cg16395997 1 3562798 WDR8 Body S_Shore 0.774 0.718 0.057 2.67E-04 2.27E-03 
cg22716738 7 27784932 TAX1BP1 5'UTR OpenSea 0.424 0.359 0.064 2.67E-04 2.27E-03 
cg10409299 7 150498843 TMEM176B;TMEM176A TSS1500;Body S_Shore 0.717 0.665 0.052 2.71E-04 2.29E-03 
cg25338454 12 26900022 ITPR2 Body OpenSea 0.764 0.706 0.058 2.76E-04 2.32E-03 
cg21992696 2 9125026 MBOAT2 Body OpenSea 0.429 0.362 0.066 2.78E-04 2.33E-03 
cg06122613 1 151297900 PI4KB Body N_Shelf 0.757 0.700 0.057 2.80E-04 2.34E-03 
cg23705979 7 92397161 CDK6 Body OpenSea 0.354 0.301 0.053 2.83E-04 2.36E-03 
cg02710015 12 55362424 KIAA0748 Body OpenSea 0.498 0.430 0.069 2.84E-04 2.37E-03 
cg05697976 12 29376483 FAR2 TSS200 OpenSea 0.518 0.453 0.066 2.86E-04 2.38E-03 
cg13088432 8 9522664 TNKS Body OpenSea 0.570 0.498 0.072 2.87E-04 2.39E-03 
cg11168614 14 87179368   OpenSea 0.651 0.588 0.063 2.87E-04 2.39E-03 
cg02264407 13 76430665 LMO7 Body OpenSea 0.833 0.777 0.056 2.90E-04 2.40E-03 
cg14111928 10 76602391 MYST4 5'UTR OpenSea 0.711 0.655 0.056 2.93E-04 2.42E-03 
cg04231677 1 184808004 FAM129A Body OpenSea 0.519 0.453 0.066 2.95E-04 2.43E-03 
cg09982419 15 68343575   N_Shelf 0.641 0.582 0.059 3.00E-04 2.46E-03 
cg05888181 8 1952319 KBTBD11 3'UTR S_Shore 0.666 0.598 0.068 3.06E-04 2.50E-03 
cg13424302 10 80516893   OpenSea 0.417 0.359 0.058 3.06E-04 2.50E-03 
cg08195176 11 116781303 SIK3 Body OpenSea 0.604 0.551 0.053 3.07E-04 2.50E-03 
cg08836481 10 882938 LARP4B Body OpenSea 0.760 0.708 0.052 3.08E-04 2.51E-03 
cg08110488 1 82136224   OpenSea 0.282 0.228 0.053 3.08E-04 2.51E-03 
cg04673465 4 85570164 CDS1 3'UTR OpenSea 0.533 0.480 0.053 3.10E-04 2.52E-03 
cg11163555 22 31736976 PATZ1 Body;3'UTR OpenSea 0.397 0.346 0.051 3.20E-04 2.57E-03 
cg10299128 4 82796846   OpenSea 0.485 0.430 0.054 3.21E-04 2.58E-03 
cg03633574 3 149954846   OpenSea 0.804 0.752 0.052 3.22E-04 2.59E-03 
cg20482280 14 105936300 MTA1 Body Island 0.667 0.615 0.052 3.24E-04 2.60E-03 
cg00416710 16 29196027   N_Shore 0.694 0.635 0.059 3.24E-04 2.60E-03 
cg18497052 5 107148418   OpenSea 0.393 0.342 0.051 3.25E-04 2.60E-03 
cg16678522 20 32149963 CBFA2T2 Body;TSS1500 OpenSea 0.698 0.644 0.054 3.27E-04 2.61E-03 
cg19494591 7 140174476 MKRN1 Body N_Shelf 0.794 0.744 0.051 3.32E-04 2.64E-03 
cg05454562 6 33254447 WDR46 Body N_Shelf 0.624 0.566 0.058 3.41E-04 2.69E-03 
cg21301224 8 56813677 LYN 5'UTR OpenSea 0.365 0.312 0.053 3.42E-04 2.69E-03 
cg20610950 17 75096202   OpenSea 0.765 0.700 0.065 3.43E-04 2.70E-03 
cg14251964 8 18396499 PSD3 Body OpenSea 0.949 0.892 0.057 3.44E-04 2.70E-03 
cg08598221 8 121824929 SNTB1 TSS1500 S_Shore 0.589 0.534 0.055 3.49E-04 2.73E-03 
cg11952340 15 63814440 USP3 Body OpenSea 0.604 0.547 0.056 3.49E-04 2.73E-03 
cg07104135 1 201799785 IPO9 Body S_Shore 0.273 0.220 0.053 3.51E-04 2.74E-03 
cg10499974 3 46244099 CCR1 3'UTR OpenSea 0.668 0.614 0.054 3.52E-04 2.75E-03 
cg26105956 1 154471433 SHE Body N_Shelf 0.733 0.668 0.065 3.52E-04 2.75E-03 
cg10536276 2 113956344 PSD4;LOC440839 Body Island 0.594 0.543 0.050 3.54E-04 2.76E-03 
cg19072817 5 176057992 EIF4E1B;SNCB 5'UTR;TSS1500;1stExon S_Shore 0.325 0.269 0.055 3.57E-04 2.77E-03 
cg06645778 2 64680425 HSPC159 TSS1500 N_Shore 0.565 0.513 0.052 3.62E-04 2.80E-03 
cg27073113 16 56228744 DKFZP434H168;GNAO1 TSS1500;Body;Body S_Shelf 0.289 0.224 0.065 3.64E-04 2.81E-03 
cg02320474 16 1758022 MAPK8IP3 Body OpenSea 0.434 0.371 0.063 3.65E-04 2.82E-03 
cg11900393 12 721502 NINJ2 Body S_Shelf 0.737 0.685 0.052 3.69E-04 2.84E-03 







cg05492071 2 202650064   S_Shelf 0.601 0.540 0.061 3.77E-04 2.88E-03 
cg23232188 3 121556543 EAF2 Body S_Shelf 0.789 0.734 0.055 3.82E-04 2.91E-03 
cg26253500 7 136641740 CHRM2 5'UTR OpenSea 0.758 0.703 0.055 3.84E-04 2.92E-03 
cg21216258 9 140942584 CACNA1B Body S_Shore 0.590 0.518 0.073 3.87E-04 2.93E-03 
cg19869035 7 2653955 IQCE 3'UTR OpenSea 0.531 0.481 0.050 3.88E-04 2.94E-03 
cg10401017 6 28887586 TRIM27 Body N_Shelf 0.830 0.767 0.063 3.89E-04 2.94E-03 
cg26742320 2 201393628 SGOL2 5'UTR S_Shelf 0.806 0.755 0.051 3.98E-04 2.99E-03 
cg07805500 6 151380818 MTHFD1L Body OpenSea 0.480 0.391 0.089 4.05E-04 3.02E-03 
cg09439920 3 99979117 TBC1D23 TSS1500 N_Shore 0.447 0.395 0.052 4.13E-04 3.06E-03 
cg26828017 16 22409023   OpenSea 0.684 0.623 0.060 4.15E-04 3.07E-03 
cg07229212 8 11056726 XKR6 Body N_Shore 0.605 0.546 0.059 4.18E-04 3.09E-03 
cg01235820 20 642782 SCRT2 3'UTR Island 0.669 0.618 0.050 4.19E-04 3.09E-03 
cg07113414 8 144652930 C8orf73 Body N_Shore 0.551 0.485 0.065 4.19E-04 3.10E-03 
cg12237948 20 2085157 STK35 Body S_Shore 0.724 0.662 0.062 4.20E-04 3.10E-03 
cg20732703 7 50744032 GRB10 5'UTR;Body OpenSea 0.521 0.470 0.051 4.21E-04 3.11E-03 
cg11261850 11 76320970   OpenSea 0.382 0.329 0.053 4.22E-04 3.11E-03 
cg22159528 19 44039727 ZNF575 Body Island 0.605 0.551 0.055 4.23E-04 3.12E-03 
cg05279761 3 132312243 ACAD11 Body OpenSea 0.568 0.498 0.069 4.28E-04 3.14E-03 
cg23207876 19 15162821 CASP14 TSS200 OpenSea 0.910 0.850 0.060 4.29E-04 3.15E-03 
cg09940188 17 1686671 SMYD4 Body OpenSea 0.599 0.538 0.061 4.37E-04 3.19E-03 
cg07922513 1 6089454 KCNAB2 5'UTR S_Shelf 0.748 0.696 0.052 4.40E-04 3.20E-03 
cg21426759 6 30303126 TRIM39 Body OpenSea 0.656 0.603 0.053 4.42E-04 3.21E-03 
cg13640297 6 170099238 WDR27 5'UTR N_Shelf 0.676 0.625 0.051 4.42E-04 3.22E-03 
cg05894754 2 210675440 UNC80 Body S_Shore 0.801 0.743 0.058 4.43E-04 3.22E-03 
cg07541020 10 44068714 ZNF239 5'UTR N_Shore 0.703 0.640 0.063 4.46E-04 3.23E-03 
cg26319363 4 753903 PCGF3 Body S_Shore 0.922 0.864 0.058 4.46E-04 3.23E-03 
cg19140262 6 99380488 FBXL4 5'UTR OpenSea 0.245 0.195 0.050 4.49E-04 3.25E-03 
cg01924292 12 1815334 ADIPOR2 5'UTR OpenSea 0.656 0.584 0.072 4.52E-04 3.26E-03 
cg05431947 11 12621248   OpenSea 0.275 0.224 0.050 4.55E-04 3.28E-03 
cg16809457 6 90399677 MDN1 Body OpenSea 0.694 0.644 0.050 4.56E-04 3.28E-03 
cg01943931 14 73373205   OpenSea 0.886 0.829 0.057 4.70E-04 3.35E-03 
cg07405121 16 2083168 SLC9A3R2 Body N_Shelf 0.472 0.422 0.050 4.73E-04 3.37E-03 
cg00117012 15 73996358 CD276 Body OpenSea 0.810 0.708 0.102 4.74E-04 3.37E-03 
cg15586392 8 142238691 SLC45A4 TSS200 S_Shore 0.612 0.554 0.058 4.81E-04 3.41E-03 
cg19851560 2 88390167 SMYD1 Body OpenSea 0.696 0.644 0.052 4.98E-04 3.49E-03 
cg22630754 15 42866523 STARD9 TSS1500 N_Shore 0.687 0.626 0.061 5.04E-04 3.52E-03 
cg07948875 1 169187004 NME7 Body OpenSea 0.314 0.257 0.058 5.15E-04 3.57E-03 
cg08805500 12 100522155 UHRF1BP1L Body OpenSea 0.306 0.250 0.056 5.17E-04 3.58E-03 
cg08760493 4 109994039 COL25A1 Body OpenSea 0.533 0.480 0.053 5.18E-04 3.59E-03 
cg02819655 2 178853377 PDE11A Body OpenSea 0.911 0.857 0.054 5.19E-04 3.59E-03 
cg22612003 2 235849504   OpenSea 0.900 0.839 0.061 5.26E-04 3.63E-03 
cg13185177 3 194119885 GP5 5'UTR S_Shore 0.739 0.676 0.062 5.27E-04 3.63E-03 
cg24753094 15 71890066 THSD4 Body OpenSea 0.706 0.579 0.128 5.29E-04 3.64E-03 
cg11321181 19 17721489 UNC13A Body S_Shelf 0.374 0.310 0.063 5.35E-04 3.67E-03 
cg12492273 7 2119499 MAD1L1 Body S_Shelf 0.433 0.374 0.059 5.41E-04 3.69E-03 
cg10603275 3 239665 CHL1 5'UTR Island 0.180 0.125 0.055 5.49E-04 3.73E-03 
cg18507018 8 92035517 TMEM55A Body OpenSea 0.726 0.654 0.072 5.52E-04 3.75E-03 







cg01431340 6 110680085 C6orf186 TSS1500 S_Shore 0.458 0.391 0.067 5.55E-04 3.76E-03 
cg25734726 19 40948296 SERTAD3 1stExon;5'UTR N_Shore 0.611 0.555 0.056 5.56E-04 3.77E-03 
cg24406240 11 88153520   OpenSea 0.614 0.549 0.065 5.57E-04 3.77E-03 
cg25698842 8 1110263   N_Shelf 0.754 0.675 0.079 5.65E-04 3.81E-03 
cg14308082 10 131568021   OpenSea 0.596 0.542 0.054 5.68E-04 3.82E-03 
cg15219811 10 104259328 ACTR1A Body N_Shelf 0.760 0.709 0.051 5.68E-04 3.83E-03 
cg26445561 11 92925402 SLC36A4 Body OpenSea 0.760 0.709 0.050 5.70E-04 3.83E-03 
cg03639671 4 145430689   OpenSea 0.645 0.593 0.052 5.70E-04 3.83E-03 
cg26975524 8 1713012 CLN8 5'UTR S_Shore 0.647 0.587 0.060 5.74E-04 3.85E-03 
cg16689761 7 141360223 KIAA1147 3'UTR OpenSea 0.298 0.246 0.051 5.75E-04 3.86E-03 
cg06162038 2 138727217 HNMT Body OpenSea 0.370 0.315 0.055 5.78E-04 3.87E-03 
cg08941853 1 59449033   OpenSea 0.445 0.381 0.064 5.79E-04 3.88E-03 
cg09069499 8 26216910 PPP2R2A Body OpenSea 0.770 0.713 0.057 5.80E-04 3.88E-03 
cg19116959 4 146841472 ZNF827 Body OpenSea 0.479 0.421 0.058 5.81E-04 3.89E-03 
cg21597811 8 123687197   OpenSea 0.685 0.631 0.054 5.84E-04 3.89E-03 
cg12437013 13 114161939 TMCO3 Body N_Shelf 0.647 0.556 0.091 5.84E-04 3.90E-03 
cg26162326 7 75957061 YWHAG 3'UTR N_Shore 0.507 0.442 0.064 5.85E-04 3.90E-03 
cg03864128 20 32398023 CHMP4B TSS1500 N_Shore 0.783 0.729 0.054 5.88E-04 3.91E-03 
cg26872780 2 149478494 EPC2 Body OpenSea 0.631 0.571 0.059 5.90E-04 3.92E-03 
cg00777445 17 48970357   OpenSea 0.652 0.592 0.061 5.96E-04 3.95E-03 
cg24575128 3 52502445 NISCH Body OpenSea 0.513 0.458 0.056 6.00E-04 3.96E-03 
cg02282631 5 42953543   S_Shore 0.696 0.635 0.060 6.03E-04 3.98E-03 
cg03967798 4 145268453   OpenSea 0.535 0.481 0.054 6.09E-04 4.01E-03 
cg04998202 1 61545546 NFIA Body N_Shelf 0.399 0.333 0.066 6.19E-04 4.05E-03 
cg19238325 3 51988425 GPR62 TSS1500 N_Shore 0.386 0.335 0.051 6.29E-04 4.10E-03 
cg21783012 1 2710376   S_Shelf 0.913 0.813 0.100 6.36E-04 4.13E-03 
cg16520357 13 53625240 OLFM4 3'UTR OpenSea 0.726 0.667 0.059 6.37E-04 4.13E-03 
cg27332878 15 80765904 ARNT2 Body OpenSea 0.261 0.203 0.058 6.38E-04 4.14E-03 
cg05624376 2 169939876 DHRS9 Body OpenSea 0.568 0.513 0.055 6.42E-04 4.16E-03 
cg04350202 10 111653363 XPNPEP1 Body OpenSea 0.554 0.501 0.053 6.43E-04 4.16E-03 
cg25116430 5 151908977   OpenSea 0.801 0.745 0.055 6.46E-04 4.18E-03 
cg07377422 19 46318633 RSPH6A TSS200 Island 0.222 0.168 0.054 6.62E-04 4.24E-03 
cg25865108 6 45559104   OpenSea 0.668 0.606 0.062 6.71E-04 4.28E-03 
cg05265607 10 98900817 SLIT1 Body OpenSea 0.695 0.628 0.067 6.74E-04 4.30E-03 
cg00421173 4 140603682 MGST2 Body OpenSea 0.855 0.796 0.059 6.74E-04 4.30E-03 
cg03269667 3 9744891 CPNE9 TSS1500 N_Shore 0.920 0.819 0.101 6.75E-04 4.30E-03 
cg23969338 5 140474005 PCDHB2 TSS1500 N_Shore 0.462 0.408 0.055 6.84E-04 4.34E-03 
cg09643312 2 160655081 CD302 TSS1500 S_Shore 0.492 0.434 0.057 6.86E-04 4.35E-03 
cg20048037 8 120605539 ENPP2 Body OpenSea 0.581 0.528 0.054 6.88E-04 4.36E-03 
cg21222426 9 20339790   OpenSea 0.340 0.281 0.059 6.91E-04 4.37E-03 
cg09101062 5 43487508 C5orf34 Body S_Shelf 0.857 0.794 0.062 6.96E-04 4.40E-03 
cg11578532 1 161008127 TSTD1 Body N_Shore 0.513 0.459 0.054 7.00E-04 4.42E-03 
cg13062455 14 81978021 SEL1L Body OpenSea 0.615 0.546 0.069 7.01E-04 4.42E-03 
cg26620655 7 1113029 C7orf50 Body OpenSea 0.494 0.432 0.062 7.19E-04 4.50E-03 
cg15965190 2 208370032   OpenSea 0.297 0.242 0.055 7.22E-04 4.51E-03 
cg19173375 6 27880117 OR2B2 TSS200 OpenSea 0.403 0.344 0.060 7.23E-04 4.51E-03 
cg05696877 1 79088769 IFI44L 5'UTR OpenSea 0.449 0.521 -0.072 7.33E-04 4.56E-03 







cg03950493 11 126582183 KIRREL3 Body OpenSea 0.516 0.443 0.073 7.49E-04 4.62E-03 
cg23395177 14 77498304   N_Shore 0.693 0.585 0.109 7.51E-04 4.63E-03 
cg23403750 5 114610319 CCDC112 Body OpenSea 0.697 0.643 0.054 7.62E-04 4.68E-03 
cg03818715 6 7591348 SNRNP48 Body S_Shore 0.588 0.528 0.059 7.62E-04 4.68E-03 
cg17083429 10 89627854 PTEN Body S_Shelf 0.507 0.436 0.071 7.65E-04 4.69E-03 
cg04885885 16 54225800   N_Shelf 0.606 0.463 0.143 7.65E-04 4.69E-03 
cg21341487 20 60760919 GTPBP5 5'UTR S_Shelf 0.497 0.440 0.057 7.71E-04 4.71E-03 
cg26537280 1 95699037 RWDD3 TSS1500 N_Shore 0.479 0.418 0.061 7.72E-04 4.72E-03 
cg21444421 12 90393807   OpenSea 0.585 0.525 0.060 7.75E-04 4.73E-03 
cg09858862 1 23887514 ID3 TSS1500 S_Shore 0.585 0.518 0.067 7.80E-04 4.75E-03 
cg04936009 2 223846845   OpenSea 0.582 0.529 0.053 7.82E-04 4.76E-03 
cg10880928 9 139715701 C9orf86 Body Island 0.370 0.318 0.052 7.84E-04 4.77E-03 
cg25656283 10 50733196 ERCC6;PGBD3 Body;TSS1500 OpenSea 0.762 0.709 0.053 7.99E-04 4.83E-03 
cg21005683 4 159191054   OpenSea 0.948 0.895 0.053 8.02E-04 4.84E-03 
cg04139465 19 51020297 LRRC4B 3'UTR Island 0.540 0.468 0.071 8.06E-04 4.86E-03 
cg24599598 10 3050893   OpenSea 0.433 0.382 0.051 8.12E-04 4.89E-03 
cg01701649 16 48589954 N4BP1 Body OpenSea 0.382 0.316 0.067 8.27E-04 4.95E-03 
cg15084543 1 79472408 ELTD1 5'UTR;1stExon Island 0.360 0.298 0.061 8.44E-04 5.02E-03 
cg24361586 17 62744534   OpenSea 0.709 0.653 0.056 8.53E-04 5.06E-03 
cg20384240 1 183799423 RGL1 Body OpenSea 0.368 0.313 0.055 8.54E-04 5.06E-03 
cg26298737 1 225964937 SRP9;SRP9 TSS1500 N_Shore 0.572 0.519 0.053 8.56E-04 5.07E-03 
cg11942594 3 167659189   OpenSea 0.223 0.173 0.050 8.56E-04 5.07E-03 
cg22243039 17 42147465 G6PC3 TSS1500 N_Shore 0.337 0.282 0.055 8.66E-04 5.11E-03 
cg27260684 16 85063742 KIAA0513 5'UTR S_Shore 0.502 0.444 0.058 8.71E-04 5.13E-03 
cg12628061 1 56453730   OpenSea 0.767 0.701 0.066 8.73E-04 5.13E-03 
cg00364747 8 10915402 XKR6 Body N_Shore 0.968 0.912 0.056 8.81E-04 5.17E-03 
cg09506675 7 112727914 GPR85 TSS1500;TSS200 OpenSea 0.546 0.491 0.055 8.81E-04 5.17E-03 
cg03075631 2 74697095   N_Shelf 0.367 0.526 -0.160 8.91E-04 5.21E-03 
cg14191024 11 110070509   OpenSea 0.727 0.665 0.061 8.94E-04 5.22E-03 
cg24553417 13 50244794 EBPL Body OpenSea 0.570 0.519 0.051 8.98E-04 5.24E-03 
cg01121603 2 242005101 SNED1 Body Island 0.804 0.753 0.051 8.99E-04 5.24E-03 
cg08023751 2 112655112 MERTK TSS1500 N_Shore 0.689 0.638 0.052 9.01E-04 5.25E-03 
cg27584135 3 15975501   OpenSea 0.609 0.536 0.073 9.04E-04 5.26E-03 
cg09357350 3 171894094 FNDC3B Body OpenSea 0.641 0.583 0.058 9.07E-04 5.27E-03 
cg06881914 11 59951663 MS4A6A TSS1500 OpenSea 0.642 0.591 0.051 9.12E-04 5.29E-03 
cg23670353 1 59833489 FGGY Body OpenSea 0.540 0.479 0.061 9.17E-04 5.31E-03 
cg17359629 13 114259310 TFDP1 Body N_Shore 0.651 0.592 0.059 9.19E-04 5.32E-03 
cg02884928 14 105251610 AKT1 Body Island 0.600 0.543 0.058 9.20E-04 5.33E-03 
cg18084609 14 31345041 COCH Body S_Shore 0.603 0.551 0.052 9.21E-04 5.33E-03 
cg25577212 7 24740509 DFNA5 Body OpenSea 0.896 0.839 0.057 9.25E-04 5.35E-03 
cg11588787 13 28181449 LNX2 5'UTR OpenSea 0.345 0.279 0.065 9.28E-04 5.36E-03 
cg26642420 4 146601345 C4orf51 TSS200 OpenSea 0.742 0.690 0.052 9.32E-04 5.38E-03 
cg11345976 2 30864107 LCLAT1 3'UTR OpenSea 0.759 0.685 0.073 9.37E-04 5.39E-03 
cg27588384 3 45674281 LIMD1 Body OpenSea 0.740 0.684 0.056 9.43E-04 5.42E-03 
cg09729012 3 72395774   OpenSea 0.396 0.325 0.071 9.46E-04 5.43E-03 
cg17797940 3 171759519 FNDC3B 5'UTR S_Shore 0.539 0.479 0.061 9.52E-04 5.46E-03 
cg20255272 1 1373678 VWA1 Body;3'UTR N_Shore 0.570 0.519 0.051 9.60E-04 5.49E-03 







cg19782686 4 124180616 SPATA5 Body OpenSea 0.540 0.477 0.063 9.64E-04 5.51E-03 
cg19214707 7 3157722   OpenSea 0.398 0.238 0.160 9.66E-04 5.51E-03 
cg15843217 4 699224 PCGF3 TSS1500 N_Shore 0.442 0.390 0.052 9.68E-04 5.52E-03 
cg13607226 9 124262699 GGTA1 TSS1500 S_Shore 0.519 0.460 0.058 9.72E-04 5.54E-03 
cg26536240 16 89509760 ANKRD11 5'UTR OpenSea 0.742 0.683 0.058 9.75E-04 5.55E-03 
cg00357551 5 169407472 FAM196B;DOCK2 5'UTR;Body;1stExon OpenSea 0.540 0.485 0.056 9.77E-04 5.55E-03 
cg26282731 4 148939288 ARHGAP10 Body OpenSea 0.761 0.710 0.051 9.78E-04 5.56E-03 
cg13276631 3 46872239 PRSS42 Body N_Shelf 0.845 0.774 0.071 9.88E-04 5.60E-03 
cg24407596 7 98718683 SMURF1 Body OpenSea 0.576 0.510 0.066 9.89E-04 5.60E-03 
cg10722267 3 197608554   OpenSea 0.779 0.718 0.061 9.97E-04 5.64E-03 
cg09039751 11 45672100 CHST1 Body Island 0.719 0.666 0.053 1.00E-03 5.65E-03 
cg01176720 10 35081047 PARD3 Body OpenSea 0.917 0.857 0.060 1.01E-03 5.68E-03 
cg08178956 2 42345201   OpenSea 0.403 0.336 0.067 1.01E-03 5.71E-03 
cg26132114 10 44223934   Island 0.714 0.659 0.055 1.02E-03 5.71E-03 
cg05382012 16 67517841 AGRP TSS200;TSS1500 S_Shelf 0.542 0.491 0.051 1.02E-03 5.73E-03 
cg04592413 2 8379999   OpenSea 0.239 0.187 0.053 1.03E-03 5.75E-03 
cg14177325 17 1541763 SCARF1 Body S_Shelf 0.669 0.618 0.051 1.03E-03 5.75E-03 
cg14207267 12 113655841 IQCD 5'UTR N_Shelf 0.398 0.337 0.061 1.04E-03 5.78E-03 
cg23254569 6 35451487 TEAD3 Body N_Shelf 0.531 0.479 0.052 1.05E-03 5.85E-03 
cg14003416 2 12557155   OpenSea 0.604 0.551 0.053 1.06E-03 5.86E-03 
cg22283115 7 4911121 RADIL Body OpenSea 0.576 0.523 0.053 1.07E-03 5.92E-03 
cg18234111 1 158155757 CD1D 3'UTR OpenSea 0.298 0.247 0.051 1.08E-03 5.95E-03 
cg06193043 1 11908199 NPPA TSS1500 OpenSea 0.524 0.472 0.052 1.08E-03 5.96E-03 
cg27073431 2 47404636 CALM2 TSS1500 S_Shore 0.680 0.629 0.051 1.09E-03 5.99E-03 
cg06347643 2 137518979   N_Shelf 0.928 0.855 0.073 1.09E-03 6.00E-03 
cg02852959 12 2944436 NRIP2 TSS1500 OpenSea 0.604 0.539 0.065 1.11E-03 6.08E-03 
cg08742502 6 106546754 PRDM1 Body;TSS200 OpenSea 0.405 0.461 -0.056 1.11E-03 6.09E-03 
cg23605961 7 751331 PRKAR1B 5'UTR N_Shore 0.553 0.493 0.060 1.12E-03 6.10E-03 
cg22566142 5 96298493 LNPEP Body;5'UTR OpenSea 0.438 0.384 0.054 1.12E-03 6.13E-03 
cg07319315 2 135149599 MGAT5 Body OpenSea 0.706 0.642 0.064 1.12E-03 6.13E-03 
cg08122070 1 1689610 NADK Body N_Shelf 0.733 0.678 0.055 1.13E-03 6.13E-03 
cg11002686 7 55412682   Island 0.523 0.472 0.051 1.13E-03 6.16E-03 
cg20168849 3 188995030 TPRG1 Body OpenSea 0.591 0.527 0.064 1.13E-03 6.17E-03 
cg23985818 4 94607780 GRID2 Body OpenSea 0.832 0.780 0.052 1.13E-03 6.17E-03 
cg04784315 9 125797284 GPR21;RABGAP1 1stExon;Body OpenSea 0.546 0.492 0.054 1.14E-03 6.18E-03 
cg00261690 1 28856281 SNHG3-RCC1;RCC1 Body;5'UTR N_Shore 0.613 0.553 0.060 1.14E-03 6.19E-03 
cg18517369 2 231899207   N_Shelf 0.596 0.543 0.053 1.15E-03 6.22E-03 
cg26426488 7 100461644 SLC12A9 Body N_Shelf 0.452 0.393 0.059 1.16E-03 6.26E-03 
cg24856673 12 2017134 CACNA2D4 Body Island 0.343 0.283 0.060 1.17E-03 6.29E-03 
cg14293575 22 18635460 USP18 5'UTR S_Shelf 0.617 0.688 -0.071 1.17E-03 6.31E-03 
cg02262553 4 87849250   OpenSea 0.506 0.453 0.052 1.18E-03 6.33E-03 
cg15704662 8 128388831   OpenSea 0.696 0.639 0.057 1.18E-03 6.34E-03 
cg15073631 13 104796427   OpenSea 0.379 0.329 0.051 1.19E-03 6.36E-03 
cg14942952 22 44576268 PARVG TSS1500;5'UTR;Body OpenSea 0.588 0.523 0.066 1.19E-03 6.38E-03 
cg05131696 12 31499320   OpenSea 0.441 0.373 0.068 1.19E-03 6.38E-03 
cg00754253 11 63259187 HRASLS5 TSS1500 S_Shore 0.447 0.392 0.055 1.22E-03 6.48E-03 
cg02922776 1 212420632   OpenSea 0.467 0.402 0.065 1.22E-03 6.49E-03 







cg19049109 7 27450882   OpenSea 0.877 0.762 0.115 1.24E-03 6.56E-03 
cg17837191 17 62318673 TEX2 5'UTR OpenSea 0.555 0.502 0.053 1.24E-03 6.56E-03 
cg10230190 1 85405081 MCOLN2 Body OpenSea 0.747 0.695 0.053 1.27E-03 6.67E-03 
cg04860432 14 52783454 PTGER2 Body S_Shore 0.528 0.473 0.055 1.27E-03 6.68E-03 
cg22629528 11 132951861 OPCML Body Island 0.638 0.578 0.060 1.29E-03 6.72E-03 
cg01305421 12 102874286 IGF1 5'UTR;1stExon OpenSea 0.326 0.267 0.059 1.31E-03 6.79E-03 
cg04089901 7 7557590 COL28A1 Body OpenSea 0.536 0.483 0.053 1.31E-03 6.80E-03 
cg21476666 3 157221200 VEPH1 TSS200;5'UTR OpenSea 0.832 0.780 0.052 1.32E-03 6.83E-03 
cg08730245 12 53902893 NPFF TSS1500 OpenSea 0.645 0.590 0.056 1.32E-03 6.84E-03 
cg01664300 6 15911690   OpenSea 0.703 0.589 0.114 1.32E-03 6.84E-03 
cg00453717 11 74344629 POLD3 Body OpenSea 0.572 0.516 0.056 1.32E-03 6.85E-03 
cg10718056 6 28884599 TRIM27 Body OpenSea 0.515 0.462 0.053 1.38E-03 7.05E-03 
cg19356022 1 154943932 SHC1 5'UTR;TSS1500 N_Shelf 0.558 0.506 0.051 1.39E-03 7.07E-03 
cg00325531 1 75591353   Island 0.219 0.167 0.051 1.39E-03 7.10E-03 
cg00782708 2 44933278 C2orf34 Body OpenSea 0.635 0.581 0.053 1.40E-03 7.14E-03 
cg07759162 15 75488313   OpenSea 0.615 0.561 0.054 1.43E-03 7.23E-03 
cg16151538 20 33676388 TRPC4AP Body N_Shelf 0.722 0.669 0.053 1.43E-03 7.24E-03 
cg14318679 17 700464   OpenSea 0.880 0.828 0.052 1.45E-03 7.28E-03 
cg17696517 8 105343133   S_Shore 0.325 0.269 0.056 1.45E-03 7.29E-03 
cg26629715 8 89379430   OpenSea 0.788 0.719 0.069 1.45E-03 7.31E-03 
cg06106428 11 110584327 ARHGAP20 TSS1500 S_Shore 0.740 0.686 0.054 1.46E-03 7.35E-03 
cg19989043 6 47468193 CD2AP Body OpenSea 0.417 0.353 0.064 1.48E-03 7.40E-03 
cg11147155 1 150595206 ENSA 3'UTR OpenSea 0.493 0.442 0.051 1.48E-03 7.41E-03 
cg05758467 2 240035894 HDAC4 Body S_Shelf 0.572 0.513 0.059 1.48E-03 7.42E-03 
cg05980785 2 197583891 CCDC150 Body OpenSea 0.527 0.460 0.067 1.49E-03 7.43E-03 
cg23668184 2 5836713 SOX11 3'UTR;1stExon Island 0.144 0.093 0.050 1.49E-03 7.44E-03 
cg05788125 6 170559721   OpenSea 0.609 0.555 0.054 1.49E-03 7.44E-03 
cg06579481 7 104621597   N_Shelf 0.675 0.623 0.052 1.50E-03 7.46E-03 
cg17591816 1 172239092 DNM3 Body OpenSea 0.728 0.667 0.060 1.51E-03 7.50E-03 
cg22022881 2 105853494   Island 0.569 0.495 0.074 1.51E-03 7.52E-03 
cg18188328 6 15505094 JARID2 Body OpenSea 0.735 0.680 0.055 1.51E-03 7.52E-03 
cg20155875 17 66452567 WIPI1 Body N_Shore 0.620 0.563 0.057 1.52E-03 7.54E-03 
cg06548519 17 34267111 LYZL6 TSS1500 OpenSea 0.682 0.630 0.052 1.53E-03 7.59E-03 
cg02462081 2 220405635 CHPF Body N_Shore 0.815 0.763 0.053 1.57E-03 7.70E-03 
cg17036458 17 28037399 SSH2 Body OpenSea 0.633 0.565 0.068 1.58E-03 7.75E-03 
cg10231675 12 2944493 NRIP2 TSS1500 OpenSea 0.596 0.537 0.059 1.60E-03 7.83E-03 
cg08113187 16 87469329 ZCCHC14 Body OpenSea 0.251 0.196 0.055 1.61E-03 7.83E-03 
cg23201812 11 34771918   OpenSea 0.624 0.564 0.060 1.63E-03 7.92E-03 
cg11740416 3 194409431 FAM43A 3'UTR;1stExon S_Shore 0.321 0.259 0.062 1.64E-03 7.95E-03 
cg20992708 4 5637894 EVC2 Body OpenSea 0.529 0.472 0.057 1.64E-03 7.95E-03 
cg19322969 1 226854847 ITPKB Body OpenSea 0.790 0.737 0.053 1.65E-03 7.96E-03 
cg17657707 20 47541362 ARFGEF2 Body S_Shelf 0.478 0.425 0.053 1.65E-03 7.97E-03 
cg25769566 6 31651278   Island 0.750 0.691 0.060 1.65E-03 7.98E-03 
cg14543285 14 103129037 RCOR1 Body OpenSea 0.602 0.552 0.050 1.66E-03 8.01E-03 
cg12475879 17 14251824   S_Shelf 0.754 0.696 0.058 1.67E-03 8.05E-03 
cg13480937 1 177112230 ASTN1 Body OpenSea 0.500 0.433 0.066 1.68E-03 8.07E-03 
cg05667818 7 116786870 ST7;ST7OT2 Body;TSS1500 OpenSea 0.473 0.412 0.061 1.69E-03 8.11E-03 







cg20824294 3 142316082 PLS1 5'UTR S_Shore 0.582 0.520 0.062 1.72E-03 8.22E-03 
cg20442379 10 60024634 IPMK Body N_Shelf 0.369 0.305 0.064 1.74E-03 8.27E-03 
cg18888137 6 32945759 BRD2 Body OpenSea 0.529 0.478 0.051 1.74E-03 8.27E-03 
cg08571738 2 2605398   OpenSea 0.671 0.619 0.052 1.76E-03 8.32E-03 
cg19587237 1 54797076 SSBP3 Body OpenSea 0.409 0.336 0.074 1.76E-03 8.33E-03 
cg15659420 11 20034979 NAV2 Body OpenSea 0.431 0.372 0.059 1.77E-03 8.36E-03 
cg19876987 3 14258049   OpenSea 0.625 0.676 -0.051 1.77E-03 8.36E-03 
cg13740929 6 31651291   Island 0.643 0.581 0.063 1.78E-03 8.40E-03 
cg14209920 19 13137642 NFIX Body S_Shore 0.804 0.748 0.057 1.78E-03 8.40E-03 
cg16735495 7 105690812   OpenSea 0.588 0.531 0.057 1.80E-03 8.46E-03 
cg21502048 14 52780158 PTGER2 TSS1500 N_Shore 0.385 0.334 0.051 1.80E-03 8.46E-03 
cg02136596 1 1384930 ATAD3C TSS200 OpenSea 0.745 0.688 0.056 1.82E-03 8.52E-03 
cg01598009 6 30286162 HCG18 Body OpenSea 0.339 0.285 0.054 1.83E-03 8.58E-03 
cg10338518 4 87895137 AFF1 Body OpenSea 0.586 0.527 0.059 1.84E-03 8.60E-03 
cg07033722 1 40539032 PPT1 3'UTR OpenSea 0.569 0.517 0.052 1.85E-03 8.62E-03 
cg06578342 16 4349215   OpenSea 0.491 0.440 0.051 1.85E-03 8.62E-03 
cg01327169 3 183738470   S_Shelf 0.703 0.650 0.053 1.86E-03 8.68E-03 
cg17620335 10 51566824 NCOA4 5'UTR S_Shore 0.711 0.655 0.057 1.88E-03 8.72E-03 
cg07277038 3 196373543 LRRC33 5'UTR OpenSea 0.595 0.535 0.059 1.88E-03 8.73E-03 
cg09750084 13 49005868 LPAR6;RB1 5'UTR;Body OpenSea 0.346 0.282 0.064 1.89E-03 8.76E-03 
cg20166027 10 51576452 NCOA4 1stExon;5'UTR;Body S_Shelf 0.621 0.566 0.054 1.90E-03 8.79E-03 
cg12847536 8 1822186 ARHGEF10 Body S_Shore 0.798 0.730 0.068 1.90E-03 8.79E-03 
cg06312985 7 32961866 RP9P Body OpenSea 0.466 0.415 0.050 1.92E-03 8.85E-03 
cg22226592 1 109439213 GPSM2 Body OpenSea 0.669 0.608 0.061 1.95E-03 8.96E-03 
cg03707599 7 75956931 YWHAG 3'UTR N_Shore 0.290 0.228 0.062 1.96E-03 8.99E-03 
cg15251256 12 46101447   OpenSea 0.735 0.680 0.055 1.97E-03 9.03E-03 
cg03123541 1 95699097 RWDD3 TSS1500 N_Shore 0.544 0.479 0.064 1.98E-03 9.06E-03 
cg16706260 12 27849370 REP15 TSS200 OpenSea 0.729 0.675 0.054 1.98E-03 9.06E-03 
cg20861489 6 55105265 HCRTR2 Body OpenSea 0.590 0.529 0.061 1.99E-03 9.07E-03 
cg04697624 12 69002178   N_Shelf 0.413 0.361 0.052 1.99E-03 9.10E-03 
cg17130518 7 76825482 CCDC146;FGL2 Body;3'UTR OpenSea 0.851 0.789 0.061 2.00E-03 9.12E-03 
cg18801945 19 13215041 LYL1 TSS1500 N_Shore 0.231 0.171 0.060 2.01E-03 9.14E-03 
cg16267322 14 92864074 SLC24A4 Body OpenSea 0.713 0.663 0.050 2.02E-03 9.17E-03 
cg17451677 10 12887270   OpenSea 0.598 0.526 0.073 2.05E-03 9.26E-03 
cg16542646 16 22175965   S_Shelf 0.848 0.790 0.059 2.05E-03 9.28E-03 
cg21587238 5 42953590   S_Shore 0.666 0.592 0.074 2.06E-03 9.30E-03 
cg01175610 12 12224246 BCL2L14 5'UTR;TSS200 OpenSea 0.611 0.674 -0.063 2.06E-03 9.30E-03 
cg22062741 8 1897075 ARHGEF10 Body S_Shelf 0.577 0.525 0.052 2.10E-03 9.43E-03 
cg16145324 6 36020012 MAPK14 Body OpenSea 0.684 0.626 0.058 2.10E-03 9.44E-03 
cg07091500 3 185678074   OpenSea 0.355 0.289 0.065 2.12E-03 9.49E-03 
cg17974145 7 101671556 CUX1 Body OpenSea 0.617 0.561 0.055 2.14E-03 9.56E-03 
cg19871394 6 11539786 TMEM170B Body S_Shore 0.758 0.707 0.051 2.14E-03 9.57E-03 
cg22431093 12 32654992 FGD4 TSS200 OpenSea 0.620 0.569 0.051 2.18E-03 9.67E-03 
cg14138235 14 56281968   OpenSea 0.507 0.455 0.053 2.18E-03 9.68E-03 
cg01752594 13 50696070 DLEU2 Body N_Shore 0.678 0.623 0.056 2.21E-03 9.78E-03 
cg05919621 10 127373136 C10orf122 TSS1500 OpenSea 0.645 0.763 -0.119 2.23E-03 9.83E-03 
cg06943912 19 10715612 SLC44A2 Body S_Shelf 0.200 0.148 0.052 2.23E-03 9.85E-03 







cg05377949 3 127951287 EEFSEC Body OpenSea 0.748 0.682 0.066 2.28E-03 9.98E-03 
cg24020157 10 43697521 RASGEF1A Body N_Shore 0.370 0.320 0.050 2.30E-03 1.00E-02 
cg24179445 10 102496915   N_Shore 0.507 0.457 0.050 2.34E-03 1.02E-02 
cg25367558 6 41840102 USP49 5'UTR OpenSea 0.730 0.676 0.054 2.34E-03 1.02E-02 
cg16490906 5 93712596 C5orf36 Body OpenSea 0.605 0.551 0.054 2.35E-03 1.02E-02 
cg26104986 11 75275303 SERPINH1 5'UTR S_Shore 0.735 0.684 0.051 2.37E-03 1.03E-02 
cg01477971 2 103405951 TMEM182 Body OpenSea 0.625 0.557 0.068 2.38E-03 1.03E-02 
cg26780042 7 6515961 KDELR2 Body OpenSea 0.681 0.614 0.066 2.40E-03 1.04E-02 
cg07091102 1 94385022   OpenSea 0.743 0.687 0.056 2.43E-03 1.04E-02 
cg10599438 19 844589 PRTN3 Body N_Shore 0.291 0.232 0.059 2.44E-03 1.05E-02 
cg01903702 1 224351941   OpenSea 0.394 0.341 0.053 2.44E-03 1.05E-02 
cg00750430 10 118654150 KIAA1598 Body OpenSea 0.447 0.392 0.056 2.44E-03 1.05E-02 
cg18854765 1 74665362 LRRIQ3;TNNI3K;FPGT TSS1500;Body;Body S_Shore 0.425 0.361 0.065 2.45E-03 1.05E-02 
cg24827600 2 169355957 LASS6 Body OpenSea 0.552 0.502 0.050 2.47E-03 1.06E-02 
cg11897887 20 23550632 CST9L TSS1500 OpenSea 0.833 0.712 0.121 2.50E-03 1.06E-02 
cg08087969 12 132657669   OpenSea 0.527 0.464 0.064 2.50E-03 1.06E-02 
cg14016236 3 171792545 FNDC3B 5'UTR OpenSea 0.494 0.424 0.070 2.50E-03 1.07E-02 
cg08920032 15 99332004 IGF1R Body OpenSea 0.623 0.568 0.055 2.51E-03 1.07E-02 
cg13589463 14 100920326 WDR25 Body OpenSea 0.738 0.688 0.050 2.52E-03 1.07E-02 
cg03322353 4 141069770 MAML3 Body N_Shore 0.642 0.585 0.057 2.64E-03 1.11E-02 
cg08930843 10 31182298 ZNF438 5'UTR;Body OpenSea 0.604 0.549 0.055 2.64E-03 1.11E-02 
cg09408143 16 524778 RAB11FIP3 Body;TSS200 OpenSea 0.561 0.510 0.052 2.66E-03 1.11E-02 
cg09991306 2 241975140 SNED1 Body Island 0.461 0.518 -0.058 2.67E-03 1.12E-02 
cg06699564 8 95651099   N_Shore 0.479 0.425 0.053 2.67E-03 1.12E-02 
cg08594554 17 72231318 TTYH2 Body OpenSea 0.333 0.280 0.053 2.68E-03 1.12E-02 
cg16095551 6 155816164   OpenSea 0.715 0.658 0.058 2.69E-03 1.12E-02 
cg23118561 13 51565237   OpenSea 0.872 0.817 0.055 2.69E-03 1.12E-02 
cg14886849 14 103367489 TRAF3 Body OpenSea 0.369 0.315 0.054 2.69E-03 1.12E-02 
cg06940110 2 118616430   N_Shore 0.564 0.513 0.051 2.69E-03 1.12E-02 
cg20922701 18 11978319   N_Shelf 0.672 0.618 0.054 2.73E-03 1.13E-02 
cg07543138 21 16434067 NRIP1 5'UTR N_Shelf 0.362 0.307 0.055 2.74E-03 1.14E-02 
cg01066472 1 75591029   Island 0.350 0.285 0.066 2.76E-03 1.14E-02 
cg00809820 17 80708513 TBCD;FN3K TSS1500;Body Island 0.612 0.516 0.097 2.78E-03 1.15E-02 
cg17797848 1 109842096 MYBPHL Body OpenSea 0.770 0.718 0.052 2.78E-03 1.15E-02 
cg04476865 13 36223476 MIR548F5;NBEA Body OpenSea 0.738 0.687 0.051 2.79E-03 1.15E-02 
cg17514528 1 11862907 MTHFR Body N_Shelf 0.562 0.503 0.059 2.81E-03 1.15E-02 
cg22962883 11 114178729 NNMT Body OpenSea 0.410 0.341 0.069 2.83E-03 1.16E-02 
cg14386624 9 91006749 SPIN1 5'UTR S_Shelf 0.455 0.384 0.070 2.83E-03 1.16E-02 
cg26874229 2 105853672   Island 0.511 0.456 0.055 2.83E-03 1.16E-02 
cg08130265 15 77519170 C15orf5;SGK269 TSS1500;5'UTR OpenSea 0.577 0.516 0.061 2.84E-03 1.16E-02 
cg11906162 19 8568808 PRAM1 TSS1500 N_Shore 0.559 0.499 0.060 2.86E-03 1.17E-02 
cg15958422 2 150845309   OpenSea 0.695 0.582 0.114 2.87E-03 1.17E-02 
cg10348234 14 31698967   OpenSea 0.254 0.203 0.051 2.89E-03 1.18E-02 
cg02322400 11 95980186 MAML2 Body OpenSea 0.333 0.279 0.054 2.90E-03 1.18E-02 
cg08599355 13 99714609 DOCK9 Body OpenSea 0.581 0.528 0.053 2.93E-03 1.19E-02 
cg16452651 21 35016873 ITSN1 5'UTR S_Shore 0.596 0.542 0.054 2.95E-03 1.20E-02 
cg27186013 4 95264127 HPGDS TSS200 OpenSea 0.259 0.207 0.052 2.96E-03 1.20E-02 







cg05194426 10 135343193 CYP2E1 Body S_Shore 0.391 0.313 0.078 2.98E-03 1.20E-02 
cg17403881 1 2847164   Island 0.926 0.854 0.072 2.99E-03 1.21E-02 
cg01841050 17 39539863 KRT34 TSS1500 OpenSea 0.774 0.723 0.051 2.99E-03 1.21E-02 
cg01044849 6 30002723 NCRNA00171 Body OpenSea 0.621 0.571 0.050 3.02E-03 1.21E-02 
cg14251267 20 62406428 ZBTB46 Body N_Shore 0.714 0.662 0.051 3.02E-03 1.22E-02 
cg18613721 12 8861225 RIMKLB 5'UTR OpenSea 0.602 0.550 0.052 3.03E-03 1.22E-02 
cg09326832 6 7243643 RREB1 Body N_Shelf 0.250 0.198 0.051 3.04E-03 1.22E-02 
cg22965561 10 13046134   S_Shelf 0.555 0.497 0.058 3.06E-03 1.23E-02 
cg13160251 15 56286575 NEDD4 TSS1500 S_Shore 0.452 0.393 0.058 3.07E-03 1.23E-02 
cg01952226 8 102507382 GRHL2 Body S_Shore 0.350 0.284 0.066 3.13E-03 1.24E-02 
cg07045054 3 10005827 TMEM111 Body OpenSea 0.929 0.847 0.082 3.15E-03 1.25E-02 
cg04414860 6 116575894 TSPYL4 TSS1500 S_Shore 0.451 0.397 0.054 3.16E-03 1.25E-02 
cg05991492 16 3988700   N_Shore 0.499 0.440 0.059 3.19E-03 1.26E-02 
cg06119452 6 169621662 THBS2 Body N_Shore 0.637 0.578 0.058 3.19E-03 1.26E-02 
cg20714551 19 3370244 NFIC;NFIC Body S_Shore 0.806 0.742 0.064 3.20E-03 1.26E-02 
cg14372705 22 19141030   S_Shelf 0.651 0.599 0.052 3.20E-03 1.26E-02 
cg04663285 11 379455 B4GALNT4 Body Island 0.847 0.787 0.060 3.22E-03 1.27E-02 
cg24475517 2 118737667 CCDC93 Body OpenSea 0.581 0.527 0.054 3.23E-03 1.27E-02 
cg02796279 2 208101334   OpenSea 0.558 0.503 0.055 3.24E-03 1.28E-02 
cg07575193 8 30402570 RBPMS Body OpenSea 0.493 0.439 0.054 3.27E-03 1.28E-02 
cg07958192 4 90033974 TIGD2 1stExon;5'UTR S_Shore 0.716 0.654 0.063 3.30E-03 1.29E-02 
cg18069568 18 43683922 ATP5A1;HAUS1 5'UTR;TSS1500 N_Shore 0.623 0.552 0.072 3.34E-03 1.30E-02 
cg06358171 1 54822008 SSBP3 Body Island 0.372 0.320 0.052 3.39E-03 1.32E-02 
cg18278694 1 179945973 CEP350 5'UTR OpenSea 0.564 0.503 0.061 3.41E-03 1.32E-02 
cg20131219 3 111676660 PHLDB2 Body OpenSea 0.517 0.389 0.128 3.43E-03 1.33E-02 
cg22301128 4 77011716 ART3 Body OpenSea 0.317 0.253 0.064 3.44E-03 1.33E-02 
cg25179758 13 36918614 SPG20 5'UTR N_Shore 0.440 0.385 0.054 3.45E-03 1.34E-02 
cg21683390 18 13259088 C18orf1 5'UTR N_Shelf 0.713 0.655 0.058 3.46E-03 1.34E-02 
cg20384231 10 131132572   OpenSea 0.810 0.749 0.061 3.47E-03 1.34E-02 
cg14076239 13 53712850   OpenSea 0.617 0.564 0.053 3.48E-03 1.34E-02 
cg14018429 9 129138146 FAM125B Body OpenSea 0.494 0.424 0.070 3.48E-03 1.34E-02 
cg18561976 2 204801508 ICOS;ICOS 5'UTR;1stExon OpenSea 0.384 0.436 -0.053 3.49E-03 1.34E-02 
cg11387340 6 166970727 RPS6KA2 Body OpenSea 0.366 0.314 0.052 3.52E-03 1.35E-02 
cg18729664 6 76203675 FILIP1 TSS200 OpenSea 0.681 0.630 0.051 3.56E-03 1.36E-02 
cg03188948 7 1209495   OpenSea 0.222 0.163 0.058 3.56E-03 1.36E-02 
cg26928972 3 122043799 CSTA TSS1500 OpenSea 0.662 0.600 0.062 3.56E-03 1.36E-02 
cg26567012 5 151202148 GLRA1 3'UTR OpenSea 0.578 0.527 0.051 3.60E-03 1.37E-02 
cg27422857 2 105853526   Island 0.667 0.601 0.066 3.61E-03 1.38E-02 
cg10620484 4 122685570 LOC100192379;TMEM155 TSS200;5'UTR N_Shore 0.295 0.240 0.055 3.63E-03 1.38E-02 
cg18363918 19 51829984 IGLON5 Body N_Shore 0.410 0.352 0.057 3.65E-03 1.39E-02 
cg17864487 2 238643342 LRRFIP1 Body N_Shore 0.761 0.711 0.050 3.67E-03 1.39E-02 
cg01440934 1 47051752 MKNK1 Body OpenSea 0.618 0.564 0.054 3.69E-03 1.40E-02 
cg26646867 5 68785451   N_Shelf 0.602 0.547 0.055 3.70E-03 1.40E-02 
cg23390684 15 32197095   OpenSea 0.763 0.705 0.058 3.71E-03 1.40E-02 
cg12940181 2 145353012   OpenSea 0.507 0.448 0.059 3.71E-03 1.40E-02 
cg26398228 4 33062845   OpenSea 0.551 0.465 0.086 3.72E-03 1.40E-02 
cg21144063 7 64035529   OpenSea 0.341 0.287 0.054 3.75E-03 1.41E-02 







cg07643696 12 25844221   OpenSea 0.522 0.464 0.058 3.78E-03 1.42E-02 
cg27035169 14 23653098 SLC7A8 TSS1500 OpenSea 0.546 0.488 0.058 3.79E-03 1.42E-02 
cg15531512 8 123706630   OpenSea 0.556 0.503 0.053 3.80E-03 1.43E-02 
cg02343628 15 93790914   OpenSea 0.545 0.493 0.052 3.80E-03 1.43E-02 
cg15912390 3 194826514 C3orf21 Body OpenSea 0.794 0.742 0.053 3.82E-03 1.43E-02 
cg21227325 9 78776599 PCSK5 Body OpenSea 0.721 0.667 0.053 3.83E-03 1.44E-02 
cg02915920 9 133736469 ABL1 Body N_Shore 0.739 0.685 0.053 3.85E-03 1.44E-02 
cg08473752 17 26517057 NLK Body OpenSea 0.765 0.713 0.053 3.85E-03 1.44E-02 
cg11494508 7 92849025 HEPACAM2 TSS200;Body OpenSea 0.292 0.238 0.054 3.86E-03 1.44E-02 
cg13506281 13 29914200 MTUS2 Body Island 0.402 0.525 -0.122 3.87E-03 1.45E-02 
cg27076160 10 64431533 ZNF365 3'UTR OpenSea 0.491 0.606 -0.115 3.88E-03 1.45E-02 
cg02404304 6 2752090 MYLK4 TSS1500 OpenSea 0.355 0.297 0.059 3.92E-03 1.46E-02 
cg18198212 5 39455917   OpenSea 0.347 0.291 0.056 3.93E-03 1.46E-02 
cg05372753 6 11804635   OpenSea 0.677 0.625 0.053 3.94E-03 1.46E-02 
cg02169713 6 31651094   Island 0.472 0.415 0.057 3.95E-03 1.47E-02 
cg02278646 12 45608691 ANO6;PLEKHA9 5'UTR;TSS1500 N_Shore 0.403 0.346 0.056 3.95E-03 1.47E-02 
cg14584535 9 125797187 GPR21;RABGAP1 1stExon;Body OpenSea 0.528 0.464 0.064 3.99E-03 1.48E-02 
cg05249836 22 45609402 C22orf9;C22orf9 Body;TSS1500 OpenSea 0.532 0.476 0.056 4.00E-03 1.48E-02 
cg21493727 8 127938624   OpenSea 0.496 0.442 0.055 4.04E-03 1.49E-02 
cg18167921 1 68963198 DEPDC1 TSS1500 S_Shore 0.448 0.389 0.059 4.05E-03 1.49E-02 
cg17065772 3 14991718 NR2C2 5'UTR S_Shore 0.607 0.551 0.056 4.05E-03 1.49E-02 
cg24197477 1 202975221 TMEM183B;TMEM183A TSS1500 N_Shore 0.757 0.703 0.054 4.05E-03 1.49E-02 
cg19903071 2 160473251 BAZ2B TSS200 S_Shore 0.328 0.265 0.063 4.10E-03 1.51E-02 
cg15976390 1 205054828 TMEM81 TSS1500 OpenSea 0.937 0.881 0.056 4.15E-03 1.52E-02 
cg23222472 7 112135961   OpenSea 0.454 0.397 0.057 4.15E-03 1.52E-02 
cg04590170 11 33893895 LMO2 5'UTR S_Shelf 0.587 0.535 0.051 4.19E-03 1.53E-02 
cg00682263 15 66188803 MEGF11 3'UTR OpenSea 0.634 0.564 0.070 4.25E-03 1.54E-02 
cg23916104 11 7110083 RBMXL2 TSS200 N_Shore 0.592 0.537 0.055 4.27E-03 1.55E-02 
cg11905488 12 10123604 CLEC12A TSS1500 OpenSea 0.621 0.556 0.065 4.27E-03 1.55E-02 
cg09365147 6 111738477 REV3L Body OpenSea 0.508 0.453 0.055 4.31E-03 1.56E-02 
cg09572125 6 33400477 SYNGAP1 Body OpenSea 0.319 0.259 0.059 4.31E-03 1.56E-02 
cg19931348 20 43803224 PI3 TSS1500 OpenSea 0.687 0.632 0.055 4.32E-03 1.56E-02 
cg06585566 19 57276794   Island 0.410 0.353 0.057 4.38E-03 1.58E-02 
cg05362850 7 150100037   N_Shore 0.802 0.739 0.063 4.39E-03 1.58E-02 
cg11540476 6 31651249   Island 0.525 0.432 0.093 4.53E-03 1.62E-02 
cg04839673 1 64105555 PGM1 Body OpenSea 0.945 0.877 0.068 4.54E-03 1.62E-02 
cg19599611 15 35148637 AQR 3'UTR OpenSea 0.753 0.694 0.059 4.54E-03 1.62E-02 
cg25537993 19 58545182 ZSCAN1 TSS1500 Island 0.181 0.128 0.054 4.57E-03 1.63E-02 
cg09422696 8 144626190   S_Shelf 0.778 0.678 0.101 4.62E-03 1.64E-02 
cg02187259 2 16804452 FAM49A 5'UTR OpenSea 0.614 0.564 0.050 4.63E-03 1.64E-02 
cg11054816 11 117183853 BACE1 Body N_Shelf 0.524 0.474 0.051 4.65E-03 1.65E-02 
cg04605532 1 234843592   OpenSea 0.682 0.624 0.058 4.66E-03 1.65E-02 
cg04182865 5 141346431 RNF14 TSS200 N_Shelf 0.635 0.574 0.060 4.83E-03 1.69E-02 
cg06885823 5 82675005   OpenSea 0.577 0.525 0.052 4.83E-03 1.69E-02 
cg23047825 15 99317340 IGF1R Body OpenSea 0.791 0.728 0.063 4.84E-03 1.70E-02 
cg00625110 16 53741731 FTO Body S_Shelf 0.566 0.496 0.070 4.85E-03 1.70E-02 
cg20760057 6 130017522 ARHGAP18 Body OpenSea 0.639 0.580 0.060 4.86E-03 1.70E-02 







cg21786601 7 116222436   OpenSea 0.890 0.837 0.053 4.92E-03 1.71E-02 
cg18075755 4 15429967 C1QTNF7 5'UTR;Body;5'UTR OpenSea 0.854 0.756 0.098 4.92E-03 1.72E-02 
cg12303247 1 155853542 SYT11 3'UTR OpenSea 0.952 0.883 0.070 4.94E-03 1.72E-02 
cg18551877 11 58612087 GLYATL2 TSS200 OpenSea 0.191 0.128 0.063 4.94E-03 1.72E-02 
cg27340480 19 44170526 PLAUR Body N_Shelf 0.530 0.470 0.061 4.96E-03 1.73E-02 
cg26508200 12 109235071 SSH1 Body OpenSea 0.680 0.621 0.059 5.01E-03 1.74E-02 
cg14086364 5 150678334 SLC36A3 Body OpenSea 0.603 0.549 0.054 5.04E-03 1.75E-02 
cg21263566 1 95561502   OpenSea 0.551 0.497 0.055 5.06E-03 1.75E-02 
cg24401441 20 21679843   N_Shelf 0.472 0.419 0.054 5.07E-03 1.75E-02 
cg15723028 8 90776474 RIPK2 Body OpenSea 0.545 0.485 0.060 5.08E-03 1.75E-02 
cg01556706 3 59804435 FHIT Body OpenSea 0.753 0.690 0.063 5.15E-03 1.77E-02 
cg11842502 6 111862202   OpenSea 0.593 0.532 0.061 5.24E-03 1.79E-02 
cg00637104 20 1785303   S_Shore 0.555 0.504 0.050 5.26E-03 1.80E-02 
cg03156546 16 24759640 TNRC6A Body OpenSea 0.647 0.586 0.061 5.26E-03 1.80E-02 
cg17500686 15 79621783   OpenSea 0.700 0.645 0.055 5.27E-03 1.80E-02 
cg08445957 8 1246463   Island 0.952 0.877 0.076 5.28E-03 1.80E-02 
cg05126289 1 156995411 ARHGEF11 Body OpenSea 0.889 0.826 0.063 5.28E-03 1.80E-02 
cg01422009 16 125896 MPG TSS1500 N_Shore 0.724 0.671 0.053 5.29E-03 1.81E-02 
cg11143674 15 99069100   OpenSea 0.403 0.352 0.051 5.31E-03 1.81E-02 
cg04313565 16 17561865 XYLT1 Body OpenSea 0.513 0.461 0.051 5.32E-03 1.81E-02 
cg21139795 3 119243933 CD80 3'UTR OpenSea 0.581 0.524 0.057 5.34E-03 1.82E-02 
cg13158272 14 74257174   S_Shelf 0.857 0.799 0.058 5.34E-03 1.82E-02 
cg04677123 5 90466501   OpenSea 0.644 0.586 0.058 5.36E-03 1.82E-02 
cg08700083 4 48382815 SLAIN2 Body OpenSea 0.506 0.440 0.066 5.39E-03 1.83E-02 
cg18789918 13 84452994 SLITRK1 3'UTR;1stExon N_Shore 0.240 0.186 0.054 5.41E-03 1.83E-02 
cg23216724 6 167571584 GPR31 TSS1500 OpenSea 0.611 0.559 0.053 5.42E-03 1.84E-02 
cg12744694 8 89300240 MMP16 Body OpenSea 0.785 0.677 0.107 5.47E-03 1.85E-02 
cg06363243 16 1630430 IFT140 Body OpenSea 0.669 0.618 0.051 5.47E-03 1.85E-02 
cg13551117 2 111979398   N_Shore 0.515 0.459 0.057 5.52E-03 1.86E-02 
cg01692842 11 134126364 ACAD8 Body S_Shelf 0.627 0.568 0.059 5.63E-03 1.89E-02 
cg09540738 8 81080281 TPD52 Body N_Shelf 0.665 0.612 0.053 5.64E-03 1.89E-02 
cg00898013 13 113819073 PROZ Body OpenSea 0.507 0.449 0.058 5.65E-03 1.89E-02 
cg17846016 17 80181015   S_Shore 0.568 0.516 0.053 5.67E-03 1.90E-02 
cg26161528 10 133208692   OpenSea 0.892 0.819 0.073 5.68E-03 1.90E-02 
cg24967811 12 123503709 PITPNM2 Body OpenSea 0.567 0.508 0.059 5.69E-03 1.90E-02 
cg14120049 19 36246408 HSPB6 3'UTR Island 0.507 0.437 0.070 5.70E-03 1.90E-02 
cg11860238 10 134726665   N_Shelf 0.823 0.745 0.078 5.71E-03 1.91E-02 
cg26930596 1 2082315 PRKCZ Body Island 0.550 0.499 0.051 5.72E-03 1.91E-02 
cg01366985 6 25167695   OpenSea 0.256 0.197 0.059 5.74E-03 1.91E-02 
cg24002158 8 142369468 GPR20 5'UTR S_Shore 0.453 0.392 0.060 5.75E-03 1.92E-02 
cg22905866 4 185468777   OpenSea 0.481 0.428 0.053 5.78E-03 1.93E-02 
cg02538681 10 90611911 ANKRD22 TSS200 OpenSea 0.651 0.594 0.058 5.80E-03 1.93E-02 
cg05089897 21 38886664 DYRK1A 3'UTR OpenSea 0.769 0.717 0.052 5.83E-03 1.94E-02 
cg13935765 9 89348726   OpenSea 0.718 0.575 0.143 5.86E-03 1.94E-02 
cg04714076 9 132426059   N_Shore 0.713 0.645 0.068 5.94E-03 1.96E-02 
cg26407841 7 81475720   OpenSea 0.459 0.400 0.059 5.95E-03 1.97E-02 
cg16788857 3 192577951 C3orf59 Body OpenSea 0.733 0.669 0.064 6.02E-03 1.98E-02 







cg13852284 10 77548353 C10orf11 Body OpenSea 0.635 0.583 0.053 6.05E-03 1.99E-02 
cg10206397 20 2085344 STK35 Body S_Shore 0.678 0.620 0.059 6.05E-03 1.99E-02 
cg04256466 4 169752398 PALLD Body;TSS1500 N_Shore 0.255 0.204 0.052 6.05E-03 1.99E-02 
cg15642380 1 172908788   OpenSea 0.467 0.402 0.066 6.08E-03 2.00E-02 
cg02862885 2 55327371   OpenSea 0.590 0.539 0.052 6.09E-03 2.00E-02 
cg01674119 6 31583231 AIF1 TSS1500;5'UTR;Body OpenSea 0.306 0.254 0.052 6.15E-03 2.01E-02 
cg10071929 9 130955135 CIZ1 TSS1500;5'UTR N_Shore 0.189 0.138 0.051 6.18E-03 2.02E-02 
cg02583091 8 145638881 SLC39A4 Body Island 0.360 0.282 0.077 6.22E-03 2.03E-02 
cg10920224 14 103367591 TRAF3 Body OpenSea 0.297 0.233 0.064 6.24E-03 2.03E-02 
cg17369406 21 34918578 SON Body OpenSea 0.414 0.352 0.062 6.24E-03 2.03E-02 
cg13801402 1 114429965 BCL2L15 1stExon OpenSea 0.724 0.672 0.052 6.27E-03 2.04E-02 
cg21927991 8 135494242 ZFAT Body S_Shelf 0.680 0.804 -0.124 6.28E-03 2.04E-02 
cg18517055 17 80581701 WDR45L Body OpenSea 0.705 0.654 0.051 6.30E-03 2.05E-02 
cg02394698 4 86594376 ARHGAP24 Body OpenSea 0.391 0.336 0.055 6.36E-03 2.06E-02 
cg20382675 3 71591429 FOXP1;MIR1284 5'UTR;TSS200 OpenSea 0.542 0.487 0.055 6.38E-03 2.06E-02 
cg16045423 22 39377790 APOBEC3B TSS1500 OpenSea 0.676 0.610 0.066 6.43E-03 2.08E-02 
cg02107279 5 14870749 ANKH Body N_Shore 0.252 0.202 0.050 6.44E-03 2.08E-02 
cg15929078 6 33267996 TAPBP;RGL2 3'UTR;TSS1500 S_Shore 0.279 0.222 0.056 6.45E-03 2.08E-02 
cg01283625 10 13568099   N_Shelf 0.698 0.648 0.050 6.46E-03 2.08E-02 
cg19699682 3 119349840   OpenSea 0.623 0.558 0.065 6.48E-03 2.09E-02 
cg13378649 1 222927856   OpenSea 0.504 0.451 0.054 6.50E-03 2.09E-02 
cg15027294 12 1609537 LOC100292680 TSS200 OpenSea 0.476 0.416 0.061 6.53E-03 2.10E-02 
cg10342963 15 99443213 IGF1R Body OpenSea 0.759 0.709 0.050 6.58E-03 2.11E-02 
cg24416910 12 132290859   N_Shelf 0.803 0.750 0.053 6.61E-03 2.12E-02 
cg25457927 22 38595422   N_Shelf 0.579 0.525 0.054 6.62E-03 2.12E-02 
cg13068698 7 35078082 DPY19L1 TSS1500 S_Shore 0.376 0.318 0.058 6.65E-03 2.13E-02 
cg13221899 13 103426862 C13orf27 TSS1500 Island 0.414 0.355 0.059 6.67E-03 2.13E-02 
cg00069771 1 233089275 C1orf57 Body S_Shelf 0.853 0.739 0.114 6.68E-03 2.13E-02 
cg22023435 16 89034099 CBFA2T3 Body Island 0.388 0.333 0.055 6.70E-03 2.14E-02 
cg21912448 1 8727007 RERE 5'UTR OpenSea 0.401 0.338 0.063 6.72E-03 2.14E-02 
cg03371275 11 95974543 MAML2 Body OpenSea 0.690 0.639 0.051 6.72E-03 2.14E-02 
cg04326337 20 36664969 RPRD1B Body S_Shelf 0.863 0.806 0.057 6.76E-03 2.15E-02 
cg26233651 1 90137953 LRRC8C 5'UTR OpenSea 0.899 0.837 0.061 6.80E-03 2.16E-02 
cg00001593 1 170490434   OpenSea 0.919 0.851 0.069 6.82E-03 2.17E-02 
cg16871435 10 65682643   OpenSea 0.717 0.662 0.055 6.84E-03 2.17E-02 
cg07600533 22 50986031 KLHDC7B TSS1500 Island 0.727 0.786 -0.059 6.90E-03 2.18E-02 
cg04958045 17 13508158   S_Shelf 0.913 0.845 0.068 6.92E-03 2.19E-02 
cg26426470 5 169181253 DOCK2 Body OpenSea 0.935 0.873 0.062 6.94E-03 2.19E-02 
cg11957400 12 2017093 CACNA2D4 Body N_Shore 0.408 0.353 0.055 7.00E-03 2.21E-02 
cg12869659 1 244213618 ZNF238 TSS1500 Island 0.201 0.151 0.050 7.10E-03 2.23E-02 
cg18558006 14 69725842 GALNTL1 TSS1500 N_Shore 0.796 0.745 0.051 7.14E-03 2.24E-02 
cg05216056 6 28887836 TRIM27 Body N_Shelf 0.646 0.595 0.051 7.20E-03 2.25E-02 
cg05681977 8 145638934 SLC39A4 Body Island 0.303 0.239 0.064 7.31E-03 2.28E-02 
cg24941342 11 95093809   OpenSea 0.523 0.470 0.053 7.32E-03 2.28E-02 
cg05976283 8 103140765   S_Shelf 0.523 0.461 0.062 7.35E-03 2.29E-02 
cg12209946 3 14987434   N_Shore 0.613 0.551 0.062 7.37E-03 2.29E-02 
cg09001226 6 32155082 PBX2 Body OpenSea 0.329 0.275 0.055 7.41E-03 2.30E-02 







cg09874643 2 239362030   S_Shore 0.836 0.929 -0.093 7.50E-03 2.32E-02 
cg16301036 12 118808298 TAOK3 5'UTR N_Shore 0.620 0.563 0.058 7.50E-03 2.32E-02 
cg07147033 1 1549615 MIB2 TSS1500 N_Shore 0.453 0.403 0.051 7.53E-03 2.33E-02 
cg10454879 8 602158   S_Shore 0.805 0.745 0.061 7.55E-03 2.33E-02 
cg23260484 1 245132134 EFCAB2 TSS1500 N_Shore 0.668 0.617 0.052 7.57E-03 2.34E-02 
cg11993173 8 54857695 RGS20 Body OpenSea 0.445 0.386 0.059 7.61E-03 2.34E-02 
cg27170268 14 104171695 XRCC3 Body OpenSea 0.579 0.522 0.057 7.63E-03 2.35E-02 
cg14221851 12 129329181   N_Shore 0.745 0.694 0.051 7.70E-03 2.36E-02 
cg03466780 9 140247365 EXD3 Body N_Shore 0.759 0.665 0.094 7.70E-03 2.37E-02 
cg23825057 12 124014409 RILPL1 Body N_Shelf 0.632 0.580 0.052 7.72E-03 2.37E-02 
cg26133399 12 62583974 FAM19A2 5'UTR N_Shore 0.326 0.270 0.056 7.85E-03 2.40E-02 
cg06033531 5 176980153 FAM193B 5'UTR;Body N_Shore 0.566 0.514 0.052 7.89E-03 2.41E-02 
cg05260346 6 158013621 ZDHHC14 Body N_Shore 0.914 0.858 0.056 7.90E-03 2.41E-02 
cg07502444 19 57682795   N_Shore 0.624 0.573 0.051 7.91E-03 2.41E-02 
cg15234627 13 33837178 STARD13 Body OpenSea 0.598 0.526 0.071 7.94E-03 2.42E-02 
cg13072943 6 167011311 RPS6KA2 Body OpenSea 0.619 0.568 0.051 7.96E-03 2.42E-02 
cg09916840 16 87248612   N_Shore 0.460 0.319 0.141 8.00E-03 2.43E-02 
cg07920381 12 132303685   OpenSea 0.596 0.541 0.056 8.29E-03 2.50E-02 
cg27105914 17 76445798 DNAH17 Body N_Shore 0.578 0.522 0.057 8.31E-03 2.50E-02 
cg19303728 4 53759295 SCFD2 Body OpenSea 0.895 0.817 0.078 8.32E-03 2.50E-02 
cg24762231 12 54690793 NFE2 TSS1500;5'UTR OpenSea 0.439 0.389 0.050 8.37E-03 2.51E-02 
cg11341144 3 185656289 TRA2B TSS1500 S_Shore 0.728 0.676 0.053 8.37E-03 2.51E-02 
cg11343072 2 160473528 BAZ2B TSS1500 S_Shore 0.524 0.465 0.059 8.44E-03 2.53E-02 
cg21153102 15 41252147   OpenSea 0.502 0.442 0.061 8.45E-03 2.53E-02 
cg11884704 9 130854313 SLC25A25 Body;1stExon OpenSea 0.524 0.465 0.059 8.48E-03 2.54E-02 
cg09976142 9 130955436 CIZ1 5'UTR Island 0.296 0.236 0.060 8.49E-03 2.54E-02 
cg23334433 17 79129051 AATK Body N_Shelf 0.618 0.554 0.064 8.54E-03 2.55E-02 
cg03051617 17 48562276 RSAD1 3'UTR OpenSea 0.885 0.787 0.097 8.60E-03 2.56E-02 
cg22579028 22 27056901 MIAT Body S_Shelf 0.702 0.643 0.059 8.61E-03 2.57E-02 
cg13460556 15 89709638 ABHD2 Body OpenSea 0.628 0.574 0.054 8.61E-03 2.57E-02 
cg03409151 5 125929671 ALDH7A1 Body N_Shore 0.758 0.702 0.056 8.65E-03 2.57E-02 
cg17111663 4 7647874 SORCS2 Body Island 0.600 0.505 0.094 8.69E-03 2.58E-02 
cg09101941 5 133775258   OpenSea 0.474 0.421 0.053 8.70E-03 2.59E-02 
cg12924402 2 218898511   Island 0.582 0.672 -0.090 8.71E-03 2.59E-02 
cg27545630 16 2013058 SNORA64;SNORA10;RPS2 Body;TSS1500 N_Shore 0.692 0.745 -0.052 8.73E-03 2.59E-02 
cg20673721 17 25859382 KSR1 5'UTR OpenSea 0.542 0.491 0.051 8.79E-03 2.60E-02 
cg21696012 1 24131000 HMGCL Body S_Shelf 0.589 0.536 0.053 8.81E-03 2.61E-02 
cg15254822 7 564137   S_Shore 0.807 0.756 0.051 8.83E-03 2.61E-02 
cg17165241 11 400385 PKP3 Body Island 0.596 0.546 0.050 8.95E-03 2.64E-02 
cg27395066 17 43221220 ACBD4 3'UTR N_Shore 0.259 0.208 0.052 8.98E-03 2.64E-02 
cg13302785 3 51104051 DOCK3 Body OpenSea 0.395 0.337 0.058 9.01E-03 2.65E-02 
cg11180667 10 101415865   N_Shelf 0.551 0.493 0.058 9.11E-03 2.67E-02 
cg16350446 2 172338747 DCAF17 Body;3'UTR OpenSea 0.498 0.441 0.057 9.13E-03 2.68E-02 
cg00114784 15 97322504   OpenSea 0.724 0.651 0.074 9.13E-03 2.68E-02 
cg20435535 6 31651151   Island 0.359 0.280 0.079 9.13E-03 2.68E-02 
cg25140190 18 13641529 C18orf1 Body N_Shore 0.576 0.518 0.058 9.14E-03 2.68E-02 
cg25416319 17 37080373   OpenSea 0.553 0.501 0.052 9.19E-03 2.69E-02 







cg13488811 11 128685313   OpenSea 0.597 0.544 0.054 9.31E-03 2.72E-02 
cg17679427 10 35480749 CREM Body;5'UTR OpenSea 0.523 0.467 0.056 9.31E-03 2.72E-02 
cg13753351 9 127134207 PSMB7 Body OpenSea 0.559 0.503 0.056 9.32E-03 2.72E-02 
cg13870520 4 77131705 SCARB2 Body N_Shelf 0.539 0.488 0.051 9.36E-03 2.73E-02 
cg16323245 3 114622118 ZBTB20;ZBTB20 5'UTR OpenSea 0.520 0.462 0.059 9.37E-03 2.73E-02 
cg05302896 7 108524793 C7orf66 TSS200 OpenSea 0.818 0.766 0.052 9.50E-03 2.75E-02 
cg11809958 12 32654929 FGD4 TSS200 OpenSea 0.693 0.638 0.055 9.51E-03 2.76E-02 
cg10926851 5 146253830 PPP2R2B Body;5'UTR N_Shelf 0.610 0.742 -0.132 9.54E-03 2.76E-02 
cg01942558 2 152214027 TNFAIP6 TSS200 OpenSea 0.714 0.658 0.056 9.57E-03 2.77E-02 
cg23050394 5 123599727   OpenSea 0.620 0.568 0.051 9.58E-03 2.77E-02 
cg27512707 6 9896436   OpenSea 0.935 0.882 0.053 9.59E-03 2.77E-02 
cg22440848 4 184320416   S_Shore 0.502 0.448 0.053 9.62E-03 2.78E-02 
cg16396191 13 42184765 KIAA0564 Body OpenSea 0.754 0.702 0.051 9.66E-03 2.79E-02 
cg27019030 14 75749992   S_Shelf 0.245 0.193 0.052 9.73E-03 2.80E-02 
cg05522042 16 85124401 KIAA0513 3'UTR OpenSea 0.671 0.605 0.066 9.74E-03 2.80E-02 
cg27598107 2 102759782   S_Shore 0.586 0.533 0.053 9.74E-03 2.80E-02 
cg08324090 17 7253189 ACAP1 Body N_Shore 0.722 0.665 0.056 9.87E-03 2.83E-02 
cg12725760 1 192873912   OpenSea 0.334 0.274 0.060 9.88E-03 2.83E-02 
cg01175220 20 30617892 C20orf160 3'UTR N_Shore 0.761 0.695 0.065 9.88E-03 2.84E-02 
cg14774440 8 37730745 RAB11FIP1 Body;5'UTR;1stExon OpenSea 0.459 0.408 0.050 9.91E-03 2.84E-02 
cg20078972 19 15391832 BRD4;BRD4 TSS1500 OpenSea 0.485 0.431 0.055 9.91E-03 2.84E-02 
cg26277026 12 22486029 ST8SIA1 Body N_Shore 0.470 0.415 0.056 9.95E-03 2.85E-02 
cg03202732 11 63655087 MARK2 TSS1500;Body OpenSea 0.427 0.366 0.061 9.95E-03 2.85E-02 
cg15930703 2 225775142 DOCK10 Body OpenSea 0.731 0.673 0.057 1.00E-02 2.86E-02 
cg13074055 14 106329206   OpenSea 0.504 0.453 0.051 1.00E-02 2.87E-02 
cg06654773 11 68199794 LRP5 Body N_Shore 0.843 0.792 0.052 1.01E-02 2.88E-02 
cg19867917 2 3642629 COLEC11 TSS200 Island 0.488 0.432 0.056 1.01E-02 2.89E-02 
cg16580197 8 67841925   S_Shelf 0.508 0.452 0.056 1.02E-02 2.91E-02 
cg27504269 12 21524305 SLCO1A2;IAPP 5'UTR;TSS1500 OpenSea 0.854 0.906 -0.052 1.02E-02 2.91E-02 
cg08173216 15 41524250 CHP;EXD1 Body;TSS1500 S_Shore 0.445 0.393 0.052 1.03E-02 2.93E-02 
cg13642260 9 130955380 CIZ1 5'UTR Island 0.215 0.164 0.050 1.04E-02 2.94E-02 
cg05162456 16 85671457 KIAA0182 5'UTR;Body S_Shore 0.858 0.795 0.064 1.04E-02 2.94E-02 
cg11147866 15 68835517   OpenSea 0.722 0.666 0.056 1.04E-02 2.94E-02 
cg09672452 15 55665236 CCPG1;MIR628;CCPG1 Body;TSS200 OpenSea 0.278 0.227 0.051 1.05E-02 2.97E-02 
cg25489105 3 129155354 MBD4 Body N_Shelf 0.432 0.376 0.056 1.06E-02 2.98E-02 
cg17586302 6 144013969 PHACTR2 Body OpenSea 0.602 0.550 0.052 1.06E-02 2.98E-02 
cg23210971 4 88049275 AFF1 Body OpenSea 0.743 0.691 0.051 1.06E-02 2.98E-02 
cg13679804 3 59734950   OpenSea 0.523 0.461 0.062 1.06E-02 2.99E-02 
cg11839815 3 127539037 MGLL Body N_Shelf 0.620 0.563 0.057 1.07E-02 3.00E-02 
cg10611016 11 6225759 C11orf42 TSS1500 OpenSea 0.632 0.574 0.058 1.07E-02 3.00E-02 
cg21892720 19 54877827 LAIR1;LAIR1 TSS1500 OpenSea 0.553 0.497 0.056 1.08E-02 3.03E-02 
cg14713146 2 171782647   N_Shelf 0.651 0.600 0.050 1.09E-02 3.06E-02 
cg00211174 3 127332098 MCM2 Body OpenSea 0.532 0.475 0.056 1.10E-02 3.07E-02 
cg21199093 1 35836009 ZMYM4 Body OpenSea 0.573 0.510 0.063 1.11E-02 3.08E-02 
cg16291589 20 6023178 LRRN4 Body S_Shore 0.736 0.685 0.051 1.11E-02 3.08E-02 
cg04563996 3 57093519 ARHGEF3;SPATA12 5'UTR;TSS1500 OpenSea 0.329 0.274 0.056 1.11E-02 3.08E-02 
cg11916609 2 102927488 IL1RL1 TSS1500 OpenSea 0.655 0.601 0.054 1.11E-02 3.10E-02 







cg03494634 19 9238958 OR7G3 TSS1500 OpenSea 0.261 0.177 0.084 1.13E-02 3.13E-02 
cg02799427 16 8623289 TMEM114 TSS1500 S_Shelf 0.725 0.669 0.055 1.13E-02 3.13E-02 
cg27019278 4 101438804 EMCN Body OpenSea 0.471 0.421 0.050 1.14E-02 3.15E-02 
cg14804593 4 189139691   OpenSea 0.683 0.620 0.063 1.14E-02 3.16E-02 
cg03018489 9 136397058 ADAMTSL2 TSS1500 N_Shelf 0.713 0.600 0.113 1.14E-02 3.16E-02 
cg18984103 14 104163025 KLC1 Body N_Shelf 0.556 0.499 0.057 1.15E-02 3.17E-02 
cg06027691 3 37998565 CTDSPL Body OpenSea 0.347 0.287 0.060 1.15E-02 3.18E-02 
cg10278149 2 208016923 KLF7 Body OpenSea 0.768 0.716 0.052 1.16E-02 3.20E-02 
cg08862479 5 177889945 COL23A1 Body OpenSea 0.799 0.748 0.051 1.17E-02 3.20E-02 
cg02206980 6 13574034 SIRT5;SIRT5 TSS1500 N_Shore 0.482 0.414 0.067 1.17E-02 3.22E-02 
cg21762728 6 170165905 C6orf70 Body OpenSea 0.751 0.693 0.057 1.18E-02 3.23E-02 
cg00278392 6 16802505   OpenSea 0.547 0.493 0.054 1.18E-02 3.23E-02 
cg22386583 17 78753756 RPTOR Body OpenSea 0.598 0.545 0.054 1.18E-02 3.24E-02 
cg18558767 3 71592056 FOXP1;MIR1284 5'UTR;TSS1500 OpenSea 0.442 0.391 0.051 1.19E-02 3.25E-02 
cg03940883 16 14380714   S_Shore 0.462 0.551 -0.089 1.19E-02 3.26E-02 
cg02747563 7 157289477   N_Shelf 0.960 0.902 0.058 1.20E-02 3.27E-02 
cg24740647 10 72681285   S_Shelf 0.589 0.529 0.060 1.21E-02 3.29E-02 
cg21386573 1 94219800   OpenSea 0.706 0.655 0.051 1.21E-02 3.30E-02 
cg13387643 1 10737562 CASZ1 Body OpenSea 0.566 0.468 0.098 1.21E-02 3.30E-02 
cg10474881 6 114181686 MARCKS Body Island 0.800 0.857 -0.057 1.22E-02 3.30E-02 
cg14419424 10 65388604   N_Shore 0.257 0.201 0.056 1.23E-02 3.33E-02 
cg00093643 15 44579510 CASC4 TSS1500 N_Shore 0.543 0.489 0.054 1.23E-02 3.33E-02 
cg26300135 1 3324243 PRDM16 Body S_Shore 0.904 0.835 0.069 1.23E-02 3.34E-02 
cg01832662 14 86086389 FLRT2 5'UTR OpenSea 0.231 0.173 0.058 1.24E-02 3.34E-02 
cg01997599 19 49689673 TRPM4 Body S_Shelf 0.368 0.288 0.080 1.24E-02 3.36E-02 
cg09727050 2 152214177 TNFAIP6;TNFAIP6 5'UTR;1stExon OpenSea 0.640 0.579 0.061 1.25E-02 3.37E-02 
cg03741458 2 200468445   N_Shore 0.504 0.446 0.058 1.25E-02 3.38E-02 
cg17750572 10 2544120   Island 0.653 0.587 0.065 1.26E-02 3.39E-02 
cg01800262 1 54360170 DIO1 1stExon;1stExon;Body;1stExon OpenSea 0.932 0.876 0.056 1.26E-02 3.40E-02 
cg14835981 7 752715 PRKAR1B TSS200;5'UTR;TSS1500;1stExon S_Shore 0.498 0.444 0.053 1.27E-02 3.41E-02 
cg16346422 11 2920819 SLC22A18;SLC22A18AS TSS200;Body N_Shelf 0.490 0.435 0.055 1.27E-02 3.42E-02 
cg02853355 16 85132373 FAM92B 3'UTR OpenSea 0.635 0.582 0.054 1.28E-02 3.44E-02 
cg02175321 11 103930844 PDGFD Body OpenSea 0.558 0.506 0.052 1.29E-02 3.44E-02 
cg00883212 2 173795201 RAPGEF4 Body OpenSea 0.649 0.597 0.052 1.30E-02 3.47E-02 
cg07283015 18 22039857 HRH4 TSS1500 OpenSea 0.614 0.563 0.051 1.30E-02 3.47E-02 
cg00614011 8 120436479 NOV 3'UTR OpenSea 0.812 0.742 0.070 1.30E-02 3.48E-02 
cg22579075 7 94250352 SGCE Body OpenSea 0.653 0.708 -0.055 1.31E-02 3.49E-02 
cg18673341 7 22481962 MGC87042 Body OpenSea 0.675 0.577 0.098 1.31E-02 3.50E-02 
cg17547295 5 157282503 CLINT1 Body N_Shelf 0.594 0.541 0.053 1.31E-02 3.50E-02 
cg15727583 3 196757701 MFI2 TSS1500 S_Shore 0.822 0.751 0.072 1.31E-02 3.50E-02 
cg18926797 14 69523229 DCAF5 Body OpenSea 0.618 0.563 0.055 1.32E-02 3.50E-02 
cg08161546 6 152011415 ESR1 TSS1500 OpenSea 0.679 0.624 0.055 1.32E-02 3.51E-02 
cg11100795 5 77583915 AP3B1 Body OpenSea 0.652 0.601 0.051 1.32E-02 3.51E-02 
cg04264638 4 56411138 CLOCK 5'UTR N_Shore 0.343 0.285 0.059 1.32E-02 3.51E-02 
cg02806156 12 89728752   OpenSea 0.572 0.516 0.057 1.33E-02 3.53E-02 
cg07903626 16 66098650   OpenSea 0.685 0.586 0.100 1.33E-02 3.53E-02 
cg10758676 6 158010406 ZDHHC14 Body N_Shelf 0.818 0.914 -0.095 1.33E-02 3.53E-02 







cg05755715 2 21646627   OpenSea 0.644 0.535 0.109 1.35E-02 3.56E-02 
cg19193595 15 67396487 SMAD3 Body OpenSea 0.391 0.322 0.069 1.35E-02 3.58E-02 
cg10881162 3 55613558 ERC2 3'UTR OpenSea 0.571 0.493 0.079 1.36E-02 3.59E-02 
cg06255004 9 139580799 AGPAT2 Body N_Shore 0.425 0.368 0.057 1.36E-02 3.59E-02 
cg25945642 3 143321098 SLC9A9 Body OpenSea 0.605 0.551 0.055 1.38E-02 3.64E-02 
cg01057573 5 118683890 TNFAIP8 Body OpenSea 0.571 0.518 0.053 1.39E-02 3.64E-02 
cg22774605 6 47247047 TNFRSF21 Body OpenSea 0.680 0.629 0.051 1.39E-02 3.65E-02 
cg13814396 2 65090621   N_Shore 0.504 0.453 0.051 1.39E-02 3.65E-02 
cg11463428 15 32607260   Island 0.782 0.708 0.074 1.40E-02 3.66E-02 
cg05025071 19 6887530 EMR1 TSS200 OpenSea 0.588 0.529 0.059 1.40E-02 3.67E-02 
cg01655008 14 93652954 C14orf109 Body S_Shore 0.713 0.658 0.054 1.40E-02 3.67E-02 
cg21932814 3 122044172 CSTA 1stExon OpenSea 0.538 0.484 0.054 1.41E-02 3.69E-02 
cg11716267 2 24367828 LOC375190 Body OpenSea 0.539 0.665 -0.126 1.42E-02 3.70E-02 
cg19677302 12 33048259 PKP2 Body N_Shore 0.711 0.656 0.055 1.42E-02 3.70E-02 
cg01561719 10 90611855 ANKRD22 TSS200 OpenSea 0.493 0.443 0.050 1.42E-02 3.70E-02 
cg00168694 21 40193056 ETS2 Body N_Shore 0.528 0.474 0.053 1.43E-02 3.72E-02 
cg03115019 17 80708279 FN3K Body Island 0.863 0.812 0.050 1.43E-02 3.73E-02 
cg13071618 8 144599125 ZC3H3 Body N_Shelf 0.449 0.374 0.075 1.44E-02 3.74E-02 
cg08185095 8 74527135 STAU2 Body OpenSea 0.687 0.629 0.058 1.45E-02 3.76E-02 
cg06627617 2 9471179 ASAP2;ASAP2 Body OpenSea 0.238 0.185 0.052 1.45E-02 3.77E-02 
cg24914483 18 2653997   N_Shore 0.583 0.517 0.067 1.45E-02 3.77E-02 
cg22851875 5 65888284   N_Shelf 0.184 0.076 0.107 1.46E-02 3.77E-02 
cg01219135 7 158766336   Island 0.737 0.677 0.060 1.46E-02 3.78E-02 
cg09231171 16 49518414   OpenSea 0.314 0.259 0.055 1.47E-02 3.79E-02 
cg00254095 18 47016218 RPL17;SNORD58C;U58;RPL17 Body;TSS1500 N_Shelf 0.352 0.478 -0.126 1.47E-02 3.81E-02 
cg12488187 12 65671664 MSRB3 TSS1500 N_Shore 0.660 0.605 0.055 1.48E-02 3.82E-02 
cg24550026 1 114430031 BCL2L15 1stExon;5'UTR OpenSea 0.557 0.494 0.063 1.49E-02 3.84E-02 
cg26836402 16 87252649   S_Shore 0.630 0.562 0.068 1.49E-02 3.84E-02 
cg13216331 1 156025757 ROBLD3 Body S_Shore 0.454 0.394 0.061 1.49E-02 3.84E-02 
cg25654653 6 133035266 VNN1 TSS200 OpenSea 0.311 0.255 0.057 1.50E-02 3.85E-02 
cg13286116 11 13302098 ARNTL 5'UTR S_Shore 0.490 0.434 0.057 1.50E-02 3.85E-02 
cg00760729 2 161236088 RBMS1 Body OpenSea 0.478 0.418 0.060 1.50E-02 3.86E-02 
cg07681748 3 112053517 CD200 Body S_Shore 0.479 0.419 0.059 1.51E-02 3.87E-02 
cg16615357 5 135416594 MIR886 TSS1500 S_Shore 0.536 0.478 0.058 1.52E-02 3.90E-02 
cg06493806 18 77278806 NFATC1 Body N_Shore 0.881 0.799 0.082 1.53E-02 3.91E-02 
cg13333954 12 1098663   N_Shore 0.506 0.455 0.051 1.53E-02 3.92E-02 
cg15837233 2 162279324 TBR1 Body N_Shore 0.431 0.380 0.050 1.54E-02 3.94E-02 
cg03313271 13 113913094 CUL4A Body N_Shelf 0.715 0.662 0.053 1.55E-02 3.96E-02 
cg00078996 12 132293329   N_Shore 0.677 0.619 0.057 1.55E-02 3.96E-02 
cg20704555 7 28127748 JAZF1 Body OpenSea 0.664 0.611 0.054 1.57E-02 3.98E-02 
cg02304584 6 31650790   Island 0.414 0.339 0.075 1.57E-02 3.99E-02 
cg21517812 11 125443136 EI24;EI24 Body S_Shelf 0.877 0.798 0.079 1.57E-02 3.99E-02 
cg07437923 16 4506231 DNAJA3 3'UTR OpenSea 0.553 0.433 0.120 1.57E-02 4.00E-02 
cg01925738 5 140480770 PCDHB3 1stExon N_Shore 0.507 0.456 0.051 1.59E-02 4.03E-02 
cg14520947 1 225942842   OpenSea 0.588 0.536 0.052 1.59E-02 4.03E-02 
cg26792295 3 16540091 RFTN1 5'UTR OpenSea 0.634 0.579 0.055 1.60E-02 4.05E-02 
cg01323964 7 65219171 SNORA22;CCT6P1 TSS1500;Body S_Shelf 0.627 0.569 0.057 1.60E-02 4.05E-02 







cg10862468 10 135342218 CYP2E1 Body Island 0.272 0.221 0.051 1.61E-02 4.07E-02 
cg07930587 6 32823566 PSMB9 Body S_Shore 0.653 0.745 -0.092 1.62E-02 4.09E-02 
cg16101346 1 186650479 PTGS2 TSS1500 S_Shore 0.469 0.412 0.057 1.63E-02 4.10E-02 
cg21727359 6 82459006 FAM46A 3'UTR N_Shelf 0.542 0.486 0.055 1.63E-02 4.10E-02 
cg25576997 14 56257750 C14orf34 Body OpenSea 0.631 0.572 0.058 1.63E-02 4.11E-02 
cg06784232 8 19463150 CSGALNACT1 Body;5'UTR S_Shelf 0.687 0.635 0.052 1.64E-02 4.12E-02 
cg04118119 13 47371987 ESD TSS1500 S_Shore 0.584 0.533 0.050 1.64E-02 4.12E-02 
cg02275784 11 85242554 DLG2 Body OpenSea 0.721 0.670 0.052 1.65E-02 4.13E-02 
cg23464284 6 166996837 RPS6KA2 Body OpenSea 0.532 0.457 0.076 1.67E-02 4.18E-02 
cg03594078 8 22131675 PIWIL2;PIWIL2 TSS1500 N_Shore 0.617 0.564 0.053 1.68E-02 4.20E-02 
cg00027155 16 11099199 CLEC16A Body OpenSea 0.765 0.667 0.098 1.68E-02 4.20E-02 
cg12319143 10 134726771   N_Shelf 0.537 0.452 0.085 1.68E-02 4.20E-02 
cg21491967 6 156276515   OpenSea 0.418 0.365 0.053 1.68E-02 4.20E-02 
cg18170989 13 49975383 CAB39L 5'UTR;5'UTR;1stExon OpenSea 0.435 0.378 0.056 1.69E-02 4.22E-02 
cg09199225 6 32149260 AGER Body OpenSea 0.813 0.732 0.082 1.69E-02 4.22E-02 
cg11956442 4 39531927   S_Shelf 0.569 0.441 0.128 1.69E-02 4.22E-02 
cg07240846 10 12438782 CAMK1D Body OpenSea 0.893 0.829 0.064 1.70E-02 4.24E-02 
cg14280181 2 223291007 SGPP2 Body S_Shore 0.421 0.363 0.058 1.70E-02 4.24E-02 
cg06975018 6 131894358 ARG1 TSS200 OpenSea 0.632 0.556 0.077 1.70E-02 4.24E-02 
cg18105134 13 113819100 PROZ Body OpenSea 0.751 0.676 0.075 1.71E-02 4.25E-02 
cg06398138 11 132912368 OPCML Body OpenSea 0.829 0.771 0.058 1.71E-02 4.25E-02 
cg08600378 13 28562900 PRHOXNB TSS200 OpenSea 0.731 0.673 0.058 1.71E-02 4.25E-02 
cg07629625 10 133961825 JAKMIP3 Body OpenSea 0.529 0.604 -0.075 1.72E-02 4.27E-02 
cg12866960 12 66635398 IRAK3 Body OpenSea 0.624 0.571 0.053 1.73E-02 4.29E-02 
cg18728025 4 121991645 C4orf31 5'UTR N_Shore 0.325 0.272 0.053 1.74E-02 4.30E-02 
cg24498885 13 45770307 KCTD4;GTF2F2 5'UTR;Body OpenSea 0.608 0.558 0.050 1.75E-02 4.33E-02 
cg00994804 21 36259383 RUNX1 1stExon;Body Island 0.246 0.304 -0.058 1.75E-02 4.33E-02 
cg02470008 7 2648343 IQCE Body S_Shelf 0.351 0.298 0.053 1.75E-02 4.34E-02 
cg06939451 5 81043172 SSBP2 Body N_Shelf 0.550 0.496 0.054 1.77E-02 4.36E-02 
cg04525852 4 125632538 ANKRD50 5'UTR N_Shore 0.355 0.303 0.052 1.77E-02 4.36E-02 
cg05608790 7 69427388 AUTS2 Body OpenSea 0.460 0.406 0.054 1.77E-02 4.37E-02 
cg19603903 19 57742345 AURKC TSS200 Island 0.680 0.627 0.053 1.77E-02 4.38E-02 
cg12296550 6 32728862 HLA-DQB2 Body N_Shore 0.784 0.733 0.051 1.78E-02 4.39E-02 
cg12656896 6 8438818   S_Shelf 0.447 0.395 0.053 1.78E-02 4.39E-02 
cg00382999 3 136649333 NCK1 Body OpenSea 0.598 0.539 0.059 1.79E-02 4.40E-02 
cg21953058 15 41309253 INO80 Body OpenSea 0.500 0.449 0.051 1.79E-02 4.40E-02 
cg14754555 2 157292018 GPD2 1stExon;TSS1500;5'UTR N_Shore 0.424 0.365 0.059 1.79E-02 4.41E-02 
cg14873022 4 146841701 ZNF827 Body OpenSea 0.727 0.671 0.056 1.79E-02 4.41E-02 
cg03348161 11 59824089 MS4A3 TSS200 OpenSea 0.535 0.483 0.052 1.80E-02 4.42E-02 
cg07734159 10 75772918 VCL;VCL Body OpenSea 0.715 0.658 0.057 1.80E-02 4.42E-02 
cg23445003 7 101535821 CUX1 Body OpenSea 0.575 0.515 0.061 1.80E-02 4.43E-02 
cg15553418 1 16696547 C1orf144 Body S_Shelf 0.511 0.458 0.052 1.83E-02 4.47E-02 
cg06160853 3 174155855   N_Shelf 0.577 0.520 0.057 1.83E-02 4.48E-02 
cg21263605 1 166818686 POGK Body OpenSea 0.912 0.858 0.054 1.83E-02 4.48E-02 
cg08347373 2 160653686 CD302 Body N_Shore 0.565 0.507 0.059 1.84E-02 4.48E-02 
cg08154963 17 33426885 RAD51L3 3'UTR OpenSea 0.530 0.477 0.053 1.84E-02 4.49E-02 
cg10530344 15 81453270   OpenSea 0.433 0.325 0.108 1.89E-02 4.58E-02 







cg00691123 3 11632974 VGLL4 Body OpenSea 0.573 0.521 0.052 1.93E-02 4.66E-02 
cg15169266 7 41376887   OpenSea 0.712 0.661 0.052 1.94E-02 4.68E-02 
cg24166916 5 78282669 ARSB TSS1500 S_Shore 0.135 0.188 -0.053 1.95E-02 4.69E-02 
cg01742370 1 228352412 C1orf69 TSS1500 N_Shore 0.705 0.651 0.054 1.95E-02 4.69E-02 
cg18876706 10 31107995   OpenSea 0.849 0.780 0.068 1.95E-02 4.69E-02 
cg00956142 1 28765031 PHACTR4 Body OpenSea 0.512 0.459 0.053 1.98E-02 4.75E-02 
cg12192749 7 17029795   OpenSea 0.566 0.513 0.053 1.99E-02 4.76E-02 
cg19951200 3 141071669 ZBTB38 5'UTR OpenSea 0.844 0.783 0.061 1.99E-02 4.76E-02 
cg24492778 15 57414740 TCF12 Body OpenSea 0.455 0.394 0.061 1.99E-02 4.77E-02 
cg19636224 1 44176844 ST3GAL3 5'UTR S_Shelf 0.689 0.630 0.058 2.00E-02 4.79E-02 
cg08539965 1 21396338 EIF4G3 5'UTR OpenSea 0.640 0.580 0.060 2.01E-02 4.80E-02 
cg14312439 3 46283902 CCR3 1stExon;5'UTR OpenSea 0.513 0.460 0.053 2.01E-02 4.81E-02 
cg03847895 12 56652945 ANKRD52 TSS1500 S_Shore 0.437 0.385 0.051 2.02E-02 4.82E-02 
cg26677549 2 236398235   N_Shelf 0.872 0.821 0.051 2.04E-02 4.85E-02 
cg25084760 13 100886412 PCCA Body OpenSea 0.674 0.618 0.056 2.05E-02 4.86E-02 
cg11876048 17 55337654 MSI2;MSI2 Body S_Shelf 0.431 0.378 0.053 2.05E-02 4.87E-02 
cg18624102 19 39523840 FBXO27 TSS1500 S_Shore 0.620 0.732 -0.112 2.06E-02 4.88E-02 
cg16744531 19 17905626 B3GNT3 TSS1500 Island 0.473 0.415 0.058 2.06E-02 4.89E-02 
cg05492904 15 51604503 CYP19A1 5'UTR OpenSea 0.627 0.577 0.050 2.08E-02 4.92E-02 
cg18025838 17 79232329 SLC38A10 Body N_Shelf 0.863 0.805 0.059 2.09E-02 4.94E-02 
cg08628635 6 20483859 E2F3 Body OpenSea 0.569 0.517 0.052 2.09E-02 4.95E-02 
cg26303777 1 230311676 GALNT2 Body OpenSea 0.619 0.736 -0.117 2.10E-02 4.96E-02 
cg21574244 15 42568411 GANC Body S_Shelf 0.653 0.595 0.058 2.10E-02 4.97E-02 
cg10968027 11 95405470   OpenSea 0.448 0.388 0.060 2.11E-02 4.97E-02 
cg10068464 2 114036953 PAX8;LOC440839 TSS1500 S_Shore 0.783 0.691 0.092 2.11E-02 4.98E-02 
cg03714676 8 48174649 KIAA0146 Body S_Shore 0.634 0.581 0.053 2.11E-02 4.98E-02 








Appendix Table 4.2: Selected differentially methylated regions (DMRs) (N=315) associated with HIV after adjustment for age, 
sex, and cell type proportion with |MaxΔβ| >0.05, Stouffer<0.05, and containing at least 2 CpG sites, sorted by Stouffer from 
smallest to largest 
 











Genes associated to region 
6 chr6:33128825-33155135 169 6.05E-33 1.07E-134 0.061 -0.011 COL11A2 
6 chr6:32184296-32191895 46 1.01E-44 3.34E-67 0.056 -0.013 NOTCH4 
1 chr1:3141992-3144710 11 5.31E-27 2.68E-31 -0.059 -0.020 NA 
6 chr6:170590562-170601120 44 7.94E-20 4.65E-28 -0.098 -0.010 DLL1, FAM120B 
5 chr5:140682503-140684561 14 5.95E-36 1.83E-27 -0.051 -0.027 SLC25A2 
6 chr6:30874989-30886161 93 5.79E-36 1.03E-25 -0.060 -0.006 GTF2H4, VARS2, RN7SL175P 
6 chr6:31021134-31027005 21 9.94E-18 2.03E-24 -0.065 -0.018 HCG22 
15 chr15:97319911-97323132 13 3.97E-17 3.89E-22 -0.073 -0.020 SPATA8-AS1 
6 chr6:32819921-32823941 53 2.06E-22 5.40E-20 0.062 0.005 TAP1, PSMB9 
17 chr17:46651186-46658170 46 5.91E-13 1.58E-19 -0.055 0.006 HOXB3, HOXB4, MIR10A 
20 chr20:62569104-62572875 9 6.87E-14 4.93E-19 -0.056 -0.021 MIR647, UCKL1, MIR1914 
1 chr1:228545604-228548842 9 4.04E-17 3.69E-18 -0.061 -0.020 NA 
1 chr1:163392482-163393693 5 3.02E-25 7.46E-18 -0.051 -0.016 RP11-408E1.1 
8 chr8:1616111-1618448 12 4.21E-23 9.06E-18 -0.066 -0.020 NA 
3 chr3:138762690-138764086 9 1.10E-19 9.33E-17 -0.062 -0.033 PRR23C 
22 chr22:33195343-33198055 17 1.23E-18 1.28E-16 -0.050 -0.007 TIMP3 
20 chr20:2728576-2731560 8 1.46E-23 1.68E-16 -0.161 -0.046 EBF4 
2 chr2:3641709-3643682 13 5.68E-18 4.45E-16 -0.057 -0.030 COLEC11 
2 chr2:168673805-168675357 4 1.39E-26 4.81E-15 -0.050 -0.016 B3GALT1 
7 chr7:27159883-27164709 18 1.84E-10 1.20E-14 0.056 -0.004 HOXA3, HOXA-AS2 
3 chr3:141495473-141497467 15 3.26E-14 1.80E-14 -0.050 -0.011 GRK7 
6 chr6:31837439-31839025 9 5.25E-19 9.90E-14 -0.057 -0.019 SLC44A4 
8 chr8:75735552-75737456 5 1.51E-15 1.35E-13 -0.051 -0.026 PI15 
16 chr16:1492791-1502837 28 4.07E-07 1.59E-13 -0.050 -0.008 CCDC154, LA16c-390E6.4, CLCN7 
6 chr6:30954150-30957462 18 5.87E-17 3.08E-13 0.066 -0.004 NA 
2 chr2:105852798-105854051 9 3.71E-13 3.98E-13 -0.073 -0.042 NA 
6 chr6:32148943-32152269 23 9.06E-17 4.34E-13 -0.099 -0.011 AGER, XXbac-BPG300A18.13 
4 chr4:122684903-122687552 17 1.95E-11 6.21E-13 -0.063 -0.012 TMEM155 
6 chr6:119470324-119471177 5 1.70E-21 6.49E-13 -0.056 -0.017 FAM184A 
2 chr2:106054920-106055507 6 9.52E-17 1.39E-12 -0.071 -0.024 FHL2 
19 chr19:11784246-11785248 14 3.44E-15 1.85E-12 -0.051 -0.019 NA 
3 chr3:196754322-196758146 13 1.25E-07 1.85E-12 -0.065 -0.007 MFI2 
2 chr2:220402771-220409543 19 2.29E-11 2.56E-12 -0.052 -0.009 CHPF, TMEM198 
11 chr11:45671015-45674702 10 1.44E-10 3.35E-12 -0.051 -0.017 RP11-495O11.1, CHST1 
16 chr16:85669462-85672175 12 3.15E-12 4.46E-12 -0.062 -0.012 NA 
13 chr13:76430089-76430722 4 1.54E-14 4.89E-12 -0.053 -0.029 LMO7 
6 chr6:31650735-31651362 20 2.84E-13 5.67E-12 -0.065 -0.038 LY6G5C 
8 chr8:1244039-1247803 8 6.07E-10 6.27E-12 -0.070 -0.013 NA 







10 chr10:135340445-135343280 16 6.26E-09 1.46E-11 -0.075 -0.036 CYP2E1, AL161645.2 
8 chr8:144398248-144401094 11 4.61E-08 4.02E-11 -0.073 -0.012 TOP1MT-013, AC087793.1-201 
1 chr1:1371844-1377656 16 1.26E-11 4.14E-11 -0.051 -0.013 VWA1, RP4-758J18.10 
6 chr6:32728862-32731127 23 4.09E-16 9.30E-11 -0.053 -0.017 HLA-DQB2 
8 chr8:1109986-1113811 14 9.56E-08 1.43E-10 -0.082 -0.018 NA 
7 chr7:26192756-26193805 6 1.70E-12 1.63E-10 0.053 0.026 NFE2L3-001 
7 chr7:157369121-157372332 15 2.22E-14 1.99E-10 -0.072 -0.014 NA 
4 chr4:187984412-187985472 6 2.04E-15 2.02E-10 -0.054 -0.023 NA 
13 chr13:46275352-46277286 5 5.31E-20 2.73E-10 -0.052 -0.020 SPERT 
16 chr16:4027502-4029363 10 1.86E-07 3.28E-10 0.051 -0.001 NA 
5 chr5:404678-405986 8 9.55E-14 4.17E-10 -0.060 -0.011 CTD-2228K2.2-001 
21 chr21:43441482-43442940 9 7.98E-14 5.82E-10 -0.086 -0.021 ZNF295-AS1 
22 chr22:25594918-25595955 10 3.91E-12 6.65E-10 -0.050 -0.014 CRYBB3 
1 chr1:15255231-15256481 6 1.16E-12 7.36E-10 -0.054 -0.020 KAZN 
2 chr2:31637622-31638511 3 1.74E-21 8.80E-10 -0.061 -0.025 XDH 
17 chr17:80004741-80012647 28 9.40E-06 1.01E-09 -0.052 -0.006 GPS1, RFNG 
3 chr3:18484742-18486958 8 4.11E-15 1.93E-09 -0.067 -0.008 AC144521.1, TBC1D5, SATB1 
20 chr20:2673003-2675996 8 1.21E-15 2.22E-09 -0.098 -0.028 AL035460.1, EBF4 
16 chr16:57022486-57023715 9 6.12E-23 2.25E-09 0.083 0.012 NLRC5 
3 chr3:52827704-52828818 8 7.47E-15 2.31E-09 -0.057 -0.018 ITIH3 
17 chr17:7381622-7383488 12 1.42E-14 3.08E-09 -0.052 -0.008 ZBTB4, SLC35G6 
4 chr4:527125-530543 11 2.31E-06 4.59E-09 0.077 0.004 PIGG 
11 chr11:1000533-1002310 10 4.39E-07 6.92E-09 0.065 0.001 AP2A2 
10 chr10:48416391-48417904 13 2.65E-13 7.32E-09 -0.050 -0.014 GDF2 
22 chr22:50246573-50249174 9 7.26E-11 8.22E-09 -0.054 -0.008 ZBED4 
14 chr14:101402494-101402822 2 3.16E-11 1.32E-08 -0.050 -0.032 SNORD113-4, AL132709.5, SNORD113-5 
12 chr12:132269563-132270829 7 5.24E-14 1.60E-08 -0.062 -0.015 SFSWAP 
22 chr22:50982818-50988451 16 7.04E-09 1.80E-08 0.072 0.006 KLHDC7B, CTA-384D8.31, CTA-384D8.35, CTA-384D8.34 
7 chr7:150099648-150105713 21 5.62E-07 2.34E-08 -0.067 -0.003 ZNF775 
11 chr11:1463541-1464792 8 9.27E-11 3.83E-08 -0.054 -0.025 BRSK2 
4 chr4:15428750-15429967 6 3.10E-07 3.86E-08 -0.092 -0.019 C1QTNF7, RP11-665G4.1 
10 chr10:133961235-133961825 5 6.56E-09 4.75E-08 0.082 0.004 NA 
6 chr6:131147216-131148736 3 3.54E-13 5.32E-08 -0.080 -0.043 SMLR1 
10 chr10:134793190-134798264 14 1.91E-09 6.56E-08 -0.053 -0.013 NA 
8 chr8:144599027-144599347 3 3.08E-10 7.31E-08 -0.076 -0.042 NA 
6 chr6:33091111-33093109 8 1.65E-07 9.06E-08 -0.068 -0.017 NA 
2 chr2:3704501-3705649 7 4.58E-09 9.23E-08 -0.054 -0.035 ALLC 
3 chr3:142314493-142316082 11 2.54E-09 1.06E-07 -0.058 -0.006 PLS1 
12 chr12:2943902-2944493 8 1.76E-08 1.09E-07 -0.052 -0.029 NRIP2, ITFG2 
6 chr6:31079152-31082631 8 3.24E-10 1.25E-07 -0.198 -0.034 C6orf15, PSORS1C1 
6 chr6:31145302-31146942 8 1.11E-14 1.26E-07 -0.062 -0.017 PSORS1C3, POU5F1 
19 chr19:5587239-5588795 5 4.60E-09 1.46E-07 -0.085 -0.024 SAFB2-010 
1 chr1:2846836-2848427 8 3.49E-08 1.61E-07 -0.072 -0.017 NA 
8 chr8:72459499-72460643 7 5.33E-15 1.67E-07 -0.050 -0.014 RP11-1102P16.1 
5 chr5:135414858-135416613 19 7.11E-07 1.80E-07 -0.062 -0.038 VTRNA2-1 
1 chr1:75590483-75591353 5 9.03E-08 1.97E-07 -0.051 -0.037 RP11-510C10.4 
6 chr6:29690766-29693534 29 2.13E-21 2.04E-07 0.076 0.007 HLA-F 







2 chr2:231989146-231989824 3 2.83E-14 2.34E-07 -0.059 -0.040 HTR2B 
17 chr17:5401814-5405260 18 2.98E-06 2.77E-07 0.065 0.009 NLRP1 
2 chr2:208027870-208028218 2 1.42E-09 2.77E-07 -0.051 -0.032 NA 
17 chr17:33473881-33475031 6 5.31E-15 2.79E-07 -0.065 -0.018 UNC45B 
6 chr6:9896436-9897093 4 1.84E-08 3.33E-07 -0.052 -0.016 NA 
19 chr19:57741325-57743416 9 2.06E-08 4.82E-07 -0.058 -0.031 AURKC 
11 chr11:39689583-39689828 2 1.28E-08 5.17E-07 -0.054 -0.036 NA 
2 chr2:242609764-242612684 10 1.13E-06 5.27E-07 -0.063 -0.011 ATG4B-029 
11 chr11:65684313-65687892 13 1.06E-06 5.66E-07 -0.073 -0.010 DRAP1, C11orf68 
11 chr11:58598239-58598338 2 1.82E-08 5.82E-07 -0.068 -0.064 NA 
8 chr8:144651767-144656997 17 7.56E-06 6.59E-07 -0.054 -0.013 MROH6, NAPRT1, MROH6, RP11-661A12.9 
7 chr7:4264980-4265548 6 1.77E-07 6.73E-07 -0.052 -0.014 SDK1 
12 chr12:41581414-41582362 5 5.96E-16 6.79E-07 -0.067 -0.025 PDZRN4 
11 chr11:126581947-126582317 5 1.08E-07 7.68E-07 -0.063 -0.033 NA 
20 chr20:61297564-61299190 9 2.23E-07 9.50E-07 -0.057 -0.015 RP11-93B14.5, SLCO4A1 
2 chr2:70141289-70143463 13 1.51E-09 9.65E-07 -0.050 -0.003 MXD1, snoU13.84 
10 chr10:134923599-134924050 2 6.65E-08 1.07E-06 -0.061 -0.044 NA 
6 chr6:76203530-76204308 7 1.41E-09 1.14E-06 -0.055 -0.028 FILIP1 
6 chr6:32802598-32807895 48 1.40E-14 1.20E-06 -0.120 -0.004 TAP2, PSMB8 
3 chr3:52302150-52303511 5 1.18E-08 1.23E-06 0.053 -0.002 MIRLET7G, WDR82 
13 chr13:28562668-28563639 7 3.71E-07 1.27E-06 -0.070 -0.013 URAD, RN7SL272P 
2 chr2:239360713-239362030 5 6.06E-07 1.32E-06 0.094 0.016 ASB1-008 
21 chr21:36258423-36261702 14 3.83E-06 1.32E-06 0.056 0.023 RUNX1 
6 chr6:28874547-28877495 13 5.80E-07 1.35E-06 -0.062 -0.012 TRIM27 
16 chr16:3988694-3989432 7 1.91E-09 1.36E-06 -0.056 -0.023 NA 
6 chr6:158013621-158014655 5 5.41E-07 1.36E-06 -0.067 -0.026 ZDHHC14 
21 chr21:42796537-42799141 10 5.01E-06 1.37E-06 0.055 0.009 MX1 
11 chr11:379296-380593 4 6.33E-07 1.64E-06 -0.058 -0.038 B4GALNT4 
14 chr14:104625249-104626668 4 3.40E-12 1.93E-06 -0.073 -0.029 NA 
3 chr3:37283665-37285071 12 3.16E-07 1.97E-06 -0.058 -0.006 AC097359.1, GOLGA4, RP11-259K5.2 
11 chr11:116657918-116664039 24 1.08E-17 2.40E-06 -0.124 -0.011 ZNF259, APOA5 
19 chr19:38039469-38040340 3 1.11E-06 2.59E-06 -0.057 -0.033 CTD-3064H18.4, ZNF540, ZNF571-AS1 
13 chr13:40107605-40108007 4 1.90E-09 2.64E-06 -0.064 -0.027 NA 
13 chr13:113819073-113819409 5 4.35E-07 2.96E-06 -0.068 -0.027 PROZ, RP11-98F14.11 
13 chr13:113663206-113664019 4 1.19E-07 3.07E-06 -0.052 -0.016 RP11-120K24.5-001, RP11-120K24.4-001 
1 chr1:2943306-2943891 2 1.55E-11 3.13E-06 -0.050 -0.040 NA 
17 chr17:39661354-39662980 5 8.48E-07 3.66E-06 0.075 0.003 KRT13 
1 chr1:166889789-166890924 7 2.86E-06 3.88E-06 -0.052 -0.020 NA 
17 chr17:33842255-33842301 2 2.41E-07 4.28E-06 -0.060 -0.053 RP11-1094M14.4 
4 chr4:167020896-167022415 3 8.55E-07 4.70E-06 -0.061 -0.030 NA 
8 chr8:1327367-1328459 5 3.04E-06 5.42E-06 0.056 0.000 NA 
19 chr19:51020297-51022341 7 4.96E-07 5.46E-06 -0.065 -0.014 NA 
20 chr20:23548991-23550632 6 5.52E-06 5.51E-06 -0.114 -0.026 CST9L 
17 chr17:34266290-34267111 2 3.39E-07 5.66E-06 -0.053 -0.036 LYZL6 
10 chr10:127371542-127373136 5 8.09E-06 5.89E-06 0.121 0.016 TEX36, RP11-383C5.3 
3 chr3:192576964-192577951 2 1.11E-07 6.05E-06 -0.068 -0.052 NA 
13 chr13:100583767-100583872 3 1.06E-09 6.52E-06 -0.058 -0.030 NA 







17 chr17:80708279-80710877 13 9.35E-07 6.58E-06 -0.091 -0.016 TBCD 
6 chr6:1101607-1102379 4 9.17E-08 7.77E-06 0.055 0.002 NA 
3 chr3:157221198-157222026 4 8.35E-07 8.61E-06 -0.057 -0.018 VEPH1 
18 chr18:71982691-71983824 3 2.21E-07 9.21E-06 -0.060 -0.032 C18orf63 
12 chr12:132654742-132657879 13 2.07E-07 9.74E-06 -0.062 -0.016 NA 
1 chr1:95698378-95700272 10 5.69E-09 1.07E-05 -0.053 -0.015 RWDD3, RP11-57H12.3 
14 chr14:103367306-103367858 4 2.30E-06 1.15E-05 -0.051 -0.039 NA 
2 chr2:1050113-1051469 4 3.35E-11 1.15E-05 -0.054 -0.021 NA 
6 chr6:166571782-166572045 4 6.97E-07 1.16E-05 0.086 0.015 NA 
14 chr14:74484925-74486651 9 6.84E-08 1.22E-05 -0.055 -0.006 ENTPD5, CCDC176 
20 chr20:30027638-30028893 9 4.14E-06 1.25E-05 -0.050 -0.017 DEFB123 
16 chr16:83985744-83986941 7 3.28E-07 1.28E-05 -0.057 -0.010 OSGIN1 
19 chr19:15162623-15163470 4 1.47E-07 1.53E-05 -0.058 -0.026 CASP14, AC004699.1 
17 chr17:1645410-1646196 4 4.22E-06 1.54E-05 0.084 0.016 SERPINF2 
17 chr17:76445798-76446821 3 3.15E-06 1.58E-05 -0.055 -0.027 DNAH17 
17 chr17:37321201-37322540 6 1.01E-04 2.06E-05 0.067 0.031 ARL5C 
2 chr2:24367779-24367888 3 3.80E-06 2.06E-05 0.120 0.037 FAM228B 
12 chr12:124826534-124827729 5 1.71E-05 2.26E-05 -0.078 -0.019 NCOR2 
10 chr10:44223934-44224459 3 1.01E-05 2.87E-05 -0.056 -0.037 RP11-272J7.6 
10 chr10:2543474-2544596 6 6.03E-05 2.99E-05 -0.055 -0.035 RP11-526P5.1 
16 chr16:22175965-22176873 2 9.77E-06 3.11E-05 -0.057 -0.040 SDR42E2 
1 chr1:54358862-54360170 7 1.34E-06 3.12E-05 -0.064 -0.018 DIO1 
5 chr5:178564818-178565937 6 3.16E-06 3.25E-05 -0.058 -0.019 NA 
12 chr12:2017093-2017746 5 7.50E-06 3.49E-05 -0.053 -0.028 NA 
8 chr8:120427810-120428692 5 5.80E-07 3.61E-05 -0.053 -0.013 NOV 
1 chr1:56453730-56454285 2 6.01E-06 3.71E-05 -0.054 -0.029 NA 
12 chr12:11422897-11423120 3 2.64E-06 4.19E-05 -0.072 -0.027 PRB3 
7 chr7:158766061-158767135 4 1.92E-05 4.28E-05 -0.063 -0.025 NA 
5 chr5:1110019-1112251 11 1.87E-05 4.71E-05 0.055 0.003 SLC12A7-001 
4 chr4:139144433-139145210 2 1.33E-06 4.83E-05 -0.054 -0.028 SLC7A11 
1 chr1:215178601-215179216 5 1.10E-06 4.95E-05 -0.052 -0.017 KCNK2 
16 chr16:8622412-8623289 4 9.08E-09 5.10E-05 -0.056 -0.034 TMEM114 
10 chr10:35080181-35081047 3 3.76E-05 5.51E-05 -0.059 -0.034 NA 
12 chr12:132293329-132293702 4 4.04E-05 5.83E-05 -0.051 -0.043 NA 
11 chr11:68199656-68201194 7 5.14E-08 6.60E-05 -0.057 -0.014 NA 
16 chr16:89219415-89220554 4 1.05E-05 7.38E-05 -0.052 -0.019 NA 
9 chr9:130955135-130956057 4 6.75E-05 7.64E-05 -0.055 -0.041 CIZ1 
2 chr2:85389840-85390041 3 5.53E-07 8.06E-05 -0.050 -0.022 NA 
1 chr1:212002970-212004468 11 2.37E-05 9.08E-05 0.062 0.005 LPGAT1, RP11-552D8.1 
1 chr1:203051472-203052423 2 2.77E-04 1.03E-04 -0.051 -0.036 NA 
1 chr1:3102750-3105326 8 1.70E-04 1.06E-04 -0.061 -0.023 NA 
17 chr17:78336395-78338052 7 5.31E-05 1.28E-04 -0.056 -0.012 RNF213 
3 chr3:9744891-9746059 9 9.35E-07 1.29E-04 -0.104 -0.016 CPNE9 
10 chr10:85985222-85986738 8 6.30E-07 1.30E-04 0.096 0.002 LRIT2 
6 chr6:170531180-170532835 11 3.78E-06 1.45E-04 0.051 0.009 NA 
8 chr8:142263798-142264816 6 6.46E-05 1.54E-04 0.082 0.010 SLC45A4, RP11-10J21.4 
10 chr10:31107995-31108101 2 1.04E-05 1.56E-04 -0.064 -0.043 NA 







5 chr5:42953543-42953590 2 2.02E-05 1.99E-04 -0.056 -0.053 NA 
19 chr19:10225927-10226701 5 7.16E-07 2.09E-04 -0.059 -0.018 EIF3G 
2 chr2:242004954-242005101 2 5.22E-05 2.10E-04 -0.053 -0.030 AC005237.4-001 
8 chr8:143645661-143645857 3 1.67E-06 2.15E-04 0.051 0.004 NA 
3 chr3:46872239-46872949 2 1.66E-04 2.26E-04 -0.076 -0.058 NA 
11 chr11:132912205-132912368 3 1.09E-04 2.28E-04 -0.080 -0.036 NA 
9 chr9:74061171-74062096 5 2.87E-05 2.28E-04 -0.052 -0.022 TRPM3 
7 chr7:112725899-112727914 14 6.66E-12 2.29E-04 -0.060 -0.014 GPR85 
7 chr7:64034943-64035529 2 6.14E-05 2.39E-04 -0.057 -0.048 NA 
14 chr14:68161980-68163792 7 9.97E-07 2.50E-04 0.060 0.008 RDH11 
7 chr7:157193063-157193615 3 3.67E-05 2.51E-04 -0.052 -0.020 NA 
2 chr2:118616155-118616576 4 1.48E-04 2.52E-04 -0.057 -0.038 HTR5BP 
15 chr15:101084509-101085710 7 3.68E-04 2.53E-04 0.053 0.027 CERS3 
10 chr10:133208486-133208984 5 1.47E-07 2.57E-04 -0.067 -0.017 NA 
11 chr11:132951838-132951950 3 3.80E-05 2.76E-04 -0.058 -0.037 NA 
1 chr1:203273149-203276595 13 4.52E-05 2.87E-04 -0.053 -0.006 BTG2, LINC01136 
11 chr11:69462783-69464272 6 4.60E-07 3.12E-04 0.069 0.011 CCND1 
16 chr16:14379220-14380714 5 2.01E-04 4.17E-04 0.107 0.023 NA 
16 chr16:72459516-72460114 7 9.62E-05 4.26E-04 0.059 0.004 AC004158.3 
13 chr13:41034925-41035061 2 2.54E-06 4.32E-04 -0.065 -0.033 LINC00598 
8 chr8:2002012-2002553 2 3.12E-06 4.41E-04 -0.080 -0.049 NA 
15 chr15:29423177-29424512 4 8.08E-05 4.50E-04 -0.050 -0.021 NA 
5 chr5:78279841-78283014 12 4.82E-05 4.82E-04 0.063 0.006 ARSB 
16 chr16:85122558-85124401 4 4.45E-06 4.83E-04 -0.085 -0.029 NA 
2 chr2:200468445-200469026 5 4.89E-04 4.94E-04 -0.052 -0.048 NA 
10 chr10:134910285-134912411 9 3.26E-04 5.66E-04 0.058 0.004 NA 
15 chr15:25123287-25124213 3 8.33E-05 5.68E-04 -0.054 -0.035 NA 
8 chr8:599963-600940 7 1.07E-03 6.13E-04 -0.050 -0.037 NA 
8 chr8:142369468-142369705 2 5.10E-05 6.31E-04 -0.060 -0.045 NA 
7 chr7:150497065-150499362 12 3.67E-06 6.36E-04 -0.056 -0.010 TMEM176A, TMEM176B 
14 chr14:74703888-74704714 3 1.01E-04 6.59E-04 -0.074 -0.036 VSX2 
11 chr11:71237522-71238205 2 5.31E-07 6.61E-04 0.052 0.015 KRTAP5-7 
9 chr9:136397058-136397740 2 2.19E-04 7.59E-04 -0.102 -0.068 ADAMTSL2 
16 chr16:83171155-83171992 3 3.65E-04 7.86E-04 -0.051 -0.038 NA 
8 chr8:140926709-140927326 3 2.86E-05 8.47E-04 0.064 0.015 RP11-284H18.1 
13 chr13:86373320-86373600 2 2.89E-05 8.54E-04 -0.050 -0.032 SLITRK6 
8 chr8:145637525-145639181 8 1.41E-05 9.37E-04 -0.092 -0.039 SLC39A4 
7 chr7:27450882-27451047 2 3.38E-04 9.90E-04 -0.107 -0.062 NA 
7 chr7:1209495-1209742 3 5.98E-04 1.03E-03 -0.073 -0.050 NA 
2 chr2:98858011-98858595 4 4.71E-05 1.12E-03 -0.053 -0.019 NA 
8 chr8:144301594-144303509 5 1.19E-04 1.32E-03 -0.061 -0.029 NA 
7 chr7:157986877-157987184 4 2.54E-04 1.39E-03 -0.057 -0.018 NA 
5 chr5:170845058-170847313 11 8.78E-06 1.43E-03 -0.059 -0.006 FGF18 
2 chr2:114035983-114037060 5 8.61E-05 1.56E-03 -0.098 -0.026 PAX8 
5 chr5:16178784-16181039 18 3.46E-08 1.57E-03 -0.059 -0.007 MARCH11, RP11-19O2.2 
3 chr3:109115356-109115491 3 1.14E-03 1.58E-03 -0.072 -0.030 RP11-702L6.1 
7 chr7:108524200-108524793 2 8.54E-04 1.60E-03 -0.060 -0.032 C7orf66 







14 chr14:94491763-94493296 8 1.62E-05 1.67E-03 -0.053 -0.009 OTUB2 
12 chr12:4829115-4829827 6 9.83E-05 1.71E-03 -0.052 -0.020 GALNT8, RP11-234B24.2 
5 chr5:180581301-180582587 7 3.59E-05 1.92E-03 0.060 0.003 OR2V2-001 
10 chr10:134723491-134725087 5 2.97E-04 1.96E-03 -0.059 -0.019 TTC40-005 
12 chr12:132290859-132290929 2 1.03E-03 2.04E-03 -0.050 -0.027 NA 
16 chr16:1019956-1022650 13 8.79E-07 2.06E-03 0.098 0.007 LMF1 
10 chr10:131669406-131669630 3 1.63E-03 2.17E-03 -0.060 -0.046 NA 
12 chr12:127226034-127226110 2 4.65E-06 2.20E-03 -0.059 -0.042 LINC00943 
21 chr21:46810558-46811242 2 5.78E-04 2.21E-03 -0.058 -0.031 NA 
4 chr4:189139691-189140097 2 1.12E-03 2.28E-03 -0.060 -0.032 NA 
1 chr1:205054684-205054828 2 1.11E-03 2.32E-03 -0.051 -0.028 TMEM81 
12 chr12:41830066-41830372 2 9.39E-05 2.47E-03 -0.095 -0.060 PDZRN4 
1 chr1:171282607-171283893 4 4.04E-04 2.71E-03 -0.065 -0.017 FMO4 
3 chr3:10005747-10005827 2 1.31E-03 2.74E-03 -0.086 -0.045 NA 
5 chr5:167830729-167831317 2 2.46E-04 2.86E-03 -0.064 -0.037 WWC1 
9 chr9:140707378-140709558 4 7.89E-05 2.89E-03 -0.054 -0.015 EHMT1 
17 chr17:17109570-17110353 10 1.44E-09 2.99E-03 -0.058 -0.026 PLD6 
22 chr22:32600722-32601654 5 3.49E-03 3.20E-03 -0.064 -0.027 RFPL2, RP1-90G24.10 
17 chr17:76449477-76449599 3 6.29E-04 3.36E-03 -0.051 -0.018 NA 
10 chr10:134726665-134726771 2 1.95E-03 3.60E-03 -0.107 -0.092 NA 
1 chr1:45285821-45286062 3 3.20E-03 3.89E-03 -0.050 -0.043 RNU5E-6P 
1 chr1:217113226-217114101 2 1.22E-04 4.18E-03 -0.054 -0.029 ESRRG 
16 chr16:83967808-83968911 3 3.01E-05 4.31E-03 0.051 0.010 NA 
11 chr11:12620869-12621248 2 5.01E-04 4.39E-03 -0.057 -0.030 NA 
4 chr4:33062752-33062845 2 2.38E-03 4.76E-03 -0.100 -0.054 NA 
1 chr1:3323806-3324671 3 2.30E-05 4.80E-03 -0.069 -0.025 NA 
3 chr3:155421970-155423168 5 1.68E-03 4.81E-03 -0.078 -0.022 PLCH1 
3 chr3:2552181-2553187 4 9.24E-03 4.84E-03 0.072 0.007 CNTN4 
4 chr4:155312410-155313256 3 3.55E-05 4.89E-03 0.066 0.014 DCHS2 
14 chr14:68167893-68168587 2 4.16E-03 5.31E-03 -0.051 -0.032 RDH12 
12 chr12:131515293-131517216 4 1.80E-10 5.45E-03 -0.050 -0.020 AC078925.1 
11 chr11:3168455-3169027 3 1.09E-03 5.83E-03 -0.056 -0.025 NA 
13 chr13:114161463-114161939 2 4.35E-04 5.84E-03 0.084 0.007 NA 
9 chr9:139606200-139608277 7 2.67E-04 6.46E-03 -0.083 -0.013 FAM69B 
16 chr16:88757588-88757816 3 1.66E-04 6.63E-03 -0.076 -0.021 NA 
19 chr19:843541-844589 4 1.70E-04 6.82E-03 -0.056 -0.023 PRTN3 
17 chr17:58165865-58166296 3 5.91E-03 6.86E-03 -0.080 -0.031 CTD-2319I12.1 
17 chr17:80849289-80849463 3 2.27E-03 7.04E-03 -0.105 -0.039 TBCD 
8 chr8:142283564-142283615 2 1.99E-03 7.30E-03 0.054 0.026 NA 
11 chr11:50257256-50258750 6 3.70E-04 7.34E-03 -0.052 -0.020 RP11-347H15.4 
7 chr7:154958558-154958976 4 7.09E-06 7.88E-03 0.053 0.006 NA 
4 chr4:753903-754733 2 4.10E-04 8.83E-03 -0.055 -0.028 NA 
7 chr7:75372083-75372874 2 3.90E-03 8.98E-03 -0.101 -0.052 NA 
13 chr13:31734946-31736727 15 3.23E-04 9.08E-03 -0.051 -0.003 HSPH1 
20 chr20:6034446-6035902 6 5.14E-04 9.31E-03 -0.083 -0.020 LRRN4 
7 chr7:158250911-158251297 3 5.23E-03 9.46E-03 -0.054 -0.032 NA 
14 chr14:77498304-77499911 9 5.69E-05 9.77E-03 -0.105 -0.012 NA 







7 chr7:157289477-157289496 2 7.40E-03 1.09E-02 -0.058 -0.030 NA 
3 chr3:108475765-108476878 5 4.88E-06 1.10E-02 -0.052 -0.022 RETNLB 
1 chr1:156616554-156617074 6 5.01E-03 1.13E-02 0.055 0.037 BCAN, RP11-284F21.10 
13 chr13:111969980-111970282 3 2.70E-04 1.25E-02 -0.091 -0.031 TEX29-001 
13 chr13:110319562-110319607 3 1.43E-02 1.31E-02 -0.055 -0.043 NA 
7 chr7:116199599-116200522 3 2.39E-03 1.33E-02 0.070 0.015 NA 
17 chr17:78039368-78039437 2 9.34E-03 1.37E-02 -0.066 -0.038 NA 
7 chr7:151134527-151135375 2 4.35E-03 1.42E-02 0.065 0.031 CRYGN 
19 chr19:18959208-18960246 4 1.55E-03 1.45E-02 -0.080 -0.026 UPF1 
17 chr17:78150934-78152466 8 7.66E-04 1.67E-02 0.056 0.001 CARD14 
6 chr6:31379258-31380248 4 2.12E-02 1.79E-02 0.100 0.022 NA 
14 chr14:97431088-97431367 4 1.40E-02 1.98E-02 -0.085 -0.023 NA 
7 chr7:91795363-91795403 2 3.32E-03 2.02E-02 0.053 0.023 LRRD1 
22 chr22:43739790-43741137 5 9.63E-03 2.11E-02 -0.054 -0.021 SCUBE1 
11 chr11:71229988-71230303 2 1.69E-02 2.13E-02 0.096 0.043 NA 
6 chr6:168435636-168436353 4 1.24E-02 2.16E-02 -0.054 -0.033 KIF25 
4 chr4:7301176-7301854 6 6.80E-03 2.25E-02 -0.051 -0.020 NA 
7 chr7:6653510-6655834 6 4.04E-04 2.32E-02 0.115 0.017 ZNF853 
12 chr12:55368244-55369150 2 5.81E-04 2.45E-02 0.069 0.033 TESPA1 
17 chr17:3833739-3833873 3 3.52E-03 2.60E-02 -0.061 -0.024 ATP2A3 
20 chr20:55664666-55665224 2 2.52E-02 2.62E-02 -0.079 -0.047 NA 
17 chr17:211482-212481 2 2.52E-02 2.95E-02 -0.057 -0.034 NA 
14 chr14:69725831-69727352 13 2.38E-04 3.05E-02 -0.051 -0.005 GALNT16, RP11-363J20.2 
1 chr1:43473840-43473978 2 2.67E-02 3.05E-02 0.073 0.035 NA 
19 chr19:51829984-51831274 6 1.43E-03 3.07E-02 -0.050 -0.011 NA 
10 chr10:601783-601816 2 2.80E-02 3.26E-02 -0.077 -0.069 NA 
1 chr1:227505845-227506868 8 3.59E-04 3.65E-02 -0.058 -0.007 CDC42BPA 
4 chr4:16077324-16077853 4 2.32E-02 3.70E-02 -0.063 -0.019 PROM1 
6 chr6:114181686-114181798 2 2.29E-02 3.97E-02 0.054 0.039 NA 
8 chr8:582908-583068 2 1.67E-02 4.01E-02 -0.057 -0.036 NA 
8 chr8:1821338-1822568 6 3.01E-06 4.10E-02 -0.069 -0.013 ARHGEF10 
12 chr12:1675846-1676077 3 1.98E-02 4.25E-02 -0.054 -0.032 NA 
19 chr19:17905332-17906309 6 1.18E-03 4.39E-02 -0.057 -0.021 B3GNT3 
18 chr18:47015710-47016218 3 2.57E-02 4.41E-02 0.118 0.038 RPL17-C18orf32, SNORD58C, SNORD58A, MIR1539, RPL17, SNORD58B 
10 chr10:79273606-79273865 2 3.71E-02 4.43E-02 -0.053 -0.029 NA 








Appendix Table 4.3: Results from gene-set enrichment analysis of biological processes performed by DAVID (95 significant 
biological processes for 862 unique genes for 1,309 selected CpG sites) 
 
Term Genes involved % (Involved Genes / Total Genes) P-Value Benjamini 
regulation of multicellular organismal process 170 20.6 2.40E-08 1.50E-04 
negative regulation of biological process 263 31.9 4.80E-08 1.50E-04 
negative regulation of cellular process 247 30 7.40E-08 1.60E-04 
cell adhesion 118 14.3 1.00E-07 1.60E-04 
biological adhesion 118 14.3 1.20E-07 1.50E-04 
cell-cell adhesion 88 10.7 1.90E-07 1.90E-04 
regulation of cellular component organization 147 17.8 5.50E-07 5.00E-04 
single-multicellular organism process 316 38.3 8.70E-07 6.80E-04 
multicellular organism development 267 32.4 1.20E-06 8.40E-04 
system development 240 29.1 1.20E-06 7.60E-04 
regulation of cell projection organization 51 6.2 1.30E-06 7.20E-04 
regulation of cell differentiation 105 12.7 1.70E-06 8.80E-04 
regulation of developmental process 135 16.4 1.80E-06 8.60E-04 
positive regulation of cellular process 259 31.4 2.60E-06 1.10E-03 
regulation of multicellular organismal development 113 13.7 3.20E-06 1.40E-03 
positive regulation of biological process 283 34.3 3.30E-06 1.30E-03 
positive regulation of RNA metabolic process 96 11.7 5.70E-06 2.10E-03 
regulation of signaling 178 21.6 7.30E-06 2.60E-03 
positive regulation of nucleic acid-templated transcription 92 11.2 7.60E-06 2.50E-03 
positive regulation of transcription, DNA-templated 92 11.2 7.60E-06 2.50E-03 
positive regulation of developmental process 78 9.5 8.00E-06 2.50E-03 
cell development 123 14.9 1.20E-05 3.60E-03 
regulation of transcription from RNA polymerase II promoter 116 14.1 1.30E-05 3.80E-03 
single organism cell adhesion 60 7.3 1.30E-05 3.70E-03 
positive regulation of RNA biosynthetic process 92 11.2 1.40E-05 3.60E-03 
regulation of neuron projection development 38 4.6 1.80E-05 4.50E-03 
regulation of cell communication 173 21 2.20E-05 5.30E-03 
developmental process 293 35.6 2.40E-05 5.50E-03 
negative regulation of protein kinase activity 26 3.2 3.00E-05 6.60E-03 
single-organism developmental process 285 34.6 3.30E-05 7.10E-03 
regulation of small GTPase mediated signal transduction 30 3.6 3.40E-05 7.20E-03 
anatomical structure development 284 34.5 4.40E-05 8.90E-03 
nervous system development 130 15.8 4.70E-05 9.10E-03 
Ras protein signal transduction 31 3.8 4.80E-05 9.10E-03 







positive regulation of gene expression 106 12.9 5.10E-05 9.10E-03 
cell-cell signaling 97 11.8 5.20E-05 9.10E-03 
neuron projection development 60 7.3 5.30E-05 8.90E-03 
positive regulation of macromolecule biosynthetic process 101 12.3 5.60E-05 9.20E-03 
positive regulation of cell differentiation 61 7.4 6.50E-05 1.00E-02 
negative regulation of phosphorylation 37 4.5 8.60E-05 1.30E-02 
positive regulation of GTPase activity 49 5.9 8.80E-05 1.30E-02 
negative regulation of macromolecule metabolic process 136 16.5 9.20E-05 1.40E-02 
negative regulation of kinase activity 26 3.2 9.30E-05 1.30E-02 
positive regulation of nucleobase-containing compound metabolic process 103 12.5 9.40E-05 1.30E-02 
regulation of GTPase activity 52 6.3 1.00E-04 1.40E-02 
positive regulation of transcription from RNA polymerase II promoter 71 8.6 1.10E-04 1.40E-02 
positive regulation of nitrogen compound metabolic process 108 13.1 1.10E-04 1.50E-02 
positive regulation of multicellular organismal process 91 11 1.20E-04 1.50E-02 
positive regulation of cellular biosynthetic process 106 12.9 1.20E-04 1.50E-02 
regulation of nervous system development 56 6.8 1.20E-04 1.50E-02 
regulation of cell growth 35 4.2 1.30E-04 1.60E-02 
behavior 44 5.3 1.30E-04 1.60E-02 
regulation of response to stimulus 197 23.9 1.40E-04 1.60E-02 
synapse organization 24 2.9 1.50E-04 1.70E-02 
regulation of neuron differentiation 44 5.3 1.50E-04 1.70E-02 
leukocyte differentiation 39 4.7 1.50E-04 1.70E-02 
regulation of Ras protein signal transduction 22 2.7 1.70E-04 1.80E-02 
neurogenesis 91 11 1.70E-04 1.80E-02 
single organismal cell-cell adhesion 53 6.4 1.80E-04 1.90E-02 
cell differentiation 197 23.9 1.80E-04 1.90E-02 
growth 64 7.8 2.00E-04 2.00E-02 
regulation of localization 141 17.1 2.10E-04 2.10E-02 
generation of neurons 86 10.4 2.10E-04 2.10E-02 
lamellipodium organization 12 1.5 2.20E-04 2.20E-02 
peptidyl-threonine modification 13 1.6 2.30E-04 2.20E-02 
positive regulation of biosynthetic process 106 12.9 2.30E-04 2.20E-02 
regulation of neurogenesis 50 6.1 2.60E-04 2.40E-02 
neuron development 65 7.9 3.00E-04 2.70E-02 
transcription from RNA polymerase II promoter 108 13.1 3.50E-04 3.10E-02 
positive regulation of cellular component organization 76 9.2 3.50E-04 3.10E-02 
cell projection organization 82 10 3.70E-04 3.20E-02 
negative regulation of protein phosphorylation 33 4 3.70E-04 3.20E-02 
regulation of cell morphogenesis 43 5.2 3.90E-04 3.30E-02 







T cell activation 36 4.4 4.10E-04 3.40E-02 
lymphocyte aggregation 36 4.4 4.20E-04 3.40E-02 
cell morphogenesis involved in differentiation 53 6.4 4.20E-04 3.40E-02 
negative regulation of multicellular organismal process 67 8.1 4.40E-04 3.60E-02 
locomotion 93 11.3 4.50E-04 3.60E-02 
regulation of signal transduction 151 18.3 4.60E-04 3.60E-02 
regulation of phagocytosis 11 1.3 5.20E-04 4.00E-02 
multicellular organismal process 344 41.7 5.40E-04 4.10E-02 
regulation of synapse structure or activity 23 2.8 5.40E-04 4.10E-02 
cell growth 35 4.2 5.50E-04 4.00E-02 
leukocyte aggregation 36 4.4 5.60E-04 4.10E-02 
cell migration 75 9.1 5.60E-04 4.10E-02 
negative regulation of cell communication 75 9.1 5.70E-04 4.10E-02 
peptidyl-threonine phosphorylation 12 1.5 5.70E-04 4.00E-02 
negative regulation of signaling 75 9.1 6.00E-04 4.20E-02 
positive regulation of cell projection organization 27 3.3 6.20E-04 4.30E-02 
leukocyte activation 52 6.3 6.50E-04 4.50E-02 
developmental growth 43 5.2 6.70E-04 4.50E-02 
regulation of protein kinase activity 51 6.2 6.70E-04 4.50E-02 








Appendix Table 4.4: CpG sites (N=60) out of the selected CpG sites for the combined group (N=1,309) that were also selected 
in stratified analyses for both boys and girls, sorted by P-value from smallest to largest.  Also presented is the rank of each 
CpG site by P-value in each relevant analysis 
 
CpG CHR Position Gene  
Relation to 
Gene 













cg22690339 6 38249061 BTBD9 Body OpenSea 0.797 0.740 0.057 3.29E-08 1.26E-04 10 957 5 
cg08237220 3 156332967   OpenSea 0.536 0.464 0.072 2.28E-07 3.54E-04 13 716 10 
cg18394552 5 159428643   OpenSea 0.737 0.661 0.076 8.50E-07 6.68E-04 16 472 17 
cg07839457 16 57023022 NLRC5 TSS1500 N_Shore 0.254 0.343 -0.089 4.31E-06 1.64E-03 3 17 29 
cg15773890 6 17259549   OpenSea 0.869 0.813 0.056 5.21E-06 1.78E-03 34 794 32 
cg12027254 17 76055290 TNRC6C Body OpenSea 0.821 0.768 0.053 5.63E-06 1.83E-03 4 27 36 
cg14418857 7 121120431   OpenSea 0.610 0.546 0.063 8.42E-06 2.24E-03 20 171 41 
cg22647738 17 34304462 CCL16 3'UTR OpenSea 0.638 0.570 0.068 1.16E-05 2.67E-03 21 221 48 
cg09722609 5 149887422 NDST1 TSS1500 OpenSea 0.608 0.549 0.059 1.62E-05 3.24E-03 48 894 55 
cg00399027 16 85676861 KIAA0182 5'UTR;Body S_Shore 0.608 0.553 0.055 2.07E-05 3.68E-03 41 349 60 
cg04339360 13 73635568 KLF5 Body S_Shore 0.704 0.649 0.055 2.27E-05 3.86E-03 49 440 66 
cg13561554 15 78795944   N_Shelf 0.627 0.577 0.050 2.63E-05 4.15E-03 66 946 73 
cg25879365 1 40510058 CAP1 5'UTR S_Shelf 0.590 0.519 0.072 3.38E-05 4.72E-03 84 913 80 
cg04961225 12 91332479   OpenSea 0.576 0.519 0.057 3.86E-05 5.10E-03 25 192 87 
cg20426710 22 50248907 ZBED4 5'UTR N_Shore 0.515 0.457 0.058 4.26E-05 5.36E-03 50 245 90 
cg00105306 15 85194978 WDR73 Body N_Shelf 0.623 0.569 0.054 4.60E-05 5.58E-03 45 344 91 
cg19624420 14 48541885   OpenSea 0.877 0.813 0.063 5.20E-05 5.94E-03 78 478 100 
cg04223006 5 82845599 VCAN Body OpenSea 0.437 0.363 0.074 6.23E-05 6.56E-03 80 941 107 
cg05512157 12 50901878 DIP2B Body S_Shelf 0.583 0.532 0.051 6.68E-05 6.83E-03 22 185 113 
cg13707760 9 95986383 WNK2 Body OpenSea 0.511 0.458 0.053 7.35E-05 7.13E-03 15 90 119 
cg00787180 14 91751731 CCDC88C Body N_Shelf 0.389 0.337 0.052 9.98E-05 8.27E-03 75 907 137 
cg10264529 14 24562064 PCK2 TSS1500 N_Shore 0.633 0.582 0.051 1.31E-04 9.58E-03 112 927 154 
cg24499605 1 3142925 PRDM16 Body OpenSea 0.556 0.505 0.052 1.31E-04 9.58E-03 46 329 155 
cg01282174 11 119630144   OpenSea 0.492 0.423 0.069 1.38E-04 9.81E-03 158 1059 158 
cg00390724 3 18484742   N_Shore 0.508 0.456 0.052 1.42E-04 9.94E-03 9 10 159 
cg14799457 18 19927125   N_Shore 0.315 0.263 0.052 1.48E-04 1.02E-02 120 797 162 
cg26475911 17 73056187 KCTD2 Body OpenSea 0.455 0.401 0.054 1.87E-04 1.16E-02 65 308 180 
cg27579313 17 7381622 ZBTB4 5'UTR;5'UTR N_Shore 0.556 0.484 0.072 2.04E-04 1.21E-02 82 453 187 
cg13518079 20 2675072 EBF4 Body S_Shore 0.344 0.263 0.081 2.13E-04 1.24E-02 87 142 191 
cg22497969 1 3143018 PRDM16 Body OpenSea 0.799 0.746 0.052 2.61E-04 1.38E-02 116 688 201 
cg14659930 3 114128301 ZBTB20 5'UTR OpenSea 0.689 0.630 0.060 2.77E-04 1.42E-02 76 421 206 
cg17781958 17 79428404 BAHCC1 Body Island 0.760 0.699 0.060 3.14E-04 1.51E-02 252 1002 218 
cg23720384 21 23747055   OpenSea 0.650 0.578 0.073 3.42E-04 1.58E-02 24 59 228 
cg25670076 6 90807675 BACH2 5'UTR OpenSea 0.761 0.707 0.055 3.59E-04 1.62E-02 92 119 232 
cg18835596 6 135540107 MYB 3'UTR; OpenSea 0.723 0.671 0.051 3.78E-04 1.66E-02 43 187 235 
cg00602295 16 81328089   OpenSea 0.432 0.381 0.052 3.92E-04 1.70E-02 36 56 241 
cg24786658 7 112727423 GPR85 TSS1500;5'UTR OpenSea 0.698 0.642 0.056 4.56E-04 1.84E-02 251 1010 254 
cg24263062 20 2730191 EBF4 Body Island 0.637 0.565 0.072 4.60E-04 1.85E-02 68 68 255 
cg17301248 12 112467203 NAA25 3'UTR OpenSea 0.636 0.575 0.061 6.75E-04 2.26E-02 162 709 292 







cg26955132 12 13181499   OpenSea 0.740 0.680 0.059 8.05E-04 2.47E-02 132 620 318 
cg18808261 3 18464935 SATB1 5'UTR N_Shore 0.293 0.240 0.053 8.64E-04 2.56E-02 201 802 325 
cg05825244 20 2730488 EBF4 Body Island 0.416 0.289 0.127 9.59E-04 2.70E-02 60 42 337 
cg15034267 22 39106452 GTPBP1 Body S_Shelf 0.767 0.711 0.057 1.03E-03 2.80E-02 169 745 346 
cg13485718 14 93315488   OpenSea 0.557 0.507 0.050 1.03E-03 2.80E-02 142 656 347 
cg03680873 3 148844300   N_Shelf 0.600 0.544 0.056 1.09E-03 2.89E-02 255 1042 359 
cg01232748 4 54928819 CHIC2 Body N_Shore 0.501 0.449 0.052 1.12E-03 2.92E-02 101 198 360 
cg10196532 13 50134640 RCBTB1 Body OpenSea 0.821 0.742 0.079 1.18E-03 3.00E-02 219 754 368 
cg06040034 8 1618448 DLGAP2 Body S_Shore 0.783 0.730 0.053 1.36E-03 3.22E-02 85 47 396 
cg14819618 8 8180214 PRAGMIN Body S_Shelf 0.795 0.742 0.053 1.51E-03 3.39E-02 242 982 417 
cg15847685 4 62129666   OpenSea 0.791 0.740 0.051 1.52E-03 3.40E-02 118 504 418 
cg05739816 6 135989395 C6orf217 Body OpenSea 0.522 0.467 0.055 1.59E-03 3.47E-02 240 868 422 
cg08602008 19 48076841   Island 0.337 0.287 0.050 1.61E-03 3.49E-02 204 748 423 
cg08739755 2 172815385 HAT1 Body;Body OpenSea 0.799 0.740 0.059 1.87E-03 3.76E-02 295 633 448 
cg07264238 17 33474376 UNC45B TSS1500 OpenSea 0.775 0.725 0.050 1.99E-03 3.87E-02 51 88 455 
cg05857996 20 2675418 EBF4 Body S_Shore 0.789 0.701 0.088 2.21E-03 4.08E-02 192 305 474 
cg00084338 6 170595920 DLL1 Body N_Shore 0.566 0.466 0.100 2.52E-03 4.36E-02 272 553 496 
cg24392970 13 86373600 SLITRK6 TSS200 OpenSea 0.534 0.481 0.053 2.78E-03 4.56E-02 259 1014 513 
cg24530147 3 138763894 PRR23C TSS200 Island 0.795 0.737 0.058 3.07E-03 4.80E-02 322 658 534 








Appendix Table 4.5: CpG sites (N=390) out of the selected 1,309 CpG sites for the primary analysis of all HIV-infected 
children compared to HIV-uninfected children that were also selected in stratified analyses for both HIV-infected children 
who started ART early and HIV-infected children who started ART late (both compared to HIV-uninfected children), sorted 
by P-value from smallest to largest.  Also presented is the rank of each CpG site by P-value in each relevant analysis 
 
















cg09239591 2 31638511 XDH TSS1500 OpenSea 0.675 0.623 0.053 2.44E-15 1.97E-11 1 1 1 
cg23101680 13 46277286 SPERT Body OpenSea 0.717 0.663 0.053 4.89E-14 1.83E-10 2 7 3 
cg07839457 16 57023022 NLRC5 TSS1500 N_Shore 0.261 0.353 -0.092 4.69E-11 2.87E-08 3 23 2 
cg12027254 17 76055290 TNRC6C Body OpenSea 0.824 0.766 0.058 1.00E-10 4.99E-08 4 18 7 
cg07970325 6 106497542 
  
OpenSea 0.569 0.512 0.057 1.39E-10 6.38E-08 5 14 14 
cg26280998 6 53589544 
  
OpenSea 0.715 0.659 0.056 1.72E-10 7.29E-08 6 37 5 
cg00390724 3 18484742 
  
N_Shore 0.519 0.456 0.063 2.66E-10 1.01E-07 9 20 22 
cg22690339 6 38249061 BTBD9 Body OpenSea 0.792 0.735 0.058 3.47E-10 1.22E-07 10 173 4 
cg05929755 1 110663559 
  
OpenSea 0.398 0.339 0.059 7.36E-10 2.15E-07 11 174 9 
cg12021671 15 42423807 
  
OpenSea 0.744 0.690 0.054 1.02E-09 2.75E-07 12 35 19 
cg08237220 3 156332967 
  
OpenSea 0.531 0.459 0.072 1.07E-09 2.85E-07 13 15 36 
cg05006384 14 95942319 C14orf49 TSS200 OpenSea 0.648 0.595 0.053 1.74E-09 4.09E-07 14 27 24 
cg13707760 9 95986383 WNK2 Body OpenSea 0.509 0.449 0.060 2.03E-09 4.58E-07 15 109 8 
cg18394552 5 159428643 
  
OpenSea 0.732 0.650 0.081 2.42E-09 5.17E-07 16 50 20 
cg10336193 1 206848389 
  
OpenSea 0.644 0.584 0.060 2.88E-09 5.88E-07 17 24 39 
cg22348290 8 72459499 
  
N_Shore 0.767 0.709 0.058 3.22E-09 6.37E-07 18 54 17 
cg26898099 5 95192949 C5orf27 Body OpenSea 0.706 0.650 0.055 6.44E-09 1.07E-06 19 112 15 
cg14418857 7 121120431 
  
OpenSea 0.616 0.535 0.080 6.86E-09 1.13E-06 20 13 109 
cg22647738 17 34304462 CCL16 3'UTR OpenSea 0.639 0.561 0.078 8.18E-09 1.29E-06 21 80 31 
cg23720384 21 23747055 
  
OpenSea 0.665 0.583 0.082 1.10E-08 1.61E-06 24 139 29 
cg09083958 12 131516365 GPR133 Body N_Shore 0.696 0.642 0.054 1.53E-08 2.04E-06 28 93 40 
cg02341197 21 34185927 C21orf62 5'UTR;1stExon OpenSea 0.466 0.408 0.058 1.54E-08 2.05E-06 29 16 123 
cg08937102 1 1690389 NADK Body N_Shore 0.481 0.428 0.053 1.75E-08 2.24E-06 30 56 66 
cg16426670 20 2675996 EBF4 Body S_Shore 0.812 0.750 0.062 2.29E-08 2.74E-06 33 90 52 
cg15773890 6 17259549 
  
OpenSea 0.866 0.812 0.054 2.73E-08 3.12E-06 34 141 51 
cg00602295 16 81328089 
  
OpenSea 0.441 0.375 0.065 2.81E-08 3.18E-06 36 134 30 
cg23429698 8 98878169 
  
N_Shelf 0.324 0.268 0.056 3.13E-08 3.44E-06 39 59 72 
cg00399027 16 85676861 KIAA0182 5'UTR;Body S_Shore 0.607 0.547 0.060 3.72E-08 3.89E-06 41 44 113 
cg18835596 6 135540107 MYB 3'UTR OpenSea 0.725 0.659 0.066 4.46E-08 4.45E-06 43 153 26 
cg03182584 7 36364854 KIAA0895 3'UTR OpenSea 0.689 0.631 0.058 4.53E-08 4.49E-06 44 307 18 
cg00105306 15 85194978 WDR73 Body N_Shelf 0.626 0.569 0.057 4.88E-08 4.75E-06 45 114 90 
cg24499605 1 3142925 PRDM16 Body OpenSea 0.550 0.489 0.061 5.85E-08 5.41E-06 46 144 65 
cg09722609 5 149887422 NDST1 TSS1500 OpenSea 0.607 0.551 0.055 6.05E-08 5.54E-06 48 261 48 
cg04339360 13 73635568 KLF5 Body S_Shore 0.710 0.644 0.066 6.23E-08 5.67E-06 49 95 83 
cg07264238 17 33474376 UNC45B TSS1500 OpenSea 0.778 0.707 0.071 7.23E-08 6.32E-06 51 63 255 
cg25718604 20 57601474 TUBB1 3'UTR S_Shelf 0.831 0.774 0.057 7.34E-08 6.40E-06 52 170 61 
cg00864012 17 62294665 TEX2 5'UTR OpenSea 0.724 0.670 0.053 8.38E-08 7.01E-06 55 132 67 
cg00991744 12 41581484 PDZRN4 TSS1500 N_Shore 0.852 0.791 0.061 8.42E-08 7.04E-06 56 420 21 
cg08066875 2 163197084 
  







cg08324152 19 57172404 
  
N_Shelf 0.283 0.216 0.067 9.18E-08 7.49E-06 59 399 69 
cg05825244 20 2730488 EBF4 Body Island 0.428 0.271 0.157 9.32E-08 7.58E-06 60 407 12 
cg26475911 17 73056187 KCTD2 Body OpenSea 0.458 0.390 0.067 1.14E-07 8.78E-06 65 89 142 
cg26413942 5 124081751 ZNF608 TSS1500 OpenSea 0.421 0.361 0.060 1.24E-07 9.27E-06 67 202 63 
cg24263062 20 2730191 EBF4 Body Island 0.636 0.550 0.086 1.30E-07 9.59E-06 68 294 25 
cg02577773 2 208027870 KLF7 Body N_Shelf 0.652 0.588 0.064 1.56E-07 1.09E-05 73 429 11 
cg00787180 14 91751731 CCDC88C Body N_Shelf 0.393 0.340 0.052 1.79E-07 1.21E-05 75 227 45 
cg14659930 3 114128301 ZBTB20 5'UTR OpenSea 0.694 0.626 0.068 1.80E-07 1.21E-05 76 535 16 
cg19624420 14 48541885 
  
OpenSea 0.869 0.798 0.071 2.00E-07 1.31E-05 78 385 23 
cg04223006 5 82845599 VCAN Body OpenSea 0.433 0.362 0.072 2.23E-07 1.42E-05 80 206 28 
cg27579313 17 7381622 ZBTB4;ZBTB4 5'UTR N_Shore 0.559 0.481 0.078 2.49E-07 1.54E-05 82 146 80 
cg25879365 1 40510058 CAP1 5'UTR S_Shelf 0.598 0.517 0.081 2.73E-07 1.64E-05 84 140 78 
cg06040034 8 1618448 DLGAP2 Body S_Shore 0.780 0.719 0.061 2.80E-07 1.67E-05 85 188 75 
cg09029192 17 76015204 TNRC6C 5'UTR OpenSea 0.709 0.654 0.054 3.16E-07 1.84E-05 86 185 88 
cg13518079 20 2675072 EBF4 Body S_Shore 0.350 0.262 0.088 3.33E-07 1.90E-05 88 413 49 
cg00059652 17 67605498 
  
OpenSea 0.639 0.579 0.061 3.37E-07 1.92E-05 89 190 122 
cg25671837 6 127513912 RSPO3 Body OpenSea 0.437 0.369 0.067 3.53E-07 1.99E-05 90 332 50 
cg04873188 2 70143463 MXD1 Body S_Shore 0.567 0.494 0.073 3.91E-07 2.14E-05 91 49 219 
cg25670076 6 90807675 BACH2 5'UTR OpenSea 0.773 0.708 0.065 4.04E-07 2.19E-05 92 449 58 
cg18640098 5 9888660 LOC285692 Body OpenSea 0.869 0.807 0.063 4.05E-07 2.19E-05 93 364 279 
cg02127888 16 1665900 CRAMP1L Body S_Shore 0.428 0.346 0.082 4.06E-07 2.20E-05 94 347 115 
cg08036553 1 64649805 
  
OpenSea 0.844 0.790 0.055 4.16E-07 2.24E-05 95 252 132 
cg12039595 1 244480459 
  
OpenSea 0.512 0.455 0.057 4.49E-07 2.36E-05 97 325 60 
cg22986770 8 61648691 CHD7 5'UTR OpenSea 0.477 0.404 0.073 4.51E-07 2.37E-05 99 47 497 
cg01232748 4 54928819 CHIC2 Body N_Shore 0.511 0.451 0.060 4.86E-07 2.50E-05 101 416 32 
cg23824801 12 54653403 CBX5 TSS200;5'UTR OpenSea 0.280 0.218 0.062 5.41E-07 2.70E-05 104 143 149 
cg08173709 3 71103443 FOXP1 Body OpenSea 0.726 0.669 0.057 5.42E-07 2.71E-05 105 212 77 
cg25217710 1 156609523 
  
N_Shelf 0.649 0.591 0.058 5.57E-07 2.76E-05 108 192 193 
cg12409074 11 129870648 PRDM10 5'UTR N_Shore 0.489 0.430 0.060 5.65E-07 2.78E-05 109 318 166 
cg16356622 1 36351841 EIF2C1 Body S_Shelf 0.522 0.466 0.056 6.43E-07 3.05E-05 111 462 68 
cg10264529 14 24562064 PCK2 TSS1500 N_Shore 0.634 0.573 0.061 6.67E-07 3.13E-05 112 256 205 
cg20755748 12 31799116 C12orf72 TSS1500 OpenSea 0.572 0.515 0.057 6.73E-07 3.15E-05 113 546 64 
cg02302089 7 23401203 IGF2BP3 Body OpenSea 0.415 0.354 0.061 6.76E-07 3.15E-05 114 421 120 
cg22497969 1 3143018 PRDM16 Body OpenSea 0.784 0.728 0.057 7.34E-07 3.35E-05 116 198 159 
cg05236731 13 41035061 LOC646982 Body OpenSea 0.852 0.797 0.055 8.46E-07 3.72E-05 117 487 155 
cg15847685 4 62129666 
  
OpenSea 0.786 0.726 0.060 8.59E-07 3.76E-05 118 241 117 
cg07349663 1 160261619 COPA Body OpenSea 0.658 0.598 0.061 8.74E-07 3.80E-05 119 180 138 
cg20433822 10 124690751 C10orf88 3'UTR OpenSea 0.278 0.214 0.063 1.09E-06 4.46E-05 123 329 106 
cg25199005 1 246446300 SMYD3 Body OpenSea 0.777 0.713 0.064 1.12E-06 4.56E-05 124 249 152 
cg07143462 2 157289513 
  
N_Shelf 0.688 0.622 0.066 1.20E-06 4.78E-05 125 550 62 
cg00391741 3 127307227 TPRA1 5'UTR N_Shore 0.735 0.679 0.056 1.25E-06 4.94E-05 128 205 161 
cg07176842 14 43972223 
  
OpenSea 0.574 0.483 0.092 1.41E-06 5.37E-05 130 377 86 
cg26955132 12 13181499 
  
OpenSea 0.744 0.673 0.070 1.46E-06 5.53E-05 132 236 176 
cg16321846 7 4050114 SDK1 Body OpenSea 0.751 0.684 0.067 1.71E-06 6.16E-05 136 390 103 
cg19956914 7 56147257 SUMF2 Body OpenSea 0.663 0.610 0.053 1.80E-06 6.42E-05 140 694 42 
cg24134261 2 33661362 RASGRP3 TSS200 OpenSea 0.403 0.346 0.057 1.88E-06 6.60E-05 141 352 105 
cg13485718 14 93315488 
  
OpenSea 0.560 0.498 0.062 1.89E-06 6.62E-05 142 264 259 







cg11945474 2 55717980 
  
OpenSea 0.773 0.711 0.062 2.00E-06 6.89E-05 145 488 89 
cg14989243 6 76203530 FILIP1 TSS200 OpenSea 0.527 0.452 0.075 2.08E-06 7.10E-05 147 268 162 
cg12081645 4 157920476 
  
OpenSea 0.444 0.375 0.069 2.31E-06 7.68E-05 149 956 44 
cg02329430 15 73921385 NPTN Body N_Shelf 0.391 0.328 0.063 2.50E-06 8.13E-05 151 258 79 
cg13717434 9 97854044 
  
OpenSea 0.602 0.545 0.057 2.65E-06 8.50E-05 152 762 43 
cg25015371 6 108874950 
  
N_Shelf 0.580 0.527 0.053 2.99E-06 9.26E-05 154 800 55 
cg23970645 14 89695299 FOXN3 Body OpenSea 0.777 0.714 0.063 3.10E-06 9.52E-05 155 301 280 
cg26837192 2 48813184 STON1;STON1
-GTF2A1L 
Body OpenSea 0.778 0.714 0.063 3.18E-06 9.69E-05 156 555 59 
cg07425204 17 66511183 PRKAR1A 5'UTR S_Shelf 0.481 0.421 0.060 3.26E-06 9.86E-05 157 401 153 
cg01282174 11 119630144 
  
OpenSea 0.484 0.415 0.069 3.35E-06 1.01E-04 158 245 173 
cg17301248 12 112467203 NAA25 3'UTR OpenSea 0.642 0.564 0.078 3.66E-06 1.07E-04 162 375 125 
cg26943120 4 5472116 STK32B Body OpenSea 0.631 0.574 0.057 3.68E-06 1.08E-04 163 530 134 
cg12549908 10 4230567 
  
OpenSea 0.761 0.705 0.056 3.80E-06 1.10E-04 164 220 242 
cg03820688 2 55477848 MTIF2 Body OpenSea 0.744 0.683 0.061 4.03E-06 1.15E-04 165 466 180 
cg24760467 10 102760784 LZTS2 5'UTR S_Shore 0.622 0.565 0.057 4.18E-06 1.18E-04 167 406 213 
cg15034267 22 39106452 GTPBP1 Body S_Shelf 0.768 0.700 0.068 4.36E-06 1.21E-04 169 316 325 
cg27416489 2 149823115 KIF5C Body OpenSea 0.750 0.686 0.064 4.46E-06 1.23E-04 172 704 54 
cg25688583 15 57510460 TCF12 TSS1500;Body OpenSea 0.674 0.610 0.064 4.48E-06 1.24E-04 173 361 160 
cg17568809 5 142153529 ARHGAP26 Body S_Shelf 0.742 0.681 0.061 4.83E-06 1.31E-04 175 581 148 
cg01948202 3 122400474 PARP14 Body S_Shore 0.156 0.211 -0.054 4.85E-06 1.31E-04 176 854 34 
cg05264870 2 206599315 NRP2 Body OpenSea 0.606 0.545 0.061 4.90E-06 1.32E-04 177 441 172 
cg16153042 6 3282307 SLC22A23 Body OpenSea 0.646 0.587 0.058 5.15E-06 1.37E-04 179 306 225 
cg15059804 1 33766318 ZNF362 3'UTR OpenSea 0.731 0.649 0.082 5.34E-06 1.41E-04 180 568 73 
cg19449565 2 240230892 HDAC4 Body OpenSea 0.898 0.843 0.055 5.85E-06 1.51E-04 181 545 209 
cg06899237 6 153353519 RGS17 Body OpenSea 0.427 0.371 0.056 6.22E-06 1.57E-04 184 426 133 
cg06832406 10 4230482 
  
OpenSea 0.810 0.758 0.052 6.22E-06 1.57E-04 185 194 227 
cg05475386 12 65723693 MSRB3 Body OpenSea 0.304 0.243 0.061 6.25E-06 1.58E-04 187 372 246 
cg22491058 1 207277466 C4BPA TSS200 OpenSea 0.502 0.448 0.054 6.38E-06 1.60E-04 188 534 190 
cg00950497 10 116393423 ABLIM1 Body S_Shore 0.630 0.569 0.062 6.73E-06 1.67E-04 190 431 147 
cg17111025 2 111936357 
  
OpenSea 0.944 0.887 0.056 6.87E-06 1.69E-04 191 1275 174 
cg05857996 20 2675418 EBF4 Body S_Shore 0.786 0.686 0.101 6.88E-06 1.69E-04 192 697 116 
cg13547053 2 179184864 OSBPL6 TSS200;Body OpenSea 0.717 0.659 0.058 7.13E-06 1.74E-04 194 1017 33 
cg03529358 17 78198361 SLC26A11 Body S_Shelf 0.935 0.875 0.060 7.78E-06 1.85E-04 196 547 338 
cg06071730 10 112021300 MXI1 Body OpenSea 0.714 0.658 0.055 7.87E-06 1.87E-04 197 587 131 
cg10366878 4 79531297 ANXA3 3'UTR OpenSea 0.657 0.594 0.063 7.98E-06 1.88E-04 198 807 124 
cg05684528 5 76473917 
  
N_Shelf 0.636 0.577 0.060 8.11E-06 1.90E-04 199 876 108 
cg10437839 11 64701910 PPP2R5B 3'UTR OpenSea 0.657 0.604 0.052 8.11E-06 1.91E-04 200 228 305 
cg08340023 16 23098187 USP31 Body OpenSea 0.689 0.623 0.066 8.33E-06 1.94E-04 202 521 202 
cg02061820 3 152046751 MBNL1 Body OpenSea 0.459 0.385 0.074 9.36E-06 2.12E-04 206 572 158 
cg27192248 15 65285669 
  
S_Shelf 0.409 0.517 -0.108 9.67E-06 2.17E-04 208 653 94 
cg07661704 4 139144433 SLC7A11 Body OpenSea 0.561 0.496 0.065 9.74E-06 2.18E-04 209 195 391 
cg15644413 1 36185939 C1orf216 TSS1500 S_Shore 0.699 0.643 0.056 9.98E-06 2.22E-04 210 464 231 
cg26235748 14 86087511 FLRT2 5'UTR OpenSea 0.531 0.454 0.077 1.01E-05 2.23E-04 211 509 261 
cg10902738 8 134895500 
  
OpenSea 0.667 0.605 0.062 1.04E-05 2.29E-04 212 771 175 
cg07291349 4 40964962 APBB2 Body OpenSea 0.643 0.572 0.071 1.07E-05 2.33E-04 213 317 494 
cg04139359 1 45085438 RNF220 Body S_Shelf 0.808 0.747 0.062 1.07E-05 2.33E-04 214 414 512 







cg26293423 5 71613149 MRPS27 Body N_Shelf 0.749 0.695 0.054 1.19E-05 2.52E-04 220 635 98 
cg00021275 2 128142155 
  
N_Shelf 0.731 0.674 0.057 1.22E-05 2.56E-04 221 573 322 
cg20141108 1 165907859 
  
N_Shelf 0.653 0.587 0.066 1.22E-05 2.57E-04 222 637 171 
cg27408285 12 54653364 CBX5 1stExon;TSS200
;5'UTR 
OpenSea 0.331 0.265 0.066 1.23E-05 2.58E-04 223 201 342 
cg14342532 2 233916534 
  
OpenSea 0.355 0.299 0.056 1.28E-05 2.65E-04 226 1150 76 
cg07624918 3 136533970 
  
N_Shelf 0.752 0.699 0.053 1.31E-05 2.69E-04 227 791 214 
cg24235882 4 54928822 CHIC2 Body N_Shore 0.572 0.518 0.055 1.32E-05 2.70E-04 228 1083 57 
cg20211629 18 48352490 MRO TSS1500 OpenSea 0.585 0.531 0.054 1.33E-05 2.73E-04 229 736 201 
cg20675439 6 82466362 
  
S_Shelf 0.695 0.636 0.059 1.34E-05 2.73E-04 230 610 154 
cg18470427 17 33842301 SLFN12L Body OpenSea 0.840 0.768 0.073 1.37E-05 2.78E-04 231 324 363 
cg19841423 20 62366755 ZGPAT;LIME1 Body;TSS1500 S_Shore 0.713 0.660 0.053 1.38E-05 2.80E-04 232 234 402 
cg22992279 4 26414901 RBPJ Body OpenSea 0.745 0.691 0.054 1.39E-05 2.81E-04 233 748 177 
cg05808246 1 221741553 
  
OpenSea 0.799 0.740 0.059 1.43E-05 2.88E-04 234 295 392 
cg10440877 2 208378475 
  
OpenSea 0.723 0.666 0.057 1.47E-05 2.93E-04 235 905 112 
cg08106319 6 37849427 ZFAND3 Body OpenSea 0.381 0.309 0.073 1.50E-05 2.96E-04 236 350 223 
cg01822050 20 304156 
  
N_Shore 0.748 0.686 0.062 1.50E-05 2.97E-04 237 1053 82 
cg16778107 16 381873 AXIN1 Body OpenSea 0.511 0.451 0.059 1.52E-05 2.99E-04 239 808 189 
cg05739816 6 135989395 C6orf217 Body OpenSea 0.534 0.459 0.074 1.53E-05 3.01E-04 240 417 345 
cg11952493 10 28570835 MPP7 5'UTR OpenSea 0.744 0.693 0.051 1.58E-05 3.09E-04 241 579 248 
cg14819618 8 8180214 PRAGMIN Body S_Shelf 0.793 0.729 0.063 1.67E-05 3.20E-04 242 313 448 
cg02543850 11 33346306 HIPK3 Body OpenSea 0.595 0.539 0.057 1.70E-05 3.25E-04 244 418 230 
cg18784409 11 67868331 CHKA Body OpenSea 0.509 0.456 0.053 1.78E-05 3.36E-04 247 270 317 
cg05850338 17 79933123 
  
N_Shelf 0.686 0.623 0.062 1.78E-05 3.36E-04 248 553 267 
cg24786658 7 112727423 GPR85 TSS1500;5'UTR OpenSea 0.705 0.647 0.058 1.90E-05 3.52E-04 251 498 340 
cg17781958 17 79428404 BAHCC1 Body Island 0.758 0.702 0.057 1.93E-05 3.56E-04 252 133 556 
cg15931921 6 170597588 DLL1 Body N_Shore 0.748 0.669 0.080 1.95E-05 3.59E-04 253 894 203 
cg03680873 3 148844300 
  
N_Shelf 0.600 0.535 0.065 2.04E-05 3.71E-04 255 388 244 
cg20176142 8 81408357 ZBTB10 Body OpenSea 0.728 0.678 0.050 2.11E-05 3.79E-04 256 949 156 
cg12114888 8 107738435 OXR1 Body OpenSea 0.336 0.283 0.053 2.28E-05 4.02E-04 257 711 169 
cg06857116 17 15885326 ZSWIM7 Body OpenSea 0.594 0.540 0.054 2.36E-05 4.11E-04 260 624 278 
cg18638434 14 74486651 C14orf45;ENT
PD5 
Body;TSS1500 S_Shore 0.732 0.670 0.063 2.39E-05 4.14E-04 263 768 299 
cg26136772 7 4754681 FOXK1 Body N_Shelf 0.708 0.647 0.061 2.54E-05 4.33E-04 267 873 300 
cg04567302 6 31846956 SLC44A4 TSS200 OpenSea 0.789 0.730 0.059 2.60E-05 4.40E-04 269 274 456 
cg00084338 6 170595920 DLL1 Body N_Shore 0.598 0.495 0.103 2.67E-05 4.49E-04 272 855 197 
cg18388786 10 134924050 GPR123 Body N_Shore 0.312 0.254 0.058 2.70E-05 4.51E-04 273 344 413 
cg27246129 6 170595947 DLL1 Body N_Shore 0.550 0.480 0.070 2.71E-05 4.52E-04 274 759 224 
cg11254053 1 33497125 AK2;AK2 Body OpenSea 0.554 0.496 0.058 2.77E-05 4.59E-04 278 924 206 
cg00634542 2 219254588 SLC11A1 Body N_Shore 0.556 0.495 0.062 2.85E-05 4.70E-04 279 221 470 
cg19723805 5 33147539 
  
OpenSea 0.452 0.396 0.055 2.92E-05 4.77E-04 280 890 249 
cg05142445 14 76309157 TTLL5 Body OpenSea 0.716 0.657 0.059 3.04E-05 4.92E-04 282 789 127 
cg12559197 5 76654783 PDE8B Body OpenSea 0.515 0.440 0.074 3.21E-05 5.10E-04 283 1105 95 
cg07539709 17 80545454 FOXK2 Body Island 0.598 0.538 0.060 3.24E-05 5.15E-04 285 788 198 
cg14324502 9 88898587 ISCA1 TSS1500 S_Shore 0.555 0.489 0.066 3.31E-05 5.23E-04 286 351 506 
cg13573513 12 14996143 ART4;ART4 5'UTR;1stExon OpenSea 0.763 0.698 0.065 3.49E-05 5.42E-04 289 330 694 
cg18067134 3 71084634 FOXP1 Body OpenSea 0.728 0.667 0.061 3.56E-05 5.50E-04 290 543 296 







cg23711422 21 43442085 C21orf121 TSS200 OpenSea 0.502 0.430 0.073 3.66E-05 5.62E-04 294 1172 298 
cg08739755 2 172815385 HAT1 Body OpenSea 0.803 0.737 0.066 3.82E-05 5.78E-04 295 1291 266 
cg19560014 12 31799118 C12orf72 TSS1500 OpenSea 0.614 0.554 0.061 3.86E-05 5.83E-04 296 434 642 
cg10584024 1 84234998 
  
OpenSea 0.541 0.469 0.072 3.95E-05 5.92E-04 300 654 328 
cg07951201 13 103340215 C13orf39 Body OpenSea 0.444 0.378 0.065 4.01E-05 5.98E-04 304 937 236 
cg12647970 6 3234297 
  
S_Shelf 0.805 0.750 0.055 4.23E-05 6.22E-04 305 778 344 
cg05233670 12 109058033 CORO1C Body OpenSea 0.479 0.415 0.064 4.24E-05 6.23E-04 306 887 354 
cg08707875 1 224575077 WDR26 3'UTR OpenSea 0.702 0.646 0.056 4.31E-05 6.31E-04 307 763 294 
cg21781157 20 47874111 ZNFX1 Body OpenSea 0.530 0.468 0.063 4.37E-05 6.37E-04 308 783 204 
cg17846127 15 89940505 LOC254559 Body N_Shelf 0.688 0.632 0.056 4.39E-05 6.38E-04 309 265 697 
cg06663615 17 79423959 BAHCC1 Body N_Shore 0.565 0.513 0.052 4.42E-05 6.42E-04 310 515 460 
cg06633438 19 6272158 MLLT1 Body Island 0.606 0.525 0.080 4.67E-05 6.66E-04 314 1319 121 
cg22596016 17 61711557 MAP3K3 Body OpenSea 0.266 0.201 0.065 4.82E-05 6.82E-04 315 824 128 
cg17129188 8 134307597 NDRG1 5'UTR N_Shore 0.774 0.722 0.052 4.82E-05 6.82E-04 316 779 222 
cg18115721 11 73567838 MRPL48 Body OpenSea 0.807 0.751 0.056 5.02E-05 7.01E-04 317 668 359 
cg02112168 14 45579561 PRPF39;SNOR
D127 
Body;TSS1500 OpenSea 0.663 0.592 0.070 5.06E-05 7.06E-04 318 1242 168 
cg27134944 13 76111107 COMMD6 Body N_Shore 0.560 0.501 0.059 5.10E-05 7.09E-04 319 1352 99 
cg08064068 14 60671024 
  
OpenSea 0.663 0.603 0.060 5.15E-05 7.14E-04 320 819 320 
cg24530147 3 138763894 PRR23C TSS200 Island 0.773 0.707 0.066 5.35E-05 7.34E-04 322 323 422 
cg26104475 5 169693176 LCP2 Body OpenSea 0.640 0.584 0.056 5.45E-05 7.43E-04 324 931 235 
cg07769015 8 142238770 SLC45A4 TSS200 S_Shore 0.624 0.568 0.057 5.55E-05 7.53E-04 327 461 486 
cg13607230 2 103352296 MFSD9 Body N_Shore 0.473 0.404 0.069 5.56E-05 7.55E-04 329 689 187 
cg08481967 6 166765599 
  
OpenSea 0.358 0.272 0.086 5.59E-05 7.57E-04 330 353 617 
cg17510957 11 121466629 SORL1 Body OpenSea 0.700 0.637 0.063 5.61E-05 7.59E-04 331 840 215 
cg22249612 12 56121485 CD63 Body N_Shore 0.659 0.589 0.069 5.65E-05 7.63E-04 332 556 532 
cg20925233 17 47661136 NXPH3 3'UTR OpenSea 0.563 0.505 0.059 5.84E-05 7.81E-04 334 442 638 
cg17164954 6 157345266 ARID1B Body S_Shelf 0.457 0.396 0.061 6.06E-05 8.02E-04 335 598 384 
cg16805291 7 36022575 
  
Island 0.692 0.623 0.069 6.14E-05 8.08E-04 336 340 323 
cg06190046 16 83986382 OSGIN1 5'UTR;TSS1500;
Body 
OpenSea 0.500 0.427 0.074 6.26E-05 8.20E-04 337 1108 250 
cg06487194 6 15345097 JARID2 Body OpenSea 0.589 0.525 0.064 6.27E-05 8.21E-04 338 642 281 
cg20043649 2 47537239 
  
OpenSea 0.699 0.636 0.064 6.60E-05 8.50E-04 339 690 417 
cg14044785 2 43560368 THADA;THA
DA 
Body OpenSea 0.692 0.623 0.069 6.70E-05 8.60E-04 341 526 459 
cg16702362 2 135078044 MGAT5 Body OpenSea 0.719 0.654 0.064 6.94E-05 8.82E-04 342 969 257 
cg24165638 19 831456 AZU1 Body N_Shelf 0.640 0.586 0.054 7.00E-05 8.88E-04 344 281 672 
cg09803321 10 104913480 NT5C2 Body OpenSea 0.727 0.670 0.057 7.10E-05 8.96E-04 345 1244 207 
cg10805254 3 72433837 RYBP Body OpenSea 0.581 0.518 0.063 7.58E-05 9.38E-04 349 614 371 
cg02209770 20 35062903 DLGAP4 Body N_Shore 0.553 0.502 0.051 7.80E-05 9.58E-04 351 1103 330 
cg05687149 11 112035945 IL18 TSS1500 OpenSea 0.278 0.227 0.052 7.82E-05 9.60E-04 352 850 273 
cg27416337 3 32748004 CNOT10 Body OpenSea 0.343 0.280 0.063 8.04E-05 9.79E-04 353 494 514 
cg03305017 7 151036715 
  
N_Shelf 0.494 0.434 0.060 8.07E-05 9.81E-04 355 595 573 
cg25263801 7 112727506 GPR85 TSS1500;1stExo
n;5'UTR 
OpenSea 0.719 0.664 0.055 8.11E-05 9.85E-04 356 615 432 
cg07772516 15 52107742 TMOD2 3'UTR OpenSea 0.611 0.537 0.074 8.54E-05 1.02E-03 360 929 339 
cg13127231 13 111806949 ARHGEF7 Body;5'UTR S_Shore 0.459 0.409 0.050 8.59E-05 1.03E-03 361 870 277 
cg21579539 18 43751229 
  







cg25757140 19 38039469 
  
N_Shore 0.611 0.553 0.058 9.06E-05 1.07E-03 364 601 424 









Body;TSS1500 N_Shore 0.699 0.641 0.058 9.15E-05 1.07E-03 366 463 541 
cg05581469 12 49413435 MLL2;PRKAG
1 
3'UTR;TSS1500 S_Shore 0.368 0.313 0.055 9.21E-05 1.08E-03 367 918 318 
cg09305680 8 117778069 UTP23 TSS1500 N_Shore 0.600 0.545 0.055 9.26E-05 1.08E-03 368 548 588 
cg10976975 2 69098569 BMP10;BMP10 5'UTR;1stExon OpenSea 0.714 0.649 0.065 9.62E-05 1.11E-03 370 833 290 
cg23679982 17 1686737 SMYD4 Body OpenSea 0.636 0.570 0.066 9.76E-05 1.12E-03 371 473 724 
cg24926791 6 31082187 PSORS1C1 TSS1500 OpenSea 0.653 0.483 0.170 1.01E-04 1.15E-03 374 939 313 
cg05916684 17 49008322 
  
N_Shore 0.503 0.444 0.059 1.05E-04 1.18E-03 381 1092 170 
cg24590430 10 99097076 
  
S_Shelf 0.792 0.718 0.074 1.06E-04 1.19E-03 383 841 641 
cg21697512 1 208081541 CD34 Body N_Shelf 0.575 0.515 0.060 1.07E-04 1.20E-03 384 1563 186 
cg01238669 7 21797276 DNAH11 Body OpenSea 0.446 0.386 0.060 1.09E-04 1.21E-03 385 851 393 
cg23098068 2 172650722 SLC25A12 Body OpenSea 0.420 0.343 0.077 1.15E-04 1.26E-03 386 471 620 
cg06740950 3 171878318 FNDC3B Body OpenSea 0.473 0.416 0.057 1.19E-04 1.29E-03 388 1213 217 
cg08131499 12 109090588 CORO1C Body OpenSea 0.308 0.247 0.061 1.20E-04 1.29E-03 389 1146 210 
cg02291010 5 96079433 CAST Body;1stExon OpenSea 0.669 0.612 0.057 1.21E-04 1.30E-03 391 885 367 
cg10789050 3 31713847 OSBPL10 Body OpenSea 0.509 0.425 0.084 1.21E-04 1.30E-03 393 693 451 
cg17797863 4 2009396 WHSC2 Body N_Shore 0.542 0.489 0.052 1.21E-04 1.31E-03 395 908 365 
cg02457461 8 9913680 MSRA Body S_Shore 0.251 0.193 0.058 1.27E-04 1.34E-03 398 1241 100 
cg06392753 2 102783282 IL1R1 Body OpenSea 0.549 0.488 0.061 1.29E-04 1.36E-03 399 695 447 
cg19947463 7 1113237 C7orf50 Body OpenSea 0.459 0.384 0.075 1.30E-04 1.37E-03 400 1416 306 
cg24265969 3 55654481 ERC2 3'UTR OpenSea 0.322 0.262 0.060 1.33E-04 1.39E-03 402 1015 307 
cg02769705 1 202975059 TMEM183B;T
MEM183A 
TSS1500 N_Shore 0.588 0.520 0.069 1.35E-04 1.41E-03 403 574 596 
cg27301230 7 65761563 TPST1 Body OpenSea 0.737 0.682 0.055 1.35E-04 1.41E-03 404 663 498 
cg18281939 5 77783895 LHFPL2 3'UTR OpenSea 0.452 0.390 0.062 1.38E-04 1.43E-03 405 1111 304 
cg06794244 2 196434818 
  
OpenSea 0.470 0.416 0.054 1.40E-04 1.44E-03 408 1482 218 
cg21932231 2 36668864 CRIM1 Body OpenSea 0.543 0.488 0.055 1.43E-04 1.47E-03 410 1304 264 
cg00819078 5 16615081 FAM134B Body N_Shore 0.686 0.627 0.059 1.48E-04 1.50E-03 411 404 546 
cg01014262 16 48533930 
  
S_Shelf 0.354 0.294 0.060 1.49E-04 1.51E-03 412 713 409 
cg24238409 10 93998677 CPEB3 Body N_Shore 0.759 0.704 0.055 1.51E-04 1.52E-03 414 842 662 
cg00796963 6 84936558 KIAA1009 5'UTR N_Shore 0.518 0.463 0.055 1.61E-04 1.59E-03 420 1309 276 
cg21487561 2 11990393 
  
OpenSea 0.916 0.850 0.066 1.62E-04 1.60E-03 421 1612 353 
cg23362032 7 126990845 
  
S_Shelf 0.770 0.717 0.052 1.62E-04 1.60E-03 422 1091 331 
cg27586596 7 41426609 
  
OpenSea 0.444 0.390 0.054 1.64E-04 1.61E-03 423 730 455 
cg03854238 6 22071933 FLJ22536 Body OpenSea 0.619 0.554 0.065 1.65E-04 1.62E-03 424 826 263 
cg25287268 13 50694004 DLEU2 Body N_Shelf 0.439 0.379 0.060 1.66E-04 1.63E-03 425 1391 245 
cg01550445 11 72929983 P2RY2 5'UTR S_Shore 0.633 0.581 0.052 1.67E-04 1.63E-03 426 1178 284 
cg25589001 10 98605052 LCOR 5'UTR OpenSea 0.557 0.501 0.055 1.81E-04 1.73E-03 434 726 400 







cg00421164 6 7111068 RREB1 5'UTR S_Shore 0.827 0.774 0.053 1.90E-04 1.79E-03 436 1099 396 
cg10368935 10 18240316 SLC39A12;SL
C39A12 
TSS1500 OpenSea 0.733 0.666 0.066 1.97E-04 1.83E-03 437 602 416 
cg14325153 3 138763899 PRR23C TSS200 Island 0.537 0.470 0.067 2.01E-04 1.86E-03 439 287 594 
cg19619014 8 37250930 
  
OpenSea 0.392 0.331 0.061 2.04E-04 1.88E-03 440 1169 327 
cg26861460 22 44575455 PARVG TSS1500;5'UTR;
Body 
OpenSea 0.528 0.474 0.054 2.06E-04 1.89E-03 443 1154 394 
cg18854872 2 198292151 SF3B1 Body OpenSea 0.631 0.576 0.056 2.06E-04 1.89E-03 444 1204 311 
cg01966791 20 62572875 MIR1914;UCK
L1 
Body S_Shore 0.479 0.411 0.068 2.08E-04 1.91E-03 445 912 315 
cg07023317 8 28961315 KIF13B Body OpenSea 0.740 0.688 0.053 2.13E-04 1.93E-03 447 998 482 
cg03673989 11 380069 B4GALNT4 Body Island 0.884 0.828 0.055 2.14E-04 1.94E-03 448 1175 505 
cg12884009 2 219079038 
  
N_Shelf 0.780 0.729 0.051 2.21E-04 1.99E-03 449 1435 272 
cg24142603 8 72753888 MSC 3'UTR Island 0.789 0.851 -0.062 2.28E-04 2.03E-03 451 1473 228 
cg14312063 3 85010606 CADM2 Body S_Shore 0.505 0.443 0.062 2.30E-04 2.05E-03 452 612 618 
cg11058932 7 130372167 TSGA13 TSS1500 OpenSea 0.706 0.649 0.057 2.39E-04 2.10E-03 456 1132 465 
cg04777091 4 6050440 JAKMIP1 Body OpenSea 0.229 0.172 0.058 2.41E-04 2.11E-03 457 479 558 
cg13059136 11 2986541 SNORA54;NA
P1L4 
TSS1500;Body OpenSea 0.664 0.607 0.056 2.47E-04 2.15E-03 460 828 476 
cg21078654 15 52130305 TMOD3 5'UTR OpenSea 0.287 0.233 0.054 2.48E-04 2.16E-03 461 1059 559 
cg05351887 16 3988869 
  
N_Shore 0.425 0.362 0.063 2.55E-04 2.20E-03 463 696 537 
cg22716738 7 27784932 TAX1BP1 5'UTR OpenSea 0.424 0.359 0.064 2.67E-04 2.27E-03 471 907 651 
cg25338454 12 26900022 ITPR2 Body OpenSea 0.764 0.706 0.058 2.76E-04 2.32E-03 473 776 685 
cg21992696 2 9125026 MBOAT2 Body OpenSea 0.429 0.362 0.066 2.78E-04 2.33E-03 474 821 598 
cg06122613 1 151297900 PI4KB Body N_Shelf 0.757 0.700 0.057 2.80E-04 2.34E-03 475 881 643 
cg23705979 7 92397161 CDK6 Body OpenSea 0.354 0.301 0.053 2.83E-04 2.36E-03 476 1137 378 
cg05697976 12 29376483 FAR2 TSS200 OpenSea 0.518 0.453 0.066 2.86E-04 2.38E-03 478 934 689 
cg13088432 8 9522664 TNKS Body OpenSea 0.570 0.498 0.072 2.87E-04 2.39E-03 479 801 561 
cg11168614 14 87179368 
  
OpenSea 0.651 0.588 0.063 2.87E-04 2.39E-03 480 1502 262 
cg14111928 10 76602391 MYST4 5'UTR OpenSea 0.711 0.655 0.056 2.93E-04 2.42E-03 482 1251 582 
cg04231677 1 184808004 FAM129A Body OpenSea 0.519 0.453 0.066 2.95E-04 2.43E-03 483 1550 268 
cg09982419 15 68343575 
  
N_Shelf 0.641 0.582 0.059 3.00E-04 2.46E-03 484 731 721 
cg05888181 8 1952319 KBTBD11 3'UTR S_Shore 0.666 0.598 0.068 3.06E-04 2.50E-03 485 649 602 
cg13424302 10 80516893 
  
OpenSea 0.417 0.359 0.058 3.06E-04 2.50E-03 486 871 429 
cg08195176 11 116781303 SIK3 Body OpenSea 0.604 0.551 0.053 3.07E-04 2.50E-03 487 1396 289 
cg03633574 3 149954846 
  
OpenSea 0.804 0.752 0.052 3.22E-04 2.59E-03 493 1273 287 
cg05454562 6 33254447 WDR46 Body N_Shelf 0.624 0.566 0.058 3.41E-04 2.69E-03 499 1441 369 
cg20610950 17 75096202 
  
OpenSea 0.765 0.700 0.065 3.43E-04 2.70E-03 501 1594 303 
cg08598221 8 121824929 SNTB1 TSS1500 S_Shore 0.589 0.534 0.055 3.49E-04 2.73E-03 503 1492 253 
cg11952340 15 63814440 USP3 Body OpenSea 0.604 0.547 0.056 3.49E-04 2.73E-03 504 879 585 
cg10499974 3 46244099 CCR1 3'UTR OpenSea 0.668 0.614 0.054 3.52E-04 2.75E-03 506 1102 673 
cg26105956 1 154471433 SHE Body N_Shelf 0.733 0.668 0.065 3.52E-04 2.75E-03 507 1042 351 
cg06645778 2 64680425 HSPC159 TSS1500 N_Shore 0.565 0.513 0.052 3.62E-04 2.80E-03 510 1657 226 
cg02320474 16 1758022 MAPK8IP3 Body OpenSea 0.434 0.371 0.063 3.65E-04 2.82E-03 512 970 496 
cg26253500 7 136641740 CHRM2 5'UTR OpenSea 0.758 0.703 0.055 3.84E-04 2.92E-03 517 1321 386 
cg21216258 9 140942584 CACNA1B Body S_Shore 0.590 0.518 0.073 3.87E-04 2.93E-03 518 1330 435 
cg07805500 6 151380818 MTHFD1L Body OpenSea 0.480 0.391 0.089 4.05E-04 3.02E-03 522 1026 426 
cg26828017 16 22409023 
  







cg07229212 8 11056726 XKR6 Body N_Shore 0.605 0.546 0.059 4.18E-04 3.09E-03 525 1049 521 
cg07113414 8 144652930 C8orf73 Body N_Shore 0.551 0.485 0.065 4.19E-04 3.10E-03 527 1516 518 
cg12237948 20 2085157 STK35 Body S_Shore 0.724 0.662 0.062 4.20E-04 3.10E-03 528 1041 452 
cg22159528 19 44039727 ZNF575 Body Island 0.605 0.551 0.055 4.23E-04 3.12E-03 531 1142 372 
cg05279761 3 132312243 ACAD11 Body OpenSea 0.568 0.498 0.069 4.28E-04 3.14E-03 532 897 640 
cg21426759 6 30303126 TRIM39 Body OpenSea 0.656 0.603 0.053 4.42E-04 3.21E-03 536 1472 484 
cg13640297 6 170099238 WDR27 5'UTR N_Shelf 0.676 0.625 0.051 4.42E-04 3.22E-03 537 1571 309 
cg07541020 10 44068714 ZNF239 5'UTR N_Shore 0.703 0.640 0.063 4.46E-04 3.23E-03 539 1598 366 
cg01924292 12 1815334 ADIPOR2 5'UTR OpenSea 0.656 0.584 0.072 4.52E-04 3.26E-03 542 1449 383 
cg00117012 15 73996358 CD276 Body OpenSea 0.810 0.708 0.102 4.74E-04 3.37E-03 547 1062 431 
cg22630754 15 42866523 STARD9 TSS1500 N_Shore 0.687 0.626 0.061 5.04E-04 3.52E-03 550 1540 373 
cg07948875 1 169187004 NME7 Body OpenSea 0.314 0.257 0.058 5.15E-04 3.57E-03 551 1480 352 
cg08760493 4 109994039 COL25A1 Body OpenSea 0.533 0.480 0.053 5.18E-04 3.59E-03 553 1349 535 
cg11321181 19 17721489 UNC13A Body S_Shelf 0.374 0.310 0.063 5.35E-04 3.67E-03 558 950 709 
cg10603275 3 239665 CHL1 5'UTR Island 0.180 0.125 0.055 5.49E-04 3.73E-03 560 1562 183 
cg18507018 8 92035517 TMEM55A Body OpenSea 0.726 0.654 0.072 5.52E-04 3.75E-03 561 1025 609 
cg24406240 11 88153520 
  
OpenSea 0.614 0.549 0.065 5.57E-04 3.77E-03 565 1547 421 
cg14308082 10 131568021 
  
OpenSea 0.596 0.542 0.054 5.68E-04 3.82E-03 567 569 730 
cg26975524 8 1713012 CLN8 5'UTR S_Shore 0.647 0.587 0.060 5.74E-04 3.85E-03 571 1405 444 
cg09069499 8 26216910 PPP2R2A Body OpenSea 0.770 0.713 0.057 5.80E-04 3.88E-03 575 1609 379 
cg19116959 4 146841472 ZNF827 Body OpenSea 0.479 0.421 0.058 5.81E-04 3.89E-03 576 822 681 
cg21597811 8 123687197 
  
OpenSea 0.685 0.631 0.054 5.84E-04 3.89E-03 577 1095 493 
cg12437013 13 114161939 TMCO3 Body N_Shelf 0.647 0.556 0.091 5.84E-04 3.90E-03 578 1400 238 
cg26162326 7 75957061 YWHAG 3'UTR N_Shore 0.507 0.442 0.064 5.85E-04 3.90E-03 579 872 543 
cg26872780 2 149478494 EPC2 Body OpenSea 0.631 0.571 0.059 5.90E-04 3.92E-03 581 1556 405 
cg02282631 5 42953543 
  
S_Shore 0.696 0.635 0.060 6.03E-04 3.98E-03 584 1018 515 
cg03967798 4 145268453 
  
OpenSea 0.535 0.481 0.054 6.09E-04 4.01E-03 585 1130 637 
cg04998202 1 61545546 NFIA Body N_Shelf 0.399 0.333 0.066 6.19E-04 4.05E-03 586 802 564 
cg19238325 3 51988425 GPR62 TSS1500 N_Shore 0.386 0.335 0.051 6.29E-04 4.10E-03 587 994 702 
cg16520357 13 53625240 OLFM4 3'UTR OpenSea 0.726 0.667 0.059 6.37E-04 4.13E-03 589 989 699 
cg04350202 10 111653363 XPNPEP1 Body OpenSea 0.554 0.501 0.053 6.43E-04 4.16E-03 592 1495 549 
cg25865108 6 45559104 
  
OpenSea 0.668 0.606 0.062 6.71E-04 4.28E-03 595 997 659 
cg03269667 3 9744891 CPNE9 TSS1500 N_Shore 0.920 0.819 0.101 6.75E-04 4.30E-03 598 1626 380 
cg09643312 2 160655081 CD302 TSS1500 S_Shore 0.492 0.434 0.057 6.86E-04 4.35E-03 600 1423 499 
cg09101062 5 43487508 C5orf34 Body S_Shelf 0.857 0.794 0.062 6.96E-04 4.40E-03 603 1676 377 
cg05696877 1 79088769 IFI44L 5'UTR OpenSea 0.449 0.521 -0.072 7.33E-04 4.56E-03 609 1334 437 
cg03950493 11 126582183 KIRREL3 Body OpenSea 0.516 0.443 0.073 7.49E-04 4.62E-03 611 1094 406 
cg23395177 14 77498304 
  
N_Shore 0.693 0.585 0.109 7.51E-04 4.63E-03 612 1046 539 
cg03818715 6 7591348 SNRNP48 Body S_Shore 0.588 0.528 0.059 7.62E-04 4.68E-03 614 1070 593 
cg21341487 20 60760919 GTPBP5 5'UTR S_Shelf 0.497 0.440 0.057 7.71E-04 4.71E-03 617 1281 492 
cg09858862 1 23887514 ID3 TSS1500 S_Shore 0.585 0.518 0.067 7.80E-04 4.75E-03 620 1106 663 
cg25656283 10 50733196 ERCC6;PGBD
3 
Body;TSS1500 OpenSea 0.762 0.709 0.053 7.99E-04 4.83E-03 623 1369 433 
cg04139465 19 51020297 LRRC4B 3'UTR Island 0.540 0.468 0.071 8.06E-04 4.86E-03 625 1410 412 
cg01701649 16 48589954 N4BP1 Body OpenSea 0.382 0.316 0.067 8.27E-04 4.95E-03 627 1623 333 
cg15084543 1 79472408 ELTD1 5'UTR;1stExon Island 0.360 0.298 0.061 8.44E-04 5.02E-03 628 1451 314 
cg24361586 17 62744534 
  







cg09506675 7 112727914 GPR85 TSS1500;TSS20
0;TSS200 
OpenSea 0.546 0.491 0.055 8.81E-04 5.17E-03 637 1153 579 
cg09357350 3 171894094 FNDC3B Body OpenSea 0.641 0.583 0.058 9.07E-04 5.27E-03 644 1456 563 
cg23670353 1 59833489 FGGY Body OpenSea 0.540 0.479 0.061 9.17E-04 5.31E-03 646 1584 567 
cg02884928 14 105251610 AKT1 Body Island 0.600 0.543 0.058 9.20E-04 5.33E-03 648 1272 738 
cg09729012 3 72395774 
  
OpenSea 0.396 0.325 0.071 9.46E-04 5.43E-03 655 1161 696 
cg17797940 3 171759519 FNDC3B 5'UTR S_Shore 0.539 0.479 0.061 9.52E-04 5.46E-03 656 619 645 
cg19214707 7 3157722 
  
OpenSea 0.398 0.238 0.160 9.66E-04 5.51E-03 660 1494 531 
cg15843217 4 699224 PCGF3 TSS1500 N_Shore 0.442 0.390 0.052 9.68E-04 5.52E-03 661 1266 415 
cg26132114 10 44223934 
  
Island 0.714 0.659 0.055 1.02E-03 5.71E-03 672 1060 589 
cg22283115 7 4911121 RADIL Body OpenSea 0.576 0.523 0.053 1.07E-03 5.92E-03 679 1165 458 
cg06193043 1 11908199 NPPA TSS1500 OpenSea 0.524 0.472 0.052 1.08E-03 5.96E-03 681 1217 635 
cg06347643 2 137518979 
  
N_Shelf 0.928 0.855 0.073 1.09E-03 6.00E-03 683 1566 718 
cg23605961 7 751331 PRKAR1B 5'UTR N_Shore 0.553 0.493 0.060 1.12E-03 6.10E-03 686 1434 679 
cg07319315 2 135149599 MGAT5 Body OpenSea 0.706 0.642 0.064 1.12E-03 6.13E-03 688 1240 529 
cg20168849 3 188995030 TPRG1 Body OpenSea 0.591 0.527 0.064 1.13E-03 6.17E-03 691 1529 725 
cg00261690 1 28856281 SNHG3-
RCC1;RCC1 
Body;5'UTR N_Shore 0.613 0.553 0.060 1.14E-03 6.19E-03 694 1432 669 
cg18517369 2 231899207 
  
N_Shelf 0.596 0.543 0.053 1.15E-03 6.22E-03 695 1668 443 
cg24856673 12 2017134 CACNA2D4 Body Island 0.343 0.283 0.060 1.17E-03 6.29E-03 697 1225 500 
cg02262553 4 87849250 
  
OpenSea 0.506 0.453 0.052 1.18E-03 6.33E-03 699 1678 578 
cg15073631 13 104796427 
  
OpenSea 0.379 0.329 0.051 1.19E-03 6.36E-03 701 1546 688 
cg14942952 22 44576268 PARVG TSS1500;5'UTR;
Body 
OpenSea 0.588 0.523 0.066 1.19E-03 6.38E-03 702 1628 603 
cg05131696 12 31499320 
  
OpenSea 0.441 0.373 0.068 1.19E-03 6.38E-03 703 1379 554 
cg22629528 11 132951861 OPCML Body Island 0.638 0.578 0.060 1.29E-03 6.72E-03 711 837 632 
cg08730245 12 53902893 NPFF TSS1500 OpenSea 0.645 0.590 0.056 1.32E-03 6.84E-03 715 1548 687 
cg01664300 6 15911690 
  
OpenSea 0.703 0.589 0.114 1.32E-03 6.84E-03 716 1442 608 
cg00782708 2 44933278 C2orf34 Body OpenSea 0.635 0.581 0.053 1.40E-03 7.14E-03 721 1429 736 
cg11147155 1 150595206 ENSA 3'UTR OpenSea 0.493 0.442 0.051 1.48E-03 7.41E-03 729 1522 675 
cg20155875 17 66452567 WIPI1 Body N_Shore 0.620 0.563 0.057 1.52E-03 7.54E-03 738 1692 711 
cg10231675 12 2944493 NRIP2 TSS1500 OpenSea 0.596 0.537 0.059 1.60E-03 7.83E-03 742 1378 729 
cg08113187 16 87469329 ZCCHC14 Body OpenSea 0.251 0.196 0.055 1.61E-03 7.83E-03 743 1306 568 
cg11740416 3 194409431 FAM43A 3'UTR;1stExon S_Shore 0.321 0.259 0.062 1.64E-03 7.95E-03 745 1606 479 
cg13480937 1 177112230 ASTN1 Body OpenSea 0.500 0.433 0.066 1.68E-03 8.07E-03 752 1385 698 
cg20824294 3 142316082 PLS1 5'UTR S_Shore 0.582 0.520 0.062 1.72E-03 8.22E-03 755 1197 684 
cg01327169 3 183738470 
  
S_Shelf 0.703 0.650 0.053 1.86E-03 8.68E-03 771 1318 542 
cg08920032 15 99332004 IGF1R Body OpenSea 0.623 0.568 0.055 2.51E-03 1.07E-02 820 1357 732 
cg22962883 11 114178729 NNMT Body OpenSea 0.410 0.341 0.069 2.83E-03 1.16E-02 839 1634 473 
cg05991492 16 3988700 
  
N_Shore 0.499 0.440 0.059 3.19E-03 1.26E-02 863 1625 624 
cg14076239 13 53712850 
  
OpenSea 0.617 0.564 0.053 3.48E-03 1.34E-02 880 1616 690 
 
